徳島大学 / 教育研究者総覧 --- 齋藤裕

専門分野

研究テーマ

著書・論文

著書:

1.	松本力三, 西尾進, 平田有紀奈, 森田沙瑛, 湯浅麻美, 山尾雅美, 柿本拓海, 齋藤裕, 楠瀬賢也, 山田博胤, 上原久典, 島田光生, 佐田政隆 : 術前の画像検査で肝細胞癌と診断された肝炎症性偽腫瘍の1例, (一社)日本超音波検査学会, 2023年10月. (要約) 症例は70代,男性.近医の定期的な血液検査で胆道系酵素の上昇を認めたため,腹部超音波検査を施行したところ,肝左葉内側区に腫瘤を認めた.当院消化器外科に紹介となり,肝内側区切除術が施行され,肝細胞癌と診断された.術後7ヵ月,当院で経過観察目的に施行した造影CT検査で肝左葉外側区に新たに腫瘤を認め,再度精査となった.血液検査では,γ-GTPの軽度上昇を認めるのみで,腫瘍マーカーの上昇は認めなかった.術前の精査目的に施行した腹部超音波検査では,肝左葉外側区(S2)に18×16mm大の腫瘤を認めた.境界明瞭,輪郭は後面が整,前面がやや不整,内部エコーは等輝度で不均質であった.辺縁に比較的厚い低エコー帯を伴っていた.心拍動の影響で血流シグナルの評価は困難であった.腹部造影CT検査では,肝左葉外側区(S2)に2cm大の腫瘤を認め,早期濃染および洗い出しが確認された.本症例は,術前の超音波検査で,肝細胞癌としては非典型的な像を呈していたが,他の画像所見および既往歴から肝細胞癌の再発が否定できず,肝部分切除術が施行され,肝炎症性偽腫瘍と診断された.本症例のように肝細胞癌のリスクが高い症例においても,新規に腫瘤を認めた際には,超音波検査でその特徴を注意深く観察し,典型像と異なる場合には肝炎症性偽腫瘍も鑑別疾患の一つとして考慮した方がよいと考える.(著者抄録) (キーワード) 肝炎(画像診断,外科的療法,病理学) 肝細胞癌肝切除 MRI 腫瘍再発鑑別診断術前評価超音波診断 X線CT 肉芽腫(画像診断,外科的療法,病理学) 肉芽腫-形質細胞(画像診断,外科的療法,病理学) Gadoxetic Acid(診断的利用) Azan染色肝肉芽腫(画像診断,外科的療法,病理学) 腹部CT ヒト高齢者(65∼79) 男 (出版サイトへのリンク) ● Publication site (DOI): 10.11272/jss.405 (文献検索サイトへのリンク) ● Search Scopus @ Elsevier (DOI): 10.11272/jss.405 (DOI: 10.11272/jss.405)
2.	鈴木佳子, 安井苑子, 西麻希, 山田静恵, 松村晃子, 齋藤裕, 濵田康弘 : がん患者さんの栄養管理を支える栄養サポートチーム(特集がんに対するチーム医療最前線), 四国医学会, 2017年4月. (要約) Several hospitals have recently established a nutrition support team(NST)for the nutritional management of inpatients. The NST includes medical doctors, nurses, dietitians, and pharmacists. The aims of the NST are to improve the nutritional condition and the quality of life(QOL)of patients. In Tokushima University Hospital, a NST was established in2002. Our team comprises physicians, surgeons, dentists, nurses, dietitians, pharmacists, dental hygienists, and physical therapists. Overall, 70% of patients undergoing a NST intervention have cancer. Nutritional management in patients with cancer plays an important role in the supportive care during cancer treatment(surgery, chemotherapy, and radiotherapy). It is focused on the improvement of undernutrition, return to oral feeding, and an improvement in QOL in palliative care. Recently, cancer cachexia has received a lot of attention, with various studies reporting on the nutritional care in patients with cancer. Malnutrition negatively impacts a patient's response to therapy, leading to an increase in the incidence of treatment-related side effects, and impairment in muscle function, performance status, immune function, and QOL. Recently, it has been reported that NST improves the treatment outcome in patients with cancer because nutritional status is an important part of cancer treatment. Therefore, nutritional management by a NST in patients with cancer has played a crucial role in cancer therapy. (キーワード) NST / cancer, malnutrition / nutritional management (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1050583647830806912 (CiNii: 1050583647830806912)
3.	濵田康弘, 安井苑子, 齋藤裕 : 根拠に基づいた経腸栄養剤の選択腎疾患, フジメディカル出版, 2015年3月.

学術論文(審査論文):

1.	Chie Takasu, Shuhai Chen, Luping Gao, Yu Saitou, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada and Mitsuo Shimada : Role of Nrf2 signaling in development of hepatocyte-like cells, The Journal of Medical Investigation : JMI, Vol.70, No.3,4, 343-349, 2023. (要約) Generation of hepatocytes from human adipose-derived mesenchymal stem cells (hADSCs) could be a promising alternative source of human hepatocytes. However, mechanisms to differentiate hepatocytes from hADSCs are not fully elucidated. We have previously demonstrated that our three-step differentiation protocol with glycogen synthase kinase (GSK) 3 inhibitor was effective to improve hepatocyte functions. In this study, we investigated the activation of the nuclear factor erythroid-2 related factor 2 (Nrf2) on hADSCs undergoing differentiation to HLC (hepatocyte-like cells). Our three-step differentiation protocol was applied for 21 days (Step 1:day 1-6, Step2:day 6-11, Step3:day 11-21). Our results show that significant nuclear translocation of Nrf2 occurred from day 11 until the end of HLC differentiation. Nuclear translocation of Nrf2 and CYP3A4 activity in the GSK3 inhibitor-treated group was obviously higher than that in Activin A-treated groups at day 11. The maturation of HLCs was delayed in Nrf2-siRNA group compared to control group. Furthermore, CYP3A4 activity in Nrf2-siRNA group was decreased at the almost same level in Activin A-treated group. Nrf2 translocation might enhance the function of HLC and be a target for developing highly functional HLC. J. Med. Invest. 70 : 343-349, August, 2023. (キーワード) Humans / NF-E2-Related Factor 2 / Glycogen Synthase Kinase 3 / Cytochrome P-450 CYP3A / Hepatocytes / Cell Differentiation / RNA, Small Interfering (出版サイトへのリンク) ● Publication site (DOI): 10.2152/jmi.70.343 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37940517 ● Search Scopus @ Elsevier (PMID): 37940517 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.70.343 (DOI: 10.2152/jmi.70.343, PubMed: 37940517)
2.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Mayuko Shimizu, Koichi Tsuneyama, Mitsue Nishiyama, Shiori Ishizawa and Mitsuo Shimada : Effect of daikenchuto (TU-100) on carcinogenesis in non-alcoholic steatohepatitis., The Journal of Medical Investigation : JMI, Vol.70, No.1.2, 66-73, 2023. (要約) TU-100 regulates the intestinal microbiome and may suppress subsequent hepatocarcinogenesis in the NASH model. J. Med. Invest. 70 : 66-73, February, 2023. (キーワード) Mice / Animals / Non-alcoholic Fatty Liver Disease / Carcinoma, Hepatocellular / Liver Neoplasms / Liver / Carcinogenesis (徳島大学機関リポジトリ) ● Metadata: 118309 (出版サイトへのリンク) ● Publication site (DOI): 10.2152/jmi.70.66 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37164745 ● Search Scopus @ Elsevier (PMID): 37164745 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.70.66 (徳島大学機関リポジトリ: 118309, DOI: 10.2152/jmi.70.66, PubMed: 37164745)
3.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Katsuki Miyazaki, Mayuko Shimizu, Koichi Tsuneyama and Mitsuo Shimada : Inhibitory effect of non-alcoholic steatohepatitis on colon cancer liver metastasis., EJSO - European Journal of Surgical Oncology, Vol.49, No.2, 410-415, 2023. (要約) Only mice fed a WD for 16 weeks showed hepatic fibrosis. These mice showed significantly higher alanine aminotransferase and total cholesterol levels compared with the control group (p < 0.05). The WD group showed significantly lower tumor number and smaller tumor diameter (p < 0.05). In the WD group, expression of SAA1, IL6, STAT3 and MMP9 mRNA in the liver was significantly lower than in the control group (p < 0.05). Serum amyloid A1 protein expression was also lower in the WD group. (キーワード) Male / Mice / Animals / Non-alcoholic Fatty Liver Disease / Mice, Inbred C57BL / Liver / Liver Neoplasms / Disease Models, Animal / Colonic Neoplasms / RNA, Messenger (出版サイトへのリンク) ● Publication site (DOI): 10.1016/j.ejso.2022.11.002 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36371329 ● Search Scopus @ Elsevier (PMID): 36371329 ● Search Scopus @ Elsevier (DOI): 10.1016/j.ejso.2022.11.002 (DOI: 10.1016/j.ejso.2022.11.002, PubMed: 36371329)
4.	Nanami Nasu, Sonoko Yasui-Yamada, Natsumi Kagiya, Mami Takimoto, Yumiko Kurokawa, Yoshiko Suzuki, Hideya Kashihara, Yu Saitou, Masaaki Nishi, Mitsuo Shimada and Yasuhiro Hamada : Muscle strength is a stronger prognostic factor than muscle mass in patients with gastrointestinal and hepatobiliary-pancreatic cancers., Nutrition, Vol.103-104, 111826, 2022. (要約) Sarcopenia has been reported as a prognostic risk factor in patients with gastrointestinal (GI) and hepatobiliary pancreatic (HBP) cancers. This study aimed to investigate whether the loss of muscle mass or strength is a stronger prognostic factor, and explore the cutoff values of skeletal muscle mass index (SMI) and handgrip strength (HGS) based on the survival outcome in patients with GI and HBP cancers. A total of 480 elderly patients with primary GI and HBP cancers who underwent their first resection surgery were analyzed retrospectively. Patients were divided into four groups: Appropriate SMI and HGS, low SMI alone, low HGS alone, and low SMI and HGS. Low SMI was derived from a bioelectrical impedance analysis, and low HGS was defined according to the Asian Working Group for Sarcopenia 2019 criteria. The multivariate analysis showed that low SMI was a significant risk factor for mortality in men only, but low HGS was significant in both sexes. From the multivariate analysis of the four groups, low HGS alone and low SMI and HGS showed a significantly higher hazard ratio than appropriate SMI and HGS in both sexes. An SMI of 7.21 kg/m and HGS of 28 kg were obtained as cutoff values based on the 3-y survival outcomes in men. Low muscle strength was a stronger prognostic factor than low muscle mass. Therefore, measuring muscle strength in all patients is essential. (キーワード) Male / Female / Humans / Aged / Sarcopenia / Hand Strength / Prognosis / Retrospective Studies / Muscle Strength / Muscle, Skeletal / Pancreatic Neoplasms (徳島大学機関リポジトリ) ● Metadata: 118201 (出版サイトへのリンク) ● Publication site (DOI): 10.1016/j.nut.2022.111826 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36122543 ● Search Scopus @ Elsevier (PMID): 36122543 ● Search Scopus @ Elsevier (DOI): 10.1016/j.nut.2022.111826 (徳島大学機関リポジトリ: 118201, DOI: 10.1016/j.nut.2022.111826, PubMed: 36122543)
5.	Mami Takimoto, Sonoko Yasui-Yamada, Nanami Nasu, Natsumi Kagiya, Nozomi Aotani, Yumiko Kurokawa, Yoshiko Suzuki, Hideya Kashihara, Yu Saitou, Masaaki Nishi, Mitsuo Shimada and Yasuhiro Hamada : Development and Validation of Cutoff Value for Reduced Muscle Mass for GLIM Criteria in Patients with Gastrointestinal and HepatobiliaryPancreatic Cancers, Nutrients, Vol.14, No.943, 1-10, 2022. (要約) The Global Leadership Initiative on Malnutrition (GLIM) criteria recommends using race- and sex-adjusted cutoff values for reduced muscle mass (RMM), but the only cutoff values available for Asians are the skeletal muscle mass index (SMI) established by the Asian Working Group for Sarcopenia (AWGS). This retrospective study aimed to develop and validate cutoff values for the fat-free mass index (FFMI) and arm circumference (AC) of Asians, and to investigate the association between GLIM malnutrition and prognosis. A total of 660 patients with primary gastrointestinal (GI) and hepatobiliary-pancreatic (HBP) cancers who underwent their first resection surgery were recruited and randomly divided into development and validation groups. The FFMI and AC cutoff values were calculated by receiver operating characteristic curve analysis for the AWGS SMI as the gold standard. The cutoff values for each RMM were used to diagnose malnutrition on the basis of GLIM criteria, and the survival rates were compared. The optimal FFMI cutoff values for RMM were 17 kg/m for men and 15 kg/m for women, and for AC were 27 cm for men and 25 cm for women. In the validation group, the accuracy of the FFMI and AC cutoff values to discriminate RMM were 85.2% and 68.8%, respectively. Using any of the three measures of RMM, overall survival rates were significantly lower in the GLIM malnutrition group. In conclusion, the cutoff values for the FFMI and AC in this study could discriminate RMM, and GLIM malnutrition using these cutoff values was associated with decreased survival. (キーワード) Female / Humans / Leadership / Male / Malnutrition / Muscles / Pancreatic Neoplasms / Retrospective Studies (徳島大学機関リポジトリ) ● Metadata: 116863 (出版サイトへのリンク) ● Publication site (DOI): 10.3390/nu14050943 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35267918 ● Search Scopus @ Elsevier (PMID): 35267918 ● Search Scopus @ Elsevier (DOI): 10.3390/nu14050943 (徳島大学機関リポジトリ: 116863, DOI: 10.3390/nu14050943, PubMed: 35267918)
6.	Yu Saitou, Mitsuo Shimada, Yuji Morine, Shin-ichiro Yamada and Maki Sugimoto : Essential updates 2020/2021: Current topics of simulation and navigation in hepatectomy., Annals of Gastroenterological Surgery, Vol.6, No.2, 190-196, 2021. (要約) With the development of three-dimensional (3D) simulation software, preoperative simulation technology is almost completely established. The remaining issue is how to recognize anatomy three-dimensionally. Extended reality is a newly developed technology with several merits for surgical application: no requirement for a sterilized display monitor, better spatial awareness, and the ability to share 3D images among all surgeons. Various technology or devices for intraoperative navigation have also been developed to support the safety and certainty of liver surgery. Consensus recommendations regarding indocyanine green fluorescence were determined in 2021. Extended reality has also been applied to intraoperative navigation, and artificial intelligence (AI) is one of the topics of real-time navigation. AI might overcome the problem of liver deformity with automatic registration. Including the issues described above, this article focuses on recent advances in simulation and navigation in liver surgery from 2020 to 2021. (徳島大学機関リポジトリ) ● Metadata: 117276 (出版サイトへのリンク) ● Publication site (DOI): 10.1002/ags3.12542 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35261944 ● Search Scopus @ Elsevier (PMID): 35261944 ● Search Scopus @ Elsevier (DOI): 10.1002/ags3.12542 (徳島大学機関リポジトリ: 117276, DOI: 10.1002/ags3.12542, PubMed: 35261944)
7.	Katsuki Miyazaki, Yuji Morine, Shin-ichiro Yamada, Yu Saitou, Kazunori Tokuda, Shohei Okikawa, Shoko Yamashita, Takeshi Oya, Tetsuya Ikemoto, Satoru Imura, Haun Hu, Hisayoshi Morioka, Koichi Tsuneyama and Mitsuo Shimada : Stromal tumor-infiltrating lymphocytes level as a prognostic factor for resected intrahepatic cholangiocarcinoma and its prediction by apparent diffusion coefficient., International Journal of Clinical Oncology, Vol.26, No.12, 2265-2274, 2021. (要約) Tumor-infiltrating lymphocytes (TILs) are a prognostic factor or an indicator of chemotherapy response for various malignancies. The aim of this study was to investigate the prognostic impact of TILs in resected intrahepatic cholangiocarcinoma (IHCC). We also investigated the usefulness of the apparent diffusion coefficient (ADC) in diffusion-weighted magnetic resonance imaging (DW-MRI) to predict TILs. We enrolled 23 patients with IHCC who underwent initial hepatic resection in Tokushima University Hospital from 2006 to 2017. We evaluated stromal TILs in the tumor marginal area and central area in surgical specimens. Patients were divided into low vs high stromal TILs groups. We analyzed the patients' clinicopathological factors, including prognosis, according to the degree of stromal TILs. We also analyzed the correlation between stromal TILs and the minimum ADC value. Stromal TILs in the marginal area reflected overall survival more accurately than that in the central area. Additionally, marginal low TILs was significantly associated with lymph node metastasis and portal vein invasion. Both overall- and disease-free survival rates in the marginal low TILs group were significantly worse than those in the marginal high TILs group (P < 0.05). In the multivariate analysis, marginal low TILs were an independent prognostic factor for both overall- and disease-free survival (P < 0.05), and marginal low TILs were significantly associated with lower minimum ADC values (P < 0.02). Stromal TILs, especially in the marginal area, might demonstrate prognostic impact in patients with IHCC. Moreover, the ADC values from MRI may predict TILs in IHCC tumor tissue. (キーワード) Bile Duct Neoplasms / Bile Ducts, Intrahepatic / Cholangiocarcinoma / Diffusion Magnetic Resonance Imaging / Humans / Lymphocytes, Tumor-Infiltrating / Prognosis (出版サイトへのリンク) ● Publication site (DOI): 10.1007/s10147-021-02026-3 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34596803 ● Search Scopus @ Elsevier (PMID): 34596803 ● Search Scopus @ Elsevier (DOI): 10.1007/s10147-021-02026-3 (DOI: 10.1007/s10147-021-02026-3, PubMed: 34596803)
8.	Yu Saitou, Tetsuya Ikemoto, Kazunori Tokuda, Katsuki Miyazaki, Shin-ichiro Yamada, Satoru Imura, Masato Miyake, Yuji Morine, Seiichi Oyadomari and Mitsuo Shimada : Effective three-dimensional culture of hepatocyte-like cells generated from human adipose-derived mesenchymal stem cells., Journal of Hepato-Biliary-Pancreatic Sciences, Vol.28, No.9, 705-715, 2021. (要約) The aim of this study was to clarify the effectiveness of a new three-dimensional (3D) culture system for hepatocyte-like cells (HLCs) generated from human adipose-derived mesenchymal stem cells (ADSCs). Human ADSCs (2 × 10 ) with or without 0.1 mg/mL human recombinant peptide μ-piece per well were seeded in a 96-well U-bottom plate and then our three-step differentiation protocol was applied for 21 days. At each step, cell morphology and gene expression were investigated. Mature hepatocyte functions were evaluated after HLC differentiation. These parameters were compared between 2D- and 3D-cultured HLCs, and, DNA microarray analysis was also performed. Finally, HLCs were transplanted in to CCl induced acute liver failure model mice. Two-dimensional-cultured HLCs at day 21 did not have a spindle shape and had formed spheroids after day 6, which gradually increased in size for 3D-cultured HLCs. Definitive endoderm, hepatoblast, and hepatocyte genes showed significantly higher expression in the 3D culture group. Three-dimensional-cultured HLCs also had higher albumin expression, CYP3A4 activity, urea synthesis, and ammonium metabolism, and much higher expression of ion transporter, blood coagulation, and cell communication genes. HLC transplantation improved serum liver function, especially in T-Bil levels, and engrafted into immunodeficient mice with HLA class I positive staining. Our new 3D culture protocol is effective to improve hepatocyte functions. Our HLCs might be promising for clinical cell transplantation to treat metabolic disease. (出版サイトへのリンク) ● Publication site (DOI): 10.1002/jhbp.1024 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34318615 ● Search Scopus @ Elsevier (PMID): 34318615 ● Search Scopus @ Elsevier (DOI): 10.1002/jhbp.1024 (DOI: 10.1002/jhbp.1024, PubMed: 34318615)
9.	Shoko Yamashita, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Chie Takasu, Shinichiro Yamada, Kazunori Tokuda, Shohei Okikawa, Katsuki Miyazaki, Takeshi Oya, Koichi Tsuneyama and Mitsuo Shimada : A new pathological classification of intrahepatic cholangiocarcinoma according to protein expression of SSTR2 and Bcl2., World Journal of Surgical Oncology, Vol.19, No.1, 142, 2021. (要約) This method could be used to classify IHCC into peripheral and perihilar type by embryological expression patterns of SSTR2 and Bcl2. (キーワード) Bile Duct Neoplasms / Bile Ducts, Intrahepatic / Cholangiocarcinoma / Humans / Prognosis / Proto-Oncogene Proteins c-bcl-2 / Receptors, Somatostatin (徳島大学機関リポジトリ) ● Metadata: 116986 (出版サイトへのリンク) ● Publication site (DOI): 10.1186/s12957-021-02216-3 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33962620 ● Search Scopus @ Elsevier (PMID): 33962620 ● Search Scopus @ Elsevier (DOI): 10.1186/s12957-021-02216-3 (徳島大学機関リポジトリ: 116986, DOI: 10.1186/s12957-021-02216-3, PubMed: 33962620)
10.	Nozomi Aotani, Sonoko Yasui-Yamada, Natsumi Kagiya, TAKIMOTO Mami, Yu Ohiwa, Matsubara Atsumi, Sayaka Matsura, Mayu Tanimura, Yoshiko Suzuki, Hideya Kashihara, Yu Saitou, Masaaki Nishi, Mitsuo Shimada and Yasuhiro Hamada : Malnutrition by European Society for Clinical Nutrition and Metabolism criteria predicts prognosis in patients with gastrointestinal and hepatobiliary-pancreatic cancer, Clinical Nutrition ESPEN, Vol.42, 265-271, 2021. (要約) The European Society for Clinical Nutrition and Metabolism (ESPEN) proposed the ESPEN diagnostic criteria (EDC) for malnutrition in 2015. There is no report on the association between the EDC and prognosis in patients with gastrointestinal (GI) and hepatobiliary-pancreatic (HBP) cancer. This study aimed to (1) determine the prevalence of EDC malnutrition, (2) investigate the validity of the EDC as a nutritional and prognostic indicator, and (3) examine which components of the EDC are most related to long-term prognosis in patients with GI and HBP cancers. A total of 634 patients with primary GI and HBP cancers who underwent their first resection surgery between July 2014 and March 2018 were retrospectively recruited. According to the EDC, patients were divided into malnourished and non-malnourished groups. Clinical parameters and survival between these two groups were compared. The prognostic effects of the EDC and the EDC components were analyzed using Cox proportional hazard models. The prevalence of EDC malnutrition was 22%. Anthropometric data and biochemical data were associated with EDC malnutrition. The 5-year survival rate was lower in the malnourished group (72%) than in the non-malnourished group (73%; P = 0.007). The multivariate analysis demonstrated that the malnourished group was an independent risk factor for mortality (hazard ratio = 1.70 in the malnourished group; 95% confidence interval 1.08-2.63; P = 0.024). Among EDC components, body mass index (BMI) of <18.5 kg/m was an independent poor prognostic factor. EDC malnutrition is associated with poor postoperative long-term prognosis. Among the EDC components, BMI of <18.5 kg/m is most associated with prognosis in patients with preoperative GI and HBP cancers. (徳島大学機関リポジトリ) ● Metadata: 115904 (出版サイトへのリンク) ● Publication site (DOI): 10.1016/j.clnesp.2021.01.023 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33745591 ● Summary page in Scopus @ Elsevier: 2-s2.0-85100771924 (徳島大学機関リポジトリ: 115904, DOI: 10.1016/j.clnesp.2021.01.023, PubMed: 33745591, Elsevier: Scopus)
11.	Yusuke Arakawa, Katsuki Miyazaki, Masato Yoshikawa, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : Value of the fibrinogen-platelet ratio in patients with resectable pancreatic cancer., The Journal of Medical Investigation : JMI, Vol.68, No.3.4, 342-346, 2021. (要約) Background : Several prognostic factors were reported in pancreatic cancer. The fibrinogen-platelet ratio (FPR) was reported as a prognostic factor of resectable gastric cancer. In this report, the FPR was evaluated in patients with resectable pancreatic cancer. Methods : Between 2004 and 2019, 163 patients with curative resection for pancreatic cancer were enrolled. Cases of non-curative resection were excluded. The FPR was calculated using the preoperative plasma fibrinogen and the platelet counts and the cut-off value was determined by receiver operating characteristic (ROC) curve analysis. The patients were divided into high and low FPR groups according to this cut-off value. Results : The cut-off value of FPR was 25.2. Among age, sex, body mass index (BMI), and surgical factors including surgery type, volume of blood loss and surgery time, there was no significant difference between the two groups. Patients in the low FPR group had significantly better overall survival (OS) and relapse-free survival (RFS) compared with the high FPR group (P < 0.05). On multivariate analysis, a high FPR, CA19-9 > 300 U /l, and receipt of adjuvant chemotherapy were independent risk factors for OS and DFS. Conclusions : The FPR might be a prognostic factor for patients with resectable pancreatic cancer. J. Med. Invest. 68 : 342-346, August, 2021. (キーワード) Biomarkers, Tumor / Fibrinogen / Humans / Neoplasm Recurrence, Local / Pancreatic Neoplasms / Prognosis / Retrospective Studies (徳島大学機関リポジトリ) ● Metadata: 116535 (出版サイトへのリンク) ● Publication site (DOI): 10.2152/jmi.68.342 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34759156 ● Search Scopus @ Elsevier (PMID): 34759156 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.68.342 (徳島大学機関リポジトリ: 116535, DOI: 10.2152/jmi.68.342, PubMed: 34759156)
12.	Sonoko Yasui-Yamada, Yu Oiwa, Yu Saitou, Aotani Nozomi, Matsubara Atsumi, Matsuura Sayaka, Tanimura Mayu, Yoshiko Suzuki, Hideya Kashihara, Masaaki Nishi, Mitsuo Shimada and Yasuhiro Hamada : Impact of phase angle on postoperative prognosis in patients with gastrointestinal and hepatobiliary-pancreatic cancer, Nutrition, Vol.79-80, 110891, 2020. (徳島大学機関リポジトリ) ● Metadata: 115901 (出版サイトへのリンク) ● Publication site (DOI): 10.1016/j.nut.2020.110891 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32731162 ● Summary page in Scopus @ Elsevier: 2-s2.0-85088663807 (徳島大学機関リポジトリ: 115901, DOI: 10.1016/j.nut.2020.110891, PubMed: 32731162, Elsevier: Scopus)
13.	Tetsu Tomonari, Yasushi Sato, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, Masahiro Sogabe, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma, Yu Saitou, Satoru Imura, Yoshimi Bando, Mitsuo Shimada and Tetsuji Takayama : Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib Three case reports., Medicine, Vol.99, No.42, e22782, 2020. (要約) Lenvatinib (LEN) is a novel potent multi-tyrosine kinase inhibitor, approved as first-line treatment for unresectable hepatocellular carcinoma (HCC). Considering its high objective response rate, LEN therapy could be expected to achieve downstaging of tumors and lead to conversion therapy with hepatectomy or ablation. However, the feasibility of conversion therapy after LEN treatment in unresectable HCC remains largely unknown. Here, we reported 3 cases of unresectable HCC: case 1, a 69-year-old man diagnosed with ruptured HCC; case 2, a 72-year-old woman with nonalcoholic steatohepatitis-based HCC; and case 3, a 73-year-old man with a history of alcoholic cirrhosis-based HCC. In all cases, cirrhosis was classified as Child-Pugh 5 and modified albumin-bilirubin grade 1 or 2a. HCC was diagnosed as Barcelona Clinic Liver Cancer (BCLC) stage B. In all cases, LEN was initiated after conventional-transcatheter arterial embolization enforcement, while maintaining liver function. In all cases, the main tumor size decreased after 6 months of LEN treatment and no satellite nodes were detected, indicating downstaging of HCC to BCLC stage A. Subsequently, conversion hepatectomy or ablation was performed. After successful conversion therapy, the general condition of the patients was good, without tumor recurrence during the observation period (median 10 months). This study demonstrated that LEN enables downstaging of HCC and thus represents a bridge to successful surgery or ablation therapy. In particular, LEN treatment may facilitate the possibility for conversion therapy of initially unresectable HCC, while maintaining the hepatic functional reserve. (キーワード) Ablation Techniques / Aged / Biomarkers / Carcinoma, Hepatocellular / Female / Hepatectomy / Humans / Liver Neoplasms / Male / Phenylurea Compounds / Protein Kinase Inhibitors / Quinolines / alpha-Fetoproteins (徳島大学機関リポジトリ) ● Metadata: 116240 (出版サイトへのリンク) ● Publication site (DOI): 10.1097/MD.0000000000022782 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33080748 ● Search Scopus @ Elsevier (PMID): 33080748 ● Search Scopus @ Elsevier (DOI): 10.1097/MD.0000000000022782 (徳島大学機関リポジトリ: 116240, DOI: 10.1097/MD.0000000000022782, PubMed: 33080748)
14.	Shuichi Iwahashi, Feng Rui, Yuji Morine, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : Hepatic Stellate Cells Contribute to the Tumor Malignancy of Hepatocellular Carcinoma Through the IL-6 Pathway., Anticancer Research, Vol.40, No.2, 743-749, 2020. (要約) The hepatic stellate cells (HSCs) have relationship to cancer progression. The aim of this study is to investigate the effect of HSCs and the role of IL-6/Stat3 pathway on hepatocellular carcinoma (HCC) progression. HCCs were co-cultured with HSCs. The viability and migration ability of cancer cells were detected. Epithelial-mesenchymal transition (EMT) marker (E-cadherin), stem cell marker (CD44) and p-signal transducer and activator of transcription 3 (p-STAT3) of cancer cells were evaluated. Finally, interleukin-6 (IL-6) neutralization was performed. Co-culture of HCCs with HSCs increased cancer cell viability and migration ability. EMT and stemness of cancer cells increased with HSCs. Following IL-6 neutralization, phospho-STAT3 activation, cancer cell viability and migration, as well as EMT, and stemness of cancer cells decreased. HSCs promoted HCC progression through the IL-6/STAT3 pathway. (キーワード) Carcinoma, Hepatocellular / Cell Communication / Cell Line, Tumor / Cell Movement / Cell Survival / Coculture Techniques / Hep G2 Cells / Hepatic Stellate Cells / Humans / Interleukin-6 / Liver Neoplasms / Neoplastic Stem Cells / STAT3 Transcription Factor / Signal Transduction (出版サイトへのリンク) ● Publication site (DOI): 10.21873/anticanres.14005 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32014916 ● Search Scopus @ Elsevier (PMID): 32014916 ● Search Scopus @ Elsevier (DOI): 10.21873/anticanres.14005 (DOI: 10.21873/anticanres.14005, PubMed: 32014916)
15.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada and Toru Utsunomiya : Effect of epigenetic modulation on cancer sphere., The Journal of Medical Investigation : JMI, Vol.67, No.1.2, 70-74, 2020. (要約) Background : Cancer stem cell properties are highly relevant to the biology of treatment-resistant cancers. Epigenetic modification regulates gene expressions by chromatin remodeling during malignant transformation. The aim of this study was to elucidate the possible strategy for cancer stem cells focusing on epigenetic modification. Methods : We made cancer sphere from HepG2 cells, and we added Histone deacetylase (HDAC) inhibitor, valproic acid to cancer sphere. And we compared methylation status and the gene expression between normal HepG2 and cancer sphere groups, and between cancer sphere and sphere with HDAC inhibitor treatment groups. Results : Valproic acid (VPA) cancelled this spheroid formation. In comparison between normal HepG2 and cancer sphere, the number of methylation status changes more than 0.1 of beta level was 826 probes, and we could isolate some epithelial-mesenchymal transition (EMT) related genes. And VPA reduced the expressions of EMT related genes in sphere with RT-PCR. On the other hand, in comparison between cancer sphere and sphere with VPA treatment, we detected 29 probe of methylation status change, and VPA reduced the expressions of Bcl-6 in sphere. Conclusions : HDAC inhibitor affected the methylation status of cancer stem cells. Histone-acetylation might overcome treatmet-resistant cancer through the regulation of cancer stem cell. J. Med. Invest. 67 : 70-74, February, 2020. (キーワード) DNA Methylation / Epithelial-Mesenchymal Transition / Hep G2 Cells / Histone Deacetylase Inhibitors / Humans / Neoplasms / Neoplastic Stem Cells / Spheroids, Cellular / Valproic Acid (徳島大学機関リポジトリ) ● Metadata: 114755 (出版サイトへのリンク) ● Publication site (DOI): 10.2152/jmi.67.70 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32378621 ● Search Scopus @ Elsevier (PMID): 32378621 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.67.70 (徳島大学機関リポジトリ: 114755, DOI: 10.2152/jmi.67.70, PubMed: 32378621)
16.	Shogo Ohta, Tetsuya Ikemoto, Yuma Wada, Yu Saitou, Shin-ichiro Yamada, Satoru Imura, Yuji Morine and Mitsuo Shimada : A change in the zinc ion concentration reflects the maturation of insulin-producing cells generated from adipose-derived mesenchymal stem cells., Scientific Reports, Vol.9, No.1, 18731, 2019. (要約) The generation of insulin-producing cells (IPCs) from pluripotent stem cells could be a breakthrough treatment for type 1 diabetes. However, development of new techniques is needed to exclude immature cells for clinical application. Dithizone staining is used to evaluate IPCs by detecting zinc. We hypothesised that zinc ion (Zn) dynamics reflect the IPC maturation status. Human adipose-derived stem cells were differentiated into IPCs by our two-step protocol using two-dimensional (2D) or 3D culture. The stimulation indexes of 2D -and 3D-cultured IPCs on day 21 were 1.21 and 3.64 (P < 0.05), respectively. The 3D-cultured IPCs were stained with dithizone during culture, and its intensity calculated by ImageJ reached the peak on day 17 (P < 0.05). Blood glucose levels of streptozotocin-induced diabetic nude mice were normalised (4/4,100%) after transplantation of 96 3D-cultured IPCs. Zn concentration changes in the medium of 3D cultures had a negative value in the early period and a large positive value in the latter period. This study suggests that Zn dynamics based on our observations and staining of zinc transporters have critical roles in the differentiation of IPCs, and that their measurement might be useful to evaluate IPC maturation as a non-destructive method. (徳島大学機関リポジトリ) ● Metadata: 114940 (出版サイトへのリンク) ● Publication site (DOI): 10.1038/s41598-019-55172-0 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31822724 ● Search Scopus @ Elsevier (PMID): 31822724 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-019-55172-0 (徳島大学機関リポジトリ: 114940, DOI: 10.1038/s41598-019-55172-0, PubMed: 31822724)
17.	Tetsuya Ikemoto, Rui Feng, Shuichi Iwahashi, Shin-ichiro Yamada, Yu Saitou, Yuji Morine, Satoru Imura, Munehide Matsuhisa and Mitsuo Shimada : In vitro and in vivo effects of insulin-producing cells generated by xeno-antigen free 3D culture with RCP piece., Scientific Reports, Vol.9, No.1, 2019. (要約) To establish widespread cell therapy for type 1 diabetes mellitus, we aimed to develop an effective protocol for generating insulin-producing cells (IPCs) from adipose-derived stem cells (ADSCs). We established a 3D culture using a human recombinant peptide (RCP) petaloid μ-piece with xeno-antigen free reagents. Briefly, we employed our two-step protocol to differentiate ADSCs in 96-well dishes and cultured cells in xeno-antigen free reagents with 0.1 mg/mL RCP μ-piece for 7 days (step 1), followed by addition of histone deacetylase inhibitor for 14 days (step 2). Generated IPCs were strongly stained with dithizone, anti-insulin antibody at day 21, and microstructures resembling insulin secretory granules were detected by electron microscopy. Glucose stimulation index (maximum value, 4.9) and MAFA mRNA expression were significantly higher in 3D cultured cells compared with conventionally cultured cells (P < 0.01 and P < 0.05, respectively). The hyperglycaemic state of streptozotocin-induced diabetic nude mice converted to normoglycaemic state around 14 days after transplantation of 96 IPCs under kidney capsule or intra-mesentery. Histological evaluation revealed that insulin and C-peptide positive structures existed at day 120. Our established xeno-antigen free and RCP petaloid μ-piece 3D culture method for generating IPCs may be suitable for clinical application, due to the proven effectiveness in vitro and in vivo. (徳島大学機関リポジトリ) ● Metadata: 114941 (出版サイトへのリンク) ● Publication site (DOI): 10.1038/s41598-019-47257-7 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31341242 ● Search Scopus @ Elsevier (PMID): 31341242 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-019-47257-7 (徳島大学機関リポジトリ: 114941, DOI: 10.1038/s41598-019-47257-7, PubMed: 31341242)
18.	齋藤裕, 居村暁, 島田光生 : 消化器外科領域, 日本コンピュータ外科学会誌, Vol.21, No.3, 150-152, 2019年. (出版サイトへのリンク) ● Publication site (DOI): 10.5759/jscas.21.150 (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1390845702278940544 ● Search Scopus @ Elsevier (DOI): 10.5759/jscas.21.150 (DOI: 10.5759/jscas.21.150, CiNii: 1390845702278940544)
19.	Rui Feng, Yuji Morine, Tetsuya Ikemoto, Satoru Imura, Shuichi Iwahashi, Yu Saitou and Mitsuo Shimada : Photobiomodulation with red light emitting diodes accelerates hepatocytes proliferation through reactive oxygen species / extracellular signal-regulated kinase pathway., Hepatology Research, Vol.48, No.11, 926-936, 2018. (出版サイトへのリンク) ● Publication site (DOI): 10.1111/hepr.13182 (文献検索サイトへのリンク) ● Summary page in Scopus @ Elsevier: 2-s2.0-85050405346 (DOI: 10.1111/hepr.13182, Elsevier: Scopus)
20.	Rui Feng, Yuji Morine, Tetsuya Ikemoto, Satoru Imura, Shuichi Iwahashi, Yu Saitou and Mitsuo Shimada : Nrf2 activation drive macrophages polarization and cancer cell epithelial-mesenchymal transition during interaction, Cell Communication & Signaling, Vol.16, No.1, 54, 2018. (要約) The M2 phenotype of tumor-associated macrophages (TAM) inhibits the anti-tumor inflammation, increases angiogenesis and promotes tumor progression. The transcription factor Nuclear Factor (erythroid-derived 2)-Like 2 (Nrf2) not only modulates the angiogenesis but also plays the anti-inflammatory role through inhibiting pro-inflammatory cytokines expression; however, the role of Nrf2 in the cancer cell and macrophages interaction is not clear. Hepatocellular carcinoma cells (Hep G2 and Huh 7) and pancreatic cancer cells (SUIT2 and Panc-1) were co-cultured with monocytes cells (THP-1) or peripheral blood monocytes derived macrophages, then the phenotype changes of macrophages and epithelial-mesenchymal transition of cancer cells were detected. Also, the role of Nrf2 in cancer cells and macrophages interaction were investigated. In this study, we found that cancer cells could induce an M2-like macrophage characterized by up-regulation of CD163 and Arg1, and down-regulation of IL-1b and IL-6 through Nrf2 activation. Also, Nrf2 activation of macrophages promoted VEGF expression. The Nrf2 activation of macrophages correlated with the reactive oxygen species induced by cancer cells derived lactate. Cancer cells educated macrophages could activate Nrf2 of the cancer cells, in turn, to increase cancer cells epithelial-mesenchymal transition (EMT) through paracrine VEGF. These findings suggested that Nrf2 played the important role in the cancer cells and macrophages interaction. Macrophage Nrf2 activation by cancer cell-derived lactate skews macrophages polarization towards an M2-like phenotype and educated macrophages activate Nrf2 of the cancer cells to promote EMT of cancer cells. This study provides a new understanding of the role of Nrf2 in the cancer cell and TAM interaction and suggests a potential therapeutic target. (キーワード) Cell Communication / Cell Movement / Cell Transformation, Neoplastic / Epithelial-Mesenchymal Transition / Gene Expression Regulation, Neoplastic / Hep G2 Cells / Humans / Lactic Acid / Macrophages / NF-E2-Related Factor 2 / Phenotype / Reactive Oxygen Species / Vascular Endothelial Growth Factor A (徳島大学機関リポジトリ) ● Metadata: 114549 (出版サイトへのリンク) ● Publication site (DOI): 10.1186/s12964-018-0262-x (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30180849 ● Summary page in Scopus @ Elsevier: 2-s2.0-85053152003 (徳島大学機関リポジトリ: 114549, DOI: 10.1186/s12964-018-0262-x, PubMed: 30180849, Elsevier: Scopus)
21.	齋藤裕, 居村暁, 池本哲也, 森根裕二, 杉本真樹, 島田光生 : 肝癌手術エキスパートへの道 (特集癌手術エキスパートになるための道), 臨床外科, Vol.73, No.9, 1108-1114, 2018年. (キーワード) 和文論文 (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1390845702315677568 (CiNii: 1390845702315677568)
22.	齋藤裕, 山田眞一郎, 岩橋衆一, 池本哲也, 居村暁, 森根裕二, 島田光生 : 胆道再建を含む肝切除術 (ビギナーズ特集手術で臓器が「どうなる?」から術後ケアが見える! わかる! イラスト理解消化器外科の術式・術後ケア), 消化器外科Nursing, Vol.23, No.8, 709-714, 2018年. (キーワード) 和文論文 (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1521980703420258944 (CiNii: 1521980703420258944)
23.	Rui Feng, Yuji Morine, Tetsuya Ikemoto, Satoru Imura, Shuichi Iwahashi, Yu Saitou and Mitsuo Shimada : Nab-paclitaxel interrupts cancer-stromal interaction through C-X-C motif chemokine 10-mediated interleukin-6 downregulation in vitro., Cancer Science, Vol.109, No.8, 2509-2519, 2018. (要約) Cancer-associated fibroblasts (CAF), derived from stroma of cancer tissues, interact with cancer cells and play an important role in cancer initiation, growth, and metastasis. Nab-paclitaxel (nab-PTX) is a 130 nm albumin-binding paclitaxel and recommended for many types of cancer chemotherapy. The nab-PTX stromal-disrupting effect during pancreatic cancer treatment has been reported. The aim of the present study was to determine the role of nab-PTX in cancer cells and CAF interaction. Cancer cells (MIA PaCa-2 and Panc-1) were cocultured with CAF or treated with CAF conditioned medium, after which their migration and invasion ability, epithelial-mesenchymal transition (EMT)-related marker expression and C-X-C motif chemokine 10 (CXCL10) expression and secretion were detected. Nab-PTX treatment was carried out during the coculture system or during preparation of CAF conditioned medium. Then cancer cell migration and invasion ability, EMT-related marker expression, CXCL10 expression and secretion, and interleukin-6 (IL-6) expression and secretion by CAF were checked After coculture with CAF, migration and invasion ability of cancer cells increased. CAF also downregulated E-cadherin and upregulated N-cadherin and vimentin expression in cancer cells. During coculture or stimulation with cancer cell-cultured medium, CAF significantly increased IL-6 expression and secretion. However, nab-PTX in the coculture system canceled CAF-induced migration and invasion promotion and EMT-related gene changes. Moreover, nab-PTX increased CXCL10 expression of cancer cells which blocked CAF IL-6 expression and secretion. Nab-PTX treatment could increase CXCL10 expression of cancer cells which blocks CAF cancer cell migration and invasion-promoting effect by inhibiting IL-6 expression. (キーワード) Albumins / Biomarkers, Tumor / Cadherins / Cell Line, Tumor / Cell Movement / Cell Proliferation / Chemokine CXCL10 / Coculture Techniques / Down-Regulation / Epithelial-Mesenchymal Transition / Fibroblasts / Humans / Interleukin-10 / Interleukin-6 / Neoplasm Invasiveness / Paclitaxel / Pancreatic Neoplasms / Up-Regulation / Vimentin (徳島大学機関リポジトリ) ● Metadata: 112899 (出版サイトへのリンク) ● Publication site (DOI): 10.1111/cas.13694 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29902349 ● Summary page in Scopus @ Elsevier: 2-s2.0-85050858344 (徳島大学機関リポジトリ: 112899, DOI: 10.1111/cas.13694, PubMed: 29902349, Elsevier: Scopus)
24.	Yu Saitou, Shin-ichiro Yamada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi and Mitsuo Shimada : A learning curve for laparoscopic liver resection: an effective training system and standardization of technique., Translational Gastroenterology and Hepatology, Vol.3, 45, 2018. (要約) The incidence of laparoscopic liver resection (LHx) has been increased in the past decade. There have been some reports about some advantages of LHx, in both short and long-term outcomes after operation. The use of a minor LHx was regarded as a standard surgical practice, and some peri-operative complications hindered worldwide increase of LHx in the Second International Consensus Conference on LHx at Morioka. However, no suggestions were described in terms with how to provide the best teaching and training necessary to shorten the learning curve for inexperienced surgeons using a new surgical technique while continuing to maintain a low rate of morbidity from the very beginning. This study includes a literature review of published research which looked at a learning curve for LHx. As well, it proposes a new step-wise training method for inexperienced surgeons and standardization of a technique for LHx focusing especially on laparoscopic left hepatectomy (LLHx). (キーワード) 欧文論文 (出版サイトへのリンク) ● Publication site (DOI): 10.21037/tgh.2018.07.03 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30148230 ● Summary page in Scopus @ Elsevier: 2-s2.0-85052017722 (DOI: 10.21037/tgh.2018.07.03, PubMed: 30148230, Elsevier: Scopus)
25.	Youichiro Kawashita, Yuji Morine, Yu Saitou, Chie Takasu, Tetsuya Ikemoto, Shuichi Iwahashi, Hiroki Teraoku, Masato Yoshikawa, Satoru Imura, Toshiyuki Yagi and Mitsuo Shimada : Role of heat shock factor 1 expression in the microenvironment of intrahepatic cholangiocarcinomas., Journal of Gastroenterology and Hepatology, Vol.33, No.7, 1407-1412, 2018. (要約) Heat shock factor 1 (HSF1), a master regulator of heat shock response, has been shown to play a multifaceted role in cancer progression. However, the clinical significance and biological effect of HSF1 expression in intrahepatic cholangiocarcinoma (IHCC) remain unknown. Forty-nine patients with IHCC who underwent hepatic resection were enrolled in this study. HSF1 expression in tumor tissue was determined by immunohistochemistry, and patients were divided into two groups, those with high (n = 20) and low (n = 29) HSF1 expression. Clinicopathological factors including prognosis were compared in these two groups. HSF1 expression was significantly higher in tumors than in normal tissue. The overall survival rate was significantly lower in patients with high than low HSF1. Multivariate analysis showed that high HSF1 expression was a factor independently prognostic of patient survival. High HSF1 expression in tumor tissues may be a prognostic biomarker in patients with IHCC. (キーワード) Adult / Aged / Aged, 80 and over / Bile Duct Neoplasms / Cell Line, Tumor / Cholangiocarcinoma / Disease Progression / Female / Gene Expression / Heat Shock Transcription Factors / Humans / Immunohistochemistry / Male / Middle Aged / Multivariate Analysis / Prognosis / Survival Rate / Tumor Microenvironment (出版サイトへのリンク) ● Publication site (DOI): 10.1111/jgh.14078 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29278438 ● Summary page in Scopus @ Elsevier: 2-s2.0-85043330492 (DOI: 10.1111/jgh.14078, PubMed: 29278438, Elsevier: Scopus)
26.	Tetsuya Ikemoto, Rui Feng, Mitsuo Shimada, Yu Saitou, Shuichi Iwahashi, Yuji Morine and Satoru Imura : A new 2-step acceleration protocol using a histone deacetylase inhibitor to generate insulin-producing cells from adipose-derived mesenchymal stem cells, Pancreas, Vol.47, No.4, 477-481, 2018. (要約) We aimed to develop a simple protocol for deriving insulin-producing cells (IPCs) from adipose-derived mesenchymal stem cells (ADSCs). We established a 2-step creation method and an acceleration strategy with a histone deacetylase inhibitor that promoted a pro-endocrine pancreatic lineage. We seeded ADSCs in 96-well dishes and cultured in Dulbecco's modified Eagle's medium/F12 medium containing 1% fetal bovine serum, 1% B27 supplement, 1% N2 supplement, 50-ng/mL human activin A, and 10-nM exendin-4 for step 1 of differentiation (7 days). Then 10-mM nicotinamide and 50-ng/mL human hepatocyte growth factor, with or without 1 mM histone deacetylase inhibitor, were added for step 2 of differentiation (14 days). After the 2-step differentiation was complete, cell morphology, immunohistochemistry, messenger RNA expression, and function were investigated. Our new differentiation protocol with the histone deacetylase inhibitor significantly accelerated IPC differentiation compared with the conventional protocol without the histone deacetylase inhibitor (median, 21.6 vs 38.8 days; P < 0.05). It also improved the islet morphology score (P < 0.05) and the glucose stimulation index (3.1). By applying our new and easy 2-step protocol using a histone deacetylase inhibitor, ADSCs may be an effective cell source for differentiation of IPCs. (キーワード) Adipose Tissue / Cell Culture Techniques / Cell Differentiation / Cells, Cultured / Culture Media / Histone Deacetylase Inhibitors / Humans / Insulin / Insulin-Secreting Cells / Mesenchymal Stem Cells / Time Factors (出版サイトへのリンク) ● Publication site (DOI): 10.1097/MPA.0000000000001017 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29517636 ● Summary page in Scopus @ Elsevier: 2-s2.0-85044238547 (DOI: 10.1097/MPA.0000000000001017, PubMed: 29517636, Elsevier: Scopus)
27.	Satoru Imura, Hiroki Teraoku, Masato Yoshikawa, Daichi Ishikawa, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Potential predictive factors for microvascular invasion in hepatocellular carcinoma classified within the Milan criteria., International Journal of Clinical Oncology, Vol.23, No.1, 98-103, 2018. (要約) Microvascular invasion (mvi) is an important risk factor for recurrent hepatocellular carcinoma (HCC), even after curative liver resection or orthotopic liver transplantation. However, mvi is difficult to detect preoperatively. The aim of this study was to clarify the risk factors of postoperative recurrence and investigate predictive factors of mvi before hepatectomy for HCC classified within the Milan criteria. One hundred fifty-nine patients with hepatocellular carcinoma (HCC) classified within the Milan criteria, who underwent hepatectomy, were enrolled in this study. We investigated the risk factors of recurrence. In addition, we divided them into two groups: mvi-negative group and mvi-positive group, based on pathological findings after surgery. We compared the clinicopathological factors between the two groups and determined the risk factors for mvi. Overall survival rate at 1, 3, and 5 years were 91.6%, 80.5%, and 74.9%, and the recurrence-free survival rate at 1, 3, and 5-years were 72.3%, 51.6%, and 37.2%. Risk factor analysis for tumor recurrence revealed that total bilirubin, albumin, ICGR15, AFP-L3, tumor number, mvi, and tumor stage had a significant predictive value. Multivariate analysis revealed that tumor number and mvi were significant independent risk factors for tumor recurrence. Predictive analysis for risk factors of mvi revealed that multiple tumors and AFP-L3 > 10% were significant independent risk factors for mvi in HCC classified within the Milan criteria. The mvi was one of the independent risk factors for tumor recurrence in HCC classified within the Milan criteria. Multiple tumors and high AFP-L3 value were independent predictive factors for mvi. (キーワード) Aged / Bilirubin / Carcinoma, Hepatocellular / Disease-Free Survival / Female / Hepatectomy / Humans / Liver Neoplasms / Male / Middle Aged / Multivariate Analysis / Neoplasm Recurrence, Local / Retrospective Studies / Risk Factors / Survival Rate (出版サイトへのリンク) ● Publication site (DOI): 10.1007/s10147-017-1189-8 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28875240 ● Summary page in Scopus @ Elsevier: 2-s2.0-85028981662 (DOI: 10.1007/s10147-017-1189-8, PubMed: 28875240, Elsevier: Scopus)
28.	Toshiaki Yoshimoto, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Chie Takasu, Daichi Ishikawa, Hiroki Teraoku, Yoshimi Bando and Mitsuo Shimada : The Outcome of Sorafenib Therapy on Unresectable Hepatocellular Carcinoma: Experience of Conversion and Salvage Hepatectomy., Anticancer Research, Vol.38, No.1, 501-507, 2018. (要約) We report the outcomes of sorafenib therapy for advanced hepatocellular carcinoma (HCC) in our Department. Thirty-eight patients with unresectable HCC who were administrated sorafenib from 2009 to 2015 were investigated retrospectively. The 1-year overall survival rate was 59.3%. The macroscopic vascular invasion and response rate were independent prognostic factors of survival. Surgical resection after sorafenib achieved long-term survival in two cases. Case 1: A patient with locally unresectable HCC showed significant response induced by sorafenib, which allowed complete surgical resection. This tumor tested positive for FGF4. Case 2: A patient with a history of hepatectomy for HCC had multiple distant metastases. Most lesions were reduced in size after sorafenib therapy and new lesions in the remnant liver and residual lung metastases were resected. The sorafenib-resistant lesions were negative for FGF4. Sorafenib combined with surgical resection is a feasible option in advanced HCC patients, if sorafenib has been effective. (キーワード) Adult / Aged / Aged, 80 and over / Antineoplastic Agents / Carcinoma, Hepatocellular / Combined Modality Therapy / Female / Fibroblast Growth Factor 4 / Hepatectomy / Hepatitis B / Humans / Liver Neoplasms / Male / Middle Aged / Niacinamide / Phenylurea Compounds / Retrospective Studies / Salvage Therapy / Sorafenib / Survival Rate (出版サイトへのリンク) ● Publication site (DOI): 10.21873/anticanres.12250 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29277815 ● Summary page in Scopus @ Elsevier: 2-s2.0-85039796842 (DOI: 10.21873/anticanres.12250, PubMed: 29277815, Elsevier: Scopus)
29.	Sonoko Yasui, Yumiko Shirai, Mayu Tanimura, Sayaka Matsuura, Yu Saitou, Kazuaki Miyata, Eiji Ishikawa, Chikao Miki and Yasuhiro Hamada : Prevalence of protein-energy wasting (PEW) and evaluation of diagnostic criteria and etiology in Japanese maintenance hemodialysis patients, Asia Pacific Journal of Clinical Nutrition, Vol.25, No.2, 292-299, 2016. (徳島大学機関リポジトリ) ● Metadata: 113992 (出版サイトへのリンク) ● Publication site (DOI): 10.6133/apjcn.2016.25.2.10 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27222412 ● Search Scopus @ Elsevier (PMID): 27222412 ● Search Scopus @ Elsevier (DOI): 10.6133/apjcn.2016.25.2.10 (徳島大学機関リポジトリ: 113992, DOI: 10.6133/apjcn.2016.25.2.10, PubMed: 27222412)
30.	Chinbold Enkhbold, Yuji Morine, Tohru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shinichiro Yamada, Daichi Ishikawa and Mitsuo Shimada : Dysfunction of liver regeneration in aged liver after partial hepatectomy., Journal of Gastroenterology and Hepatology, Vol.30, No.7, 1217-1224, 2015. (要約) A remarkable feature of the liver is its regenerative capacity following partial hepatectomy. However, the regenerative capacity of many organs and tissues loses its natural ability to divide with aging. In this study, we investigated the association of aging with endoplasmic reticulum stress, the cell cycle, autophagy, and apoptosis-related genes during liver regeneration after hepatectomy. Balb/c 4-week and 40-week-old male mice were subjected to 70% hepatectomy. Animals were sacrificed at 24, 48, and 72 h after hepatectomy. Immunohistochemical stainings for proliferating cell nuclear antigen, LC3, Atg5, and caspase-3 were used to quantify protein expression. Real-time reverse transcription-polymerase chain reaction was used to detect p16, CHOP, LC3, Atg5, hepatocyte growth factor, cMet, cyclin D1, cyclin A2, and caspase-3 expression. After hepatectomy, old group showed a lower survival rate and significantly lower expression of hepatocyte growth factor, cMet, cyclin D1, cyclin A2, proliferating cell nuclear antigen labeling index, and SMP30 compared with young group. The liver weight/body weight ratio was significantly lower at 48 h and 72 h after hepatectomy and was accompanied by markedly elevated levels of the liver cell injury markers, LC3 and caspase-3. Immunohistochemical results showed that LC3, Atg5, and caspase-3 protein expression were higher in old group than in young group. These results revealed that impaired liver regeneration was due to aging, which was expressed by decreased cell cycle and increased autophagy and apoptosis. Therefore, understanding the molecular basis for aged liver regeneration might provide a new therapeutic option for old patients. (キーワード) 欧文論文 (出版サイトへのリンク) ● Publication site (DOI): 10.1111/jgh.12930 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25682855 ● Search Scopus @ Elsevier (PMID): 25682855 ● Search Scopus @ Elsevier (DOI): 10.1111/jgh.12930 (DOI: 10.1111/jgh.12930, PubMed: 25682855)
31.	Tetsuya Ikemoto, Koji Sugimoto, Mitsuo Shimada, Tohru Utsunomiya, Yuji Morine, Satoru Imura, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou and Shinichiro Yamada : Clinical role of Notch signaling pathway in intraductal papillary mucinous neoplasm of the pancreas., Journal of Gastroenterology and Hepatology, Vol.30, No.1, 217-222, 2015. (要約) This study was performed to elucidate the expression of the Notch signaling pathway and its correlations to clinicopathological factors of intraductal papillary mucinous neoplasms (IPMNs). It is incontrovertible that regulatory T cells (Tregs) play an important role in tumor immunity. However, the whole mechanism of control of peripheral Tregs remains unclear. It is also known that the Notch signaling pathway is involved in Treg suppressor function. Moreover, IPMNs have a high malignant potential. Peripheral blood samples and resected specimens from 18 patients with IPMN were evaluated. All patients were pathologically diagnosed with IPMN. Resected specimens were immunohistochemically evaluated (anti-Notch1, anti-Notch2, and anti-Notch2-intracellular domain antibody staining) and compared in terms of clinicopathological factors. Peripheral Treg populations were analyzed with an automated flow cytometer. Disease-free survival was significantly worse in the Notch1 high-expression group (P = 0.023). Notch2 family expressions were higher in intraductal papillary mucinous carcinoma (IPMC) than in intraductal papillary mucinous adenoma (IPMA) (Notch2, P = 0.012; Notch2-intracellular domain, P = 0.036). Jagged1 expression was significantly higher in IPMC than in IPMA (P < 0.05) and was significantly related to recurrence. The Treg population in peripheral blood was higher in patients with IPMC than in those with IPMA (P < 0.01). Notch signaling, especially Jagged1 expression, reflects IPMN aggressiveness. Our data may suggest that the Notch signaling pathway is a key pathway that determines IPMN pathological aggressiveness and reflects the peripheral Treg population. (キーワード) Adenocarcinoma, Mucinous / Aged / Calcium-Binding Proteins / Carcinoma, Pancreatic Ductal / Carcinoma, Papillary / Female / Gene Expression Regulation, Neoplastic / Humans / Intercellular Signaling Peptides and Proteins / Male / Membrane Proteins / Middle Aged / Pancreatic Neoplasms / Receptor, Notch1 / Receptor, Notch2 / Signal Transduction / 欧文論文 (出版サイトへのリンク) ● Publication site (DOI): 10.1111/jgh.12660 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25041344 ● Search Scopus @ Elsevier (PMID): 25041344 ● Search Scopus @ Elsevier (DOI): 10.1111/jgh.12660 (DOI: 10.1111/jgh.12660, PubMed: 25041344)
32.	Michihito Asanoma, Hiroki Mori, Tetsuya Ikemoto, Toru Utsunomiya, Satoru Imura, Yuji Morine, Jun Hanaoka, Mami Kanamoto, Yu Saitou, Shinichiro Yamada and Mitsuo Shimada : Clinical role of Foxp3+ regulatory T cell in Living donor related liver transplantation for prediction of life-threatening complications., The Journal of Medical Investigation : JMI, Vol.62, No.1-2, 37-40, 2015. (要約) It is no doubt that regulatory T cells (Foxp3(+)CD4(+)CD25(+)T cells: Treg) play important roles in transplant immunity. We investigated the significance of Treg expression in acute stage of living donorrelated liver transplantation (LDLT) for the possibility of the sensitive marker for immunological state and homeostatic stress after liver transplantation. Peripheral blood was drawn from 5 recipients of LDLT preoperatively and on post operative 1, 4, 7, and 14 days. The peripheral blood mononuclear cells (PBMCs) were stained with CD4, CD25, Foxp3, and were analyzed with FACScan. This data was compared with clinical output of LDLT. The populations of Treg were significantly decreased in all patients on day 1 after LDLT and significantly increased in patients who had early postoperative complications compared with patients who had no complications. The population of Treg in peripheral blood may reflect the surgical stress such as life-threatening complications after LDLT. (キーワード) 欧文論文 (徳島大学機関リポジトリ) ● Metadata: 111243 (出版サイトへのリンク) ● Publication site (DOI): 10.2152/jmi.62.37 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25817281 ● Summary page in Scopus @ Elsevier: 2-s2.0-84925882618 (徳島大学機関リポジトリ: 111243, DOI: 10.2152/jmi.62.37, PubMed: 25817281, Elsevier: Scopus)
33.	Yu Saitou, Hiroki Mori, Chie Takasu, Masato Komatsu, Jun Hanaoka, Shin-ichiro Yamada, 淺野間理仁, Tetsuya Ikemoto, Satoru Imura, Yuji Morine, Toru Utsunomiya and Mitsuo Shimada : Beneficial effects of green tea catechin on massive hepatectomy model in rats., Journal of Gastroenterology, 2013. (要約) BACKGROUND: Green tea catechin, especially epigallocatechin gallate (EGCG), is a well-known scavenger of reactive oxygen species and it may also function as an antioxidant through modulation of transcriptional factors and enzyme activities. METHODS: Green tea extract (GTE(®)) which contained numerous EGCG was used. Wistar rats were performed 90 % hepatectomy and classified into 2 groups with (GTEHx, n = 25) or without GTE treatment (Hx, n = 25) and sacrificed at 1, 3, 7 and 14 days after operations. All rats had free access to drinking water supplemented with or without GTE from the 7th pre-operative day. Liver regeneration, hepatic inducible nitric oxide synthase (iNOS), anti-oxidative enzymes [superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px)] and inflammatory markers [cyclooxygenase-2 (COX-2), nuclear factor kappa B (NFκB), tumor necrosis factor-α (TNF-α)] were investigated. RESULTS: The liver weight to body weight ratio (p < 0.01), proliferating cell nuclear antigen labeling index (p < 0.05) and phosphorylated extracellular signal-regulated kinase 1/2 (p < 0.05) at day 1 in the GTEHx group significantly increased compared to the Hx group. Hepatic iNOS levels at day 1 significantly decreased (p < 0.01) in the GTEHx group. Hepatic SOD, CAT and GSH-Px levels at day 1 significantly increased (SOD: p < 0.01, CAT and GSH-Px: p < 0.05) in the GTEHx group. In contrast, COX-2, NFκB and TNF-α levels at day 1 significantly decreased (COX-2: p < 0.01, NFκB and TNF-α: p < 0.05) in the GTEHx group. CONCLUSIONS: GTE pretreatment stimulated liver regeneration and improved liver damage after massive hepatectomy through anti-oxidative and anti-inflammatory effects. Green tea catechin might have the potential to attenuate liver dysfunction in early stage after massive hepatectomy. (キーワード) 欧文論文 (出版サイトへのリンク) ● Publication site (DOI): 10.1007/s00535-013-0799-9 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23543313 ● Summary page in Scopus @ Elsevier: 2-s2.0-84899985774 (DOI: 10.1007/s00535-013-0799-9, PubMed: 23543313, Elsevier: Scopus)
34.	Jun Hanaoka, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Koji Sugimoto, Yu Saitou, Shinichiro Yamada and Michihito Asanoma : Beneficial effects of enteral nutrition containing with hydrolyzed whey peptide on warm ischemia/reperfusion injury in the rat liver., Hepatology Research, Vol.44, No.1, 114-121, 2013. (要約) This study examined the efficacy of enteral nutrition containing hydrolyzed whey peptide (HWP) on warm ischemia/reperfusion (I/R) injury in the rat liver. Male Wistar rats were subjected to 30 min of warm hepatic ischemia followed by immediate p.o. intake of enteral nutrition with WHP (HWP group) or 20% glucose solution (control group) (0.025 mL/g). The animals were killed at 6 or 12 h after reperfusion. The serum aspartate aminotransferase (AST) and alanine aminotransferase alt (ALT) levels were measured. The necrotic areas were assessed histologically. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining and caspase-3 activation were assessed to evaluate apoptosis. The expressions of hepatic tumor necrosis factor (TNF)-α, interleukin (IL)-6 and nuclear factor (NF)-κB in the liver tissue were assessed by real time reverse transcription polymerase chain reaction. Significant reductions in the serum AST and ALT levels were seen in the HWP group compared with the control group at both 6 and 12 h after reperfusion. The necrotic areas and numbers of TUNEL positive cells were significantly decreased in the HWP group at 6 and 12 h after reperfusion. The caspase-3/7 activities were significantly decreased in HWP group at 6 and 12 h after reperfusion. The mRNA expressions of TNF-α and IL-6 were significantly reduced in the HWP group at 12 h after reperfusion. NF-κB mRNA expression was significantly increased in the HWP group at 6 and 12 h after reperfusion. Enteral nutrition containing HWP ameliorated the hepatic warm I/R injury possibly through the suppression of pro-inflammatory cytokine expressions and the induction of NF-κB in the rat liver. (キーワード) 欧文論文 (出版サイトへのリンク) ● Publication site (DOI): 10.1111/hepr.12097 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23578099 ● Summary page in Scopus @ Elsevier: 2-s2.0-84891758377 (DOI: 10.1111/hepr.12097, PubMed: 23578099, Elsevier: Scopus)
35.	宇都宮徹, 島田光生, 居村暁, 森根裕二, 池本哲也, 花岡潤, 森大樹, 金本真美, 岩橋衆一, 齋藤裕, 三宅秀則 : 【内視鏡外科手術をめぐる最近のトピックス】新たな領域への手術適応保険収載後の腹腔鏡下肝切除術の展開, 消化器外科, Vol.34, No.1, 69-77, 2011年. (キーワード) 質問紙法; 医療保険; 肝細胞癌(外科的療法); 肝切除(有害作用); 空気塞栓症(病因); 術後合併症; 胆管癌(外科的療法); 胆管腫瘍(外科的療法); 腹腔鏡法(有害作用); 失血-外科; 近代医学史 / ヒト / 和文論文
36.	池本哲也, 島田光生, 岩橋衆一, 川田祐子, 齋藤裕, 花岡潤, 森大樹, 居村暁, 森根裕二, 宇都宮徹 : 乳癌が併存するレシピエント，高度脂肪肝ドナーという組み合わせに施行した生体肝移植., 臨床と研究, Vol.87, No.9, 1280-1281, 2010年. (キーワード) 和文論文

学術論文(紀要・その他):

1.	Shuhai Chen, Yu Saitou, Yuhei Waki, Tetsuya Ikemoto, Hiroki Teraoku, Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : Generation of Highly Functional Hepatocyte-like Organoids from Human Adipose-Derived Mesenchymal Stem Cells Cultured with Endothelial Cells., Cells, Vol.13, No.6, 2024. (要約) Previously, we successfully established a highly functional, three-dimensional hepatocyte-like cell (3D-HLC) model from adipose-derived mesenchymal stem cells (ADSCs) via a three-step differentiation protocol. The aim of the present study was to investigate whether generating hepatocyte-like organoids (H-organoids) by adding endothelial cells further improved the liver-like functionality of 3D-HLCs and to assess H-organoids' immunogenicity properties. Genes representing liver maturation and function were detected by quantitative reverse transcription-PCR analysis. The expression of hepatic maturation proteins was measured using immunofluorescence staining. Cytochrome P (CYP)450 metabolism activity and ammonia metabolism tests were used to assess liver function. H-organoids were successfully established by adding human umbilical vein endothelial cells at the beginning of the definitive endoderm stage in our 3D differentiation protocol. The gene expression of alpha-1 antitrypsin, carbamoyl-phosphate synthase 1, and apolipoprotein E, which represent liver maturation state and function, was higher in H-organoids than non-organoid 3D-HLCs. H-organoids possessed higher CYP3A4 metabolism activity and comparable ammonia metabolism capacity than 3D-HLCs. Moreover, although H-organoids expressed human leukocyte antigen class I, they expressed little human leukocyte antigen class II, cluster of differentiation (CD)40, CD80, CD86, and programmed cell death ligand 1, suggesting their immunogenicity properties were not significantly upregulated during differentiation from ADSCs. In conclusion, we successfully established an H-organoid model with higher liver-like functionality than previously established 3D-HLCs and comparable immunogenicity to ADSCs. (キーワード) Humans / Ammonia / Hepatocytes / Human Umbilical Vein Endothelial Cells / Mesenchymal Stem Cells / Organoids / HLA Antigens (出版サイトへのリンク) ● Publication site (DOI): 10.3390/cells13060547 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38534391 ● Search Scopus @ Elsevier (PMID): 38534391 ● Search Scopus @ Elsevier (DOI): 10.3390/cells13060547 (DOI: 10.3390/cells13060547, PubMed: 38534391)
2.	Yuhei Waki, Yuji Morine, Takayuki Noma, Chie Takasu, Hiroki Teraoku, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto and Mitsuo Shimada : Association between high expression of intratumoral fibroblast activation protein and survival in patients with intrahepatic cholangiocarcinoma., BMC Gastroenterology, Vol.23, No.1, 415, 2023. (要約) Cancer-associated fibroblasts (CAFs) have been reported to exhibit protumorigenic effects. Among the well-known CAF markers such as smooth muscle actin (SMA) and fibroblast activation protein (FAP), high expression of SMA in the peritumoral stroma has been reported to be a prognostic factor in various cancers. However, the effect of high FAP expression in intrahepatic cholangiocarcinoma (IHCC) has not been fully clarified. We evaluated the expression of CAF markers, focusing on FAP expression in the peripheral and intratumoral regions, to clarify the association with survival in patients with IHCC. The study cohort comprised 37 patients who underwent curative resection for IHCC. The FAP expressions were evaluated in the peripheral and intratumoral regions of the resected tissues. Clinicopathological factors and survival outcomes were investigated between patients with high versus low FAP expression. Uni- and multivariate analyses were performed to identify the prognostic factors for overall survival and relapse-free survival. The median area percentages of FAP expression in the peripheral and intratumoral regions were 15.5% and 17.8%, respectively. High FAP expression in the intratumoral region was significantly associated with worse overall survival and disease-free survival than low FAP expression in the intratumoral region. Multivariate analysis identified high intratumoral FAP expression as a risk factor for worse overall survival (hazard ratio, 2.450; p = 0.049) and relapse-free survival (hazard ratio, 2.743; p = 0.034). High intratumoral FAP expression was associated with worse survival, suggesting that intratumoral FAP expression represents malignant progression in patients with IHCC. (キーワード) Humans / Neoplasm Recurrence, Local / Cholangiocarcinoma / Cancer-Associated Fibroblasts / Bile Ducts, Intrahepatic / Bile Duct Neoplasms / Prognosis (徳島大学機関リポジトリ) ● Metadata: 119225 (出版サイトへのリンク) ● Publication site (DOI): 10.1186/s12876-023-03012-x (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38017374 ● Search Scopus @ Elsevier (PMID): 38017374 ● Search Scopus @ Elsevier (DOI): 10.1186/s12876-023-03012-x (徳島大学機関リポジトリ: 119225, DOI: 10.1186/s12876-023-03012-x, PubMed: 38017374)
3.	Yuhei Waki, Yu Saitou, Shuhai Chen, Tetsuya Ikemoto, Takayuki Noma, Hiroki Teraoku, Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : Effects of green light-emitting diode irradiation on hepatic differentiation of hepatocyte-like cells generated from human adipose-derived mesenchymal cells., Scientific Reports, Vol.13, No.1, 19954, 2023. (要約) Light-emitting diode (LED) irradiation has been used in the differentiation of mesenchymal stem cells into a variety of cell types. This study investigated the effect of green LED (GLED) irradiation on the differentiation of adipocyte-derived mesenchymal cells into hepatocyte-like cells (HLCs) and the mechanism of its action. HLCs in the hepatocyte maturation phase were irradiated with GLED (520 nm, 21 W/m, 5 min/day for 10 days). The cells were then assessed for expression of hepatocyte maturity genes and opsin 3 (OPN3), hepatocyte function, viability, apoptosis, and levels of reactive oxygen species (ROS), intracellular adenosine triphosphate (ATP) and calcium ions (Ca). GLED irradiation increased Alpha-1 antitrypsin and Ornithine transcarbamylase gene expression, promoted Cytochrome P450 3A4 activity and urea synthesis, and elevated intracellular ROS, ATP and Ca levels. OPN3 expression was significantly more upregulated in GLED-irradiated HLCs than in the non-irradiated HLCs. No significant difference in cell viability or apoptosis was observed between GLED-irradiated and non-irradiated HLCs. GLED irradiation can promote hepatocyte maturation and functions through OPN3. GLED irradiation also stimulated mitochondrial function via Ca/ATP/ROS activation. GLED irradiation has potential to support cell-based transplantation in patients. (キーワード) Humans / Reactive Oxygen Species / Hepatocytes / Cell Differentiation / Adipocytes / Adenosine Triphosphate / Rod Opsins (徳島大学機関リポジトリ) ● Metadata: 119238 (出版サイトへのリンク) ● Publication site (DOI): 10.1038/s41598-023-45967-7 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37968291 ● Search Scopus @ Elsevier (PMID): 37968291 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-023-45967-7 (徳島大学機関リポジトリ: 119238, DOI: 10.1038/s41598-023-45967-7, PubMed: 37968291)
4.	Yu Saitou, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Hiroki Teraoku, Sonoko Yasui-Yamada, Maki Nishi, Hiroshi Sakaue, Motomu Kamada, Tetsuya Matsuura and Mitsuo Shimada : Preoperative Weight Loss Program for Hepatocellular Carcinoma Patients with High Body Mass Index in Hepatectomy., World Journal of Surgery, Vol.47, No.12, 3348-3355, 2023. (要約) This study aimed to investigate the usefulness of a weight-loss program (WLP) in patients with a high body mass index (BMI) prior to liver resection (Hx) for hepatocellular carcinoma (HCC). Among 445 patients with HCC who underwent initial Hx between 2000 and 2020, 19 with a high BMI (≥25.0) were enrolled in our WLP since 2014. For calorie restriction, the amount of energy consumed was calculated as the standard body weight (SBW) kg × 20-25 kcal/day. Protein mass was calculated as SBW kg × 1.0-1.2 g/day to maintain skeletal muscle mass. Patients also performed both aerobic and resistance exercises. The before-and-after changes were compared, and the effect of WLP on the short- and long-term results was investigated. The average length of WLP was 21 days, and weight loss was successfully achieved in all patients. Body fat mass was reduced during the program, while skeletal muscle mass was maintained. WLP led to improvements in liver function and fibrotic markers, without tumor progression. There were no postoperative complications (≥Clavien-Dindo [CD] III). A retrospective comparison between with and without WLP using propensity score-matching analysis revealed that WLP group showed better NLR value, however, there were no significant differences in both short and long-term outcomes after Hx based on participation in the WLP. WLP with multidisciplinary intervention improved immune-nutrition status and liver function of obese patients. WLP had not affected both short and long-term outcomes after Hx. (キーワード) Humans / Carcinoma, Hepatocellular / Hepatectomy / Liver Neoplasms / Body Mass Index / Weight Reduction Programs / Retrospective Studies / Propensity Score / Treatment Outcome / Laparoscopy (出版サイトへのリンク) ● Publication site (DOI): 10.1007/s00268-023-07220-0 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37840060 ● Search Scopus @ Elsevier (PMID): 37840060 ● Search Scopus @ Elsevier (DOI): 10.1007/s00268-023-07220-0 (DOI: 10.1007/s00268-023-07220-0, PubMed: 37840060)
5.	仲須千春, 山田眞一郎, 寺奥大貴, 齋藤裕, 池本哲也, 森根裕二, 島田光生 : 原因が不明であった肝palisading granulomaの1例, 肝臓, Vol.64, No.10, 504-509, 2023年. (要約) 患者は50代女性.検診の腹部超音波検査で肝S3に16×14mm大の腫瘤を指摘され精査加療目的に当科紹介となった.既往歴・生肉食歴なし.術前の血液検査で異常なく,末梢好酸球も正常.造影CTの動脈・門脈相では辺縁に造影効果を認めるが,平衡相では造影されず,MRI T1強調像で低信号,T2強調像で低∼等信号,拡散強調像でやや高信号であった.PET-CTで肝臓への集積は認めなった.悪性腫瘍の可能性を完全に否定できず,腹腔鏡下肝部分切除を施行した.病理組織学的には腫瘤全体に凝固壊死像が見られ,辺縁に線維増生を伴い,組織球が柵状に配列したpalisading granulomaであった.原因特定のために複数の染色を行ったが,病原体は同定できなかった.palisading granulomaは術前診断が困難であり,診断的治療として腹腔鏡下肝切除術は有用であると考えられた.(著者抄録) (キーワード) 肝切除肝臓疾患(病理学,画像診断,外科的療法) 超音波診断肉芽腫-好酸球性(病理学,画像診断,外科的療法) 腹腔鏡法幼虫移行症-内臓拡散MRI PET-CT検査ヒト中年(45∼64) 女 (出版サイトへのリンク) ● Publication site (DOI): 10.2957/kanzo.64.504 (文献検索サイトへのリンク) ● Search Scopus @ Elsevier (DOI): 10.2957/kanzo.64.504 (DOI: 10.2957/kanzo.64.504)
6.	Kouzou Yoshikawa, Mitsuo Shimada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku and Shoichiro Takao : Clinical impact of myosteatosis measured by magnetic resonance imaging on long-term outcomes of hepatocellular carcinoma after radical hepatectomy., BMC Surgery, Vol.23, No.1, 281, 2023. (要約) A variety of factors have been reported to affect long-term outcomes after radical resection of hepatocellular carcinoma (HCC). However, the indicators remain controversial. The purpose of this study was to evaluate the relationship between myosteatosis of the multifidus muscle and long-term outcomes after radical surgery for HCC. We retrospectively analyzed clinicopathological data for 187 patients with HCC who underwent radical surgery at Tokushima University between January 2009 and December 2020 and measured the density of fat in the multifidus muscle at L3 on their preoperative magnetic resonance images (MRI). Associations of myosteatosis and clinicopathological factors with long-term outcomes were evaluated. The patients were divided into a myosteatosis-negative group (n = 122) and a myosteatosis-positive group (n = 65). The cancer-specific survival rate after hepatectomy was significantly worse in the myosteatosis-positive group than in the myosteatosis-negative group (p = 0.03). Univariate analysis identified multiple tumors, stage III/IV disease, an alfa-fetoprotein level ≥ 10 ng/ml, PIVKA-II ≥ 400 AU/ml, vp(+) status, and myosteatosis to be prognostic factors for cancer-specific survival. Multivariate analysis revealed multiple tumors, an alfa-fetoprotein level ≥ 10 ng/ml, and myosteatosis to be independent prognostic factors. Myosteatosis measured by MRI is a simple and useful predictor of the long-term outcome after radical surgery for HCC. (キーワード) Humans / Carcinoma, Hepatocellular / Hepatectomy / Retrospective Studies / Liver Neoplasms / Magnetic Resonance Imaging / Fetal Proteins (徳島大学機関リポジトリ) ● Metadata: 119226 (出版サイトへのリンク) ● Publication site (DOI): 10.1186/s12893-023-02188-z (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37715229 ● Search Scopus @ Elsevier (PMID): 37715229 ● Search Scopus @ Elsevier (DOI): 10.1186/s12893-023-02188-z (徳島大学機関リポジトリ: 119226, DOI: 10.1186/s12893-023-02188-z, PubMed: 37715229)
7.	Shuhai Chen, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : TU-100 Antagonizes the M2 Polarization Phenotype of Macrophages in the Tumor Microenvironment by Suppressing the TLR4/NF-B/STAT3 Axis., Anticancer Research, Vol.43, No.5, 1985-1992, 2023. (要約) Macrophages are the most abundant immune cells in the tumor stroma, and their polarization states within the tumor microenvironment (TME) exert critical roles in tumorigenesis. TU-100 (Daikenchuto) is a commonly prescribed Japanese herbal medicine that has shown anti-cancer effects by regulating cancer-associated fibroblasts (CAFs) in the TME. However, its effects on tumor-associated macrophages (TAMs) remain unclear. TAMs were generated by macrophage exposure to tumor-conditioned medium (CM), and their polarization states were evaluated after TU-100 treatment. The underlying mechanism was further studied. TU-100 exhibited little cytotoxicity over a range of doses in M0 macrophages and TAMs. However, it could antagonize the M2-like polarization of macrophages evoked by tumor-CM exposure. These effects might be caused by the inhibition of TLR4/NF-B/STAT3 signaling in the M2-like phenotype of macrophages. Interestingly, TU-100 antagonized the malignancy promoting effects of M2 macrophages on hepatocellular carcinoma cell lines in vitro. Mechanistically, the administration of TU-100 restrained the high expression of MMP-2, COX-2, and VEGF in TAMs. TU-100 may alleviate the progression of cancer by regulating the M2 polarization of macrophages within the TME, suggesting a viable therapeutic approach. (キーワード) Humans / Cell Line, Tumor / Cell Polarity / Macrophages / Naphthoquinones / NF-kappa B / Signal Transduction / Tumor Microenvironment / Antineoplastic Agents, Phytogenic / Carcinoma, Hepatocellular (出版サイトへのリンク) ● Publication site (DOI): 10.21873/anticanres.16359 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37097685 ● Search Scopus @ Elsevier (PMID): 37097685 ● Search Scopus @ Elsevier (DOI): 10.21873/anticanres.16359 (DOI: 10.21873/anticanres.16359, PubMed: 37097685)
8.	Takuya Tokunaga, Maki Sugimoto, Yu Saitou, Hideya Kashihara, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada, Yuhei Waki, Toshiaki Yoshimoto, Takayuki Noma and Mitsuo Shimada : Transanal lateral lymph node dissection with intraoperative hologram support in low rectal cancer., Surgical Endoscopy, Vol.37, No.7, 5414-5420, 2023. (要約) In Japan, the standard treatment for stage II/III advanced low rectal cancer is total mesorectal excision plus lateral lymph node dissection (LLND). There are also recent reports on the use of transanal LLND. However, the transanal anatomy is difficult to understand, and additional support tools are required to improve the surgical safety. The present study examined the utility of holograms with mixed reality as an intraoperative support tool for assessing the complex pelvic anatomy. Polygon (stereolithography) files of patients' pelvic organs were created and exported from the SYNAPSE VINCENT imaging system and uploaded into the Holoeyes MD virtual reality software. Three-dimensional images were automatically converted into patient-specific holograms. Each hologram was then installed into a head mount display (HoloLens2), and the surgeons and assistants wore the HoloLens2 when they performed transanal LLND. Twelve digestive surgeons with prior practice in hologram manipulation evaluated the utility of the intraoperative hologram support by means of a questionnaire. Intraoperative hologram support improved the surgical understanding of the lateral lymph node region anatomy. In the questionnaire, 75% of the surgeons answered that the hologram accurately reflected the anatomy, and 92% of the surgeons answered that the anatomy was better understood by simulating the hologram intraoperatively than preoperatively. Moreover, 92% of the surgeons agreed that intraoperative holograms were a useful support tool for improving the surgical safety. Intraoperative hologram support improved the surgical understanding of the pelvic anatomy for transanal LLND. Intraoperative holograms may represent a next-generation surgical tool for transanal LLND. (キーワード) Humans / Treatment Outcome / Lymph Node Excision / Lymph Nodes / Rectal Neoplasms / Dissection (出版サイトへのリンク) ● Publication site (DOI): 10.1007/s00464-023-09977-w (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37017769 ● Search Scopus @ Elsevier (PMID): 37017769 ● Search Scopus @ Elsevier (DOI): 10.1007/s00464-023-09977-w (DOI: 10.1007/s00464-023-09977-w, PubMed: 37017769)
9.	野間隆礼, 寺奥大貴, 山田眞一郎, 齋藤裕, 池本哲也, 森根裕二, 島田光生 : 術前に肝細胞癌との鑑別が困難であった筋腫型肝血管筋脂肪腫の1例, 肝臓, Vol.64, No.4, 201-208, 2023年. (要約) 患者は40代女性.検診で肝から突出する15cmの巨大腫瘤を指摘され,精査加療目的に当科紹介となった.既往歴や背景肝に特記事項なく,腫瘍マーカーは正常であったが,造影CTの動脈・門脈相で肝右葉に15cm大の早期濃染と遅延相でwashoutを認めた.EOB-MRI肝細胞相ではdefectとして描出され肝細胞癌が疑われた.破裂の危険性を考慮し,まずTACEを行い,その後拡大肝右葉切除を施行した.病理組織学的には腫瘍の大半が平滑筋様細胞で構成されており,脂肪細胞は認めず,免疫組織化学染色にてVimentin,αSMA,HMB-45,melan Aが陽性であり,Perivascular epithelioid cell tumor(PEComa)として包括される腫瘍群の中の筋腫型の肝血管筋脂肪腫(Angiomyolipoma;AML)と診断した.今回我々は,術前に肝細胞癌との鑑別が困難であった,若年女性に発生した肝原発筋腫型AMLを経験したため報告する.(著者抄録) (キーワード) 肝細胞癌肝切除肝臓腫瘍(画像診断,病理学,外科的療法) 筋腫(画像診断,病理学,外科的療法) 鑑別診断術前評価超音波診断 X線CT 免疫組織化学 *血管筋脂肪腫(画像診断,病理学,外科的療法) 拡散MRI 腹部CT ヒト女 (出版サイトへのリンク) ● Publication site (DOI): 10.2957/kanzo.64.201 (文献検索サイトへのリンク) ● Search Scopus @ Elsevier (DOI): 10.2957/kanzo.64.201 (DOI: 10.2957/kanzo.64.201)
10.	Katsuki Miyazaki, Yuji Morine, Caiming Xu, Chiharu Nakasu, Yuuma Wada, Hiroki Teraoku, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Mitsuo Shimada and Ajay Goel : Curcumin-Mediated Resistance to Lenvatinib via EGFR Signaling Pathway in Hepatocellular Carcinoma., Cells, Vol.12, No.4, 612, 2023. (要約) Lenvatinib is a multi-kinase inhibitor approved as a first-line treatment for patients with unresectable advanced hepatocellular carcinoma (HCC). However, its response rate is unsatisfactory, primarily due to the acquisition of resistance, which limits its clinical significance for treating patients with HCC. Recent evidence suggests that epidermal growth factor receptor (EGFR) activation can trigger Lenvatinib-resistance; and is considered an important therapeutic target in HCC. Curcumin, one of the most studied naturally occurring botanicals with robust anti-cancer activity, is also reported to be a potent tyrosine kinase inhibitor. In this study, we hypothesized that the anti-EGFR potential of Curcumin might help overcome Lenvatinib resistance in HCC. We established two Lenvatinib-resistant cells and discovered that a combination of Curcumin and Lenvatinib exhibited a synergistic anti-tumor efficacy in the resistant HCC cell lines. In line with previous reports, Lenvatinib-resistant cell lines revealed significant activation of the EGFR, and genomewide transcriptomic profiling analysis identified that the PI3K-AKT pathway was associated with Lenvatinib resistance. The combination treatment with Curcumin and Lenvatinib dramatically suppressed gene and protein expression of the EGFR-PI3K-AKT pathway, suggesting Curcumin overcomes Lenvatinib resistance via inhibition of EGFR. We further validated these findings in tumor spheroids derived from resistant cell lines. In conclusion, we, for the first time, report that Curcumin reverses Lenvatinib resistance in HCC, and that their combination has clinical application potential for adjunctive treatment in HCC. (キーワード) Humans / Carcinoma, Hepatocellular / Curcumin / Liver Neoplasms / Proto-Oncogene Proteins c-akt / Phosphatidylinositol 3-Kinases / Cell Line, Tumor / Signal Transduction / Protein Kinase Inhibitors / ErbB Receptors (徳島大学機関リポジトリ) ● Metadata: 118580 (出版サイトへのリンク) ● Publication site (DOI): 10.3390/cells12040612 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36831279 ● Search Scopus @ Elsevier (PMID): 36831279 ● Search Scopus @ Elsevier (DOI): 10.3390/cells12040612 (徳島大学機関リポジトリ: 118580, DOI: 10.3390/cells12040612, PubMed: 36831279)
11.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Yuhei Waki, Takayuki Noma, Tetsuya Ikemoto and Mitsuo Shimada : Multiplication of tumor maximum diameter and number as a new surgical indicator for Barcelona Clinic Liver Cancer intermediate-stage hepatocellular carcinoma., Hepatology Research, Vol.53, No.6, 531-539, 2023. (要約) Recent advances in treatment modalities have been made, limiting the indication of hepatic resection in the treatment strategy for hepatocellular carcinoma (HCC) patients. This retrospective study investigated the significance of multiplication of tumor maximum diameter and number (MDN) as a surgical indicator for Barcelona Clinic Liver Cancer intermediate-stage HCC. A total of 49 patients with Barcelona Clinic Liver Cancer intermediate-stage HCC who underwent curative hepatic resection between 2000 and 2020 were enrolled in this study. Prognostic factors of overall survival and disease-free survival, including the product of MDN, were analyzed. Patients with MDN >12 experienced significantly worse prognosis compared with those with MDN ≤12 (p = 0.0395), and 5-year overall survival rates after hepatic resection were 60.0% and 23.4%, respectively. Furthermore, the disease-free survival rate of patients with MDN >12 was significantly worse compared with those with MDN ≤12 (p = 0.0049), and all patients with MDN >12 experienced recurrence within 3 years after hepatic resection. In the multivariate analysis, MDN >12 was identified as the only independent prognostic factor of both overall survival and disease-free survival. In addition, patients with MDN >12 suffered from uncontrollable recurrence by locoregional treatment, such as more than four intrahepatic and extrahepatic recurrences, after hepatic resection. MDN index might be a new surgical indicator for Barcelona Clinic Liver Cancer intermediate-stage HCC, and influence clinical decision-making for individual treatment strategies. (出版サイトへのリンク) ● Publication site (DOI): 10.1111/hepr.13887 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36755370 ● Search Scopus @ Elsevier (PMID): 36755370 ● Search Scopus @ Elsevier (DOI): 10.1111/hepr.13887 (DOI: 10.1111/hepr.13887, PubMed: 36755370)
12.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, Yuhei Waki, Chiharu Nakasu and Mitsuo Shimada : Impact of apparent diffusion coefficient on prognosis of early hepatocellular carcinoma: a case control study., BMC Surgery, Vol.23, No.1, 6, 2023. (要約) We investigated the usefulness of apparent diffusion coefficients (ADC) from diffusion-weighted images (DWI) obtained using magnetic resonance imaging (MRI) for prognosis of early hepatocellular carcinoma (HCC): Barcelona Clinic Liver Cancer (BCLC) stage 0 and A. We enrolled 102 patients who had undergone surgical resection for early HCC: BCLC stage 0 and A, and calculated their minimum ADC using DWI-MRI. We divided patients into ADC (n = 72) and ADC (n = 30) groups, and compared clinicopathological factors between the two groups. The ADC group showed higher protein induced by vitamin K absence-II (PIVKA-II) levels (p = 0.02) compared with the ADC group. In overall survival, the ADC group showed significantly worse prognosis than the ADC group (p < 0.01). Univariate analysis identified multiple tumors, infiltrative growth, high PIVKA-II, and low ADC value as prognostic factors. Multivariate analysis identified infiltrative growth and low ADC value as an independent prognostic factor. ADC values can be used to estimate the prognosis of early HCC. (キーワード) Humans / Carcinoma, Hepatocellular / Liver Neoplasms / Case-Control Studies / Retrospective Studies / Prognosis (徳島大学機関リポジトリ) ● Metadata: 118558 (出版サイトへのリンク) ● Publication site (DOI): 10.1186/s12893-022-01892-6 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36631851 ● Search Scopus @ Elsevier (PMID): 36631851 ● Search Scopus @ Elsevier (DOI): 10.1186/s12893-022-01892-6 (徳島大学機関リポジトリ: 118558, DOI: 10.1186/s12893-022-01892-6, PubMed: 36631851)
13.	Katsuki Miyazaki, Yuuma Wada, Keisuke Okuno, Tatsuro Murano, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroaki Ikematsu, Yusuke Kinugasa, Mitsuo Shimada and Ajay Goel : An exosome-based liquid biopsy signature for pre-operative identification of lymph node metastasis in patients with pathological high-risk T1 colorectal cancer., Molecular Cancer, Vol.22, No.1, 2, 2023. (要約) According to current guidelines, more than 70% of patients with invasive submucosal colorectal cancer (T1 CRC) undergo a radical operation with lymph node dissection, even though only ~ 10% have lymph node metastasis (LNM). Hence, there is imperative to develop biomarkers that can help robustly identify LNM-positive patients to prevent such overtreatments. Given the emerging interest in exosomal cargo as a source for biomarker development in cancer, we examined the potential of exosomal miRNAs as LNM prediction biomarkers in T1 CRC. We analyzed 200 patients with high-risk T1 CRC from two independent cohorts, including a training (n = 58) and a validation cohort (n = 142). Cell-free and exosomal RNAs from pre-operative serum were extracted, followed by quantitative reverse-transcription polymerase chain reactions for a panel of miRNAs. A panel of four miRNAs (miR-181b, miR-193b, miR-195, and miR-411) exhibited robust ability for detecting LNM in the exosomal vs. cell-free component. We subsequently established a cell-free and exosomal combination signature, successfully validated in two independent clinical cohorts (AUC, 0.84; 95% CI 0.70-0.98). Finally, we developed a risk-stratification model by including key pathological features, which reduced the false positive rates for LNM by 76% without missing any true LNM-positive patients. Our novel exosomal miRNA-based liquid biopsy signature robustly identifies T1 CRC patients at risk of LNM in a preoperative setting. This could be clinically transformative in reducing the significant overtreatment burden of this malignancy. (キーワード) Humans / Lymphatic Metastasis / Exosomes / Colorectal Neoplasms / Biomarkers, Tumor / MicroRNAs / Liquid Biopsy (徳島大学機関リポジトリ) ● Metadata: 118926 (出版サイトへのリンク) ● Publication site (DOI): 10.1186/s12943-022-01685-8 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36609320 ● Search Scopus @ Elsevier (PMID): 36609320 ● Search Scopus @ Elsevier (DOI): 10.1186/s12943-022-01685-8 (徳島大学機関リポジトリ: 118926, DOI: 10.1186/s12943-022-01685-8, PubMed: 36609320)
14.	齋藤裕, 森根裕二, 山田眞一郎, 寺奥大貴, 池本哲也, 島田光生 : Fontan associated liver disease(FALD)関連肝癌に対しての腹腔鏡肝切除の1例 Fontan循環における肝離断対策, 肝臓, Vol.64, No.1, 18-25, 2023年. (要約) 30代男性,3歳時に単心房・単心室症を背景にFontan手術を受けた.Fontan associated liver disease(FALD)として肝臓内科にフォローを開始されて以来3年後にFALD関連肝癌を疑われ,腹腔鏡肝切除を施行した.肝離断中は,Central venous pressure(CVP)圧を下げるため,positive end expiratory pressureをオフし,最小限の輸液量,利尿剤併用しながらの麻酔管理を行うも,Fontan循環の影響でCVPコントロールは不良で,静脈性出血が継続したままの肝離断となった.本症例は,術後合併症なく経過したものの,FALD関連肝癌症例は,Fontan循環による高CVP下での肝離断を余儀なくされるため,そのジレンマを解決する必要があり,その対策に関して考察を加え報告する.(著者抄録) (キーワード) 肝細胞癌(画像診断,病理学,外科的療法) 肝切除肝内胆管(画像診断,病理学,外科的療法) 超音波診断胆管癌(画像診断,病理学,外科的療法) 胆管腫瘍(画像診断,病理学,外科的療法) X線CT 中心静脈圧 *腹腔鏡法免疫組織化学複合腫瘍と混合腫瘍(画像診断,病理学,外科的療法) 超音波外科拡散MRI 腹部CT ヒト成人(19∼44) 男 (出版サイトへのリンク) ● Publication site (DOI): 10.2957/kanzo.64.18 (文献検索サイトへのリンク) ● Search Scopus @ Elsevier (DOI): 10.2957/kanzo.64.18 (DOI: 10.2957/kanzo.64.18)
15.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Yuhei Waki, Shohei Okikawa, Katsuki Miyazaki, Chiharu Nakasu, Takayuki Noma, Akira Takahashi and Mitsuo Shimada : Impact of pancreatic resection in patients with liver cirrhosis., The Journal of Medical Investigation : JMI, Vol.70, No.1.2, 189-194, 2023. (要約) Several reports have shown a high mortality rate in patients with liver cirrhosis (LC) who undergo pancreaticoduodenectomy, however, there are few reports on its long-term prognosis. Twelve patients with LC who had undergone pancreatic resection were enrolled. To compare clinicopathological variables, 159 non-LC patients who had undergone resection for pancreatic cancer were enrolled. Pancreaticoduodenectomy (PD) was performed in 5 LC patients and distal pancreatectomy (DP) was performed in 7 LC patients. Patients in the LC group had more co-morbidities, lower platelet counts and higher Fib4 index than the non-LC group. The postoperative complication rate was higher in the LC group (83.3% vs 47.8%). While the postoperative hospital stay and 30-day mortality rate were not different, the 90-day mortality rate was higher in the LC group (25.0% vs 2.5% ; p<0.01). Comparison by operative procedure showed no significant differences of postoperative outcomes in DP cases. However, in PD cases, postoperative complications were more frequent (100% vs 42.3%) and 90-day mortality was higher (40.0% vs 2.9% ; p<0.01) in the LC group. PD resulted in higher postoperative morbidity and mortality rates in patients with LC compared with non-LC patients. DP could be tolerated in the LC patients. J. Med. Invest. 70 : 189-194, February, 2023. (キーワード) Humans / Pancreatectomy / Treatment Outcome / Retrospective Studies / Pancreaticoduodenectomy / Pancreatic Neoplasms / Postoperative Complications / Liver Cirrhosis (出版サイトへのリンク) ● Publication site (DOI): 10.2152/jmi.70.189 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37164719 ● Search Scopus @ Elsevier (PMID): 37164719 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.70.189 (DOI: 10.2152/jmi.70.189, PubMed: 37164719)
16.	Baasansuren Selenge, Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Chie Takasu, Hiroki Teraoku, Shohei Okikawa and Mitsuo Shimada : Impact of L-type amino acid transporter 1 on intrahepatic cholangiocarcinoma., The Journal of Medical Investigation : JMI, Vol.70, No.1.2, 160-165, 2023. (要約) Amino acid transporters, such as L-type amino acid transporter 1 (LAT1), have an effect on tumor growth, metastasis, and survival of various solid tumors. However, the role of LAT1 in patients with intrahepatic cholangiocarcinoma (IHCC) remains unknown. Forty-six patients who had undergone initial hepatic resection for IHCC at Tokushima University Hospital were enrolled in this study. Immunohistochemical analysis of LAT1 and phosphorylated Akt (p-AKT) was performed using resected specimens. Clinicopathological factors, including prognosis, were analyzed between LAT1-high and LAT1-low groups. The LAT1-high group showed a higher proportion of periductal infiltrating type and higher carcinoembryonic antigen/carbohydrate antigen 19-9 levels compared with the LAT1-low group. Multivariate analysis revealed that LAT1-high expression was an independent prognostic factor for disease-free survival. Furthermore, the proportion of p-AKT positivity was higher in the LAT1-high group than in the LAT1-low group. LAT1 expression was associated with poor prognosis of IHCC and higher p-Akt expression. J. Med. Invest. 70 : 160-165, February, 2023. (キーワード) Humans / Bile Duct Neoplasms / Bile Ducts, Intrahepatic / Biomarkers, Tumor / Cholangiocarcinoma / Prognosis / Proto-Oncogene Proteins c-akt (出版サイトへのリンク) ● Publication site (DOI): 10.2152/jmi.70.160 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37164714 ● Search Scopus @ Elsevier (PMID): 37164714 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.70.160 (DOI: 10.2152/jmi.70.160, PubMed: 37164714)
17.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Shohei Okikawa, Katsuki Miyazaki and Mitsuo Shimada : Short- and long-term outcomes of pancreatectomy in patients with hemodialysis., The Journal of Medical Investigation : JMI, Vol.70, No.1.2, 105-109, 2023. (要約) Several reports have shown the high mortality rate of pancreatic resection in patients with hemodialysis (HD), however, its long-term outcome remains unclear. In this study, we examined cases of pancreatic resection in patients with HD and conducted a literature review. Four patients with HD who underwent pancreatic resection from 2004 to 2019 were enrolled. To compare the clinicopathological variables of HD and non-HD patients, 161 non-HD patients who had undergone surgical resection for pancreatic cancer were enrolled. Among four cases of pancreatic resection with HD, three cases were malignant diseases. All patients with HD had some co-morbidities (100% in HD group, 45.3% in the non-HD group) and postoperative complications (100% in the HD group, vs 46.6% in the non-HD group). Although one patient had severe postoperative complications and length of postoperative hospital stay was longer, the 30- and 90-day mortality rates were both 0% in patients with HD. However, three cases in the HD group (75%) died approximately 6 months after surgery, including one cancer-related death. Pancreatic surgery in patients with HD should be carefully indicated, especially pancreaticoduodenectomy or total pancreatectomy, because of the poor prognosis induced by non-cancer-related causes of death. J. Med. Invest. 70 : 105-109, February, 2023. (キーワード) Humans / Pancreatectomy / Pancreatic Neoplasms / Pancreaticoduodenectomy / Postoperative Complications / Retrospective Studies (出版サイトへのリンク) ● Publication site (DOI): 10.2152/jmi.70.105 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37164704 ● Search Scopus @ Elsevier (PMID): 37164704 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.70.105 (DOI: 10.2152/jmi.70.105, PubMed: 37164704)
18.	齋藤裕, 森根裕二, 山田眞一郎, 寺奥大貴, 池本哲也, 島田光生 : 【胆膵疾患と最新テクノロジーの融合】胆膵疾患における最新の術前術中手術支援システム, 胆と膵, Vol.43, No.12, 1631-1636, 2022年. (要約) 胆膵手術における術前シミュレーションは,腫瘍進展範囲あるいは主要脈管解剖をいかに正確にイメージできるかが,ポイントとなる．空間認識力という意味で,extended realityは有用である．また,術中ナビゲーションに関しては,ICG蛍光法がゴールドスタンダードとなるが,人工知能を駆使した最新の知見,ならびに自験例も踏まえて,本稿で紹介する．(著者抄録) (キーワード) Indocyanine Green(診断的利用) 術中モニタリング人工知能膵臓疾患(X線診断,外科的療法) 膵頭十二指腸切除ソフトウェア X線CT 胆道疾患(X線診断,外科的療法) DICOM 蛍光血管撮影シミュレーション訓練手術ナビゲーションシステム胆管切除術ヒト
19.	Yuji Morine, Tohru Utsunomiya, Hisami Yamanaka-Okumura, Yu Saitou, Shin-ichiro Yamada, Tetsuya Ikemoto, Satoru Imura, Shohei Kinoshita, Akiyoshi Hirayama, Yasuhito Tanaka and Mitsuo Shimada : Essential amino acids as diagnostic biomarkers of hepatocellular carcinoma based on metabolic analysis., Oncotarget, Vol.13, 1286-1298, 2022. (要約) Metabolomics, defined as the comprehensive identification of all small metabolites in a biological sample, has the power to shed light on phenotypic changes associated with various diseases, including cancer. To discover potential metabolomic biomarkers of hepatocellular carcinoma (HCC), we investigated the metabolomes of tumor and non-tumor tissue in 20 patients with primary HCC using capillary electrophoresis-time-of-flight mass spectrometry. We also analyzed blood samples taken immediately before and 14 days after hepatectomy to identify associated changes in the serum metabolome. Marked changes were detected in the different quantity of 61 metabolites that could discriminate between HCC tumor and paired non-tumor tissue and additionally between HCC primary tumors and colorectal liver metastases. Among the 30 metabolites significantly upregulated in HCC tumors compared with non-tumor tissues, 10 were amino acids, and 7 were essential amino acids (leucine, valine, tryptophan, isoleucine, methionine, lysine, and phenylalanine). Similarly, the serum metabolomes of HCC patients before hepatectomy revealed a significant increase in 16 metabolites, including leucine, valine, and tryptophan. Our results reveal striking differences in the metabolomes of HCC tumor tissue compared with non-tumor tissue, and identify the essential amino acids leucine, valine, and tryptophan as potential metabolic biomarkers for HCC. (キーワード) Humans / Amino Acids, Essential / Carcinoma, Hepatocellular / Tryptophan / Leucine / Liver Neoplasms / Valine (出版サイトへのリンク) ● Publication site (DOI): 10.18632/oncotarget.28306 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36441784 ● Search Scopus @ Elsevier (PMID): 36441784 ● Search Scopus @ Elsevier (DOI): 10.18632/oncotarget.28306 (DOI: 10.18632/oncotarget.28306, PubMed: 36441784)
20.	Baasansvren Selenge, Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Chie Takasu, Hiroki Teraoku and Mitsuo Shimada : Impact of L-type amino acid transporter 3 on the prognosis of hepatocellular carcinoma., Oncology Letters, Vol.24, No.5, 418, 2022. (要約) The aim of the present study was to investigate the impact of L-type amino acid transporter 3 (LAT3) expression on the prognosis of hepatocellular carcinoma (HCC). A total of 135 patients who had undergone initial hepatic resection for HCC at Tokushima University Hospital (Tokushima, Japan) were enrolled in the present study. Immunohistochemical analysis of LAT3 and phosphorylated AKT (p-AKT) was performed using resected specimens. Clinicopathological factors, including prognosis, were compared between the LAT3-high and -low expression groups. The results demonstrated that the LAT3-high group showed significantly higher protein induced by vitamin K absence-II levels (P=0.01) compared with the LAT3-low group. The LAT3-high group showed significantly worse prognosis compared with the LAT3-low group regarding cancer-specific survival and disease-free survival (P<0.05). Multivariate analysis revealed that high LAT3 expression and multiple tumors were independent prognostic factors for cancer-specific survival. Furthermore, the rate of p-AKT-positive cases was higher in the LAT3-high group than in the LAT3-low group. Overall, these findings suggested that LAT3 expression was associated with poor prognosis of HCC and high p-AKT expression. (徳島大学機関リポジトリ) ● Metadata: 118271 (出版サイトへのリンク) ● Publication site (DOI): 10.3892/ol.2022.13538 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36245821 ● Search Scopus @ Elsevier (PMID): 36245821 ● Search Scopus @ Elsevier (DOI): 10.3892/ol.2022.13538 (徳島大学機関リポジトリ: 118271, DOI: 10.3892/ol.2022.13538, PubMed: 36245821)
21.	Takuya Tokunaga, Maki Sugimoto, Yu Saitou, Hideya Kashihara, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita, Yosuke Iwakawa, Noriko Yokota and Mitsuo Shimada : Intraoperative holographic image-guided surgery in a transanal approach for rectal cancer., Langenbeck's Archives of Surgery / Deutsche Gesellschaft für Chirurgie, Vol.407, No.6, 2579-2584, 2022. (要約) Urethral injury is one of the most important complications in transanal total mesorectal excision (TaTME) in male patients with rectal cancer. The purpose of this study was to investigate holographic image-guided surgery in TaTME. Polygon (stereolithography) files were created and exported from SYNAPSE VINCENT, and then uploaded into the Holoeyes MD system (Holoeyes Inc., Tokyo, Japan). After uploading the data, the three-dimensional image was automatically converted into a case-specific hologram. The hologram was then installed into the head mount display, HoloLens (Microsoft Corporation, Redmond, WA). The surgeons and assistants wore the HoloLens when they performed TaTME. In a Wi-Fi-enabled operating room, each surgeon, wearing a HoloLens, shared the same hologram and succeeded in adjusting the hologram by making simple hand gestures from their respective angles. The hologram contributed to better comprehension of the positional relationships between the urethra and the surrounding pelvic organs during surgery. All surgeons were able to properly determine the dissection line. This first experience suggests that intraoperative holograms contributed to reducing the risk of urethral injury and understanding transanal anatomy. Intraoperative holograms have the potential to become a new next-generation surgical support tool for use in spatial awareness and the sharing of information between surgeons. (キーワード) Dissection / Humans / Laparoscopy / Male / Postoperative Complications / Proctectomy / Rectal Neoplasms / Rectum / Surgery, Computer-Assisted / Transanal Endoscopic Surgery (出版サイトへのリンク) ● Publication site (DOI): 10.1007/s00423-022-02607-4 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35840706 ● Search Scopus @ Elsevier (PMID): 35840706 ● Search Scopus @ Elsevier (DOI): 10.1007/s00423-022-02607-4 (DOI: 10.1007/s00423-022-02607-4, PubMed: 35840706)
22.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada and Mitsuo Shimada : A Hepatectomy Based on a Hybrid Concept of Portal Perfusion of Anterior Segment and Venous Drainage Area of Superior Right Hepatic Vein., The American Surgeon, 3134820984872, 2022. (要約) Right hepatic vein sometimes could not be a reliable landmark between the anterior and posterior segment. The aim of this study was to clarify the portal perfusion area of the anterior segment and to propose a less invasive hepatectomy based on both the portal perfusion and the hepatic venous drainage. Three-dimensional computerized tomography images of 66 patients were constructed. A case, in which the perfusion area of the anterior segment crossed over superior right hepatic vein (SRHV), was called as SRHV-inclusion. It was defined as inclusion of more than 1 cm of the proximal site of SRHV surrounded by the portal perfusion area of the anterior segment. SRHV-inclusion was observed in 26%. The cases with large inferior right hepatic vein (IRHV) had more frequent SRHV-inclusion (47%). The elderly patient with hepatic disorder, who had hepatocellular carcinoma near the root of the SRHV, underwent a less invasive hepatectomy (anterior segment + SRHV drainage area) resulting in the preservation of the IRHV. The perfusion area of the anterior segment crossed over SRHV in one fourth of patients in the study. Our proposed less invasive hepatectomy based on a hybrid concept might be an alternative operative procedure other than right hepatectomy. (出版サイトへのリンク) ● Publication site (DOI): 10.1177/0003134820984872 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33382339 ● Search Scopus @ Elsevier (PMID): 33382339 ● Search Scopus @ Elsevier (DOI): 10.1177/0003134820984872 (DOI: 10.1177/0003134820984872, PubMed: 33382339)
23.	Yu Saitou, Maki Sugimoto, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shin-ichiro Yamada and Mitsuo Shimada : Intraoperative support with three-dimensional holographic cholangiography in hepatobiliary surgery., Langenbeck's Archives of Surgery / Deutsche Gesellschaft für Chirurgie, Vol.407, No.3, 1285-1289, 2022. (要約) This study was performed to investigate the potential of intraoperative three-dimensional (3D) holographic cholangiography, which provides a computer graphics model of the biliary tract, with mixed reality techniques. Two patients with intraductal papillary neoplasm of the bile duct were enrolled in the study. Intraoperative 3D cholangiography was performed in a hybrid operating room. Three-dimensional polygon data using the acquired cholangiography data were installed into a head mount display (HoloLens; Microsoft Corporation, Redmond, WA, USA). Upon completion of intraoperative 3D cholangiography, a hologram was immediately and successfully made in the operating room using the acquired cholangiography data, and several surgeons wearing the HoloLens succeeded in sharing the same hologram. Compared with usual two-dimensional cholangiography, this 3D holographic cholangiography technique contributed to more accurate reappearance of the bile ducts, especially the B1 origination site, and moving the hologram from the respective operators' angles by means of easy gesture-handling without any monitors. Intraoperative 3D holographic cholangiography might be a new next-generation operation-support tool in terms of immediacy, accurate anatomical reappearance, and ease of handling. (キーワード) Bile Duct Neoplasms / Bile Ducts / Biliary Tract / Cholangiography / Humans (出版サイトへのリンク) ● Publication site (DOI): 10.1007/s00423-021-02336-0 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34557939 ● Search Scopus @ Elsevier (PMID): 34557939 ● Search Scopus @ Elsevier (DOI): 10.1007/s00423-021-02336-0 (DOI: 10.1007/s00423-021-02336-0, PubMed: 34557939)
24.	Kazunori Tokuda, Tetsuya Ikemoto, Shoko Yamashita, Katsuki Miyazaki, Shohei Okikawa, Shin-ichiro Yamada, Yu Saitou, Yuji Morine and Mitsuo Shimada : Syngeneically transplanted insulin producing cells differentiated from adipose derived stem cells undergo delayed damage by autoimmune responses in NOD mice., Scientific Reports, Vol.12, No.1, 5852, 2022. (要約) Insulin-producing cells (IPCs) generated by our established protocol have reached the non-clinical 'proof of concept' stage. Our strategy for their clinical application is the autotransplantation of IPCs into patients with type 1 diabetes mellitus (T1DM). In this context, the autoimmunity that characterized T1DM is important, rather than allorejection. We aimed to determine how these IPCs respond to T1DM autoimmunity. IPCs were generated from the subcutaneous fat tissue of non-obese diabetic (NOD) mice using our protocol. IPCs derived from NOD mice were transplanted under the kidney capsules of NOD mice at the onset of diabetes and the subsequent changes in blood glucose concentration were characterized. Blood glucose decreased within 30 days of transplantation, but increased again after 40-60 days in three of four recipient NOD mice. In tissue samples, the numbers of CD4 and CD8 T cells were significantly higher 60 days after transplantation than 30 days after transplantation. In conclusion, IPCs significantly ameliorate the diabetes of mice in the short term, but are damaged by autoimmunity in the longer term, as evidenced by local T cells accumulation. This study provides new insights into potential stem cell therapies for T1DM. (キーワード) Animals / Autoimmunity / Blood Glucose / CD8-Positive T-Lymphocytes / Diabetes Mellitus, Experimental / Diabetes Mellitus, Type 1 / Humans / Insulin / Insulin-Secreting Cells / Mice / Mice, Inbred NOD / Stem Cells (出版サイトへのリンク) ● Publication site (DOI): 10.1038/s41598-022-09838-x (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35393479 ● Search Scopus @ Elsevier (PMID): 35393479 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-022-09838-x (DOI: 10.1038/s41598-022-09838-x, PubMed: 35393479)
25.	Shohei Okikawa, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Kazunori Tokuda, Hiroki Teraoku, Katsuki Miyazaki, Shoko Yamashita, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : Inhibition of the VEGF signaling pathway attenuates tumor-associated macrophage activity in liver cancer., Oncology Reports, Vol.47, No.4, 2022. (要約) Tumor-associated macrophage (TAMs) are paramount for tumor progression and immune tolerance in the tumor microenvironment of various types of cancer, including liver cancer. The aim of the present study was to investigate the effect of vascular endothelial growth factor (VEGF) inhibition on TAM polarization and function during their interactions with macrophages and liver cancer cells. TAMs were induced by culturing M0 macrophages with cancer cell-conditioned medium. TAMs cultured with cancer cell-conditioned medium and vascular endothelial growth factor (VEGF) inhibitor were defined as modified TAMs, and the expression levels of TAM-associated markers and VEGF receptor 2 were evaluated using reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The effects of TAMs and modified TAMs on cancer cell proliferation and migration were investigated using conditioned medium. Programmed death-ligand 1 (PD-L1) mRNA expression in modified TAMs and cancer cells cultured in modified TAM-conditioned medium (TAM-CM) for 48 h was examined using RT-qPCR. In order to investigate signaling pathways in macrophages, western blot analysis was performed. CD163 and CD206 and M2 macrophage marker expression was upregulated in TAMs and modified TAMs. Modified TAM-CM exhibited a decreased ability to promote cancer cell proliferation and migration in comparison with the use of TAM-CM. The VEGF concentration was significantly higher in the TAMs than in M0 macrophages; however, the modified TAMs displayed a significantly lower VEGF secretion than TAMs. PD-L1 expression was decreased in modified TAMs as compared with TAMs. Western blot analysis revealed that the Akt/mTOR signaling pathway was significantly suppressed in the modified TAMs compared with TAMs. It was observed that TAMs cultured in a VEGF-depleted environment displayed lower secretion levels of cytokines involved in tumor progression and a decreased immune tolerance-inducing ability. On the whole, the results of the present study suggested that VEGF inhibition in TAMs may be a potential therapeutic target for liver cancer. (キーワード) Cell Line, Tumor / Humans / Liver Neoplasms / Signal Transduction / Tumor Microenvironment / Tumor-Associated Macrophages / Vascular Endothelial Growth Factor A (徳島大学機関リポジトリ) ● Metadata: 118964 (出版サイトへのリンク) ● Publication site (DOI): 10.3892/or.2022.8282 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35169858 ● Search Scopus @ Elsevier (PMID): 35169858 ● Search Scopus @ Elsevier (DOI): 10.3892/or.2022.8282 (徳島大学機関リポジトリ: 118964, DOI: 10.3892/or.2022.8282, PubMed: 35169858)
26.	Yuuma Wada, Mitsuo Shimada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hideo Baba, Masaki Mori and Ajay Goel : A blood-based noninvasive miRNA signature for predicting survival outcomes in patients with intrahepatic cholangiocarcinoma., British Journal of Cancer, Vol.126, No.8, 1196-1204, 2022. (要約) The prognosis in patients with intrahepatic cholangiocarcinoma (ICC) is generally poor. To improve treatment selection, we sought to identify microRNA (miRNA) signature associated with survival outcomes in ICC. We first analysed the miRNA expression profiles of primary ICC from two public datasets to identify a miRNA panel to detect patients for short-term survival. We then analysed 309 specimens, including 241 FFPE samples from two clinical cohorts (training: n = 177; validation: n = 64) and matched plasma samples (n = 68), and developed a risk-stratification model incorporating the panel and CA 19-9 levels to predict survival outcomes in ICC. We identified a 7-miRNA panel that robustly classified patients with poor outcomes in the discovery cohorts (AUC = 0.80 and 0.88, respectively). We subsequently trained this miRNA panel in a clinical cohort (AUC = 0.83) and evaluated its performance in an independent validation cohort (AUC = 0.82) and plasma samples from the additional validation cohort (AUC = 0.78). Patients in both clinical cohorts who were classified as high-risk had significantly worse prognosis (p < 0.01). The risk-stratification model demonstrated superior performance compared to models (AUC = 0.85). We established a novel miRNA signature that could robustly predict survival outcomes in resected tissues and liquid biopsies to improve the clinical management of patients with ICC. (キーワード) Bile Duct Neoplasms / Bile Ducts, Intrahepatic / Cholangiocarcinoma / Humans / MicroRNAs / Prognosis (出版サイトへのリンク) ● Publication site (DOI): 10.1038/s41416-022-01710-z (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35079106 ● Search Scopus @ Elsevier (PMID): 35079106 ● Search Scopus @ Elsevier (DOI): 10.1038/s41416-022-01710-z (DOI: 10.1038/s41416-022-01710-z, PubMed: 35079106)
27.	Yuuma Wada, Mitsuo Shimada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hideo Baba, Masaki Mori and Ajay Goel : A transcriptomic signature that predicts cancer recurrence after hepatectomy in patients with colorectal liver metastases., European Journal of Cancer, Vol.163, 66-76, 2022. (要約) Cancer recurrence is an important predictor of survival outcomes in patients with colorectal cancer-associated liver metastasis (CRLM), who undergo radical hepatectomy. Therefore, identification of patients with the greatest risk of recurrence is critical for developing a precision oncology strategy that might include frequent surveillance (in low-risk patients) or a more aggressive treatment approach (in high-risk patients). We performed genome-wide expression profiling, to identify and develop a transcriptomic signature for predicting recurrence in patients with CRLM. We analysed a total of 383 patients with CRLM, including 63 patients from a publicly available data set (the NCBI's Gene Expression Omnibus with accession number GSE81423). and 320 patients from whom surgical specimens were collected for independent training (n = 169) and validation (n = 151) of identified biomarkers. Using Cox's proportional hazard regression analysis, we evaluated the clinical significance of the identified gene signature by comparing its performance with several key clinical factors. We identified a six-gene panel that robustly categorised patients with recurrence in the discovery (area under the curve (AUC) = 0.90). We showed that the panel was a significant predictor of recurrence in the clinical training (AUC = 0.83) and validation cohorts (AUC = 0.81). By combining our panel with key clinical factors, we established a risk-stratification model that emerged as an independent predictor of recurrence (AUC = 0.85; univariate: hazard ratio (HR) = 4.34, 95% confidence interval (CI) = 2.71-6.93, P < 0.001; multivariate: HR = 3.40, 95% CI = 1.76-6.56, P < 0.001). The stratification model revealed recurrence prediction in 89% of high-risk group and non-recurrence in 62% of low-risk group. We established a novel transcriptomic signature that robustly predicts recurrence, which has significant implications for the management of patients with CRLM. (キーワード) Biomarkers, Tumor / Colorectal Neoplasms / Gene Expression Regulation, Neoplastic / Hepatectomy / Humans / Liver Neoplasms / Neoplasm Recurrence, Local / Precision Medicine / Prognosis / Transcriptome (出版サイトへのリンク) ● Publication site (DOI): 10.1016/j.ejca.2021.12.013 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35042069 ● Search Scopus @ Elsevier (PMID): 35042069 ● Search Scopus @ Elsevier (DOI): 10.1016/j.ejca.2021.12.013 (DOI: 10.1016/j.ejca.2021.12.013, PubMed: 35042069)
28.	Shuhai Chen, Tetsuya Ikemoto, Takuya Tokunaga, Shohei Okikawa, Katsuki Miyazaki, Shin-ichiro Yamada, Yu Saitou, Yuji Morine and Mitsuo Shimada : Newly Generated 3D Schwann-Like Cell Spheroids From Human Adipose-Derived Stem Cells Using a Modified Protocol., Cell Transplantation, Vol.31, 9636897221093312, 2022. (要約) Peripheral nerve injury (PNI) is a relatively frequent type of trauma that results in the suffering of many patients worldwide every year. Schwann cells (SCs) are expected to be applied in cell therapy because of their ability to promote peripheral nerve regeneration. However, the lack of clinically renewable sources of SCs hinders the application of SC-based therapies. Adipose-derived stem cells (ADSCs) have generated great interest in recent years because of their multipotency and ease of harvest, and they have already been verified to differentiate into Schwann-like cells (SLCs) in vitro. However, the efficiency of differentiation and the functions of SLCs remain unsatisfactory. We newly generated three-dimensional (3D) SLC spheroids from ADSCs using a modified protocol with human recombinant peptide (RCP) petaloid -piece. Morphological analysis, gene expression analysis by qRT-PCR, ELISA measurement of the secretion capabilities of neurotrophic factors, and neurite formation assay were performed to evaluate the functions of these 3D SLCs in vitro. Motor function recovery was measured in a sciatic nerve injury mouse model to analyze the nerve regeneration-promoting effect of 3D SLCs in vivo. The differentiation efficiency and the secretion of neurotrophic factors were enhanced in 3D SLCs compared with conventional SLCs. 3D SLCs could more effectively promote neurite growth and longer neurite extension in a neuron-like SH-SY5Y model. Additionally, 3D SLCs had a better therapeutic effect on nerve regeneration after transplantation into the sciatic nerve injury mouse model. These findings demonstrated that the potential of ADSC-derived SLCs to promote nerve regeneration could be significantly increased using our modified differentiation protocol and by assembling cells into a 3D sphere conformation. Therefore, these cells have great potential and can be used in the clinical treatment of PNI. (キーワード) Adipocytes / Adipose Tissue / Animals / Humans / Mice / Nerve Growth Factors / Peripheral Nerve Injuries / Schwann Cells / Stem Cells (徳島大学機関リポジトリ) ● Metadata: 117435 (出版サイトへのリンク) ● Publication site (DOI): 10.1177/09636897221093312 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35469470 ● Search Scopus @ Elsevier (PMID): 35469470 ● Search Scopus @ Elsevier (DOI): 10.1177/09636897221093312 (徳島大学機関リポジトリ: 117435, DOI: 10.1177/09636897221093312, PubMed: 35469470)
29.	Yuuma Wada, Mitsuo Shimada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Zhongxu Zhu, Xin Wang, Ane Etxart, Yangsoon Park, Luis Bujanda, In Ja Park and Ajay Goel : Circulating miRNA Signature Predicts Response to Preoperative Chemoradiotherapy in Locally Advanced Rectal Cancer., JCO Precision Oncology, Vol.5, 2021. (要約) Patients with locally advanced rectal cancer (LARC) are recommended to receive preoperative chemoradiotherapy (PCRT) followed by surgery. Response to PCRT varies widely: 60%-70% of patients with LARC do not derive therapeutic benefit from PCRT, whereas 15%-20% of patients achieve pathologic complete response (pCR). We sought to develop a liquid biopsy assay for identifying response to PCRT in patients with LARC. We analyzed two genome-wide microRNA (miRNA) expression profiling data sets from tumor tissue samples for discovery (GSE68204) and validation (GSE29298). We prioritized biomarkers in pretreatment plasma specimens from clinical training (n = 41; 15 responders and 26 nonresponders) and validation (n = 65; 29 responders and 36 nonresponders) cohorts of patients with LARC. We developed an integrated miRNA panel and established a risk assessment model, which was combined with the miRNA panel and carcinoembryonic antigen levels. Our comprehensive discovery effort identified an 8-miRNA panel that robustly predicted response to PCRT, with an excellent accuracy in the discovery (area under the curve [AUC] = 0.95) and validation (AUC = 0.92) cohorts. We successfully established a circulating miRNA panel with remarkable diagnostic accuracy in the clinical training (AUC = 0.82) and validation (AUC = 0.81) cohorts. Moreover, the predictive accuracy of the panel was significantly superior to conventional clinical factors in both cohorts ( < .01) and the risk assessment model was superior (AUC = 0.83). Finally, we applied our model to detect patients with pathologic complete response and showed that it was dramatically superior to currently used pathologic features (AUC = 0.92). Our novel risk assessment signature for predicting response to PCRT has a potential for clinical translation as a liquid biopsy assay in patients with LARC. (キーワード) Chemoradiotherapy / Circulating MicroRNA / Humans / Liquid Biopsy / MicroRNAs / Rectal Neoplasms (出版サイトへのリンク) ● Publication site (DOI): 10.1200/PO.21.00015 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34913022 ● Search Scopus @ Elsevier (PMID): 34913022 ● Search Scopus @ Elsevier (DOI): 10.1200/PO.21.00015 (DOI: 10.1200/PO.21.00015, PubMed: 34913022)
30.	Luping Gao, Yuji Morine, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Kazunori Tokuda, Chie Takasu, Katsuki Miyazaki and Mitsuo Shimada : Nrf2 signaling promotes cancer stemness, migration, and expression of ABC transporter genes in sorafenib-resistant hepatocellular carcinoma cells., PLoS ONE, Vol.16, No.9, e0256755, 2021. (要約) As a multiple tyrosine kinase inhibitor, sorafenib is widely used to treat hepatocellular carcinoma (HCC), but patients frequently face resistance problems. Because the mechanism controlling sorafenib-resistance is not well understood, this study focused on the connection between tumor characteristics and the Nrf2 signaling pathway in a sorafenib-resistant HCC cell line. A sorafenib-resistant HCC cell line (Huh7) was developed by increasing the dose of sorafenib in the culture medium until the target concentration was reached. Cell morphology, migration/invasion rates, and expression of stemness-related and ATP-binding cassette (ABC) transporter genes were compared between sorafenib-resistant Huh7 cells and parental Huh7 cells. Next, a small interfering RNA was used to knock down Nrf2 expression in sorafenib-resistant Huh7 cells, after which cell viability, stemness, migration, and ABC transporter gene expression were examined again. Proliferation, migration, and invasion rates of sorafenib-resistant Huh7 cells were significantly increased relative to the parental cells with or without sorafenib added to the medium. The expression levels of stemness markers and ABC transporter genes were up-regulated in sorafenib-resistant cells. After Nrf2 was knocked down in sorafenib-resistant cells, cell migration and invasion rates were reduced, and expression levels of stemness markers and ABC transporter genes were reduced. Nrf2 signaling promotes cancer stemness, migration, and expression of ABC transporter genes in sorafenib-resistant HCC cells. (キーワード) ATP-Binding Cassette Transporters / Antineoplastic Agents / Carcinoma, Hepatocellular / Cell Line, Tumor / Cell Movement / Cell Proliferation / Cell Survival / Drug Resistance, Neoplasm / Gene Expression / Gene Expression Regulation, Neoplastic / Gene Knockdown Techniques / Humans / Liver Neoplasms / NF-E2-Related Factor 2 / Protein Kinase Inhibitors / Signal Transduction / Sorafenib / Transfection (徳島大学機関リポジトリ) ● Metadata: 117382 (出版サイトへのリンク) ● Publication site (DOI): 10.1371/journal.pone.0256755 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34473785 ● Search Scopus @ Elsevier (PMID): 34473785 ● Search Scopus @ Elsevier (DOI): 10.1371/journal.pone.0256755 (徳島大学機関リポジトリ: 117382, DOI: 10.1371/journal.pone.0256755, PubMed: 34473785)
31.	Kazunori Tokuda, Yuji Morine, Katsuki Miyazaki, Shin-ichiro Yamada, Yu Saitou, Masaaki Nishi, Tetsuya Ikemoto and Mitsuo Shimada : Frailty Can Predict Prognosis After Hepatectomy in Patients With Colorectal Liver Metastasis., Anticancer Research, Vol.41, No.9, 4637-4644, 2021. (要約) The aim of this study was to investigate frailty as a prognostic factor in patients with colorectal liver metastasis undergoing hepatectomy. Eighty-seven patients who underwent hepatectomy at our institution were enrolled. Frailty was defined as a score of ·4 on a clinical frailty scale. Patients were divided into frailty (n=29) and non-frailty (n=58) groups. Overall and cancer-specific survival rates were significantly worse in the frailty group compared with the non-frailty group, and multivariate analysis revealed frailty as an independent prognostic factor. Disease-free survival tended to be worse in the frailty group. Fifty-eight patients relapsed after the first hepatectomy. Twenty-one of 58 recurrent patients were allocated to the frailty group. After recurrence, chemotherapy was significantly more frequently performed in the non-frailty group compared with the frailty group. Frailty can predict the prognosis of patients with colorectal liver metastasis undergoing hepatectomy. (キーワード) Adult / Aged / Aged, 80 and over / Colorectal Neoplasms / Drug Therapy / Female / Frailty / Hepatectomy / Humans / Liver Neoplasms / Male / Middle Aged / Multivariate Analysis / Neoplasm Recurrence, Local / Prognosis / Retrospective Studies / Survival Analysis / Treatment Outcome (出版サイトへのリンク) ● Publication site (DOI): 10.21873/anticanres.15277 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34475092 ● Search Scopus @ Elsevier (PMID): 34475092 ● Search Scopus @ Elsevier (DOI): 10.21873/anticanres.15277 (DOI: 10.21873/anticanres.15277, PubMed: 34475092)
32.	Luping Gao, Yuji Morine, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Kazunori Tokuda, Katsuki Miyazaki, Shouhei Okikawa, Chie Takasu and Mitsuo Shimada : The BAFF/NF B axis is crucial to interactions between sorafenib-resistant HCC cells and cancer-associated fibroblasts., Cancer Science, Vol.112, No.9, 3545-3554, 2021. (要約) The tumor microenvironment affects malignancy in hepatocellular carcinoma (HCC) cells, and cancer-associated fibroblasts (CAFs) play an important role in the microenvironment. As recent studies indicated a difference between CAFs isolated from chemoresistant and non-resistant cancer tissues, therefore we investigated the intracellular mechanism in resistant HCC co-cultured CAFs and interactions between these CAFs with cancer cells. We established a sorafenib-resistant (SR) Huh7 (human HCC) cell line, and characterized it with cytokine assays, then developed CAFs by co-culturing human hepatic stellate cells with resistant or parental Huh7 cells. The 2 types of CAFs were co-cultured with parental Huh7 cells, thereafter the cell viability of these Huh7 cells was checked under sorafenib treatment. The SR Huh7 (Huh7 ) cells expressed increased B-cell activating factor (BAFF), which promoted high expression of CAF-specific markers in Huh7 -co-cultured CAFs, showed activated BAFF, BAFF-R, and downstream of the NF B-Nrf2 pathway, and aggravated invasion, migration, and drug resistance in co-cultured Huh7 cells. When we knocked down BAFF expression in Huh7 cells, the previously increased malignancy and BAFF/NF B axis in Huh7 -co-cultured CAFs reversed, and enhanced chemoresistance in co-cultured Huh7 cells returned as well. In conclusion, the BAFF/NF B pathway was activated in CAFs co-cultured with cell-culture medium from resistant Huh7, which promoted chemoresistance, and increased the malignancy in co-cultured non-resistant Huh7 cells. This suggests that the BAFF/NF B axis in CAFs might be a potential therapeutic target in chemoresistance of HCC. (キーワード) Antineoplastic Agents / B-Cell Activating Factor / Cancer-Associated Fibroblasts / Carcinoma, Hepatocellular / Cell Communication / Cell Line, Tumor / Cell Movement / Cell Survival / Coculture Techniques / Drug Resistance, Neoplasm / Gene Knockdown Techniques / Humans / Liver Neoplasms / NF-kappa B / Signal Transduction / Sorafenib / Transfection (徳島大学機関リポジトリ) ● Metadata: 116388 (出版サイトへのリンク) ● Publication site (DOI): 10.1111/cas.15041 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34159680 ● Search Scopus @ Elsevier (PMID): 34159680 ● Search Scopus @ Elsevier (DOI): 10.1111/cas.15041 (徳島大学機関リポジトリ: 116388, DOI: 10.1111/cas.15041, PubMed: 34159680)
33.	Shuhai Chen, Yuji Morine, Kazunori Tokuda, Shin-ichiro Yamada, Yu Saitou, Masaaki Nishi, Tetsuya Ikemoto and Mitsuo Shimada : Cancerssociated fibroblastnduced M2olarized macrophages promote hepatocellular carcinoma progression via the plasminogen activator inhibitor 1 pathway., International Journal of Oncology, Vol.59, No.2, 59, 2021. (要約) Targeting the tumor stroma is an important strategy in cancer treatment. Cancerssociated fibroblasts (CAFs) and tumorssociated macrophages (TAMs) are two main components in the tumor microenvironment (TME) in hepatocellular carcinoma (HCC), which can promote tumor progression. Plasminogen activator inhibitor 1 (PAI 1) upregulation in HCC is predictive of unfavorable tumor behavior and prognosis. However, the crosstalk between cancer cells, TAMs and CAFs, and the functions of PAI 1 in HCC remain to be fully investigated. In the present study, macrophage polarization and key paracrine factors were assessed during their interactions with CAFs and cancer cells. Cell proliferation, wound healing and Transwell and Matrigel assays were used to investigate the malignant behavior of HCC cells . It was found that cancer cells and CAFs induced the M2 polarization of TAMs by upregulating the mRNA expression levels of CD163 and CD206, and downregulating IL 6 mRNA expression and secretion in the macrophages. Both TAMs derived from cancer cells and CAFs promoted HCC cell proliferation and invasion. Furthermore, PAI 1 expression was upregulated in TAMs after being stimulated with CAFonditioned medium and promoted the malignant behavior of the HCC cells by mediating epithelialesenchymal transition. CAFs were the main producer of C motif chemokine ligand 12 (CXCL12) in the TME and CXCL12 contributed to the induction of PAI 1 secretion in TAMs. In conclusion, the results of the present study suggested that CAFs promoted the M2 polarization of macrophages and induced PAI 1 secretion via CXCL12. Furthermore, it was found that PAI 1 produced by the TAMs enhanced the malignant behavior of the HCC cells. Therefore, these factors may be targets for inhibiting the crosstalk between tumor cells, CAFs and TAMs. (キーワード) Cancer-Associated Fibroblasts / Carcinoma, Hepatocellular / Cell Communication / Cell Line, Tumor / Cell Movement / Cell Polarity / Cell Proliferation / Coculture Techniques / Disease Progression / Gene Expression Regulation, Neoplastic / Humans / Liver Neoplasms / Macrophage Activation / Plasminogen Activator Inhibitor 1 / Prognosis / Signal Transduction / THP-1 Cells / Tumor Microenvironment / Tumor-Associated Macrophages / Up-Regulation (徳島大学機関リポジトリ) ● Metadata: 117319 (出版サイトへのリンク) ● Publication site (DOI): 10.3892/ijo.2021.5239 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34195849 ● Search Scopus @ Elsevier (PMID): 34195849 ● Search Scopus @ Elsevier (DOI): 10.3892/ijo.2021.5239 (徳島大学機関リポジトリ: 117319, DOI: 10.3892/ijo.2021.5239, PubMed: 34195849)
34.	Satoru Imura, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Utility of cone unit liver resection for small hepatocellular carcinoma: a propensity score matched analysis., HPB, Vol.23, No.5, 739-745, 2021. (要約) Anatomical resection (AR) is performed widely for hepatocellular carcinoma (HCC). However, it is controversial whether typical AR, which removes the whole feeding territory of the tumor-bearing portal branch bordered by the landmark veins, is necessary. The aim of this study was to investigate the utility of small AR, so-called cone unit resection, for small HCC. Between 2007 and 2019, 372 hepatectomies were performed for HCC. Among them, 91 initial resections for small (<5 cm) solitary HCC were performed by typical AR (n = 44) or cone unit AR (n = 47). Propensity score matching was performed and clinicopathological features including prognosis were compared. At baseline, platelet count was higher, and liver function (serum albumin level) and indocyanine green retention at 15 min were better in the typical AR than cone unit AR group. There was no significant difference between the typical AR and cone unit AR group for tumor characteristics, short- and long-term outcomes. Even after propensity score matching (n = 29), the short- and long-term outcomes were also equivalent in between the two groups. There was no difference in prognosis of typical and cone unit AR. Therefore, cone unit AR is a feasible procedure for small HCC. (キーワード) Carcinoma, Hepatocellular / Hepatectomy / Humans / Liver Neoplasms / Propensity Score / Retrospective Studies (出版サイトへのリンク) ● Publication site (DOI): 10.1016/j.hpb.2020.09.010 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32988753 ● Search Scopus @ Elsevier (PMID): 32988753 ● Search Scopus @ Elsevier (DOI): 10.1016/j.hpb.2020.09.010 (DOI: 10.1016/j.hpb.2020.09.010, PubMed: 32988753)
35.	Katsuki Miyazaki, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Kazunori Tokuda, Shohei Okikawa, Shoko Yamashita, Takeshi Oya, Koichi Tsuneyama and Mitsuo Shimada : Preoperative lymphocyte/C-reactive protein ratio and its correlation with CD8 tumor-infiltrating lymphocytes as a predictor of prognosis after resection of intrahepatic cholangiocarcinoma., Surgery Today, Vol.51, No.12, 1985-1995, 2021. (要約) To clarify whether the preoperative lymphocyte/C-reactive protein (CRP) ratio (LCR) is a prognostic factor for patients with intrahepatic cholangiocarcinoma (IHCC), and investigate its mechanism via tumor-infiltrating lymphocytes. The subjects of this retrospective study were 42 patients who had undergone hepatectomy for IHCC. We divided the patients into low LCR and high LCR groups (cutoff value: 8780) and analyzed their overall survival (OS) and disease-free survival (DFS) with respect to LCR and other clinicopathological factors. We also investigated the levels of stromal tumor-infiltrating lymphocytes (TILs) and CD8 TILs in surgical specimens, and the relationship between LCR and TILs. A low LCR was identified in 21 patients and was significantly correlated with older age, a high CRP-albumin ratio, and advanced disease stage, and was a prognostic factor for OS and DFS. Multivariate analysis revealed that a low LCR was an independent prognostic factor for worse OS (HR 10.40, P = 0.0077). Although the LCR and levels of stromal TILs were not significantly related, LCR and levels of CD8 TILs were significantly related (P = 0.0297). The preoperative LCR may predict the postsurgical prognosis of patients with IHCC and reflect the CD8 TILs. (キーワード) Bile Duct Neoplasms / Biomarkers, Tumor / C-Reactive Protein / CD8-Positive T-Lymphocytes / Cholangiocarcinoma / Female / Humans / Lymphocyte Count / Lymphocytes, Tumor-Infiltrating / Male / Predictive Value of Tests / Preoperative Period / Prognosis (出版サイトへのリンク) ● Publication site (DOI): 10.1007/s00595-021-02295-5 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34009433 ● Search Scopus @ Elsevier (PMID): 34009433 ● Search Scopus @ Elsevier (DOI): 10.1007/s00595-021-02295-5 (DOI: 10.1007/s00595-021-02295-5, PubMed: 34009433)
36.	Yuuma Wada, Mitsuo Shimada, Tatsuro Murano, Hiroyuki Takamaru, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Francesc Balaguer, Luis Bujanda, Maria Pellise, Ken Kato, Yutaka Saito, Hiroaki Ikematsu and Ajay Goel : A Liquid Biopsy Assay for Noninvasive Identification of Lymph Node Metastases in T1 Colorectal Cancer., Gastroenterology, Vol.161, No.1, 151-162.e1, 2021. (要約) We recently reported use of tissue-based transcriptomic biomarkers (microRNA [miRNA] or messenger RNA [mRNA]) for identification of lymph node metastasis (LNM) in patients with invasive submucosal colorectal cancers (T1 CRC). In this study, we translated our tissue-based biomarkers into a blood-based liquid biopsy assay for noninvasive detection of LNM in patients with high-risk T1 CRC. We analyzed 330 specimens from patients with high-risk T1 CRC, which included 188 serum samples from 2 clinical cohorts-a training cohort (N = 46) and a validation cohort (N = 142)-and matched formalin-fixed paraffin-embedded samples (N = 142). We performed quantitative reverse-transcription polymerase chain reaction, followed by logistic regression analysis, to develop an integrated transcriptomic panel and establish a risk-stratification model combined with clinical risk factors. We used comprehensive expression profiling of a training cohort of LNM-positive and LMN-negative serum specimens to identify an optimized transcriptomic panel of 4 miRNAs (miR-181b, miR-193b, miR-195, and miR-411) and 5 mRNAs (AMT, forkhead box A1 [FOXA1], polymeric immunoglobulin receptor [PIGR], matrix metalloproteinase 1 [MMP1], and matrix metalloproteinase 9 [MMP9]), which robustly identified patients with LNM (area under the curve [AUC], 0.86; 95% confidence interval [CI], 0.72-0.94). We validated panel performance in an independent validation cohort (AUC, 0.82; 95% CI, 0.74-0.88). Our risk-stratification model was more accurate than the panel and an independent predictor for identification of LNM (AUC, 0.90; univariate: odds ratio [OR], 37.17; 95% CI, 4.48-308.35; P < .001; multivariate: OR, 17.28; 95% CI, 1.82-164.07; P = .013). The model limited potential overtreatment to only 18% of all patients, which is dramatically superior to pathologic features that are currently used (92%). A novel risk-stratification model for noninvasive identification of T1 CRC has the potential to avoid unnecessary operations for patients classified as high-risk by conventional risk-classification criteria. (キーワード) Adult / Aged / Aged, 80 and over / Biomarkers, Tumor / Colorectal Neoplasms / Decision Support Techniques / Feasibility Studies / Female / Gene Expression Profiling / Hepatocyte Nuclear Factor 3-alpha / Humans / Liquid Biopsy / Lymph Nodes / Lymphatic Metastasis / Male / Matrix Metalloproteinase 1 / Matrix Metalloproteinase 9 / MicroRNAs / Middle Aged / Neoplasm Staging / Nomograms / Predictive Value of Tests / RNA, Messenger / Receptors, Polymeric Immunoglobulin / Reproducibility of Results / Retrospective Studies / Risk Assessment / Risk Factors / Transcriptome / Young Adult (出版サイトへのリンク) ● Publication site (DOI): 10.1053/j.gastro.2021.03.062 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33819484 ● Search Scopus @ Elsevier (PMID): 33819484 ● Search Scopus @ Elsevier (DOI): 10.1053/j.gastro.2021.03.062 (DOI: 10.1053/j.gastro.2021.03.062, PubMed: 33819484)
37.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Katsuki Miyazaki, Takuya Tokunaga and Masaaki Nishi : Significance of frailty in prognosis after surgery in patients with pancreatic ductal adenocarcinoma., World Journal of Surgical Oncology, Vol.19, No.1, 94, 2021. (要約) Frailty is an important consideration for older patients undergoing surgery. We aimed to investigate whether frailty could be a prognostic factor in patients with pancreatic ductal adenocarcinoma who underwent pancreatic resection. One hundred and twenty patients who underwent pancreatic resection for pancreatic ductal adenocarcinoma were enrolled. Frailty was defined as a clinical frailty scale score ·4. Patients were divided into frailty (n = 29) and non-frailty (n=91) groups, and clinicopathological factors were compared between the two groups. The frailty group showed an older age, lower serum albumin concentration, lower prognostic nutritional index, larger tumor diameter, and higher rate of lymph node metastasis than the non-frailty group (p < 0.05). Neutrophil-lymphocyte ratio and modified Glasgow prognostic score tended to be higher in the frailty group. Cancer-specific and disease-free survival rates were significantly poor in the frailty group (p < 0.05). With a multivariate analysis, frailty was an independent prognostic factor of cancer-specific survival. Frailty can predict the prognosis of patients with pancreatic ductal adenocarcinoma who undergo pancreatic resection. (キーワード) Aged / Carcinoma, Pancreatic Ductal / Frailty / Humans / Pancreatectomy / Pancreatic Neoplasms / Prognosis (徳島大学機関リポジトリ) ● Metadata: 116675 (出版サイトへのリンク) ● Publication site (DOI): 10.1186/s12957-021-02205-6 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33781262 ● Search Scopus @ Elsevier (PMID): 33781262 ● Search Scopus @ Elsevier (DOI): 10.1186/s12957-021-02205-6 (徳島大学機関リポジトリ: 116675, DOI: 10.1186/s12957-021-02205-6, PubMed: 33781262)
38.	Yuuma Wada, Mitsuo Shimada, Kensuke Yamamura, Takeo Toshima, Jasjit K. Banwait, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hideo Baba, Masaki Morishima and Ajay Goel : A Transcriptomic Signature for Risk-Stratification and Recurrence Prediction in Intrahepatic Cholangiocarcinoma., Hepatology, Vol.74, No.3, 1371-1383, 2021. (要約) Tumor recurrence is frequent even in intrahepatic cholangiocarcinoma (ICC), and improved strategies are needed to identify patients at highest risk for such recurrence. We performed genome-wide expression profile analyses to discover and validate a gene signature associated with recurrence in patients with ICC. For biomarker discovery, we analyzed genome-wide transcriptomic profiling in ICC tumors from two public data sets: The Cancer Genome Atlas (n = 27) and GSE107943 (n = 28). We identified an eight-gene panel (BIRC5 [baculoviral IAP repeat containing 5], CDC20 [cell division cycle 20], CDH2 [cadherin 2], CENPW [centromere protein W], JPH1 [junctophilin 1], MAD2L1 [mitotic arrest deficient 2 like 1], NEIL3 [Nei like DNA glycosylase 3], and POC1A [POC1 centriolar protein A]) that robustly identified patients with recurrence in the discovery (AUC = 0.92) and in silico validation cohorts (AUC = 0.91). We next analyzed 241 specimens from patients with ICC (training cohort, n = 64; validation cohort, n = 177), followed by Cox proportional hazard regression analysis, to develop an integrated transcriptomic panel and establish a risk-stratification model for recurrence in ICC. We subsequently trained this transcriptomic panel in a clinical cohort (AUC = 0.89; 95% confidence interval [CI] = 0.79-0.95), followed by evaluating its performance in an independent validation cohort (AUC = 0.86; 95% CI = 0.80-0.90). By combining our transcriptomic panel with various clinicopathologic features, we established a risk-stratification model that was significantly superior for the identification of recurrence (AUC = 0.89; univariate HR = 6.08, 95% CI = 3.55-10.41, P < 0.01; and multivariate HR = 3.49, 95% CI = 1.81-6.71, P < 0.01). The risk-stratification model identified potential recurrence in 85% of high-risk patients and nonrecurrence in 76% of low-risk patients, which is dramatically superior to currently used pathological features. We report a transcriptomic signature for risk-stratification and recurrence prediction that is superior to currently used clinicopathological features in patients with ICC. (出版サイトへのリンク) ● Publication site (DOI): 10.1002/hep.31803 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33725402 ● Search Scopus @ Elsevier (PMID): 33725402 ● Search Scopus @ Elsevier (DOI): 10.1002/hep.31803 (DOI: 10.1002/hep.31803, PubMed: 33725402)
39.	齋藤裕, 居村暁, 森根裕二, 池本哲也, 山田眞一郎, 島田光生 : 【肝胆膵外科における再切除と再手術-最新の治療戦略】肝細胞癌切除後再発に対する再肝切除適応と治療成績, 手術, Vol.75, No.3, 249-256, 2021年. (キーワード) 肝細胞癌(外科的療法,予後) 肝切除再手術術後合併症(外科的療法) 腫瘍再発腹腔鏡法癒着(病因,外科的療法) 診療ガイドライン治療成績ヒト (出版サイトへのリンク) ● Publication site (DOI): 10.18888/op.0000002091 (文献検索サイトへのリンク) ● Search Scopus @ Elsevier (DOI): 10.18888/op.0000002091 (DOI: 10.18888/op.0000002091)
40.	Yu Saitou, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Current status of hepatocyte-like cell therapy from stem cells., Surgery Today, Vol.51, No.3, 340-349, 2021. (要約) Organ liver transplantation and hepatocyte transplantation are not performed to their full potential because of donor shortage, which could be resolved by identifying new donor sources for the development of hepatocyte-like cells (HLCs). HLCs have been differentiated from some stem cell sources as alternative primary hepatocytes throughout the world; however, the currently available techniques cannot differentiate HLCs to the level of normal adult primary hepatocytes. The outstanding questions are as follows: which stem cells are the best cell sources? which protocol is the best way to differentiate them into HLCs? what is the definition of differentiated HLCs? how can we enforce the function of HLCs? what is the difference between HLCs and primary hepatocytes? what are the problems with HLC transplantation? This review summarizes the current status of HLCs, focusing on stem cell sources, the differentiation protocol for HLCs, the general characterization of HLCs, the generation of more functional HLCs, comparison with primary hepatocytes, and HLCs in cell-transplantation-based liver regeneration. (キーワード) Bone Morphogenetic Proteins / Cell Differentiation / Cell- and Tissue-Based Therapy / Cells, Cultured / Coculture Techniques / Cytological Techniques / Fibroblast Growth Factors / Hepatocyte Nuclear Factor 4 / Hepatocytes / Homeodomain Proteins / Humans / Liver Diseases / Liver Regeneration / SOXF Transcription Factors / Stem Cells / Transcription Factors (出版サイトへのリンク) ● Publication site (DOI): 10.1007/s00595-020-02092-6 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32754843 ● Search Scopus @ Elsevier (PMID): 32754843 ● Search Scopus @ Elsevier (DOI): 10.1007/s00595-020-02092-6 (DOI: 10.1007/s00595-020-02092-6, PubMed: 32754843)
41.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada and Mitsuo Shimada : Preoperative prognostic nutritional index predicts short- and long-term outcomes after liver resection in patients with hepatocellular carcinoma., Oncology Letters, Vol.21, No.2, 153, 2021. (要約) The prognostic nutritional index (PNI) is one of the immune parameters calculated on the basis of the serum albumin and the total lymphocyte count. The aim of the present study was to investigate the prognostic significance of the PNI for short- and long-term outcomes after liver resection for patients with hepatocellular carcinoma (HCC). Data from 162 surgically treated patients with HCC (without any previous treatment) were retrospectively analyzed. The cutoff value of preoperative PNI was 45.0, which was calculated by a receiver operating characteristic curve for predicting the recurrence of HCC after liver resection. Patients were divided into low (n=86) and high (n=76) PNI groups. In short-term outcomes, patients in the low PNI group were more likely to experience postoperative complications compared with those in the high PNI group. The 5-year disease-free survival (DFS) rate in the low PNI group was significantly lower compared with that in the high PNI group (20.5% vs. 48.7%). In the multivariate analysis, a low PNI was an independent prognostic factor for DFS (HR, 1.65; 95% CI, 1.00-2.71). In conclusion, the preoperative PNI may be a prognostic factor for evaluating short- and long-term outcomes after liver resection in patients with HCC. (出版サイトへのリンク) ● Publication site (DOI): 10.3892/ol.2020.12414 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33552271 ● Summary page in Scopus @ Elsevier: 2-s2.0-85099380892 (DOI: 10.3892/ol.2020.12414, PubMed: 33552271, Elsevier: Scopus)
42.	Kazunori Tokuda, Yuji Morine, Katsuki Miyazaki, Shin-ichiro Yamada, Yu Saitou, Masaaki Nishi, Takuya Tokunaga, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : The interaction between cancer associated fibroblasts and tumor associated macrophages via the osteopontin pathway in the tumor microenvironment of hepatocellular carcinoma., Oncotarget, Vol.12, No.4, 333-343, 2021. (要約) Cancer-tumor associated macrophage (TAM)-cancer associated fibroblast (CAF) interactions are an important factor in the tumor microenvironment of hepatocellular carcinoma. Hepatic stellate cells (HSCs) were cultured with cancer cell-conditioned medium (Ca.-CM), TAM-CM and CAF-CM, and the expression of CAF markers were evaluated by RT-PCR. Whether HSCs cultured with Ca.-CM, TAM-CM and CAF-CM contributed to the enhanced malignancy of cancer cells was examined using proliferation, invasion and migration assays. Furthermore, the differences between these three types of CM were evaluated using cytokine arrays. HSCs cultured with Ca.-CM, TAM-CM and CAF-CM showed significantly increased mRNA expression of SMA, FAP and IL-6. All HSCs cultured with each CM exhibited significantly increased proliferation, invasion and migration of cancer cells. The osteopontin concentration was significantly higher in HSCs cultured with TAM-CM than the other CAF-CMs. Osteopontin inhibition significantly reduced osteopontin secretion from HSCs cultured with TAM-CM and suppressed the proliferation and invasion of cancer cells enhanced by HSCs cultured with TAM-CM. We observed enhanced osteopontin secretion from TAMs, and this increased osteopontin further promoted osteopontin secretion from HSCs cultured with TAM-CM, leading to increased malignancy. For the first time, we demonstrated the importance of cancer-TAM-CAF interactions via osteopontin in hepatocellular carcinoma. (徳島大学機関リポジトリ) ● Metadata: 116612 (出版サイトへのリンク) ● Publication site (DOI): 10.18632/oncotarget.27881 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33659044 ● Search Scopus @ Elsevier (PMID): 33659044 ● Search Scopus @ Elsevier (DOI): 10.18632/oncotarget.27881 (徳島大学機関リポジトリ: 116612, DOI: 10.18632/oncotarget.27881, PubMed: 33659044)
43.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Masato Yoshikawa and Katsuki Miyazaki : Significance of Frailty in Prognosis After Hepatectomy for Elderly Patients with Hepatocellular Carcinoma., Annals of Surgical Oncology, Vol.28, No.1, 439-446, 2021. (要約) The concept of frailty becomes important for patients who undergo surgery in this recent aging society. The aim of this study is to investigate the frailty as a prognostic factor in elderly patients with hepatocellular carcinoma (HCC) who underwent hepatectomy. A total of 92 patients over 75 years old who underwent hepatectomy were enrolled in this study. Frailty was defined as clinical frailty scale (CFS) 4. Patients were divided into two groups, i.e., frailty group (n = 21) and no-frailty group (n = 71), and clinicopathological features were compared between them. The frailty group showed significant higher PIVKA-II level and larger tumor diameter (p < 0.05). CRP level and modified Glasgow prognostic score were significantly higher in the frailty group (p < 0.05). The frailty group showed higher rate of postoperative complications of Clavien-Dindo III (p = 0.06) and longer postoperative stay (p = 0.08). Cancer-specific, overall, and disease-free survival rates were significantly worse in the frailty group (p < 0.05). Frailty was detected as an independent prognostic factor on multivariate analysis of cancer-specific survival. Frailty can estimate the prognosis of HCC patients who underwent hepatectomy. (キーワード) Aged / Carcinoma, Hepatocellular / Frail Elderly / Frailty / Hepatectomy / Humans / Liver Neoplasms / Neoplasm Recurrence, Local / Prognosis (出版サイトへのリンク) ● Publication site (DOI): 10.1245/s10434-020-08742-w (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32562115 ● Search Scopus @ Elsevier (PMID): 32562115 ● Search Scopus @ Elsevier (DOI): 10.1245/s10434-020-08742-w (DOI: 10.1245/s10434-020-08742-w, PubMed: 32562115)
44.	Hiroki Mori, Yuji Morine, Kazuaki Mawatari, Ayumi Chiba, Shin-ichiro Yamada, Yu Saitou, Hiroki Ishibashi, Akira Takahashi and Mitsuo Shimada : Bile Metabolites and Risk of Carcinogenesis in Patients With Pancreaticobiliary Maljunction: A Pilot Study., Anticancer Research, Vol.41, No.1, 327-334, 2021. (要約) Pancreaticobiliary maljunction (PBM), a disease with reflux of pancreatic and bile juice in the pancreaticobiliary tract, is a high-risk factor for biliary tract cancer. The aim of this study was to investigate the mechanism of carcinogenesis in PBM using a metabolomics analysis of bile sampled during surgery. Three patients with PBM without biliary tract cancer, four patients with extrahepatic bile duct cancer (EHBC), and three controls with benign disease were enrolled. Metabolomics analysis of bile samples was performed using capillary electrophoresis-mass spectrometry and liquid chromatography-mass spectrometry to discriminate the amino acid and lipidomic profiles. The principal component analysis in the capillary electrophoresis-mass spectrometry and liquid chromatography-mass spectrometry revealed similar metabolites in patients with PBM and those with EHBC; furthermore, there was a clear difference between patients with PBM or EHBC compared to controls. The amino acid profiles revealed the following 20 potential carcinogenic candidates for PBM: isoleucine, phenylalanine, tyrosine, leucine, tryptophan, arginine, lysine, valine, asparagine, methionine, aspartic acid, serine, threonine, histidine, glutamine, alanine, proline, glutamic acid, and pyruvic acid. The lipidomic profiles revealed the following 11 carcinogenic candidates: lysophosphatidylcholine, lysophosphatidylethanolamine, phosphatidyl glycerol, lysophosphatidyl glycerol, triacylglycerol, diacylglycerol, ceramide, sphyngomyeline, fatty acid, hyperforin, and vitamin D. Among these characteristic metabolites, the branched-chain amino acids, methionine and lysophosphatidylcholine are known to be related to carcinogenesis. The bile metabolites were extremely similar in patients with PBM and those with EHBC. Furthermore, amino acid and lipid metabolism was markedly different in patients with PBM or EHBC compared to healthy controls. (キーワード) Bile / Bile Duct Neoplasms / Cell Transformation, Neoplastic / Chromatography, Liquid / Disease Susceptibility / Electrophoresis, Capillary / Female / Humans / Male / Mass Spectrometry / Metabolomics / Pancreaticobiliary Maljunction / Pilot Projects / Risk Assessment / Risk Factors (出版サイトへのリンク) ● Publication site (DOI): 10.21873/anticanres.14779 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33419827 ● Search Scopus @ Elsevier (PMID): 33419827 ● Search Scopus @ Elsevier (DOI): 10.21873/anticanres.14779 (DOI: 10.21873/anticanres.14779, PubMed: 33419827)
45.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada and Mitsuo Shimada : Regeneration of caudate lobe after living donor liver transplantation : Comparison with a surrogate model of left lobe graft., The Journal of Medical Investigation : JMI, Vol.68, No.3.4, 330-333, 2021. (要約) Background : The aim of this study is to clarify the regeneration of the CL (caudate lobe) without any reconstructions of short hepatic veins (SHVr) after LDLT (living donor liver transplantation) and compare the regeneration of the CL after right hepatectomy (Rt. Hx), as the surrogate model of extended left lobe graft (Ex LLG) with complete SHVr. Methods : Eleven Ex LLGs with CL were included in this study. SHVr was not performed in all cases. The volumetry was performed before, one month and six months after LDLT. Seven patients who underwent Rt. Hx were also included in this study as the surrogate model. Results : In Ex LLGs with CL, the regeneration rate of the large CL (> 30 ml) was worse than that of small CL (< 30 ml). In the surrogate model, the regeneration rate of the CL was not worse than other segments. However, the regeneration rate of the large CL was also worse than that of small CL even in the presence of complete SHVr. Conclusions : The regeneration of the large CL was worse than that of the small CL regardless of the presence or absence of SHVr, indicating that SHVr in Ex LLG with CL might not be necessary. J. Med. Invest. 68 : 330-333, August, 2021. (キーワード) Hepatectomy / Hepatic Veins / Humans / Liver / Liver Transplantation / Living Donors (徳島大学機関リポジトリ) ● Metadata: 116533 (出版サイトへのリンク) ● Publication site (DOI): 10.2152/jmi.68.330 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34759154 ● Search Scopus @ Elsevier (PMID): 34759154 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.68.330 (徳島大学機関リポジトリ: 116533, DOI: 10.2152/jmi.68.330, PubMed: 34759154)
46.	Yusuke Arakawa, Katsuki Miyazaki, Masato Yoshikawa, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : Value of the CRP-albumin ratio in patients with resectable pancreatic cancer., The Journal of Medical Investigation : JMI, Vol.68, No.3.4, 244-255, 2021. (要約) Background : The C-reactive protein (CRP)-albumin ratio (CAR) was reported as a prognostic factor of resectable hepatocellular carcinoma. The aim of this study was to analyse the significance of CAR in resectable pancreatic cancer. Patients and Methods : 163 patients with curative resection for pancreatic cancer were enrolled in this retrospective study. Cases of non-curative resection were excluded. The CAR was calculated with the preoperative plasma CRP and albumin values, with a cut-off value of 0.06, as calculated in a previous report. Results : Patients in the low CAR group had significantly better overall survival (OS) and disease-free survival (DFS) compared with the high CAR group (P < 0.05). On multivariate analysis, for high CAR, CA19-9 > 300 U /l and receipt of adjuvant chemotherapy were independent risk factors for OS and DFS. High CAR was significantly associated with advanced T stage. Conclusion : The CAR might be a prognostic factor for patients with resectable pancreatic cancer. J. Med. Invest. 68 : 244-248, August, 2021. (キーワード) Albumins / C-Reactive Protein / Humans / Pancreatic Neoplasms / Prognosis / Retrospective Studies (徳島大学機関リポジトリ) ● Metadata: 116489 (出版サイトへのリンク) ● Publication site (DOI): 10.2152/jmi.68.244 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34759138 ● Search Scopus @ Elsevier (PMID): 34759138 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.68.244 (徳島大学機関リポジトリ: 116489, DOI: 10.2152/jmi.68.244, PubMed: 34759138)
47.	Shuhai Chen, Tetsuya Ikemoto, Takuya Tokunaga, Shohei Okikawa, Katsuki Miyazaki, Kazunori Tokuda, Shin-ichiro Yamada, Yu Saitou, Satoru Imura, Yuji Morine and Mitsuo Shimada : Effective in vitro differentiation of adipose-derived stem cells into Schwann-like cells with folic acid supplementation., The Journal of Medical Investigation : JMI, Vol.68, No.3.4, 347-353, 2021. (要約) Peripheral nerve injury (PNI) after pelvic surgery is a common issue with a significant impact on patients. Autologous nerve grafting is the gold standard treatment for PNI, but this technique cannot be applied to fine nerve fibers in the pelvis. Schwann-like cell (SLC) differentiation is a novel therapeutic strategy for this clinical condition. However, the efficiency of SLC differentiation remains unsatisfactory. We modified an SLC differentiation protocol using adipose-derived stem cells (ADSCs) and folic acid. Morphology, gene expression and secretion of neurotrophic factors were examined to assess the differentiation quality and phenotypic characteristics. Our new modified protocol effectively induced a Schwann cell (SC) phenotype in ADSCs as assessed by morphology and expression of SC markers [S100 calcium-binding protein B (S100B), P < 0.01 ; p75 neurotrophic receptor (p75NTR), P < 0.05]. SLCs produced by the new protocol displayed a repair phenotype with decreased expression of ERBB2 and early growth response protein 2 (EGR2) /ROX20 (P < 0.01). Furthermore, our new protocol enhanced both mRNA expression and secretion of nerve growth factors by SLCs (P < 0.01). This protocol enhanced the SC characteristics and functions of ADSC-derived SLCs. This promising protocol requires further research and may contribute to SC-based nerve regeneration. J. Med. Invest. 68 : 347-353, August, 2021. (キーワード) Adipose Tissue / Cell Differentiation / Cells, Cultured / Dietary Supplements / Folic Acid / Humans / Stem Cells (徳島大学機関リポジトリ) ● Metadata: 116542 (出版サイトへのリンク) ● Publication site (DOI): 10.2152/jmi.68.347 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34759157 ● Search Scopus @ Elsevier (PMID): 34759157 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.68.347 (徳島大学機関リポジトリ: 116542, DOI: 10.2152/jmi.68.347, PubMed: 34759157)
48.	Yuji Morine, Toru Utsunomiya, Yu Saitou, Shin-ichiro Yamada, Satoru Imura, Tetsuya Ikemoto, Akihiro Kitagawa, Yuta Kobayashi, Seiichiro Takao, Keisuke Kosai, Koshi Mimori, Yasuhito Tanaka and Mitsuo Shimada : Reduction of T-Box 15 gene expression in tumor tissue is a prognostic biomarker for patients with hepatocellular carcinoma., Oncotarget, Vol.11, No.52, 4803-4812, 2020. (要約) Genome-wide analysis is widely applied to detect molecular alterations during oncogenesis and tumor progression. We analyzed DNA methylation profiles of hepatocellular carcinoma (HCC), and investigated the clinical role of most heypermethylated of tumor, encodes T-box 15 (TBX15), which was originally involved in mesodermal differentiation. We conducted a genome-wide analysis of DNA methylation of tumor and non-tumor tissue of 15 patients with HCC, and revealed was the most hypermethylated gene of tumor (Beta-value in tumor tissue = 0.52 compared with non-tumor tissue). Another validation set, which comprised 58 HCC with radical resection, was analyzed to investigate the relationships between tumor phenotype and mRNA expression. mRNA levels in tumor tissues were significantly lower compared with those of nontumor tissues ( < 0.0001). When we assigned a cutoff value = 0.5-fold, the overall survival 5-year survival rates of the low-expression group ( = 17) were significantly shorter compared with those of the high-expression group ( = 41) (43.3% vs. 86.2%, = 0.001). Multivariate analysis identified low expression as an independent prognostic factor for overall and disease-free survival. Therefore, genome-wide DNA methylation profiling indicates that hypermethylation and reduced expression of in tumor tissue represents a potential biomarker for predicting poor survival of patients with HCC. (徳島大学機関リポジトリ) ● Metadata: 116613 (出版サイトへのリンク) ● Publication site (DOI): 10.18632/oncotarget.27852 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33447348 ● Search Scopus @ Elsevier (PMID): 33447348 ● Search Scopus @ Elsevier (DOI): 10.18632/oncotarget.27852 (徳島大学機関リポジトリ: 116613, DOI: 10.18632/oncotarget.27852, PubMed: 33447348)
49.	Yuuma Wada, Kazunori Tokuda, Yuji Morine, Shohei Okikawa, Shoko Yamashita, Tetsuya Ikemoto, Satoru Imura, Yu Saitou, Shin-ichiro Yamada and Mitsuo Shimada : The inhibitory effect of TU-100 on hepatic stellate cell activation in the tumor microenvironment., Oncotarget, Vol.11, No.49, 4593-4604, 2020. (要約) The tumor microenvironment is involved in acquiring tumor malignancies of colorectal liver metastasis (CRLM). We have reported that TU-100 (Daikenchuto) suppresses hepatic stellate cell (HSC) activation in obstructive jaundice. In this study, we report new findings as the direct and indirect inhibitory effects of TU-100 on cancer cell growth through the suppression of HSC activation. The HSCs (LX2) were cultured in colon cancer cells (HCT116 and HT29)-conditioned medium (CM) with or without TU-100 treatment (90, 270, 900 g/ml). Activated HSCs (aHSCs) were detected by -SMA and IL-6 mRNA expressions and cytokine arrays of HSC's culture supernatants. Cancer cell growth was analyzed for proliferation and migration ability, compared with TU-100 treatment. To investigate the direct anti-tumor effect of TU-100, cancer cells were cultured in the presence of aHSC-CM and TU-100 (90, 270, 900) or aHSC-CM alone, and assessed autophagosomes, conversion to LC3-II protein, and Beclin-1 mRNA expression. Colon cancer-CM significantly increased -SMA and IL-6 mRNA expressions of aHSC. -SMA and IL-6 mRNA expressions of aHSC, and IL-6 secretions from aHSCs were significantly decreased with TU-100 (270, 900) treatment, compared to colon cancer-CM alone. Compared with normal culture medium, aHSC-CM led to a significantly increased cell number and modified HSC-CM (TU-100; 270, 900) significantly suppressed cancer cell growth and migration. TU-100 (900) treatment induced autophagy and significantly promoted the autophagic cell death. TU-100 inhibited colon cancer cell malignant potential by both suppressing HSC activation and inducing directly autophagy of cancer cells. (徳島大学機関リポジトリ) ● Metadata: 116616 (出版サイトへのリンク) ● Publication site (DOI): 10.18632/oncotarget.27835 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33346211 ● Search Scopus @ Elsevier (PMID): 33346211 ● Search Scopus @ Elsevier (DOI): 10.18632/oncotarget.27835 (徳島大学機関リポジトリ: 116616, DOI: 10.18632/oncotarget.27835, PubMed: 33346211)
50.	Tetsuya Ikemoto, Kazunori Tokuda, Yuuma Wada, Luping Gao, Katsuki Miyazaki, Shin-ichiro Yamada, Yu Saitou, Satoru Imura, Yuji Morine and Mitsuo Shimada : Adipose Tissue From Type 1 Diabetes Mellitus Patients Can Be Used to Generate Insulin-Producing Cells., Pancreas, Vol.49, No.9, 1225-1231, 2020. (要約) We aimed to determine whether responsive insulin-producing cells (IPCs) could be generated from adipose-derived stem cells (ADSCs) isolated from patients with type 1 diabetes mellitus (T1DM). We isolated ADSCs from adipose tissue of 4 patients (one patient with T1DM and 3 nondiabetic patients), who underwent surgery and differentiated them into IPCs with using a 2-step xeno-antigen free, 3-dimensional culture method. Characteristics of isolated ADSCs, in vitro cell quality, programmed cell death ligand-1 (PDL-1) expression, and transplantation into streptozotocin induced diabetic nude mice were investigated. Adipose-derived stem cells from T1DM patients and commercially obtained ADSCs showed the same surface markers; CD31CD34CD45CD90CD105CD146. Moreover, the generated IPCs at day 21 demonstrated appropriate autonomous insulin secretion (stimulation index, 3.5; standard deviation, 0.8). Nonfasting blood glucose concentrations of IPC-transplanted mice were normal at 30 days. The normalized rate of IPC-transplanted mice was significantly higher than that of the sham-operated group (P < 0.05). Insulin-producing cells generated from T1DM adipose tissue expressed high levels of PDL-1. Insulin-producing cells obtained from adipose tissue of T1DM patients are capable of secreting insulin long-term and achieve normoglycemia after transplantation. Expression of PDL-1 suggests the potential for immune circumvention. (出版サイトへのリンク) ● Publication site (DOI): 10.1097/MPA.0000000000001663 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32898009 ● Search Scopus @ Elsevier (PMID): 32898009 ● Search Scopus @ Elsevier (DOI): 10.1097/MPA.0000000000001663 (DOI: 10.1097/MPA.0000000000001663, PubMed: 32898009)
51.	Yuuma Wada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Chie Takasu, Shin-ichiro Yamada and Mitsuo Shimada : HIF-1 expression in liver metastasis but not primary colorectal cancer is associated with prognosis of patients with colorectal liver metastasis., World Journal of Surgical Oncology, Vol.18, No.1, 241, 2020. (要約) The role of hypoxia-inducible factor-1 (HIF-1 ) in primary colorectal cancer (CRC) and colorectal liver metastasis (CRLM) has remained unclear. The aim of this study was to investigate HIF-1 expression and its association with prognosis in patients with CRLM with a focus on hepatic stellate cells (HSCs). Colon cancer cells were cultured in HSC-conditioned medium (CM), and HIF-1 expression and cell migration were analyzed. Seventy-five patients with CRLM who underwent an initial curative hepatectomy were enrolled. We examined HIF-1 expressions and patient prognosis between primary CRCs and the matched liver metastatic specimens. Activated HSCs induced HIF-1 mRNA and protein expression in colon cancer cells (p < 0.01) and promoted cell migration (p < 0.01). The positive rates of HIF-1 expression in primary CRCs and liver metastases were 68.0 and 72.0%, respectively. There were no differences in overall (OS) and disease-free survival (DFS) of HIF-1 expression in primary CRC. However, HIF-1 expression in liver metastasis correlated to poor prognosis in both OS and DFS. Furthermore, patients with HIF-1 positive expression in liver metastasis had poor prognosis. HIF-1 expression in liver metastasis determines poor prognosis of CRLM patients. HSCs might play a key role in aggressive phenotypes of tumor cells. (キーワード) Colonic Neoplasms / Colorectal Neoplasms / Humans / Hypoxia-Inducible Factor 1, alpha Subunit / Liver Neoplasms / Prognosis (徳島大学機関リポジトリ) ● Metadata: 116676 (出版サイトへのリンク) ● Publication site (DOI): 10.1186/s12957-020-02012-5 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32895059 ● Search Scopus @ Elsevier (PMID): 32895059 ● Search Scopus @ Elsevier (DOI): 10.1186/s12957-020-02012-5 (徳島大学機関リポジトリ: 116676, DOI: 10.1186/s12957-020-02012-5, PubMed: 32895059)
52.	Kazunori Tokuda, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Katsuki Miyazaki, Shoko Yamashita, Shohei Okikawa, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : Effectiveness of repeat surgery for recurrence after primary hepatectomy in patients with intrahepatic cholangiocarcinoma., International Journal of Clinical Oncology, Vol.25, No.12, 2083-2089, 2020. (要約) Intrahepatic cholangiocarcinoma (IHCC) has a poor prognosis, and surgery remains the only effective treatment. However, tumor recurrence after primary hepatectomy is common. We examined the significance of repeat surgery for IHCC. We collected data for all patients with IHCC between 1992 and 2018 (n = 67) in our database. Fifty-three (79.1%) of all 67 patients experienced recurrence after primary hepatectomy and we analyzed data for those 53 recurrent patients. We divided recurrent patients into a repeat surgery group (n = 9), chemotherapy group (n = 19), and best supportive care group (n = 25). We analyzed differences in patients' clinicopathological factors, including prognosis, between the three groups. The IHCC recurrence rate after hepatectomy in our institution was 79.1%. Of the 53 patients with recurrence, nine underwent repeat surgery (17.0%). The characteristics of the patients undergoing repeat surgery was lower stage at primary hepatectomy. Recurrence sites in the repeat surgery group were liver (n = 6), lung (n = 2), and adrenal gland (n = 1), as a single nodule. The period between primary hepatectomy and recurrence was comparatively longer in the repeat surgery group, at 1.8 years. The prognosis in patients undergoing repeat surgery was significantly better compared with the other groups. Not undergoing repeat surgery (hazard ratio: 5.506; p = 0.0077) and positive lymph node metastasis (hazard ratio: 2.207; p = 0.0242) were independent poor prognostic factors. Repeat surgery should be considered in patients with IHCC with a single recurrence site and negative lymph node metastasis at primary surgery and at least more than 6 months of disease-free period after primary surgery. (キーワード) Adrenal Gland Neoplasms / Adrenalectomy / Adult / Aged / Aged, 80 and over / Bile Duct Neoplasms / Bile Ducts, Intrahepatic / Cholangiocarcinoma / Female / Hepatectomy / Humans / Liver Neoplasms / Lung Neoplasms / Lymphatic Metastasis / Male / Middle Aged / Neoplasm Recurrence, Local / Prognosis / Proportional Hazards Models / Reoperation / Treatment Outcome (出版サイトへのリンク) ● Publication site (DOI): 10.1007/s10147-020-01775-x (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32869120 ● Search Scopus @ Elsevier (PMID): 32869120 ● Search Scopus @ Elsevier (DOI): 10.1007/s10147-020-01775-x (DOI: 10.1007/s10147-020-01775-x, PubMed: 32869120)
53.	Shuichi Iwahashi, AHMAD AMMAR GHAIBEH, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Jun Hirose : Predictability of postoperative recurrence on hepatocellular carcinoma through data mining method., Molecular and Clinical Oncology, Vol.13, No.5, 46, 2020. (要約) Hepatocellular carcinoma (HCC) is a highly lethal tumor and the majority of postoperative patients experience recurrence. In the present study, we focus on the predictability of postoperative recurrence on HCC through the data mining method. In total, 323 patients with HCC who underwent hepatic resection were included in the present study, 156 of whom suffered from cancer recurrence. Clinicopathological data including prognosis were analyzed using the data mining method for the predictability of postoperative recurrence on HCC. The resulting alternating decision tree (ADT) was described using data mining method. This tree was validated using a 10-fold cross validation process. The average and standard deviation of the accuracy, sensitivity, and specificity were 69.0 8.2, 59.7 14.5 and 77.7 10.2%, respectively. The identified postoperative recurrence factors were age, viral hepatitis, stage, GOT and T-cholesterol. Data mining method could identify the factors associated at different levels of significance with postoperative recurrence of HCC. These factors could help to predict the postoperative recurrence of HCC. (出版サイトへのリンク) ● Publication site (DOI): 10.3892/mco.2020.2116 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32874576 ● Search Scopus @ Elsevier (PMID): 32874576 ● Search Scopus @ Elsevier (DOI): 10.3892/mco.2020.2116 (DOI: 10.3892/mco.2020.2116, PubMed: 32874576)
54.	Toshiaki Yoshimoto, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Yu Saitou, Shin-ichiro Yamada, Katsuki Miyazaki, Yukako Takehara and Mitsuo Shimada : Impact of using a perioperative artificial endocrine pancreas in pancreatic resection., Annals of Gastroenterological Surgery, Vol.4, No.5, 591-596, 2020. (要約) Pancreatectomy causes both hyperglycemia, secondary to surgical stress, and pancreatic diabetes, which leads to difficult-to-control postoperative blood glucose levels. We investigated whether using an artificial pancreas perioperatively to provide appropriate blood glucose control could reduce postoperative complications following pancreatectomy. We retrospectively enrolled 52 patients who underwent pancreatectomy at Tokushima University Hospital from 2015 to 2019. The most recent 26/52 patients received perioperative blood glucose control using an artificial pancreas. Postoperative blood glucose control with manual insulin injections based on a sliding scale was performed in the earlier 26 patients (controls). We compared surgical outcomes between the artificial pancreas group and the control group. There was no significant difference in patients' white blood cell or neutrophil counts, prognostic nutritional index, neutrophil-lymphocyte ratio, and C-reactive protein-to-albumin ratio on postoperative day 1; however, lymphocyte counts were higher in the artificial pancreas group. The number of serious complications of Clavien-Dindo grade >IIIa was significantly lower in the artificial pancreas group ( < .05). Using an artificial pancreas for perioperative blood glucose control in patients undergoing pancreatectomy decreased the number of serious complications through proper management of blood glucose levels without hypoglycemia, and may influence peripheral lymphocytes. (徳島大学機関リポジトリ) ● Metadata: 116476 (出版サイトへのリンク) ● Publication site (DOI): 10.1002/ags3.12374 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33005854 ● Search Scopus @ Elsevier (PMID): 33005854 ● Search Scopus @ Elsevier (DOI): 10.1002/ags3.12374 (徳島大学機関リポジトリ: 116476, DOI: 10.1002/ags3.12374, PubMed: 33005854)
55.	Hiroki Teraoku, Yuji Morine, Naoto Uyama, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Chie Takasu, Satoru Imura, Masafumi Harada and Mitsuo Shimada : Role of Central Hypo-enhancement in the Hepatic Arterial Phase of Dynamic Computed Tomography in Patients with Mass-Forming Intrahepatic Cholangiocarcinoma., World Journal of Surgery, Vol.44, No.7, 2350-2358, 2020. (要約) The enhancement pattern in the hepatic arterial phase (HAP) of dynamic computed tomography (CT) is reportedly a prognostic marker in patients with intrahepatic cholangiocarcinoma (IHCC). This study was performed to clarify the significance of central hypo-enhancement in the HAP in patients with mass-forming IHCC. Forty patients who had undergone initial surgical resection for mass-forming IHCC were enrolled. The dynamic CT was scanned 40 s after contrast agent injection as the HAP. A radiologist classified the patients into three groups based on the vascular pattern: the hyper-enhancement group (Hyper group), rim-enhancement group (Rim group), and hypo-enhancement group (Hypo group). The surgical specimens were immunohistochemically stained for hypoxia-inducible factor 1 (HIF-1). The correlation with clinicopathological findings and HIF-1 expression was investigated. The Hyper, Rim, and Hypo groups comprised 8, 7, and 25 patients, respectively. There were no significant correlations between the groups and clinicopathological factors. Overall survival (OS) was significantly worse in the Hypo than in the Hyper group (p = 0.03). OS was also significantly worse in the Rim +ypo group (i.e., hypo-enhancement in the central tumor) than in the Hyper group (p = 0.04). Furthermore, inclusion in the Rim +ypo group was a prognostic factor for OS (hazard ratio 6.68). High HIF-1 expression in the central part of the tumor was correlated with central hypo-enhancement (Hyper group: 25% and Rim +ypo group: 72%). Central hypo-enhancement was a prognostic factor in patients with IHCC. The high malignant potential of tumors with central hypo-enhancement might be associated with HIF-1 upregulation. (キーワード) Adult / Aged / Bile Duct Neoplasms / Bile Ducts, Intrahepatic / Biomarkers, Tumor / Cholangiocarcinoma / Contrast Media / Female / Follow-Up Studies / Hepatectomy / Hepatic Artery / Humans / Hypoxia-Inducible Factor 1, alpha Subunit / Male / Middle Aged / Multidetector Computed Tomography / Prognosis / Proportional Hazards Models / Retrospective Studies (出版サイトへのリンク) ● Publication site (DOI): 10.1007/s00268-020-05456-8 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32152739 ● Search Scopus @ Elsevier (PMID): 32152739 ● Search Scopus @ Elsevier (DOI): 10.1007/s00268-020-05456-8 (DOI: 10.1007/s00268-020-05456-8, PubMed: 32152739)
56.	Katsuki Miyazaki, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Kazunori Tokuda, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : Pancreatoduodenectomy co-morbid with celiac axis compression syndrome: a report of three cases., Surgical Case Reports, Vol.6, No.1, 113, 2020. (要約) Celiac axis compression syndrome (CACS) is a relatively rare disease. Because of the nature of the blood flow in the celiac region when a pancreatoduodenectomy (PD) is performed for CACS, the celiac region can become ischemic. The aim of this study is to report on the importance of pre-operative diagnosis of CACS in terms of the outcomes for patients post-operatively. In this study, three 3 cases of PD co-morbid with CACS are reported: one intra-operative diagnosis case and two pre-operative diagnosis cases. The one case, not diagnosed with CACS prior to the operation, had a hard post-operative course because of complication caused by ischemia of the celiac region compared with the two cases diagnosed prior to the operation, who had a good post-operative course because of pre-operative or intra-operative intervention. Post-operative complications due to CACS are preventable by pre-operative diagnosis and appropriate interventions. (出版サイトへのリンク) ● Publication site (DOI): 10.1186/s40792-020-00878-x (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32449014 ● Search Scopus @ Elsevier (PMID): 32449014 ● Search Scopus @ Elsevier (DOI): 10.1186/s40792-020-00878-x (DOI: 10.1186/s40792-020-00878-x, PubMed: 32449014)
57.	齋藤裕, 島田光生 : 【最先端医療を支える病理学】肝胆膵外科の最先端手術画像支援と病理診断のコラボ, 四国医学雑誌, Vol.76, No.1-2, 9-12, 2020年. (要約) We introduced the pre and intra-operative3D hologram support system, which was a computer graphics model, with extended reality(XR)techniques. It contributed to a more extensive view of 3D anatomy from various angles and the sharing of the same hologram from several respective operators' angles. The colabolation between such an operative supporrt and pathological diagnosis enables more safe and higher quality operations. (キーワード) ホログラフィー肝臓疾患(画像診断,外科的療法,病理学) コンピュータグラフィックス細胞診術中期消化器外科コンピュータ支援診断膵臓疾患(画像診断,外科的療法,病理学) 胆道疾患(画像診断,外科的療法,病理学) ヒト (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1050302172852511104 (CiNii: 1050302172852511104)
58.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Masato Yoshikawa, Katsuki Miyazaki and Mitsuo Shimada : Prognostic prediction of apparent diffusion coefficient obtained by diffusion-weighted MRI in mass-forming intrahepatic cholangiocarcinoma., Journal of Hepato-Biliary-Pancreatic Sciences, Vol.27, No.7, 388-395, 2020. (要約) We evaluated apparent diffusion coefficient (ADC) of diffusion-weighted image MRI as a prognostic factor for mass-forming intrahepatic cholangiocarcinoma (IHCC). We enrolled 26 patients who had undergone hepatic resections for mass-forming-type IHCC in this study, and calculated their mean ADC, using diffusion-weighted image MRI (b: 0, 20, 800 seconds/mm ; 1.5 T MRI). Patients were divided into the ADC and the ADC groups at the median ADC value (n = 13 for both). We also immunohistochemically evaluated hypoxia-inducible factor (HIF)-1 in tumor tissue. Median age in the ADC was older (P = .03), and showed significant higher rate of scirrhous tumor (P = .02). The 5-year overall survival rate in the ADC group was significantly worse than in the ADC group (P = .04). In multivariate analysis, hilar tumor, portal vein invasion and low ADC were independent prognostic factors (P < .05). The ADC group also had a higher rate of high HIF-1 expression than the ADC group (P < .05). Representative case of ADC group showed rich stroma and high HIF-1 expression. The ADC values in MRIs can predict IHCC prognosis, and correlated with stromal density and HIF-1 expression. (キーワード) Aged / Algorithms / Bile Duct Neoplasms / Biomarkers, Tumor / Cholangiocarcinoma / Contrast Media / Diffusion Magnetic Resonance Imaging / Female / Hepatectomy / Humans / Hypoxia-Inducible Factor 1, alpha Subunit / Male / Neoplasm Invasiveness / Prognosis / Survival Rate / Tomography, X-Ray Computed (出版サイトへのリンク) ● Publication site (DOI): 10.1002/jhbp.732 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32162483 ● Search Scopus @ Elsevier (PMID): 32162483 ● Search Scopus @ Elsevier (DOI): 10.1002/jhbp.732 (DOI: 10.1002/jhbp.732, PubMed: 32162483)
59.	Yu Saitou, Maki Sugimoto, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Shin-ichiro Yamada and Mitsuo Shimada : Intraoperative 3D Hologram Support With Mixed Reality Techniques in Liver Surgery., Annals of Surgery, Vol.271, No.1, e4-e7, 2020. (要約) The aim of this study was to investigate the potential of an intraoperative 3D hologram, which was a computer graphics model liver, with mixed reality techniques in liver surgery. The merits for the application of a hologram for surgical support are: 1) no sterilized display monitor; 2) better spatial awareness; and 3) 3D images shared by all the surgeons. 3D polygon data using preoperative computed tomography data was installed into head mount displays, HoloLens (Microsoft Corporation, Redmond, WA). In a Wi-Fi-enabled operative room, several surgeons wearing HoloLens succeeded in sharing the same hologram and moving that hologram from respective operators' angles by means of easy gesture-handling without any monitors. The intraoperative hologram contributed to better imagination of tumor locations, and for determining the parenchymal dissection line in the hepatectomy for the patients with more than 20 multiple colo-rectal liver metastases. In another case, the hologram enabled a safe Gliisonean pedicle approach for hepato-cellular carcinoma with a hilar anatomical anomaly. Surgeons could easily compare the real patient's anatomy and that of the hologram just before the hepatic hilar procedure. This initial experience suggested that an intraoperative hologram with mixed reality techniques contributed to "last-minute simulation," not for "navigation." The intraoperative hologram might be a new next-generation operation-supportive tool in terms of spatial awareness, sharing, and simplicity. (徳島大学機関リポジトリ) ● Metadata: 114184 (出版サイトへのリンク) ● Publication site (DOI): 10.1097/SLA.0000000000003552 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31425293 ● Search Scopus @ Elsevier (PMID): 31425293 ● Search Scopus @ Elsevier (DOI): 10.1097/SLA.0000000000003552 (徳島大学機関リポジトリ: 114184, DOI: 10.1097/SLA.0000000000003552, PubMed: 31425293)
60.	Kazunori Tokuda, Tetsuya Ikemoto, Yu Saitou, Katsuki Miyazaki, Shoko Yamashita, Shin-ichiro Yamada, Satoru Imura, Yuji Morine and Mitsuo Shimada : The Fragility of Cryopreserved Insulin-producing Cells Differentiated from Adipose-tissue-derived Stem Cells., Cell Transplantation, Vol.29, 963689720954798, 2020. (要約) The aim of our study is to determine whether insulin-producing cells (IPCs) differentiated from adipose-tissue-derived stem cells (ADSCs) can be cryopreserved. Human ADSCs were differentiated into IPCs using our two-step protocol encompassing a three-dimensional culture and xenoantigen-free method. Thereafter, IPCs were frozen using three different methods. First, IPCs were immediately frozen at -80 C (-80 C group). Second, IPCs were initially placed into a Bicell freezing container before freezing at -80 C (BICELL group). Third, a vitrification method for oocytes and embryos was used (CRYOTOP group). Cell counting kit-8 (CCK-8) assay showed that cell viability was decreased in all groups after cryopreservation ( < 0.01). Corroboratively, the amount of adenosine triphosphate was markedly decreased after cryopreservation in all groups ( < 0.01). Immunofluorescence staining showed a reduced positive staining area for insulin in all cryopreservation groups. Furthermore, 4',6-diamidino-2-phenylindole and merged immunofluorescence images showed that cryopreserved cells appeared to be randomly reduced in the -80 C group and CRYOTOP group, while only the central region was visibly reduced in the BICELL group. Using immunohistochemical staining, IPCs after cryopreservation were shown to be positive for cleaved caspase-3 antibody in all groups. Finally, insulin secretion following glucose stimulation was significantly reduced in IPCs from all groups after cryopreservation ( < 0.01). In conclusion, IPCs may be too fragile for cryopreservation with accomplished methods and further investigations for a suitable preservation method are required. (キーワード) Adenosine Triphosphate / Adipose Tissue / Caspase 3 / Cell Differentiation / Cell Shape / Cell Survival / Cryopreservation / Dithizone / Glucose / Humans / Insulin / Insulin Secretion / Insulin-Secreting Cells / Staining and Labeling / Stem Cells (徳島大学機関リポジトリ) ● Metadata: 116513 (出版サイトへのリンク) ● Publication site (DOI): 10.1177/0963689720954798 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32878465 ● Search Scopus @ Elsevier (PMID): 32878465 ● Search Scopus @ Elsevier (DOI): 10.1177/0963689720954798 (徳島大学機関リポジトリ: 116513, DOI: 10.1177/0963689720954798, PubMed: 32878465)
61.	Shogo Oota, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Yuuma Wada, Shoko Iwahashi, Yoshimi Bando and Mitsuo Shimada : Carbohydrate Antigen 19-9 Is a Prognostic Factor Which Correlates With HDAC1 and HIF-1 for Intrahepatic Cholangiocarcinoma., Anticancer Research, Vol.39, No.11, 6025-6033, 2019. (要約) Carbohydrate antigen 19-9 (CA19-9) is a poor prognostic marker in intrahepatic cholangiocarcinoma (IHCC). Previous studies have shown a link between hypoxia and CA19-9 in cancer, and we have previously demonstrated a correlation between HDAC1 and HIF-1 in IHCC. Here, we evaluated the expression and correlation of CA19-9 with HIF-1 and HDAC in IHCC. This study included 62 patients with IHCC who underwent primary hepatectomy at our department. Clinicopathological characteristics were examined. Immunohistochemical expression of HIF-1 and HDAC1 in specimens was quantitatively evaluated. Patients with high preoperative serum CA19-9 levels showed clinicopathological characteristics associated with tumour progression. High CA19-9 levels were associated with worse overall and recurrence-free survival. Univariate and multivariate analysis detected high CA19-9 levels as an independent poor prognostic factor for IHCC. Serum CA19-9 was significantly correlated with both HIF-1 and HDAC1 expression. High serum CA19-9 level is a poor prognostic factor for overall survival in IHCC and correlates with HIF-1 and HDAC1 expression. (キーワード) Aged / Bile Duct Neoplasms / Biomarkers, Tumor / CA-19-9 Antigen / Cholangiocarcinoma / 女性 (female) / Follow-Up Studies / Gene Expression Regulation, Neoplastic / Histone Deacetylase 1 / Humans / Hypoxia-Inducible Factor 1, alpha Subunit / Liver Neoplasms / 男性 (male) / Neoplasm Recurrence, Local / Prognosis / Survival Rate (出版サイトへのリンク) ● Publication site (DOI): 10.21873/anticanres.13808 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31704828 ● Search Scopus @ Elsevier (PMID): 31704828 ● Search Scopus @ Elsevier (DOI): 10.21873/anticanres.13808 (DOI: 10.21873/anticanres.13808, PubMed: 31704828)
62.	Yuuma Wada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Yu Saitou, Shin-ichiro Yamada and Mitsuo Shimada : The Differences in the Characteristics of Insulin-producing Cells Using Human Adipose-tissue Derived Mesenchymal Stem Cells from Subcutaneous and Visceral Tissues., Scientific Reports, Vol.9, No.1, 13204, 2019. (要約) The aim of this study was to investigate the characteristics of insulin producing cells (IPCs) differentiated from adipose-tissue derived stem cells (ADSCs) isolated from human subcutaneous and visceral adipose tissues and identify ADSCs suitable for differentiation into efficient and functional IPCs. Subcutaneous and visceral adipose tissues collected from four (4) patients who underwent digestive surgeries at The Tokushima University (000035546) were included in this study. The insulin secretion of the generated IPCs was investigated using surface markers by: fluorescence activated cell sorting (FACS) analysis; cytokine release; proliferation ability of ADSCs; in vitro (glucose-stimulated insulin secretion: (GSIS) test/in vivo (transplantation into streptozotocin-induced diabetic nude mice). The less fat-related inflammatory cytokines secretions were observed (P < 0.05), and the proliferation ability was higher in the subcutaneous ADSCs (P < 0.05). Insulin expression and GISI were higher in the subcutaneous IPCs (P < 0.01 and P < 0.05, respectively). The hyperglycaemic state of all mice that received IPCs from subcutaneous fat tissue converted into normo-glycaemia in thirty (30) days post-transplantation (4/4,100%). Transplanted IPCs were stained using anti-insulin and anti-human leukocyte antigen antibodies. The IPCs generated from the ADSCs freshly isolated from the human fat tissue had sufficient insulin secreting ability in vitro and in vivo. (徳島大学機関リポジトリ) ● Metadata: 114942 (出版サイトへのリンク) ● Publication site (DOI): 10.1038/s41598-019-49701-0 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31519950 ● Search Scopus @ Elsevier (PMID): 31519950 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-019-49701-0 (徳島大学機関リポジトリ: 114942, DOI: 10.1038/s41598-019-49701-0, PubMed: 31519950)
63.	Hiroki Mori, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : Impact of Bevacizumab on Liver Damage After Massive Hepatectomy in Rats., In Vivo, Vol.33, No.5, 1469-1476, 2019. (要約) The aim of this study was to evaluate the impact of pretreatment with bevacizumab on liver damage in a rat model of massive hepatectomy (Hx) model, as a surrogate model of massive Hx for liver metastasis from colorectal cancer. Male Wister rats (n=24) were separated into the following two groups: 90% Hx and 90% Hx plus bevacizumab group. Bevacizumab (5 mg/kg) was injected intraperitoneally 7 days before Hx. Samples of blood and remnant liver tissue were obtained 24 hours after hepatectomy and the following parameters were evaluated: Biochemical analysis; liver regeneration rate; survival rate; and real-time polymerase chain reaction for interleukin-1 beta (Il1b), tumor necrosis factor alpha (Tnfa), matrix metalloproteinase (Mmp) 2 and Mmp9 mRNA. In addition, samples of whole liver tissue were obtained immediately before Hx and real-time polymerase chain reaction was performed for X-box binding protein 1 (Xbp1), activating transcription factor 6 (Atf6), C/EBP homologous protein (Chop), glucose-regulated protein 78 (Grp78) and heat-shock protein 70 (Hsp70), as markers of endoplasmic reticulum stress response. The levels of transaminases 24 hours after Hx were significantly reduced in the group pretreated with bevacizumab compared to that not pretreated (p<0.05). The liver regeneration rate at 24 hours after Hx was significantly increased in the group pretreated with bevacizumab compared with the group which underwent Hx alone (p<0.05). The survival rate for the group pretreated with bevacizumab tended to be higher than that of the Hx-only group, 72 hours after Hx (p=0.09). The expressions of Il1b, Mmp2 and Mmp9 mRNA 24 hours after Hx in the group pretreated with bevacizumab tended to be lower than that of rats which underwent Hx alone (p=0.11, 0.09 and 0.15, respectively). The expression of Xbp1, Chop, Grp78 and Hsp70 mRNA immediately before Hx in the group pretreated with bevacizumab were significantly higher than the 90% Hx group (p<0.05). Bevacizumab pretreatment had protective effects on liver injury after massive hepatectomy in rats, apparently via the induction of the endoplasmic reticulum stress response, i.e. the so-called unfolded protein response. (出版サイトへのリンク) ● Publication site (DOI): 10.21873/invivo.11626 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31471394 ● Search Scopus @ Elsevier (PMID): 31471394 ● Search Scopus @ Elsevier (DOI): 10.21873/invivo.11626 (DOI: 10.21873/invivo.11626, PubMed: 31471394)
64.	Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Chie Takasu, Jun Higashijima, Satoru Imura and Mitsuo Shimada : Clinical Impact of FOLFOXIRI Aiming for Conversion Surgery in Unresectable Multiple Colorectal Liver Metastasis., Anticancer Research, Vol.39, No.9, 5089-5096, 2019. (要約) We evaluated the clinical impact of FOLFOXIRI regimen aiming for conversion surgery in patients with unresectable multiple colorectal liver metastasis (CRLM). A total of 42 patients with unresectable multiple CRLM who received chemotherapy with molecular agents were included in the analysis. The clinical results of FOLFOXIRI with other regimens were compared. The total conversion rate of 42 unresectable CRLM was 48.1%, and conversion cases had a better prognosis. Clinicopathological characteristics of conversion cases were more frequent in FOLFOXIRI induction, liver limited disease and maximum diameter number (MDN) over 70. FOLFOXIRI achieved a higher conversion rate compared to other regimens (72.2% vs. 37.5%, p=0.0334), and significantly reduced the medication period until conversion surgery (median 5.8 courses) with a higher tumour necrotic rate. Consequently, the overall survival of conversion cases with FOLFOXIRI was better than that with other regimens (p=0.0055). FOLFOXIRI plus molecular agents might provide a higher probability of conversion surgery with a prognostic benefit. (キーワード) Antineoplastic Combined Chemotherapy Protocols / Camptothecin / Colorectal Neoplasms / Combined Modality Therapy / Conversion to Open Surgery / 女性 (female) / Fluorouracil / Hepatectomy / Humans / Kaplan-Meier Estimate / Leucovorin / Liver Neoplasms / 男性 (male) / Neoplasm Grading / Neoplasm Staging / Organoplatinum Compounds / Prognosis / Treatment Outcome / Tumor Burden (出版サイトへのリンク) ● Publication site (DOI): 10.21873/anticanres.13703 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31519620 ● Search Scopus @ Elsevier (PMID): 31519620 ● Search Scopus @ Elsevier (DOI): 10.21873/anticanres.13703 (DOI: 10.21873/anticanres.13703, PubMed: 31519620)
65.	Shoko Iwahashi, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Toshiaki Yoshimoto, Koichi Tsuneyama and Mitsuo Shimada : Two cases of non-mucinous cystadenomas of the pancreas with pancreatobiliary phenotype and ovarian-like stroma., Surgical Case Reports, Vol.5, No.1, 117, 2019. (要約) Diagnosis of cystic tumor of the pancreas is based on the World Health Organization criteria that classify pancreatic cystadenomas into four types: intra-ductal papillary mucinous neoplasms, mucinous cystic neoplasms (MCNs), serous cystic neoplasms, and solid pseudo-papillary neoplasms depending on their secretion and presence of ovarian-like stroma. Recently, Albores-Saavedra identified non-mucinous cystadenomas of the pancreas with pancreato-biliary phenotype and ovarian-like stroma. This precipitated examination of the proportions of these rare tumors in patients treated at Tokushima University Hospital. Case 1 was a 40-year-old woman with a cystic tumor in the tail of the pancreas. Computed tomography (CT) revealed a diffuse and non-enhanced cystic tumor in the tail of the pancreas. This tumor was diagnosed as a simple cyst at this point. However, 2ears later, the tumor had increased in size by 3m. Thus, laparoscopic distal pancreatectomy was performed. The content of the cyst was serous. The epithelial cells were lined with a single layer of cuboidal cells and the tumor had ovarian-like stroma pathologically. The final pathological diagnosis was non-mucinous cystadenoma of the pancreas with ovarian-like stroma. In Case 2, a cystic tumor in the pancreas was found by medical examination in a woman in her sixties who presented without symptoms. CT showed a 1.5-cm cystic tumor in the tail and body of the pancreas and a septum in the cyst. Nine years later, the tumor had grown to 2.4m in diameter and had a clear septum in the cyst. This tumor was diagnosed preoperatively as MCN. Thus, laparoscopic distal pancreatectomy was performed. The cyst contained serous fluid. Microscopic examination showed no ovarian-like stroma and the epithelial cells were lined by a single layer of cuboidal cells. The final pathological diagnosis was non-mucinous cystadenoma of the pancreas with ovarian-like stroma. Accurate preoperative diagnosis of this type of pancreatic cystic tumor may be difficult, although it occurs more often than expected. Non-mucinous cystadenomas of the pancreas with ovarian-like stroma need to be considered as a differential diagnosis. (出版サイトへのリンク) ● Publication site (DOI): 10.1186/s40792-019-0673-y (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31338648 ● Search Scopus @ Elsevier (PMID): 31338648 ● Search Scopus @ Elsevier (DOI): 10.1186/s40792-019-0673-y (DOI: 10.1186/s40792-019-0673-y, PubMed: 31338648)
66.	Yuuma Wada, Atsushi Takata, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou and Mitsuo Shimada : The protective effect of epigallocatechin 3-gallate on mouse pancreatic islets via the Nrf2 pathway., Surgery Today, Vol.49, No.6, 536-545, 2019. (要約) Epigallocatechin 3-gallate (EGCG), a green tea polyphenol, has been shown to have anti-oxidant and anti-inflammatory effects in vitro and in vivo. The aim of this study was to investigate the effects and mechanism of EGCG on isolated pancreatic islets as pre-conditioning for pancreatic islet transplantation. The pancreatic islets were divided into two groups: an islet culture medium group (control) and an islet culture medium with EGCG (100 M) group. We investigated the islet viability, Nrf2 expression, reactive oxygen species (ROS) production, and heme oxygenase-1 (HO-1) mRNA. Five hundred islet equivalents after 12 h of culture for the EGCG 100 M and control group were transplanted under the kidney capsule of streptozotocin-induced diabetic ICR mice. The cell viability and insulin secretion ability in the EGCG group were preserved, and the nuclear translocation of Nrf2 was increased in the EGCG group (p < 0.01). While the HO-1 mRNA levels were also higher in the EGCG group than in the control group (p < 0.05), the ROS production was lower (p < 0.01). An in vivo functional assessment showed that the blood glucose level had decreased in the EGCG group after transplantation (p < 0.01). EGCG protects the viability and function of islets by suppressing ROS production via the Nrf2 pathway. (キーワード) Animals / Blood Glucose / カテキン (catechin) / Cell Survival / 遺伝子発現 (gene expression) / Heme Oxygenase-1 / In Vitro Techniques / Insulin Secretion / Islets of Langerhans / Islets of Langerhans Transplantation / 男性 (male) / Mice, Inbred C57BL / Mice, Inbred ICR / NF-E2-Related Factor 2 / RNA, Messenger / 活性酸素種 (reactive oxygen species) / Tissue Culture Techniques / Transplantation Conditioning (徳島大学機関リポジトリ) ● Metadata: 114154 (出版サイトへのリンク) ● Publication site (DOI): 10.1007/s00595-019-1761-0 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30730004 ● Search Scopus @ Elsevier (PMID): 30730004 ● Search Scopus @ Elsevier (DOI): 10.1007/s00595-019-1761-0 (徳島大学機関リポジトリ: 114154, DOI: 10.1007/s00595-019-1761-0, PubMed: 30730004)
67.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Chie Takasu, Masato Yoshikawa, Hiroki Teraoku and Toshiaki Yoshimoto : A new formula to calculate the resection limit in hepatectomy based on Gd-EOB-DTPA-enhanced magnetic resonance imaging., PLoS ONE, Vol.14, No.1, e0210579, 2019. (要約) Dynamic magnetic resonance imaging with gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (EOB-MRI) can be used not only to detect liver tumors but also to estimate liver function. The aim of this study was to establish a new EOB-MRI-based formula to determine the resection limit in patients undergoing hepatectomy. Twenty-eight patients with a normal liver (NL group) and five with an unresectable cirrhotic liver (UL group) who underwent EOB-MRI were included. Standardized liver function (SLF) was calculated based on the signal intensity (SI), the volume of each subsegment (S1-S8), and body surface area. A formula defining the resection limit was devised based on the difference in the SLF values of patients in the NL and UL groups. The formula was validated in 50 patients who underwent EOB-MRI and hepatectomy. The average SLF value in the NL and UL groups was 2038 and 962 FV/m2, respectively. The difference (1076 FV/m2) was consistent with a 70% in resection volume. Thus, the resection limit for hepatectomy was calculated as a proportion of 70%: 70 (SLF-962)/1076 (%). The one patient who underwent hepatectomy over the resection limit died due to liver failure. In other 49 patients, in whom the resection volume was less than the resection limit, procedures were safely performed. Our formula for resection limit based on EOB-MRI can improve the safety of hepatectomy. (徳島大学機関リポジトリ) ● Metadata: 113041 (出版サイトへのリンク) ● Publication site (DOI): 10.1371/journal.pone.0210579 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30682046 ● Search Scopus @ Elsevier (PMID): 30682046 ● Search Scopus @ Elsevier (DOI): 10.1371/journal.pone.0210579 (徳島大学機関リポジトリ: 113041, DOI: 10.1371/journal.pone.0210579, PubMed: 30682046)
68.	Yu Saitou, Yuji Morine, Shuichi Iwahashi, Tetsuya Ikemoto, Satoru Imura, Hisami Yamanaka-Okumura, Akiyoshi Hirayama, Tomoyoshi Soga, Masaru Tomita and Mitsuo Shimada : Changes of liver metabolites following hepatectomy with ischemia reperfusion towards liver regeneration., Annals of Gastroenterological Surgery, Vol.2, No.3, 204-211, 2018. (要約) Metabolome analysis is one of the omics which investigates the final product of a central dogma. Changes of liver metabolites during liver regeneration following hepatectomy (Hx) continue to remain unclear. The aim of the present study was to investigate the changes of liver metabolites following Hx with ischemia reperfusion (I/R) towards liver regeneration. Twenty-three patients who underwent Hx were enrolled in this study. Non-tumor tissues were sampled immediately before and after Hx and a comparison was made between the liver samples taken before and after Hx using capillary electrophoresis (CE)-time-of-flight mass spectrometry (TOFMS) as metabolome analysis. The metabolic pathway showed that there was a significant increase in "lactate" following Hx. There was a significant decrease in metabolites only in the first half of the tricarboxylic acid cycle (TCA) cycle, and adenosine triphosphate (ATP) by anaerobiotic glycolysis did not occur in time for energy consumption of the Hx. Principal component analysis revealed remarkably different component profiles between the samples taken before and after Hx. One hundred and three metabolites were selected as critical metabolites for separating components. Valine and tryptophan increased significantly after Hx and they were regulated by resected liver volume, ischemic time and liver function. The liver metabolites changed remarkably between before and after Hx. Especially, liver valine and tryptophan were increased. (出版サイトへのリンク) ● Publication site (DOI): 10.1002/ags3.12058 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29863192 ● Search Scopus @ Elsevier (PMID): 29863192 ● Search Scopus @ Elsevier (DOI): 10.1002/ags3.12058 (DOI: 10.1002/ags3.12058, PubMed: 29863192)
69.	Toshiaki Yoshimoto, Yuji Morine, Chie Takasu, Rui Feng, Tetsuya Ikemoto, Kouzou Yoshikawa, Shuichi Iwahashi, Yu Saitou, Hideya Kashihara, Masatake Akutagawa, Takahiro Emoto, Yosuke Kinouchi and Mitsuo Shimada : Blue light-emitting diodes induce autophagy in colon cancer cells by Opsin 3., Annals of Gastroenterological Surgery, Vol.2, No.2, 154-161, 2018. (要約) Light emitting-diodes (LED) have various effects on living organisms and recent studies have shown the efficacy of visible light irradiation from LED for anticancer therapies. However, the mechanism of LED's effects on cancer cells remains unclear. The aim of the present study was to investigate the effects of LED on colon cancer cell lines and the role of photoreceptor Opsin 3 (Opn3) on LED irradiation in vitro. Human colon cancer cells (HT-29 or HCT-116) were seeded onto laboratory dishes and irradiated with 465-nm LED at 30 mW/cm for 30 minutes. Cell Counting Kit-8 was used to measure cell viability, and apoptosis and caspase 3/8 expression were evaluated by AnnexinV/PI and reverse transcription-polymerase chain reaction (RT-PCR), respectively. Autophagy and expression of LC-3 and beclin-1 were also evaluated by autophagy assays, RT-PCR and Western blotting. We further tested Opn3 knockdown by Opn3 siRNA and the G G-protein inhibitor NF023 in these assays. Viability of HT-29 and HCT-116 cells was lower in 465-nm LED-irradiated cultures than in control cultures. LC-3 and beclin-1 expressions were significantly higher in LED-irradiated cultures, and autophagosomes were detected in irradiated cells. The reductive effect of cancer cell viability following blue LED irradiation was reversed by Opn3 knockdown or NF023 treatment. Furthermore, increased LC-3 and beclin-1 expression that resulted from blue LED irradiation was suppressed by Opn3 knockdown or NF023 treatment. Blue LED irradiation suppressed the growth of colon cancer cells and Opn3 may play an important role as a photoreceptor. (徳島大学機関リポジトリ) ● Metadata: 113689 (出版サイトへのリンク) ● Publication site (DOI): 10.1002/ags3.12055 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29863164 ● Search Scopus @ Elsevier (PMID): 29863164 ● Search Scopus @ Elsevier (DOI): 10.1002/ags3.12055 (徳島大学機関リポジトリ: 113689, DOI: 10.1002/ags3.12055, PubMed: 29863164)
70.	Toshiaki Yoshimoto, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Daichi Ishikawa, Hiroki Teraoku, Masato Yoshikawa, Jun Higashijima, Chie Takasu and Mitsuo Shimada : Maximum Diameter and Number of Tumors as a New Prognostic Indicator of Colorectal Liver Metastases., In Vivo, Vol.31, No.3, 419-423, 2017. (要約) Surgical resection is currently considered the only potentially curative option as a treatment strategy of colorectal liver metastases (CRLM). However, the criteria for selection of resectable CRLM are not clear. The aim of this study was to confirm a new prognostic indicator of CRLM after hepatic resection. One hundred thirty nine patients who underwent initial surgical resection from 1994 to 2015 were investigated retrospectively. Prognostic factors of overall survival including the product of maximum diameter and number of metastases (MDN) were analyzed. Primary tumor differentiation, vessel invasion, lymph node (LN) metastasis, non-optimally resectable metastases, H score, grade of liver metastases, resection with non-curative intent and MDN were found to be prognostic factors of overall survival (OS). In multivariate analyses of clinicopathological features associated with OS, MDN and non-curative intent were independent prognostic factors. Patients with MDN ·30 had shown significantly poorer prognosis than patients with MDN <30 in OS and relapse-free survival (RFS). MDN ·30 is an independent prognostic factor of survival in patients with CRLM and optimal surgical criterion of hepatectomy for CRLM. (キーワード) Adult / Aged / Aged, 80 and over / Cell Differentiation / Colorectal Neoplasms / Female / Follow-Up Studies / Hepatectomy / Humans / Liver Neoplasms / Lymphatic Metastasis / Male / Middle Aged / Multivariate Analysis / Prognosis / Retrospective Studies (出版サイトへのリンク) ● Publication site (DOI): 10.21873/invivo.11076 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28438872 ● Search Scopus @ Elsevier (PMID): 28438872 ● Search Scopus @ Elsevier (DOI): 10.21873/invivo.11076 (DOI: 10.21873/invivo.11076, PubMed: 28438872)
71.	Masato Yoshikawa, Yuji Morine, Tetsuya Ikemoto, Satoru Imura, Jun Higashijima, Shuichi Iwahashi, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, Daichi Ishikawa, Hiroki Teraoku, Atsushi Takata, Toshiaki Yoshimoto and Mitsuo Shimada : Elevated Preoperative Serum CEA Level Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma Through the Epithelial-Mesenchymal Transition., Anticancer Research, Vol.37, No.3, 1169-1175, 2017. (要約) Serum carcinoembryonic antigen (CEA) is used as an indicator of tumor progression in a variety of carcinomas. A subset of patients with hepatocellular carcinoma (HCC) exhibit increased serum CEA level, but the significance of this is unclear. In this study, we investigated the prognosis of patients with HCC with increased serum CEA, and explored the correlations with expression of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) and epithelial-mesenchymal transition (EMT) and tumor angiogenesis. One hundred and twenty-three patients with HCC who underwent radical resection were divided into two groups according to a cut-off value of 5.0 ng/ml for serum CEA: high (n=24) and normal (n=99) groups. We compared the clinicopathological factors with serum CEA levels and its correlations with CEACAM1 expression, EMT-related factors and microvessel density (MVD) of tumor tissues by immunohistochemistry. In the high CEA group, the disease-free survival (DFS) rate was significantly worse than in the normal CEA group. Multivariate analysis revealed that a high CEA level was an independent factor predictive of recurrence. Furthermore, increased serum CEA levels were positively correlated with CEACAM1 expression. Moreover, CEACAM1 expression was positively correlated with expression of EMT-related factors and MVD of tumor tissues. Increased serum CEA level reflected CEACAM1 expression and was an independent factor predictive of recurrence in HCC through EMT and tumor angiogenesis. (キーワード) Adult / Aged / Aged, 80 and over / Antigens, CD / Antigens, CD34 / Cadherins / Carcinoembryonic Antigen / Carcinoma, Hepatocellular / Cell Adhesion Molecules / Disease-Free Survival / Epithelial-Mesenchymal Transition / Female / Follow-Up Studies / Humans / Immunohistochemistry / Liver Neoplasms / Male / Microcirculation / Middle Aged / Neovascularization, Pathologic / Predictive Value of Tests / Preoperative Period / Prognosis / Recurrence / Vimentin (徳島大学機関リポジトリ) ● Metadata: 112034 (出版サイトへのリンク) ● Publication site (DOI): 10.21873/anticanres.11430 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28314278 ● Search Scopus @ Elsevier (PMID): 28314278 ● Search Scopus @ Elsevier (DOI): 10.21873/anticanres.11430 (徳島大学機関リポジトリ: 112034, DOI: 10.21873/anticanres.11430, PubMed: 28314278)
72.	M Davaadorj, Yu Saitou, Yuji Morine, Tetsuya Ikemoto, Satoru Imura, Chie Takasu, Shin-ichiro Yamada, Hiroki Teraoku, Masato Yoshikawa and Mitsuo Shimada : Loss of Secreted Frizzled-Related Protein-1 expression is associated with poor prognosis in intrahepatic cholangiocarcinoma., EJSO - European Journal of Surgical Oncology, Vol.43, No.2, 344-350, 2017. (要約) Secreted Frizzled-Related Protein-1 (SFRP1) is a well-known negative regulator of the wingless type (Wnt)- -catenin pathway and its inactivation plays an important role in the development and progression of many cancers. In this study, we aimed to determine the clinical significance of SFRP1 expression in intrahepatic cholangiocarcinoma (IHCC) and to define the relationship to Wnt- -catenin pathway. Fifty IHCC patients who had liver resection were enrolled in this study. SFRP1 protein expression was examined by immunohistochemistry in tumor tissues. The patients were divided into two groups: SFRP1 positive (n = 30) and negative (n = 20). Clinicopathological characteristics were analyzed. SFRP1 significantly correlated with curability (Cur A, B vs. C, p = 0.029); and recurrent pattern (intrahepatic vs. extrahepatic, p = 0.010). The negative SFRP1 group had significantly poorer prognosis, and 5-year survival rates were 8.1% of the negative SFRP1 group and 44.6% of the positive SFRP1 group, respectively. Moreover, the disease-free survival rate in the negative SFRP1 group was significantly poorer (p < 0.001). Multivariate analysis revealed that loss of SFRP1served as an independent prognostic factor in IHCC for both overall (HR, 2.923; 95% CI, 1.30-6.56; p = 0.009) and disease-free (HR, 2.631; 95% CI, 1.31-5.27; p = 0.006) survival. In addition, SFRP1 expression negatively correlated to -catenin expression (p = 0.005). Those results suggested that the loss of SFRP1 could be a poor prognostic factor for IHCC, through the Wnt- -catenin pathway. (キーワード) Aged / Biomarkers, Tumor / Cholangiocarcinoma / Female / Hepatectomy / Humans / Immunohistochemistry / Japan / Liver Neoplasms / Male / Prognosis / Proteins / Survival Rate (徳島大学機関リポジトリ) ● Metadata: 110034 (出版サイトへのリンク) ● Publication site (DOI): 10.1016/j.ejso.2016.11.017 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28062160 ● Search Scopus @ Elsevier (PMID): 28062160 ● Search Scopus @ Elsevier (DOI): 10.1016/j.ejso.2016.11.017 (徳島大学機関リポジトリ: 110034, DOI: 10.1016/j.ejso.2016.11.017, PubMed: 28062160)
73.	Daichi Ishikawa, Mitsuo Shimada, Tohru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, Shinichiro Yamada and Hidenori Miyake : Effect of Twist and Bmi1 on intraductal papillary mucinous neoplasm of the pancreas., Journal of Gastroenterology and Hepatology, Vol.29, No.12, 2032-2037, 2014. (要約) Intraductal papillary mucinous neoplasm (IPMN) is a well-established entity among pancreatic neoplasms that ranges from low-grade dysplasia to invasive carcinoma. Epithelial-mesenchymal transition (EMT) contributes to tumor progression in various cancers. Moreover, Notch signaling is one of the important upstream effectors of EMT promotion. Currently, it is unclear whether EMT causes pathological progression of IPMN. We evaluated the expression of EMT-promoting transcription factors Twist and B cell-specific Moloney murine leukemia virus insertion site 1 (Bmi1) in IPMN. Patients who underwent resections at our institute and its affiliated hospital were enrolled in this study (n = 35). Protein expression of EMT markers Twist, Bmi1, Jagged1, and E-cadherin in resected specimens was investigated by immunohistochemistry. Expression of these proteins was compared with the clinicopathological factors and patient survival. Positive expression of Twist and Bmi1 was observed in 40.0% and 42.9% of IPMNs, respectively. Twist and Bmi1 expression was significantly higher in IPMNs with high-grade dysplasia (P < 0.05) and invasive carcinoma (P < 0.05) than that in IPMNs with low-grade dysplasia. High expression of Twist was correlated with Jagged1 expression and inversely correlated with expression of E-cadherin (P = 0.06 and P < 0.05, respectively). In survival analyses, the recurrence rate was significantly higher in the group that showed simultaneous high expression of Twist and Bmi1 (P < 0.05). Expression of Twist and Bmi1 is associated with aggressiveness and poor prognoses of IPMN through EMT promotion that might be induced by Notch signaling. (徳島大学機関リポジトリ) ● Metadata: 106298 (出版サイトへのリンク) ● Publication site (DOI): 10.1111/jgh.12652 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24909638 ● Search Scopus @ Elsevier (PMID): 24909638 ● Search Scopus @ Elsevier (DOI): 10.1111/jgh.12652 (徳島大学機関リポジトリ: 106298, DOI: 10.1111/jgh.12652, PubMed: 24909638)
74.	Gizachew Yismaw Wubetu, Tohru Utsunomiya, Daichi Ishikawa, Tetsuya Ikemoto, Shinichiro Yamada, Yuji Morine, Shuichi Iwahashi, Yu Saitou, Yusuke Arakawa, Satoru Imura, Hideki Arimochi and Mitsuo Shimada : Branched chain amino acid suppressed insulin-initiated proliferation of human cancer cells through induction of autophagy., Anticancer Research, Vol.34, No.9, 4789-4796, 2014. (要約) Branched chain amino acid (BCAA) dietary supplementation inhibits activation of the insulin-like growth factor (IGF)/IGF-I receptor (IGF-IR) axis in diabetic animal models. However, the in vitro effect of BCAA on human cancer cell lines under hyper-insulinemic conditions remains unclear. Colon (HCT-116) and hepatic (HepG2) tumor cells were treated with varying concentrations of BCAA with or without fluorouracil (5-FU). The effect of BCAA on insulin-initiated proliferation was determined. Gene and protein expression was analyzed by quantitative real-time polymerase chain reaction (qRT-PCR) and western blotting, respectively. BCAA supplementation had no significant effect on cell proliferation and did not show significant synergistic or antagonistic effects with 5-FU. However, BCAA significantly decreased insulin-initiated proliferation of human colon and hepatic cancer cell lines in vitro. BCAA supplementation caused a marked decrease in activated IGF-IR expression and significantly enhanced both mRNA and protein expression of LC3-II and BECN1 (BECLIN-1). BCAA could be a useful chemopreventive modality for cancer in hyperinsulinemic conditions. (キーワード) Amino Acids, Branched-Chain / Apoptosis / Autophagy / Cell Line, Tumor / Cell Proliferation / Dietary Supplements / HCT116 Cells / Hep G2 Cells / Humans / Insulin / Phosphorylation / Receptor, IGF Type 1 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25202059 ● Search Scopus @ Elsevier (PMID): 25202059 (PubMed: 25202059)
75.	Gizachew Yismaw Wubetu, Tohru Utsunomiya, Daichi Ishikawa, Shinichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Shuichi Iwahashi, Yu Saitou, Yusuke Arakawa, Satoru Imura, Mami Kanamoto, Chengzhan Zhu, Yoshimi Bando and Mitsuo Shimada : High STAT4 expression is a better prognostic indicator in patients with hepatocellular carcinoma after hepatectomy., Annals of Surgical Oncology, Vol.21 Suppl 4, S721-8, 2014. (要約) Signal transducer and activator of transcription 4 (STAT4) mediates the intracellular effects of interleukin-12, leading to the production of interferon gamma (IFN-γ) and natural killer cells cytotoxicity. However, the clinical significance of STAT4 expression in patients with hepatocellular carcinoma (HCC) remains virtually unknown. A total of 66 HCC patients who underwent hepatectomy were enrolled in this study. Quantitative real-time polymerase chain reaction was performed to determine STAT4 and IFNG mRNA expression levels. Tissue microarray-based immunohistochemistry was performed to examine CD8(+) T cells, STAT4, and INF-γ proteins. STAT4 was differentially expressed in tumor and nontumor tissues (P = 0.001) and positively correlated with IFNG expression (R (2) = 0.506, P < 0.05) and CD8(+) T cell infiltration (R (2) = 0.53, P < 0.001). Significant correlations were observed between STAT4 expression and tumor TNM stage (P = 0.043), hepatic venous invasion (P = 0.003), des-gamma-carboxy prothrombin (P = 0.011), tumor size (P = 0.036), and tumor differentiation (P = 0.034). Patients with high STAT4 expression had significantly better recurrence-free survival (P = 0.009). Low STAT4 expression (P = 0.030) and presence of portal venous invasion or hepatic venous invasion (P = 0.006) were independent risk factors for HCC recurrence. Downregulation of STAT4 in HCC indicated aggressive tumor behavior and predicted a worse clinical outcome. STAT4 might be a useful biomarker to identify patients at high risk of recurrence after hepatectomy. (徳島大学機関リポジトリ) ● Metadata: 109697 (出版サイトへのリンク) ● Publication site (DOI): 10.1245/s10434-014-3861-9 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24965572 ● Search Scopus @ Elsevier (PMID): 24965572 ● Search Scopus @ Elsevier (DOI): 10.1245/s10434-014-3861-9 (徳島大学機関リポジトリ: 109697, DOI: 10.1245/s10434-014-3861-9, PubMed: 24965572)
76.	Noriko Matsumoto, Yuji Morine, Tohru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Shiniciro Yamada, Daichi Ishikawa, Chie Takasu, Hidenori Miyake and Mitsuo Shimada : Role of CD151 expression in gallbladder carcinoma., Surgery, Vol.156, No.5, 1212-1217, 2014. (要約) CD151 is a member of the tetraspanin family, which interacts with laminin-binding integrins and other tetraspanins. CD151 is involved in several pathologic activities associated with tumor progression, including metastasis and angiogenesis. The aim of this study was to clarify the clinical use of CD151 expression in gallbladder cancer (GBC). Forty-five patients with GBC who had undergone operative treatment were enrolled in this study. Expressions of CD151 in the resected GBC specimens were evaluated with anti-CD151 antibody. The patients were divided into positive and negative groups according to CD151 expression: CD151-positive group (n = 26) and CD151-negative group (n = 19). Clinicopathologic factors, including Ki-67 and matrix metallopeptidase 9, also were compared between the two groups. CD151-positive expression was 58% and correlated with poorer prognosis; 5-year survival of CD151-positive and CD151-negative groups was 29% and 78%, respectively (P = .006). CD151 expression also correlated with lymphatic invasion and curability. Multivariate analysis revealed that CD151-positive expression was an independent prognostic factor (hazard ratio 2.97, P = .02). In addition, CD151 expression correlated with matrix metallopeptidase 9 expression (P < .05) but not with Ki67 expression. Those findings suggested that CD151-positive expression might be a potential prognostic indicator and one of the target molecules for the regulation of tumor metastasis for patients with GBC. (キーワード) Adult / Aged / Aged, 80 and over / Antigens, CD151 / Carcinoma / Female / Gallbladder / Gallbladder Neoplasms / Humans / Immunohistochemistry / Ki-67 Antigen / Male / Matrix Metalloproteinase 9 / Middle Aged / Multivariate Analysis / Prognosis / Tumor Markers, Biological (出版サイトへのリンク) ● Publication site (DOI): 10.1016/j.surg.2014.04.053 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24890568 ● Search Scopus @ Elsevier (PMID): 24890568 ● Search Scopus @ Elsevier (DOI): 10.1016/j.surg.2014.04.053 (DOI: 10.1016/j.surg.2014.04.053, PubMed: 24890568)
77.	Chinbold Enkhbold, Tohru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa and Mitsuo Shimada : Loss of FBXW7 expression is associated with poor prognosis in intrahepatic cholangiocarcinoma., Hepatology Research, Vol.44, No.14, E346-52, 2014. (要約) FBXW7 acts as a tumor suppressor gene by targeting several oncogenic regulators of proliferation, growth and apoptosis for proteasomal degradation. However, the significance of this protein is not yet well understood in intrahepatic cholangiocarcinoma (IHCC). In this study, we aimed to investigate the correlation between FBXW7 expression and clinicopathological variables in IHCC patients. Thirty-one patients with IHCC who underwent hepatic resection were enrolled. FBXW7 expression in tumor tissue was determined by immunohistochemistry and patients were divided into two groups, the FBXW7 high expression group (n = 11) and the FBXW7 low expression group (n = 20). We then compared clinicopathological variables including prognosis between the high and low expression groups in tumor tissue. FBXW7 expression was significantly correlated with staging (P = 0.006), and tended to correlate with lymph node metastasis. The FBXW7 low expression group had significantly poorer prognosis compared with the FBXW7 high expression group (P = 0.020); 3-year survival rates were 29.4% and 72.7%, respectively. Furthermore, the disease-free survival rate in the FBXW7 low expression group was significantly worse than in the FBXW7 high expression group (P = 0.022). On multivariate analysis, intrahepatic metastasis (P = 0.006) was a significant independent prognostic factor for disease-free survival, and FBXW7 low expression tended to be an independent prognostic factor for both overall (P = 0.067) and disease-free survival (P = 0.083). Our results confirmed that low expression of FBXW7 in IHCC correlates with tumor progression and poor prognosis in IHCC. (徳島大学機関リポジトリ) ● Metadata: 109369 (出版サイトへのリンク) ● Publication site (DOI): 10.1111/hepr.12314 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24552289 ● Search Scopus @ Elsevier (PMID): 24552289 ● Search Scopus @ Elsevier (DOI): 10.1111/hepr.12314 (徳島大学機関リポジトリ: 109369, DOI: 10.1111/hepr.12314, PubMed: 24552289)
78.	Shinichiro Yamada, Tohru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusue Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, Chie Takasu, Daichi Ishikawa and Mitsuo Shimada : Expressions of hypoxia-inducible factor-1 and epithelial cell adhesion molecule are linked with aggressive local recurrence of hepatocellular carcinoma after radiofrequency ablation therapy., Annals of Surgical Oncology, Vol.21 Suppl 3, S436-42, 2014. (要約) Radiofrequency ablation (RFA) is a widely used therapy for hepatocellular carcinoma (HCC). Several reports have demonstrated the aggressive local recurrence of HCC after RFA, suggesting that induction of further malignant transformation of HCC has occurred. Eighty-eight (88) patients with HCC who underwent hepatic resection were included in this study. Hepatectomy was indicated for local recurrence of HCC after RFA (n = 10, RFA group) and for HCC without prior RFA (n = 78, non-RFA group). Clinicopathological data and the patient's prognosis after hepatectomy were compared between the two groups. Expression levels of hypoxia-inducible factor-1 (HIF-1), epithelial cell adhesion molecule (EpCAM), CD44, and vascular endothelial growth factor messenger RNA (mRNA) in the tumor tissues were also examined. The RFA group showed higher frequency of portal vein invasion and less tumor differentiation compared with the non-RFA group (p < 0.05). Overall and disease-free survival rates in the RFA group were significantly worse than those in the non-RFA group (p < 0.05). HIF-1 and EpCAM mRNA expression levels in the RFA group were significantly higher than those in the non-RFA group (p < 0.05). These results suggest that local HCC recurrence after RFA shows an aggressive tumor phenotype and poor prognosis through the enhanced expressions of HIF-1 and EpCAM in the residual HCC tumors after insufficient or sub-lethal treatment by RFA. (キーワード) Aged / Antigens, CD44 / Antigens, Neoplasm / Carcinoma, Hepatocellular / Case-Control Studies / Catheter Ablation / Cell Adhesion Molecules / Combined Modality Therapy / Female / Follow-Up Studies / Hepatectomy / Humans / Hypoxia-Inducible Factor 1, alpha Subunit / Liver Neoplasms / Male / Neoplasm Recurrence, Local / Neoplasm Staging / Neoplasm, Residual / Prognosis / RNA, Messenger / Real-Time Polymerase Chain Reaction / Reverse Transcriptase Polymerase Chain Reaction / Survival Rate / Tumor Markers, Biological (出版サイトへのリンク) ● Publication site (DOI): 10.1245/s10434-014-3575-z (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24566861 ● Search Scopus @ Elsevier (PMID): 24566861 ● Search Scopus @ Elsevier (DOI): 10.1245/s10434-014-3575-z (DOI: 10.1245/s10434-014-3575-z, PubMed: 24566861)
79.	荒川悠佑, 島田光生, 石川大地, 齋藤裕, 岩橋衆一, 池本哲也, 居村暁, 森根裕二, 宇都宮徹 : 3.肝疾患ウイルス性肝炎, 日本臨床外科学会誌, Vol.69, No.11, 2014年.
80.	岩橋衆一, 居村暁, 宇都宮徹, 森根裕二, 池本哲也, 森大樹, 荒川悠佑, 金本真美, 齋藤裕, 髙須千絵, 島田光生 : 肝移植, 日本臨床外科学会誌, Vol.69, No.4, 2014年.
81.	Shinichiro Yamada, Mitsuo Shimada, Tohru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi and Yu Saitou : CXC receptor 4 and stromal cell-derived factor 1 in primary tumors and liver metastases of colorectal cancer., The Journal of Surgical Research, Vol.187, No.1, 107-112, 2013. (要約) It has been determined that the chemokine receptor CXC receptor 4 (CXCR4) and its ligand, stromal cell-derived factor 1 (SDF-1), regulate several key processes in a wide variety of cancers. In this study, we investigate the possible role of SDF-1 (noncancerous liver tissue) and CXCR4 in liver metastases of colorectal cancer (CRC). Reverse transcription-polymerase chain reaction was performed to examine the expression of SDF-1 in noncancerous liver tissues of 16 CRC patients with liver metastasis and in normal liver tissues of six patients with benign liver disease. We also examined the expression of CXCR4 in cancerous tissues from primary and metastatic tumors. Using reverse transcription-polymerase chain reaction, CXCR4 expression in metastatic tumors tended to be higher than that in primary tumors (P = 0.16). High CXCR4 expression in a primary tumor was found to be related to an increased lymphatic invasion (P = 0.01), an advanced depth of tumor invasion (P = 0.07), and a decrease in the overall survival rate. The SDF-1 expression observed in noncancerous liver tissues of CRC with liver metastasis was significantly higher than that observed in normal liver tissues of benign liver disease (P < 0.05). In CRC with liver metastasis, CXCR4 expression demonstrated associations with local progression, liver metastasis, and poor overall survival. (キーワード) Aged / Chemokine CXCL12 / Colorectal Neoplasms / Female / Humans / Liver Neoplasms / Male / Middle Aged / Neoplasm Staging / Prognosis / Receptors, CXCR4 / Retrospective Studies / Risk Factors (出版サイトへのリンク) ● Publication site (DOI): 10.1016/j.jss.2013.10.030 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24238971 ● Search Scopus @ Elsevier (PMID): 24238971 ● Search Scopus @ Elsevier (DOI): 10.1016/j.jss.2013.10.030 (DOI: 10.1016/j.jss.2013.10.030, PubMed: 24238971)
82.	Lkhagva-Ochir Tovuu, Tohru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Hiroki Mori, Jun Hanaoka, Mami Kanamoto, Koji Sugimoto, Yu Saitou, Shinichiro Yamada, Michihito Asanoma and Mitsuo Shimada : The role of Aurora B expression in non-tumor liver tissues of patients with hepatocellular carcinoma., International Journal of Clinical Oncology, Vol.19, No.4, 622-628, 2013. (要約) Aurora B is a serine-threonine kinase and chromosomal passenger protein involved in the control of chromosome assembly and segregation during mitosis. Aberrant expression of Aurora B has been reported in some tumors, including lung and hepatocellular carcinoma (HCC). We investigated the role of Aurora B expression in both HCC and matched adjacent non-tumor tissue. Sixty-three patients with HCC who underwent hepatic resection were enrolled in this study. Aurora B expression in tumor and non-tumor tissue was examined by use of quantitative reverse transcription-polymerase chain reaction. The patients were divided into high and low gene expression groups by median value, and clinicopathological data were compared between the two groups. Aurora B expression was significantly higher in tumor tissue than in non-cancerous tissue (P < 0.001). Disease-free survival was not significantly different between groups with high and low expression in the tumor tissues. For non-tumor tissues, disease-free survival of the low-expression group was significantly better than that of the high-expression group (P < 0.05). The gene expression level of Aurora B correlated with results from liver function tests, for example prothrombin time. Aurora B expression in non-cancerous tissues may be a prognostic factor for HCC. (キーワード) Adult / Aged / Aurora Kinase B / Carcinoma, Hepatocellular / Disease-Free Survival / Female / Gene Expression Regulation, Neoplastic / Humans / Liver / Liver Neoplasms / Male / Middle Aged / Prognosis / Prothrombin Time / Tumor Markers, Biological (出版サイトへのリンク) ● Publication site (DOI): 10.1007/s10147-013-0593-y (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23893130 ● Search Scopus @ Elsevier (PMID): 23893130 ● Search Scopus @ Elsevier (DOI): 10.1007/s10147-013-0593-y (DOI: 10.1007/s10147-013-0593-y, PubMed: 23893130)

総説・解説:

1.	齋藤裕, 濵田康弘, 山田苑子, 池本哲也, 森根裕二, 居村暁, 島田光生 : 周術期の体組成評価:―サルコペニアの観点より―, 外科と代謝·栄養, Vol.53, No.4, 147-156, 2019年8月. (出版サイトへのリンク) ● Publication site (DOI): 10.11638/jssmn.53.4_147 (文献検索サイトへのリンク) ● Search Scopus @ Elsevier (DOI): 10.11638/jssmn.53.4_147 (DOI: 10.11638/jssmn.53.4_147)
2.	Yoichiro Kawashita, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shuichi Iwahashi, Shin-ichiro Yamada, Jun Higashijima, Satoru Imura, Hirohisa Ogawa, Toshiyuki Yagi and Mitsuo Shimada : Loss of Fbxw7 expression is a predictor of recurrence in colorectal liver metastasis., Journal of Hepato-Biliary-Pancreatic Sciences, Vol.24, No.10, 576-583, Oct. 2017. (要約) Fbxw7 is a tumor suppressor through ubiquitination and degradation of multiple oncoproteins. Loss of Fbxw7 is frequently observed in various human cancers. In this study, we examined the role of Fbxw7 expression in colorectal liver metastasis (CRLM) and its mechanism. Fifty-six patients with CRLM who undergo curative resection were enrolled. Fbxw7 in tumor tissue was determined by immunohistochemistry. Patients were divided into two groups, the Fbxw7 high and low groups. Clinicopathological factors including miR-223 expression were compared between the high (n = 32) and low Fbxw7 groups (n = 24). Fbxw7 expression in tumor tissues was significantly lower than that in normal tissues. The disease-free survival in the low Fbxw7 group was significantly worse than that in the high Fbxw7 group, and 3 years disease-free survival of the low and high Fbxw7 groups were 12.5% and 47.0%, respectively (P = 0.023). On multivariate analysis, loss of Fbxw7 was detected as one of the independent risk factors for recurrence of CRLM (hazard ratio: 2.390, P = 0.017). Likewise, Fbxw7 expression inversely correlated to miR-223 expression (P = 0.017). Loss of Fbxw7 in tumor tissues could be a reliable predictor of recurrence after hepatectomy in patients with CRLM, and miR-223 might be a possible regulator of Fbxw7. (徳島大学機関リポジトリ) ● Metadata: 110995 (出版サイトへのリンク) ● Publication site (DOI): 10.1002/jhbp.500 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28846828 ● Search Scopus @ Elsevier (PMID): 28846828 ● Search Scopus @ Elsevier (DOI): 10.1002/jhbp.500 (徳島大学機関リポジトリ: 110995, DOI: 10.1002/jhbp.500, PubMed: 28846828)
3.	齋藤裕, 森根裕二, 居村暁, 池本哲也, 東島潤, 島田光生 : 【Conversion Surgery-進行消化器がんのトータル治療戦略】がん種別Conversion Surgeryの戦略転移性肝癌, 臨床外科, Vol.72, No.10, 1211-1216, 2017年10月. (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1390283684865555456 (CiNii: 1390283684865555456)
4.	岩橋衆一, 寺奥大貴, 齋藤裕, 池本哲也, 森根裕二, 居村暁, 島田光生 : 【どこをどう切る?どうつなぐ?なぞって覚える!消化器外科術式理解イラストノート】肝臓・胆道の手術肝切除術, 消化器外科Nursing, Vol.22, No.8, 704-708, 2017年10月.
5.	齋藤裕, 居村暁, 島田光生 : 【肝細胞癌診断・治療におけるエビデンスとトピックス】肝細胞癌に対する外科的治療のエビデンスとトピックス, 日本消化器病学会雑誌, Vol.114, No.9, 1611-1620, 2017年9月. (要約) <p>肝細胞癌に対する外科的治療のエビデンスとして，ガイドライン(2013年版)における，手術(外科的治療)に関係するClinical Questionの中で，CQ21 腫瘍条件からみた肝切除の適応は?，CQ22 肝切除後の予後因子は何か?，CQ24 系統的切除は予後に寄与するか?，CQ31 肝細胞癌に対する肝移植の適応基準は何か?，について概説する．また，今後エビデンス構築が期待されるトピックスとして，腹腔鏡下肝切除の治療適応，BCLC Stage Bに対する外科的治療選択，Conversion Hepatectomyに関しても言及する．</p> (キーワード) 肝細胞癌 / 外科治療 / 腹腔鏡下肝切除 / BCLC / Conversion (出版サイトへのリンク) ● Publication site (DOI): 10.11405/nisshoshi.114.1611 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28883290 ● CiNii @ 国立情報学研究所 (CRID): 1390001206403613312 ● Summary page in Scopus @ Elsevier: 2-s2.0-85028969066 (DOI: 10.11405/nisshoshi.114.1611, PubMed: 28883290, CiNii: 1390001206403613312, Elsevier: Scopus)
6.	柏原秀也, 森根裕二, 東島潤, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 島田光生 : 【胆膵進行癌に対する外科治療戦略】閉塞性黄疸に対する最新の術前減黄戦略, 外科, Vol.79, No.8, 708-713, 2017年8月. (キーワード) 術前減黄処置 / 分肝機能 / 胆汁返還 / 大建中湯 (出版サイトへのリンク) ● Publication site (DOI): 10.15106/j00393.2017324283 (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1390846634830490368 ● Search Scopus @ Elsevier (DOI): 10.15106/j00393.2017324283 (DOI: 10.15106/j00393.2017324283, CiNii: 1390846634830490368)
7.	Shin-ichiro Yamada, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Chie Takasu, Masato Yoshikawa, Hiroki Teraoku, Toshiaki Yoshimoto and Atsushi Takata : Effective stepwise training and procedure standardization for young surgeons to perform laparoscopic left hepatectomy., Surgical Endoscopy, Vol.31, No.6, 2623-2629, Dec. 2016. (要約) Laparoscopic hepatectomy remains one of the most difficult procedures for young surgeons to perform. We recently developed a new training method and standardization procedure for teaching young surgeons to perform laparoscopic left hepatectomy (Lap-LHx). The aim of this study was to assess the effectiveness of our method. In 2004, we standardized a laparoscopic procedure for Lap-LHx, using a laparoscopy-assisted method as a stepping stone. The laparoscopic training method comprised the following three steps: (1) training in fundamental procedures using a dry box and checking by mentors; (2) detailed preoperative simulation using Vincent three-dimensional software for each patient; and (3) self-assessment including understanding of relevant anatomy and completion grade for each procedure using a check sheet and feedback by both mentors and a professor. Twenty-three Lap-LHx procedures performed during the study period were divided into two groups: those performed by young non-board-certified surgeons (n = 9) and those performed by senior board-certified surgeons (n = 14). The blood loss and operative time were similar in the young surgeon (194 g and 336 min, respectively) and senior surgeon groups (208 g and 322 min, respectively). Our standardized Lap-LHx procedure and stepwise training to perform it enable young surgeons to perform Lap-LHx as confidently and safely as more experienced surgeons. (出版サイトへのリンク) ● Publication site (DOI): 10.1007/s00464-016-5273-3 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27928671 ● Search Scopus @ Elsevier (PMID): 27928671 ● Search Scopus @ Elsevier (DOI): 10.1007/s00464-016-5273-3 (DOI: 10.1007/s00464-016-5273-3, PubMed: 27928671)
8.	Shinichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Masato Yoshikawa, Hiroki Teraoku and Mitsuo Shimada : Liver regeneration after splenectomy in patients with liver cirrhosis., Hepatology Research, Vol.46, No.5, 443-449, Oct. 2016. (要約) Splenectomy is a well-known procedure to improve thrombocytopenia and liver function in patients with liver cirrhosis (LC). However, the effect of splenectomy on liver regeneration remains unclear. The aim of this study is to investigate the effect of splenectomy on liver regeneration. Twenty patients with LC who underwent splenectomy were included in this study. Liver and splenic volumes were measured by a 3-D simulation imaging system. Liver volume (LV) and clinicopathological data were compared before and 6 months after splenectomy. Thereafter, patients were divided into two groups: the elevated LV group and the reduced LV group. Patient characteristics were compared between the two groups. Postoperative LV was increased in 14 patients compared with the preoperative state. Thrombocytopenia, leukopenia, total bilirubin and prothrombin time were improved after splenectomy. In the elevated LV group, four patients exhibited improved Child-Pugh grades after splenectomy, whereas no patients demonstrated improvement in the reduced LV group. The elevated LV group exhibited high albumin level, good indocyanine green retention rate at 15 min and large splenic volume compared with the same measurements in the decreased group. Patients with larger spleen volumes and higher albumin values before splenectomy showed increased rates of LV after splenectomy. Splenectomy for patients with LC improved pancytopenia and liver function. Especially, in patients with large spleen and high albumin levels, considerable increases in LV and improved liver function were observed. (出版サイトへのリンク) ● Publication site (DOI): 10.1111/hepr.12573 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26428414 ● Search Scopus @ Elsevier (PMID): 26428414 ● Search Scopus @ Elsevier (DOI): 10.1111/hepr.12573 (DOI: 10.1111/hepr.12573, PubMed: 26428414)
9.	濵田康弘, 谷佳子, 安井苑子, 齋藤裕 : 客観的栄養評価(Objective Data Assessment: ODA), 内分泌·糖尿病·代謝内科, Vol.43, No.3, 185-189, 2016年9月. (キーワード) Bioelectrical impedance analysis / Nutritional assessment / Rapid turnover protein / Subjective global assessment (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1522543655827288704 (CiNii: 1522543655827288704)
10.	Shuichi Iwahashi, Mitsuo Shimada, Tohru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Chie Takasu, Yu Saitou and Shinichiro Yamada : Epithelial-mesenchymal transition-related genes are linked to aggressive local recurrence of hepatocellular carcinoma after radiofrequency ablation., Cancer Letters, Vol.375, No.1, 47-50, Mar. 2016. (要約) We reported that poor prognoses of hepatocellular carcinoma (HCC) patients after radiofrequency ablation (RFA) are owing to up-regulation of expression of hypoxia-inducible factor-1 and epithelial cell adhesion molecule. We investigated aggressive progression in residual liver tumors (RLTs) after RFA to focus on expression of epithelial-mesenchymal transition (EMT)-related genes and miRNAs. Ten patients with recurrent HCC post-RFA who underwent hepatectomy (RFA group) and 78 patients with HCC without prior RFA (non-RFA group) were enrolled. We examined expression of transforming growth factor (TGF)-β, Twist, vimentin, and Snail-1 mRNAs in tumor tissues, and expression of miR-34a and miR-200c. Expression of TGF-β, Twist and Snail-1 in the RFA group was significantly higher than that in the non-RFA group (P < 0.05); vimentin expression in the RFA group was higher than that in the non-RFA group (P = 0.07). Expression of miR-200c and miR-34a in the RFA group was significantly lower than that in the non-RFA group (miR-200c: P = 0.04; miR-34a: P < 0.01). Increased expression of EMT markers through down-regulation of miRNA expression in RLTs after RFA may be related to poor prognoses of HCC patients with aggressive local recurrence after RFA. (出版サイトへのリンク) ● Publication site (DOI): 10.1016/j.canlet.2016.02.041 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26940140 ● Search Scopus @ Elsevier (PMID): 26940140 ● Search Scopus @ Elsevier (DOI): 10.1016/j.canlet.2016.02.041 (DOI: 10.1016/j.canlet.2016.02.041, PubMed: 26940140)
11.	池本哲也, 島田光生, 森根裕二, 居村暁, 齋藤裕, 山田眞一郎 : 【最新肝胆膵高難度外科手術アトラス】高難度外科手術手技肝臓肝下部下大静脈再建を伴う肝切除, 手術, Vol.70, No.4, 431-438, 2016年3月. (キーワード) *下大静脈(外科的療法)
12.	齋藤裕, 濵田康弘, 安井苑子, 池本哲也, 森根裕二, 居村暁, 島田光生 : 【外科領域におけるサルコペニア】周術期サルコペニア発生の予防法, 外科と代謝·栄養, Vol.50, No.1, 21-28, 2016年2月. (キーワード) 周術期 / サルコペニア / 予防 (出版サイトへのリンク) ● Publication site (DOI): 10.11638/jssmn.50.1_21 (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1390282679740177664 ● Search Scopus @ Elsevier (DOI): 10.11638/jssmn.50.1_21 (DOI: 10.11638/jssmn.50.1_21, CiNii: 1390282679740177664)
13.	Gizachew Yismaw Wubetu, Yuji Morine, Hiroki Teraoku, Masato Yoshikawa, Daichi Ishikawa, Shinichiro Yamada, Tetsuya Ikemoto, Yu Saitou, Satoru Imura and Mitsuo Shimada : High NEK2 Expression Is a Predictor of Tumor Recurrence in Hepatocellular Carcinoma Patients After Hepatectomy., Anticancer Research, Vol.36, No.2, 757-762, Feb. 2016. (要約) Better prognosis of cancer including hepatocellular carcinoma (HCC) remains unsatisfactory due to recurrence and chemoresistance. In this respect it is important to identify molecular targets specific to the disease in order to design effective therapeutic strategies. In the present study, we investigated the prognostic role of Never-in-mitosis-A-related kinase 2 (NEK2) in HCC. Fifty HCC patients who underwent hepatectomy were enrolled in the study. NEK2 gene and protein expression was examined by quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry, respectively. Higher expression of NEK2 was detected in HCC tumoral compared to adjacent non-tumor tissues (p<0.001), and protein expression was also relatively high in tumor than corresponding non-tumor tissues. Furthermore, high NEK2 expression was positively correlated with hepatic venous invasion (p=0.047), des-gammacarboxy prothrombin (p=0.003), and alpha-fetoprotein (AFP) (p=0.024). Patients with high NEK2 expression had significantly poor recurrence-free survival (p=0.042) and early recurrence. Overall, these results suggest that NEK2 could be a promising biomarker for HCC recurrence. (キーワード) Aged / Biomarkers, Tumor / Carcinoma, Hepatocellular / Disease-Free Survival / Female / Gene Expression Regulation, Enzymologic / Gene Expression Regulation, Neoplastic / Hepatectomy / Humans / Kaplan-Meier Estimate / Liver Neoplasms / Male / Middle Aged / Neoplasm Invasiveness / Neoplasm Recurrence, Local / Proportional Hazards Models / Protein-Serine-Threonine Kinases / Risk Factors / Time Factors / Treatment Outcome / Up-Regulation / 欧文論文 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26851035 ● Summary page in Scopus @ Elsevier: 2-s2.0-84979824116 (PubMed: 26851035, Elsevier: Scopus)
14.	Mandakhnaran Davaadorj, Satoru Imura, Yu Saitou, Yuji Morine, Tetsuya Ikemoto, Shinichiro Yamada, Chie Takasu, Teraoku Hiroki, Masato Yoshikawa and Mitsuo Shimada : Loss of SFRP1 Expression Is Associated with Poor Prognosis in Hepatocellular Carcinoma., Anticancer Research, Vol.36, No.2, 659-664, Feb. 2016. (要約) Secreted frizzled-related protein-1 (SFRP1) is a well-known inhibitor of the wingless type (WNT)-β-catenin signaling pathway and its inactivation plays an important role in the development and progression of various types of cancer. However, the clinical significance of SFRP1 expression in patients with hepatocellular carcinoma (HCC) remains unknown. A total of 63 patients with HCC who underwent hepatectomy at our Institution were enrolled in this study. A quantitative real-time polymerase chain reaction (RT-PCR) was performed to determine the SFRP1 mRNA expression level in both the tumorous and non-tumorous tissues of HCC. The patients were divided into low and high gene-expression groups based on the SFRP1 gene expression level in their tumor tissues. We analyzed the differences in clinicopathological characteristics between these two groups of patients. The expression level of SFRP1 was significantly lower in tumor tissue than in non-tumor tissue (p<0.0001). Significant correlations were observed between a high expression of SFRP1 in tumor tissue and older than 65 years (p=0.030), tumor size less than 5 cm (p=0.011); and no vascular invasion (p=0.004). Patients with high SFRP1 expression in tumor tissue had a significantly better overall survival rate (p=0.040). However, the SFRP1 expression level was not defined as an independent risk factor for patient survival based on results of multivariate analysis. SFRP1 may play a role in the development and progression of HCC. Therefore, more studies are required to investigate a potential role of SFRP1 in HCC prognosis. (キーワード) Adult / Aged / Aged, 80 and over / Biomarkers, Tumor / Carcinoma, Hepatocellular / Disease Progression / Disease-Free Survival / Down-Regulation / Female / Gene Expression Regulation, Neoplastic / Hepatectomy / Humans / Intercellular Signaling Peptides and Proteins / Kaplan-Meier Estimate / Liver Neoplasms / Male / Membrane Proteins / Middle Aged / Multivariate Analysis / Neoplasm Recurrence, Local / Proportional Hazards Models / Prospective Studies / RNA, Messenger / Real-Time Polymerase Chain Reaction / Risk Factors / Time Factors / Treatment Outcome / 欧文論文 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26851021 ● Summary page in Scopus @ Elsevier: 2-s2.0-84979837519 (PubMed: 26851021, Elsevier: Scopus)
15.	Gizachew Y. Wubetu, Mitsuo Shimada, Yuji Morine, Tetsuya Ikemoto, Daichi Ishikawa, Shuichi Iwahashi, Shinichiro Yamada, Yu Saitou, Yusuke Arakawa and Satoru Imura : Epigallocatechin gallate hinders human hepatoma and colon cancer sphere formation., Journal of Gastroenterology and Hepatology, Vol.31, No.1, 256-264, Jan. 2016. (要約) The long-term survival of patients with hepatocellular carcinoma remains unsatisfactory because of the presence of cancer stem cells (CSCs), which are responsible for tumor recurrence and chemoresistance after hepatectomy. Drugs that selectively target CSCs thus offer great promise for cancer treatment. Although the antitumor effects of epigallocatechin gallate (EGCG) have been reported in some cancer cells, its effects on CSCs remain poorly studied. In this study, we investigated the effects of EGCG on human hepatoma and colon CSCs. HepG2 and HCT-116 cell lines were enriched by sphere formation, and their gene-expression profiles were analyzed by quantitative real-time polymerase chain reaction. EGCG-induced growth inhibition in the parental cells was determined by WST-8 assay, and protein expression was assessed by western blotting. Cell cycle profile and apoptosis analysis was performed using flow cytometer. Sphere-derived cells grown in serum-free, nonadherent cultures showed increased expression of stem cell markers, Nek2, and ATP-binding cassette transporter genes, compared with parental cells grown in conventional culture. EGCG induced growth inhibition in the parental cells in a dose-dependent manner. EGCG also inhibited self-renewal in hepatoma and colon CSCs, attenuated the expression of stem cell markers and ATP-binding cassette transporter genes, which are putative molecules associated with treatment resistance in CSCs, and decreased the transcription of Nek2 and p-Akt, resulting in the inhibition of Akt signaling. EGCG also altered cell cycle profile and apoptosis, which may in part play an important role in EGCG-induced cancer cell death. Overall, these results suggest that EGCG could be a useful chemopreventive agent for targeting hepatocellular carcinoma and colon CSCs, in combination with standard chemotherapies. (出版サイトへのリンク) ● Publication site (DOI): 10.1111/jgh.13069 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26241688 ● Search Scopus @ Elsevier (PMID): 26241688 ● Search Scopus @ Elsevier (DOI): 10.1111/jgh.13069 (DOI: 10.1111/jgh.13069, PubMed: 26241688)
16.	Hiroki Teraoku, Yusuke Arakawa, Masato Yoshikawa, Shinichiro Yamada, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : Complication of portal vein thrombosis after right hemihepatectomy in a patient lacking the portal vein bifurcation., The Journal of Medical Investigation : JMI, Vol.63, No.3-4, 315-318, 2016. (要約) Absence of portal vein bifurcation is a rare anomaly. We report a patient with this anomaly who underwent right hemihepatectomy for treatment of hepatocellular carcinoma. Although the procedure was carefully performed with a preoperative three-dimensional simulation and intraoperative cholangiography, postoperative portal vein thrombosis occurred. J. Med. Invest. 63: 315-318, August, 2016. (キーワード) Hepatectomy / Humans / Male / Middle Aged / Portal Vein / Postoperative Complications / Venous Thrombosis (徳島大学機関リポジトリ) ● Metadata: 111201 (出版サイトへのリンク) ● Publication site (DOI): 10.2152/jmi.63.315 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27644579 ● Search Scopus @ Elsevier (PMID): 27644579 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.63.315 (徳島大学機関リポジトリ: 111201, DOI: 10.2152/jmi.63.315, PubMed: 27644579)
17.	濵田康弘, 安井苑子, 齋藤裕 : CKDにおけるサルコペニア・フレイル対策 CKD患者のサルコペニア・フレイルに対する栄養サポート, 臨床透析, Vol.31, No.8, 1059-1065, 2015年.
18.	安井苑子, 齋藤裕, 濵田康弘 : 栄養療法のピットフォール・よりよい栄養ケアのために Part1.栄養アセスメント Rapid turnover protein値とその解釈, 臨床栄養, Vol.126, No.6, 720-725, 2015年5月.
19.	齋藤裕, 安井苑子, 濵田康弘, 髙須千絵, 池本哲也, 森根裕二, 居村暁, 島田光生 : 肝胆膵手術例の術前栄養管理, 外科, Vol.76, No.11, 1201-1209, 2014年11月.
20.	森根裕二, 島田光生, 石橋広樹, 岩橋衆一, 齋藤裕, 山田眞一郎 : 【膵・胆管合流異常の診断基準の改訂をめぐって】膵・胆管合流異常の診断の最前線胆汁中アミラーゼ値, 胆と膵, Vol.35, No.10, 921-925, 2014年10月. (キーワード) 和文論文
21.	齋藤裕, 島田光生, 石橋広樹, 森根裕二, 居村暁, 森大樹, 荒川悠佑, 岩橋衆一, 髙須千絵 : 【肝胆膵・術後病態を學ぶ】膵胆管合流異常・先天性胆道閉鎖症術後膵胆管合流異常術後発癌の特徴, 肝·胆·膵, Vol.69, No.1, 37-49, 2014年7月. (キーワード) 和文論文
22.	金本真美, 島田光生, 宇都宮徹, 居村暁, 森根裕二, 池本哲也, 荒川悠佑, 岩橋衆一, 齋藤裕, 山田眞一郎, 髙須千絵, 三宅秀則 : 【各種デバイスを応用した私の手術―使用法と工夫】各種デバイスを応用した肝・胆手術, 外科, Vol.75, No.9, 954-959, 2013年9月. (キーワード) 和文論文
23.	Shuichi Iwahashi, Toru Utsunomiya, Mitsuo Shimada, Yu Saitou, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka and Yoshimi Bando : High expressions of cancer stem cell markers in cholangiolocellular carcinoma., Surgery Today, Vol.43, No.6, 654-660, Jun. 2013. (要約) Cholangiolocellular carcinoma (CLC) is an extremely rare malignant liver tumor. It is thought to originate from the ductules and/or canals of Hering, where hepatic stem cells (HpSC) are located, but there are few reports on cancer stem cell markers in CLC. Thus, we evaluated the significance of cancer stem cell markers, including CD133, CD44, and EpCAM, in CLC. The subjects of this study were three patients with CLC and one patient with an intermediate type of combined hepatocellular cholangiocarcinoma (CHC). The cancer cell markers, CK7, CK19, and EMA, were evaluated immunohistochemically. Histological examination of the CLC revealed morphologically cholangiolar features and immunohistochemical examination revealed positivity for CD133, CD44, and EpCAM. On the other hand, in the intermediate type of CHC, only CD44 was positive, whereas CD133 and EpCAM were negative. CLC may have stronger features derived from HpSCs than an intermediate type of CHC. (キーワード) 英文論文 (徳島大学機関リポジトリ) ● Metadata: 115811 (出版サイトへのリンク) ● Publication site (DOI): 10.1007/s00595-012-0437-9 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23192764 ● Summary page in Scopus @ Elsevier: 2-s2.0-84878013011 (徳島大学機関リポジトリ: 115811, DOI: 10.1007/s00595-012-0437-9, PubMed: 23192764, Elsevier: Scopus)
24.	Yu Saitou, Mitsuo Shimada, Toru Utsunomiya, Tetsuya Ikemoto, 山田眞一郎, Yuji Morine, Satoru Imura, Hiroki Mori, 杉本光司, Shuichi Iwahashi and 浅野間理仁 : The protective effect of adipose-derived stem cells against liver injury by trophic molecules., The Journal of Surgical Research, Vol.180, No.1, 162-168, Mar. 2013. (要約) In this study we investigated whether adipose-derived stem cells (ADSCs) had any beneficial protective effects on liver injury and regeneration in vivo. Moreover, we examined whether ADSCs protect hepatocytes via trophic molecules. We transplanted ADSCs into mice after 70% hepatectomy and ischemia-reperfusion, and observed liver injury and regeneration after reperfusion. We co-cultured hepatocytes with ADSCs using a Transwell system for 7 d and evaluated the viabilities of hepatocytes and the cytokine levels in the culture medium. Bevacizumab was used to confirm the effect of vascular endothelial growth factor (VEGF) on hepatocytes. ADSCs improved serum liver function at 6 h after reperfusion in a nonlethal model and stimulated liver regeneration at 24 h after reperfusion in a lethal model. VEGF levels in the culture medium were increased by co-culture ADSCs with hepatocytes. ADSCs improved the viabilities of hepatocytes. The inhibited production of VEGF by bevacizumab did not affect the viability of hepatocytes. ADSCs were able to ameliorate liver injury and stimulate liver regeneration in subsequent hepatectomy and ischemia-reperfusion-injured model mice. Furthermore, hepatocytes were protected by the trophic molecules of the ADSCs. However, such protective effects might be provided by mechanisms other than VEGF signaling. (キーワード) 英文論文 (徳島大学機関リポジトリ) ● Metadata: 105888 (出版サイトへのリンク) ● Publication site (DOI): 10.1016/j.jss.2012.10.009 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23117122 ● Summary page in Scopus @ Elsevier: 2-s2.0-84873706630 (徳島大学機関リポジトリ: 105888, DOI: 10.1016/j.jss.2012.10.009, PubMed: 23117122, Elsevier: Scopus)
25.	森大樹, 島田光生, 宇都宮徹, 石橋広樹, 佐藤宏彦, 居村暁, 森根裕二, 池本哲也, 荒川悠佑, 金本真美, 岩橋衆一, 齋藤裕, 淺野間理仁, 山田眞一郎, 石川大地, 三宅秀則 : 【膵・胆管合流異常診療ガイドラインを巡る残された問題点】非拡張型膵・胆管合流異常の胆管癌発生頻度を巡る問題点, 胆と膵, Vol.34, No.3, 241-244, 2013年3月. (キーワード) 和文論文
26.	Tetsuya Ikemoto, Mitsuo Shimada, Shuichi Iwahashi, Yu Saitou, Mami Kanamoto, Hiroki Mori, Yuji Morine, Satoru Imura and Toru Utsunomiya : Changes of immunological parameters with administration of Japanese Kampo medicine (Juzen-Taihoto/TJ-48) in patients with advanced pancreatic cancer., International Journal of Clinical Oncology, Vol.19, No.1, 81-86, Mar. 2013. (要約) The prognosis of pancreatic cancer is extremely poor regardless of various combination therapies. Immunoaugumentation against tumor cells was recently A focus. We reported that the population of Foxp3(+)CD25(+)CD4(+) regulatory T cells (Foxp3(+)Treg) was the new parameter for the estimation of host immunity and had correlation with tumor aggressiveness. Here we show the immunoaugumentation effects of Japanese Kampo medicine, Juzen-Taihoto/TJ-48, empirically considered as an immunoaugumentation drug, with investigation of Treg and other immunological parameters. Peripheral Foxp3(+) Treg populations, CD4/CD8 ratio, and CD57(+) cells (NK cells) populations in advanced pancreatic cancer patients (n = 30, stage VI A and B according to TNM classification) were estimated after TJ-48 administration for 14 days before the anti-cancer therapy. Treg populations were significantly increased compared to healthy donors (Mann-Whitney U test, P < 0.001). Administration of Juzen-Taihoto/TJ-48 significantly decreased Treg populations (Mann-Whitney U test, P < 0.001) and increased the CD4/CD8 ratio (Mann-Whitney U test, P < 0.01), even though CD57(+) cell populations did not change significantly. Juzen-Taihoto/TJ-48 increased regulatory activities in T cells through decreasing Foxp3(+) Treg populations in advanced pancreatic cancer patients. This effect can lead to immunoaugumentation for various combination therapies. (キーワード) 欧文論文 (出版サイトへのリンク) ● Publication site (DOI): 10.1007/s10147-013-0529-6 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23443635 ● Summary page in Scopus @ Elsevier: 2-s2.0-84894563665 (DOI: 10.1007/s10147-013-0529-6, PubMed: 23443635, Elsevier: Scopus)
27.	Yu Saitou, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Shuichi Iwahashi, 山田眞一郎 and 浅野間理仁 : Regulatory T cells in the blood: a new marker of surgical stress., Surgery Today, Vol.43, No.6, 608-612, Jan. 2013. (キーワード) 英文論文 (出版サイトへのリンク) ● Publication site (DOI): 10.1007/s00595-013-0517-5 (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1573105975985904384 ● Search Scopus @ Elsevier (DOI): 10.1007/s00595-013-0517-5 (DOI: 10.1007/s00595-013-0517-5, CiNii: 1573105975985904384)
28.	Yu Saitou, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 杉本光司, Shuichi Iwahashi, 山田眞一郎, 浅野間理仁 and Hiroki Ishibashi : Hepatic epithelioid angiomyolipoma with arterioportal venous shunting mimicking hepatocellular carcinoma : report of a case., The Journal of Medical Investigation : JMI, Vol.60, No.3-4, 262-266, 2013. (要約) A patient with hepatic epithelioid angiomyolipoma (Epi-AML) with arterioportal venous shunting, who was successfully treated by a laparoscopic left lateral sectionectomy, is presented herein. AML is an uncommon benign neoplasm of the liver. Tumors composed predominantly of epithelioid cells have been subcategorized into Epi-AML, and the treatment strategy for Epi-AML is currently undetermined. There are no reports describing Epi-AML with arterioportal venous shunting to date. An arterioportal venous shunting of the liver tumor was suggested to be one of the malignant signs of the liver tumor. It would be important to differentiate Epi-AML with arterioportal venous shunting from hepatocellular carcinoma and hypervascular metastatic tumors. Minimally invasive resection, such as laparoscopic hepatectomy, for patients having Epi-AML with arterioportal venous shunting may be recommended. (キーワード) Angiomyolipoma / Carcinoma, Hepatocellular / Diagnosis, Differential / Hepatic Artery / Humans / Liver Neoplasms / Magnetic Resonance Imaging / Male / Middle Aged / Portal Vein / Tomography, X-Ray Computed (徳島大学機関リポジトリ) ● Metadata: 106366 (出版サイトへのリンク) ● Publication site (DOI): 10.2152/jmi.60.262 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24190045 ● Search Scopus @ Elsevier (PMID): 24190045 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.60.262 (徳島大学機関リポジトリ: 106366, DOI: 10.2152/jmi.60.262, PubMed: 24190045)
29.	Shinichiro Yamada, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Mami Kanamoto, Jun Hanaoka, Shuichi Iwahashi, Yu Saitou and Hiroki Ishibashi : Hilar cholangiocarcinoma accompanied by pancreaticobiliary maljunction without bile duct dilatation 20 years after cholecystectomy: report of a case, The Journal of Medical Investigation : JMI, Vol.60, No.1-2, 169-173, 2013. (要約) Pancreaticobiliary maljunction (PBM) is associated with the occurrence of biliary cancer due to pancreatobiliary reflux. From the perspective of carcinogenesis, the treatment for PBM is controversial. We herein report a case of hilar cholangiocarcinoma 20 years after the occurrence of gallbladder cancer. A 75-year-old man was referred to our hospital regarding an obstructive jaundice and bile duct tumor. A cholecystectomy was performed for cholelithiasis on this patient 20 years ago, and cancer in situ was detected. Computed tomography (CT) and endoscopic retrograde cholangiopancreatography (ERCP) revealed a tumor of the portal hepatic region and PBM without dilatation of the bile duct. Adenocarcinoma was detected from bile cytology, and we diagnosed hilar cholangiocarcinoma. Despite the biliary decompression, jaundice was prolonged and the patient passed away. Our case suggests that not only cholecystectomy but also biliary diversion is needed for PBM regardless of the existence of bile duct dilatation. (キーワード) 欧文論文 (徳島大学機関リポジトリ) ● Metadata: 106060 (出版サイトへのリンク) ● Publication site (DOI): 10.2152/jmi.60.169 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23614928 ● Search Scopus @ Elsevier (PMID): 23614928 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.60.169 (徳島大学機関リポジトリ: 106060, DOI: 10.2152/jmi.60.169, PubMed: 23614928)
30.	LO Tovuu, Satoru Imura, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Hiroki Mori, Jun Hanaoka, Mami Kanamoto, 杉本光司, Shuichi Iwahashi, Yu Saitou, 山田眞一郎, 淺野間理仁, Hidenori Miyake and Mitsuo Shimada : Role of CD44 expression in non-tumor tissue on intrahepatic recurrence of hepatocellular carcinoma., International Journal of Clinical Oncology, Vol.18, No.4, 651-656, Jun. 2012. (要約) CD44 is well known to be one of the cancer stem cell markers and is a cell-surface glycoprotein involved in cell-cell interactions, cell adhesion, and cell migration. We investigated the role of CD44 expression in both tumor and non-tumor tissues on recurrence of hepatocellular carcinoma (HCC). Forty-eight patients with HCC who underwent hepatic resection at our institution were enrolled in this study. CD44 expressions in both tumor and non-tumor tissues were examined using real time reverse transcription-polymerase chain reaction. The patients were divided into two groups: high and low gene-expression group, based on the CD44 expression level. We compared the clinicopathological factors between the high expression and low expression groups in both tumor and non-tumor tissues. In the tumor tissues, the gene-expression levels of CD44 did not correlate with any clinicopathological parameters. The disease-free survival rate showed no significant difference between the two groups. In non-tumor tissues, although there was no significant relationship between the CD44 expression levels and clinicopathological factors, disease-free survival rate in the CD44 low expression group was significantly better than that in the CD44 high expression group (P < 0.05). In multivariate analysis, the risk factors in tumor recurrence were presence of microscopic portal invasion and high expression level of CD44. The CD44 expressions in the non-tumor tissues may predict HCC recurrence. (徳島大学機関リポジトリ) ● Metadata: 106069 (出版サイトへのリンク) ● Publication site (DOI): 10.1007/s10147-012-0432-6 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22706704 ● Search Scopus @ Elsevier (PMID): 22706704 ● Search Scopus @ Elsevier (DOI): 10.1007/s10147-012-0432-6 (徳島大学機関リポジトリ: 106069, DOI: 10.1007/s10147-012-0432-6, PubMed: 22706704)

国際会議:

1.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Yuhei Waki and Mitsuo Shimada : Preoperative weight loss program for HCC patients with high body mass index in hepatectomy., APASL 2024 Kyoto(アジア太平洋肝臓学会), Kyoto, Mar. 2024.
2.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, Yuhei Waki and Mitsuo Shimada : New onlocogical resectability of CRLM and multidisciplinary treatment strategy, APASL 2024 Kyoto(アジア太平洋肝臓学会), Kyoto, Mar. 2024.
3.	Yu Saitou, Yuji Morine, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : Preoperative weight loss program for hepatocellular carcinoma patients with high body mass index in hepatectomy., ASCO-GI 2024, San Francisco, Jan. 2024.
4.	Mitsuo Shimada, Yuuma Wada, Takayuki Noma, Yu Saitou and Yuji Morine : The combination of CD8 and TIM3 expression to predict survival outcomes in hepatocellular carcinoma., ASCO-GI 2024, San Francisco, Jan. 2024.
5.	Yu Saitou : Holographic Navigation with Extended Reality in Hepatobiliary Pancreatic(HBP)Surgery, ACS 2022, San Diego, Oct. 2022.
6.	Hiroki Teraoku, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Shin-ichiro Yamada : Computed Tomography in Patients with Mass-Forming Intrahepatic Cholangiocarcinoma, IHPBA2020, Melbourne, Nov. 2020.
7.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou and Shin-ichiro Yamada : Treatment Strategy for Synchronous Liver Metastases from Colorectal Cancer, IHPBA2020, Melbourne, Nov. 2020.
8.	Kazunori Tokuda, Mitsuo Shimada, Tetsuya Ikemoto, Katsuki Miyazaki, Shin-ichiro Yamada, Yu Saitou, Yusuke Arakawa, Satoru Imura and Yuji Morine : The investigation of optimal transplantation site of insulin producing cell differentiated from human adipose derived stem cell., ISCT2020, Paris, May 2020. (出版サイトへのリンク) ● Publication site (DOI): 10.1016/j.jcyt.2020.03.194 (文献検索サイトへのリンク) ● Search Scopus @ Elsevier (DOI): 10.1016/j.jcyt.2020.03.194 (DOI: 10.1016/j.jcyt.2020.03.194)
9.	Yu Saitou, Tetsuya Ikemoto, Kazunori Tokuda, Shin-ichiro Yamada, Yusuke Arakawa, Satoru Imura, Yuji Morine and Mitsuo Shimada : Effective 3D culture of hepatocyte like cells from human adipose derived mesenchymal stem cells., ISCT2020, Paris, May 2020. (出版サイトへのリンク) ● Publication site (DOI): 10.1016/j.jcyt.2020.03.178 (文献検索サイトへのリンク) ● Search Scopus @ Elsevier (DOI): 10.1016/j.jcyt.2020.03.178 (DOI: 10.1016/j.jcyt.2020.03.178)
10.	Tetsuya Ikemoto, Mitsuo Shimada, Kazunori Tokuda, Katsuki Miyazaki, Shin-ichiro Yamada, Yu Saitou, Yusuke Arakawa, Satoru Imura and Yuji Morine : The generation of effective insulin-producing cells from ADSC derived from type 1 diabetes mellitus patients., ISCT2020, Paris, May 2020. (出版サイトへのリンク) ● Publication site (DOI): 10.1016/j.jcyt.2020.03.147 (文献検索サイトへのリンク) ● Search Scopus @ Elsevier (DOI): 10.1016/j.jcyt.2020.03.147 (DOI: 10.1016/j.jcyt.2020.03.147)
11.	Mitsuo Shimada, Tetsuya Ikemoto, Kazunori Tokuda, Yu Saitou, Katsuki Miyazaki, Yusuke Arakawa, Satoru Imura and Yuji Morine : Long-term results of transplanted insulin producing cells differented from human adipose stem cells in mice., ISCT2020, Paris, May 2020. (出版サイトへのリンク) ● Publication site (DOI): 10.1016/j.jcyt.2020.03.186 (文献検索サイトへのリンク) ● Search Scopus @ Elsevier (DOI): 10.1016/j.jcyt.2020.03.186 (DOI: 10.1016/j.jcyt.2020.03.186)
12.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Masato Yoshikawa and Katsuki Miyazaki : Significance of frailty in prognosis after hepatectomy in older patients with hepatocellular carcinoma., ASCO-GI, San Francisco, Jan. 2020. (出版サイトへのリンク) ● Publication site (DOI): 10.1245/s10434-020-08742-w (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32562115 ● Search Scopus @ Elsevier (PMID): 32562115 ● Search Scopus @ Elsevier (DOI): 10.1245/s10434-020-08742-w (DOI: 10.1245/s10434-020-08742-w, PubMed: 32562115)
13.	Yusuke Arakawa, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa and Katsuki Miyazaki : Evaluation of the ratio of plasma fibrinogen to platelet in resectable pancreatic cancer., ASCO-GI, San Francisco, Jan. 2020. (出版サイトへのリンク) ● Publication site (DOI): 10.1200/JCO.2020.38.4_suppl.756 (文献検索サイトへのリンク) ● Search Scopus @ Elsevier (DOI): 10.1200/JCO.2020.38.4_suppl.756 (DOI: 10.1200/JCO.2020.38.4_suppl.756)
14.	Masato Yoshikawa, Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou and Katsuki Miyazaki : Prognostic prediction of mass-forming intrahepatic cholangiocarcinoma from ADC value of DWI-MRI, IASGO2019, Bangkok, Oct. 2019.
15.	Katsuki Miyazaki, Tetsuya Ikemoto, Mitsuo Shimada, Feng Rui, Yu Saitou, Shuichi Iwahashi, Yuji Morine and Satoru Imura : THE IMPACT OF RED LED IRRADIATION ON DIFFERENTIATION FOR INSULIN-PRODUCING CELLS FROM MESENCHYMAL STEM CELL, ESOT2019, Copenhagen, Sep. 2019.
16.	Yu Saitou, Shogo Oota, Tetsuya Ikemoto, Shuichi Iwahashi, Yuji Morine, Satoru Imura, Shin-ichiro Yamada and Mitsuo Shimada : THE NEW ROLE OF ZINC ION IN INSULIN-PRODUCING CELLS DIFFERENTIATION FROM ADIPOSE DERIVED MESENCHYMAL STEM CELLS., ESOT2019, Copenhagen, Sep. 2019.
17.	Tetsuya Ikemoto, Mitsuo Shimada, Yu Saitou, Feng Rui, Shin-ichiro Yamada, Shuichi Iwahashi, Yuji Morine and Satoru Imura : THE POTNETIALLY CLINICAL APPLICATION OF XENO-ANTIGEN FREE DIFFERENTIATION PROTOCOL FOR INSULINPRODUCING CELLS USING HUMAN RECOMBINANT PEPTIDE PETALOID Μ-PIECE FROM ADIPOSE-TISSUE DERIVED MESENCHYMAL STEM CELL, ESOT2019, Copenhagen, Sep. 2019.
18.	Mitsuo Shimada, Tetsuya Ikemoto, Yuuma Wada, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada and Shogo Oota : Characteristic difference of adiposederived mesenchymal stem cells from subcutaneous and visceral fat tissue for generating insulin-producing cell, ESOT2019, Copenhagen, Sep. 2019.
19.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou and Shin-ichiro Yamada : Standardization of surgical technique in laparoscopic distal pancreatectomy, SAGES 2019, Baltimore, Apr. 2019.
20.	Shin-ichiro Yamada, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Toshiaki Yoshimoto, Masaaki Nishi and Chie Takasu : Prognostic Prediction of Mass-Forming Intrahepatic Cholangiocarcinoma from Diffusion Weighted Image of Magnetic Resonance Image, SSO's 72nd Annual Cancer Symposium, San Diego, Mar. 2019.
21.	Shogo Oota, Shuichi Iwahashi, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada and Mitsuo Shimada : The feasibility of hepatectomy for the super-elderly patients with HCC., ASCO-GI, San Francisco, Jan. 2019. (出版サイトへのリンク) ● Publication site (DOI): 10.1200/JCO.2019.37.4_suppl.274 (文献検索サイトへのリンク) ● Search Scopus @ Elsevier (DOI): 10.1200/JCO.2019.37.4_suppl.274 (DOI: 10.1200/JCO.2019.37.4_suppl.274)
22.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada and 馮睿 : The effect of hepatic stellate cells on hepatocellular carcinoma progression., ASCO-GI, San Francisco, Jan. 2019. (出版サイトへのリンク) ● Publication site (DOI): 10.1200/JCO.2019.37.4_suppl.265 (文献検索サイトへのリンク) ● Search Scopus @ Elsevier (DOI): 10.1200/JCO.2019.37.4_suppl.265 (DOI: 10.1200/JCO.2019.37.4_suppl.265)
23.	Satoru Imura, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Validity of hepatic cone-unit resection for hepatocellular carcinoma., ASCO-GI, San Francisco, Jan. 2019. (出版サイトへのリンク) ● Publication site (DOI): 10.1200/JCO.2019.37.4_suppl.228 (文献検索サイトへのリンク) ● Search Scopus @ Elsevier (DOI): 10.1200/JCO.2019.37.4_suppl.228 (DOI: 10.1200/JCO.2019.37.4_suppl.228)
24.	Mitsuo Shimada, Hiroki Teraoku, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Chie Takasu and Shin-ichiro Yamada : Role of central hypovascularity in the hepatic arterial phase of dynamic CT on mass-forming intrahepatic cholangiocarcinoma., ASCO-GI, San Francisco, Jan. 2019. (出版サイトへのリンク) ● Publication site (DOI): 10.1200/JCO.2019.37.4_suppl.205 (文献検索サイトへのリンク) ● Search Scopus @ Elsevier (DOI): 10.1200/JCO.2019.37.4_suppl.205 (DOI: 10.1200/JCO.2019.37.4_suppl.205)
25.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou and Shin-ichiro Yamada : The approach for establishing safe, reliable and rapid pancreatoduodenectomy, 第9回日本・モンゴル国際消化器癌シンポジウム, Aug. 2018.
26.	Satoru Imura, Hiroki Teraoku, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Outcome of left lobe living-donor liver transplantation in Tokushima, 27th International Congress of The Transplantation Society(TTS), Jun. 2018.
27.	Yu Saitou, Rui Feng, Chie Takasu, Tetsuya Ikemoto, Shuichi Iwahashi, Hiroki Teraoku, Yuji Morine, Satoru Imura and Mitsuo Shimada : Establishment of effective differentiation protocols for insulin-producing cells using a new 3D culture system from adipose-tissue derived mesenchymal stem cell, 27th International Congress of The Transplantation Society(TTS), Jun. 2018.
28.	Mitsuo Shimada, Rui Feng, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou and Chie Takasu : Establishment of insulin producing cells differentiated from human adipose-derived mesenchymal stem cells using a 3D-culture system with xenoantigen free reagents, 27th International Congress of The Transplantation Society(TTS), Jun. 2018.
29.	Toshiaki Yoshimoto, Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Hiroki Teraoku and Mitsuo Shimada : The Outcome of Sorafenib Therapy on Unresectable Hepatocellular Carcinoma: Experience of Sorafenib therapy combined with surgical resection or TACE, APASL STC2018, Yokohama, May 2018.
30.	Shuichi Iwahashi, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yu Saitou and Hiroki Teraoku : Reduced-port laparoscopic cholecystectomy for young surgeons, SAGES, Seattle, Apr. 2018.
31.	Satoru Imura, Hiroki Teraoku, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Laparoscopic hemi-hepatectomy for liver tumor, SAGES, Seattle, Apr. 2018.
32.	Mitsuo Shimada, Shuichi Iwahashi, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku and Jun Higashijima : Usefulness of one-stop shop simulation for liver surgery using EOB-MRI., SAGES, Seattle, Apr. 2018.
33.	Yuuma Wada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Hiroki Teraoku, Shogo Oota, Jun Higashijima and Mitsuo Shimada : Significance of hypoxia inducible factor-1 expression in liver metastasis of colorectal cancer., ASCO-GI, San Francisco, Jan. 2018.
34.	Yuji Morine, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou and Mitsuo Shimada : Reduction of T-Box 15gene expression in tumor tissue as a prognostic biomarker for patients with heparocellular carcinoma., ASCO-GI, San Francisco, Jan. 2018.
35.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Masato Yoshikawa, Toshiaki Yoshimoto and Mitsuo Shimada : Preoperative Prognostic Nutritional Index Predicts Both Short-and Long-Term Outcomes after Liver Resection For Hepatocellular Carcinoma, AMERICAN COLLEGE OF SURGEONS 2017(ACS), San Diego, Oct. 2017.
36.	Tetsuya Ikemoto, Mitsuo Shimada, Shuichi Iwahashi, Rui Feng, Yu Saitou, Satoru Imura and Yuji Morine : The establishmenmt of effective differentiation protocols for insulin-producing cells using 3D culture system from rat adipose-tissue derived mesenchymal stem cell, 18th Congress of the European Society for Organ Transplantation(ESOT), Barcelona, Sep. 2017.
37.	Rui Feng, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Kouzou Yoshikawa, Toshiaki Yoshimoto and Jun Higashijima : The impact of red LED irradiation on hepatocytes preservation, 18th Congress of the European Society for Organ Transplantation(ESOT)2017, Barcelona, Aug. 2017.
38.	Mitsuo Shimada, Rui Feng, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Toshiaki Yoshimoto and Jun Higashijima : A new 2-step protocol for human adipose derived mesenchymal stem cell differentiation to insulin-producing cells using xeno-antigen free reagents, 18th Congress of the European Society for Organ Transplantation(ESOT), Barcelona, Aug. 2017.
39.	Tetsuya Ikemoto, Mitsuo Shimada, Yu Saitou, Shuichi Iwahashi, Masaaki Nishi, Jun Higashijima, Satoru Imura and Yuji Morine : Clinical impact of Tr1 and FOXP3+regulatory Tcell as precise immunological biomarkers for reflecting cancer status, 47th World Congress of Surgery(WCS), バーゼル, Aug. 2017.
40.	Shuichi Iwahashi, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yu Saitou and Masato Yoshikawa : Reduced-port laparoscopic cholecystectomy with 3mm minute-diameter forceps., SAGES, Houston, Mar. 2017.
41.	Satoru Imura, Atsushi Takata, Toshiaki Yoshimoto, Masato Yoshikawa, Hiroki Teraoku, Daichi Ishikawa, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Comparative analysis of the outcome between open and laparoscopic partial liver resection for hepatocellular carcinoma., SAGES, Houston, Mar. 2017.
42.	Mitsuo Shimada, Shuichi Iwahashi, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa and Jun Higashijima : New technology of `One-stop shop' liver surgery simulation equipped with assessment of total and regional liver functional reserve., SAGES, Houston, Mar. 2017.
43.	Yu Saitou, Yuji Morine, Chie Takasu, Shuichi Iwahashi, Jun Higashijima, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : Role of HSF1 expression for tumor microenvironment in intrahepatic cholangiocarcinoma., ASCO-GI, San Francisco, Jan. 2017. (出版サイトへのリンク) ● Publication site (DOI): 10.1200/JCO.2017.35.4_suppl.249 (文献検索サイトへのリンク) ● Search Scopus @ Elsevier (DOI): 10.1200/JCO.2017.35.4_suppl.249 (DOI: 10.1200/JCO.2017.35.4_suppl.249)
44.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Hiroki Teraoku, Masato Yoshikawa and Jun Higashijima : Treatment strategy for colorectal liver metastases:Clinical impact of FOLFOXIRI regimen for unresectable cases., ASCO-GI, San Francisco, Jan. 2017. (出版サイトへのリンク) ● Publication site (DOI): 10.1200/JCO.2017.35.4_suppl.780 (文献検索サイトへのリンク) ● Search Scopus @ Elsevier (DOI): 10.1200/JCO.2017.35.4_suppl.780 (DOI: 10.1200/JCO.2017.35.4_suppl.780)
45.	Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Masato Yoshikawa, Hiroki Teraoku and Jun Higashijima : Characteristics of intrahepatic cholangiocarcinoma according to tumor location., ASCO-GI, San Francisco, Jan. 2017. (出版サイトへのリンク) ● Publication site (DOI): 10.1200/JCO.2017.35.4_suppl.406 (文献検索サイトへのリンク) ● Search Scopus @ Elsevier (DOI): 10.1200/JCO.2017.35.4_suppl.406 (DOI: 10.1200/JCO.2017.35.4_suppl.406)
46.	Masato Yoshikawa, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Atsushi Takata and Toshiaki Yoshimoto : Current status and effect of laparoscopic training for young surgeon, 40th World Congress of the International College of Surgeons (ICS 2016), Kyoto, Oct. 2016.
47.	Daichi Ishikawa, Tetsuya Ikemoto, Toshiaki Yoshimoto, Atsushi Takata, Masato Yoshikawa, Chie Takasu, Yu Saitou, Shuichi Iwahashi, Yuji Morine, Satoru Imura and Mitsuo Shimada : Signigficance of CD4+CD49b+regulatory T cells and Foxp3+regulatory T cells in the peripheral blood of cancer patients, 40th World Congress of the International College of Surgeons (ICS 2016), Kyoto, Oct. 2016.
48.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Atsushi Takata and Toshiaki Yoshimoto : Recurrent feature after radiofrequency ablation therapy for hepatocellular carcinoma, 4th International Conference of FACO, 廈門, Sep. 2016.
49.	Masato Yoshikawa, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Atsushi Takata and Toshiaki Yoshimoto : Elevated preoperative serum CEA levels in patients with HCC is associated with prognosis and EMT, 26th World Congress Of the IASGO 2016, Seoul, Sep. 2016.
50.	Masato Yoshikawa, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Atsushi Takata and Toshiaki Yoshimoto : Elevated preoperative serum CEA levels in patients with HCC is associated with prognosis and EMT, 第8回日本・モンゴル消化器癌国際シンポジウム, ウランバートル, Aug. 2016.
51.	Satoru Imura, Masato Yoshikawa, Daichi Ishikawa, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Our strategy for antibody mediated rejection in living donor liver transplantation, 第8回日本・モンゴル消化器癌国際シンポジウム, ウランバートル, Aug. 2016.
52.	Atsushi Takata, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Kouzou Yoshikawa and Toshiaki Yoshimoto : The correlation between serum CA19-9 level and the epigenetic alteration in intrahepatic cholangiocarcinoma., IASGO Advanced Post-Graduate Course in Sendai 2016, Sendai, Apr. 2016.
53.	Yu Saitou, Atsushi Takata, Hiroki Teraoku, Masato Yoshikawa, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : The effect od HDACi in ADSC differentiation in to insulin producing cells., Transplantation Science Symposium (TSS) Asian Regional Meeting 2016, Tokyo, Apr. 2016.
54.	Satoru Imura, Takuya Tokunaga, Masayuki Sumitomo, Shin-ichiro Yamada, Chie Takasu, Yu Saitou, Jun Higashijima, Kouzou Yoshikawa, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Usefulness of telementoring system to develop laparoscopic surgery in rural hospital, Society American Gastrointestinal Endoscopic Surgeons (SAGES 2016), Boston, Mar. 2016.
55.	Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Yamada Shinichiro, Teraoku Hiroki, Yoshikawa Masato and Chie Takasu : Effective stepwise training and procedure-standardization for young surgeons to perform laparoscopic left hepatectomy., Society American Gastrointestinal Endoscopic Surgeons (SAGES 2016), Boston, Mar. 2016.
56.	Yoshikawa Masato, Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Yamada Shinichiro, Yoshimoto Toshiaki and Takata Atsushi : Elevated preoperative serum CEA levels in patients with HCC is associated with prognosis and EMT., The Asian Pacific Association for the Study of the Liver, Tokyo, Feb. 2016.
57.	Shinichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Teraoku Hiroki, Yoshikawa Masato, Yoshimoto Toshiaki and Takata Atsushi : High NEK2 expression in hepatocellular carcinoma patients after hepatectomy, The Asian Pacific Association for the Study of the Liver, Tokyo, Feb. 2016.
58.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa and Hiroki Teraoku : Treatment strategy for intrahepatic cholangiocarcinoma: From optimal surgical management to adjuvant therapy., 2016 Gastrointestinal Cancers Symposium, San Francisco, Jan. 2016.
59.	Yu Saitou : The usefulness of peri-operative nutritional assessment in hepatobiliary pancreatic surgery using body composition analyzer and subjective global assessment., ACS Chicago 2015, Oct. 2015.
60.	Yu Saitou : The liver regeneration of left lobe after right liver resection;the comparison among caudate lobe,lateral and median segment., 17th Congress of the European Society for Organ Transplantation (ESOT)2015, Sep. 2015.
61.	Sonoko Yasui, Yumiko Shirai, Mayu Tanimura, Atsumi Matsubara, Miyu Kubo, Yu Saitou, Kazuaki Miyata, Eiji Ishikawa, Chikao Miki and Yasuhiro Hamada : Possible contributing factors to protein-energy wasting (PEW) in Japanese maintenance hemodialysis patients, The European Society for Clinical Nutrition and Metabolism (ESPEN) Congress, Sep. 2015.
62.	Teraoku Hiroki, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Higashijima, Yu Saitou and Chie Takasu : The expression of KI-67 is a useful prognostic factor in patients with colorectal liver metastasis., 46th World Congress of Surgery (WCS)2015, Aug. 2015.
63.	Mitsuo Shimada, Yuji Morine, Satoru Imura, Yu Saitou, Shin-ichiro Yamada, Jun Higashijima and Chie Takasu : Folfoxiri regimen brings early ``conversion'' and better long-term outcome in patients with initially unresectable colorectal liver metastases, 46th World Congress of Surgery (WCS)2015, Aug. 2015.
64.	Sonoko Yasui, Yumiko Shirai, Mayu Tanimura, Sayaka Matsuura, Yu Saitou, Kazuaki Miyata, Eiji Ishikawa, Chikao Miki and Yasuhiro Hamada : Prevalence of protein energy wasting (PEW) and evaluation of diagnostic criteria in patients on maintenance hemodialysis, Parenteral and Enteral Nutrition Society of Asia, Nagoya, Vol.25, No.2, 292-299, Nagoya, Jul. 2015. (要約) The International Society of Renal Nutrition and Metabolism (ISRNM) has recently recommended the use of the term "protein-energy wasting" (PEW). PEW is a state of malnutrition with decreased body stores of protein and energy fuel in hemodialysis patients and is known as a risk factor for morbidity and mortality. We examined the prevalence of PEW and the characteristics of PEW patients in a hemodialysis center in Japan. Fifty-nine outpatients undergoing maintenance hemodialysis at Iga City General Hospital were evaluated. We observed their biochemical data, body composition, dietary intake, and the number of steps prospectively. PEW was defined according to ISRNM criteria. Nine patients (15% of total) were diagnosed as having PEW. Among indicators of PEW criteria, the relevance ratios of "reduced muscle mass" and "unintentional low dietary energy intake" were significantly higher in PEW than in non-PEW. The number of steps was lower, and serum levels of glucose and C-reactive protein were higher in PEW. About 15% of Japanese hemodialysis patients are estimated to have PEW. Our results suggested that major contributing factors to PEW were reduced muscle mass, unintentional low dietary energy intake, lower amount of exercise, insulin resistance, and chronic inflammation. (キーワード) Aged / Blood Glucose / C-Reactive Protein / Comorbidity / Female / Humans / 日本 (Japan) / Male / Prevalence / Protein-Energy Malnutrition / Renal Dialysis / Renal Insufficiency, Chronic / Wasting Syndrome (出版サイトへのリンク) ● Publication site (DOI): 10.6133/apjcn.2016.25.2.10 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27222412 ● Summary page in Scopus @ Elsevier: 2-s2.0-84979094686 (DOI: 10.6133/apjcn.2016.25.2.10, PubMed: 27222412, Elsevier: Scopus)
65.	Yu Saitou : Loss of Fbxw7 expression is associated with poor prognosis in intrahepatic cho langiocarcinoma regulating cell proliferation, apoptosis and EMT., The 6th Asia-Pacific Primary Liver Cancer Expert Meeting(APPLE2015), Jul. 2015.
66.	Yu Saitou : Loss of Fbxw7 expression is associated with poor prognosis in intrahepatic cho langiocarcinoma regulating cell proliferation, apoptosis and EMT., The 6th Asia-Pacific Primary Liver Cancer Expert Meeting(APPLE2015), Jul. 2015.
67.	Teraoku Hiroki, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, Daichi Ishikawa and Yoshikawa Masato : The expression of Ki-67 is a useful prognostic factor in patients with colorectal liver metastasis, IASGO 2015 post graduate course, Tokyo, Jun. 2015.
68.	良元俊昭, GY Wubetu, Shin-ichiro Yamada, 石川大地, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou and Mitsuo Shimada : Impact of STAT4 expression on cellular immunity and prognosis in hepatocellular carcinoma., ASCO-GI 2015 Gastrointestinal Cancers Symposium, Jan. 2015.
69.	Shuichi Iwahashi, Yismaw Gizachew, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, 吉川雅登, 寺奥大貴 and Mitsuo Shimada : The antitumor effect of epigallocatechin-3-gallate on gastroenterological cancer., ASCO-GI 2015 Gastrointestinal Cancers Symposium, Jan. 2015.
70.	Satoru Imura, Mitsuo Shimada, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Hiroshi Shibata and Hidenori Miyake : Long-term survivors after sorafenib therapy in unresectable hepatocellular carcinoma., ASCO-GI 2015 Gastrointestinal Cancers Symposium, Jan. 2015.
71.	Mitsuo Shimada, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, 寺奥大貴, 吉川雅登, Jun Higashijima and Chie Takasu : Impact of FOLFOXIRI regimen on early ``Conversion'' and long-term outcome in patients with initially unresectable colorectal liver metastases, ASCO-GI 2015 Gastrointestinal Cancers Symposium, Jan. 2015.
72.	Yu Saitou : Recent refinements of Glissonian approach for liver resection., IASGO2014, オーストリア, Dec. 2014. (キーワード) 国際学会
73.	Yu Saitou : Recent Refinements of Glissonean Pedicle Approach for Liver Resection, 第6回日本・モンゴル国際消化器癌シンポジウム, モンゴル, Sep. 2014. (キーワード) 国際学会
74.	Kohei Sugihara, Hisami Okumura, Arisa Teramoto, Momo Yamamoto, Yutaka Taketani, Yu Saitou, Yusuke Arakawa, Mitsuo Shimada and Eiji Takeda : The non-protein respiratory quotient as biomarker for the recover from hepatectomy in patients with hepatocellular carcinoma., 36th European Congress for Nutrition and Metabolism, Geneva, Switzerland 2014, September 6-9, Sep. 2014.
75.	Yu Saitou, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto and Shuichi Iwahashi : Useless of 3D-virtual hepatectomy and intraoperative navigation system in liver resection, 第28回国際コンピュータ支援放射線医学・外科学会議(CARS), Fukuoka, Jun. 2014. (キーワード) 国際学会
76.	Yu Saitou : The organ-specific protective effects of human adipose derived stem cells., International Hepato-Pancreato-Biliary Association 11th world Congress(IHPBA), Seoul, Mar. 2014.
77.	Shuichi Iwahashi, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto and Yu Saitou : Effects of valporic acid as a histone deacetylase inhibitor in combination with S-1 on advanced pancreatobiliary tract cancers:Clinical study phases and ., Gastrointestinal Cancers Symposium(ASCO-GI), San Francisco, Jan. 2014.
78.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Yusuke Arakawa, Hiroki Mori, Mami Kanamoto, Shuichi Iwahashi and Yu Saitou : Clinical impact of reflection to expression of EMT marker in intraductal papillary mucinous neoplasm., Gastrointestial Cancers Symposium(ASCO-GI), Jan. 2014. (キーワード) 国際学会
79.	Toru Utsunomiya, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, D Ishikawa, Chie Mikami, Z Chengzhan, A Tajima and I Imoto : Identification of aberrant DNA methylation profiles in non-tumor liver tissues of patients with non-B, non-C hepatocellular carcinoma., Gastrointestinal Cancers Symposium(ASCO-GI), San Francisco, Jan. 2014. (キーワード) 国際学会
80.	Shuichi Iwahashi, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto and Yu Saitou : Effects of valproic acid as a histone deacetylase inhibitor in combination with S-1 on advanced pancreatobiliary tract cancers: Clinical study phases I and II., Gastrointestinal Cancers Symposium(ASCO-GI), San Francisco, Jan. 2014.
81.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Yusuke Arakawa, Hiroki Mori, Mami Kanamoto, Shuichi Iwahashi and Yu Saitou : Clinical impact of reflection to expression of EMT marker in intraductal papillary mucinous neoplasm., Gastrointestinal Cancers Symposium(ASCO-GI), San Francisco, Jan. 2014.
82.	Toru Utsunomiya, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Chie Takasu, Chengzhan Zhu, Tajima A and Imoto I : Identification of aberrant DNA methylation profiles in non-tumor liver tissues of patients with non-B, non-C hepatocellular carcinoma., Gastrointestinal Cancers Symposium(ASCO-GI), San Francisco, Jan. 2014.
83.	Satoru Imura, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou and Chie Takasu : Potential Predictive Factors for Microscopic Portal Invasion in Hepatocellular Carcinoma wwithout Macroscopic Vascular Invasion., American College of Surgeons 2013(ACS), Washington, D.C., Oct. 2013.
84.	Zhu Chengzhan, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, 石川大地, A Tajima, I Imoto and Mitsuo Shimada : Hypomethylation of LINE-1 is associated with a poor prognosis after hepatectomy for patients with hepatocellular carcinoma., 1st International Conference of Federation of Asian Clinical Oncology(FACO), 中国, Sep. 2013.
85.	Toru Utsunomiya, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, 石川大地, Zhu Chengzhan, A Tajima and I. Imoto : Genome-wide analysis of aberrant DNA methylation profiling in non-tumor liver tissues of patients with non-B non-C hepatocellular carcinoma, 1st International Conference of Federation of Asian Clinical Oncology(FACO), 中国, Sep. 2013.
86.	Yu Saitou, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 石川大地 and Bat-Erdene Batsaikhan : Prediction of Recurrence of Hepatocellular Carcinoma after Curative Hepatectomy Using Preoperative lens Culinaris Agglutinin-Reactive Fraction of Alpha-Fetoprotein(AFP-L3)., 第5回日本・モンゴル消化器がんシンポジウム, モンゴル, Sep. 2013.
87.	Satoru Imura, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, 石川大地 and Bat-Erdene Batsaikhan : Recent Advancements in Liver Surgery : Assessment of Functional Reserve, Simulation, and Navigation., 第5回日本・モンゴル消化器がんシンポジウム, モンゴル, Sep. 2013.
88.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, 山田眞一郎 and 石川大地 : Strategy for Intrahepatic Cholangiocarcinoma: From Cancer Stem Cell to Multidisciplinary., International Association of Surgeons, Gastroenterologists and Oncologists 2013(IASGO), ルーマニア, Sep. 2013.
89.	Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, Chie Takasu and 山田眞一郎 : Recent Advancements in Liver Surgery: Assessment of Funcional Reserve, Simulation and Navigation., International Association of Surgeons, Gastroenterologists and Oncologists 2013(IASGO), ルーマニア, Sep. 2013.
90.	Yu Saitou, Mitsuo Shimada, Toru Utsunomiya, Tetsuya Ikemoto, 山田眞一郎 and Chie Takasu : The homing effect of adipose-derived stem cells to the injured liver: The shift of stromal cellderived factor 1 expressions., The 13th Congress of the Asian Society Of Transplantation 2013(CAST), Kyoto, Sep. 2013.
91.	Yusuke Arakawa, Mitsuo Shimada, 石川大地, 山田眞一郎, Yu Saitou, Chie Takasu, Shuichi Iwahashi, Mami Kanamoto, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Toru Utsunomiya, Horohiko Sato and Hidenori Miyake : The gene profile in the spleen under rat small-for-size graft model using cDNA microarray and pathway analaysis., The 13th Congress of the Asian Society Of Transplantation 2013(CAST), Kyoto, Sep. 2013.
92.	Satoru Imura, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi and Yu Saitou : Successfully treated case of liver transplant recipient with donor-specific antibody against human leukocyte antigen., The 13th Congress of the Asian Society Of Transplantation 2013(CAST), Kyoto, Sep. 2013.
93.	Mitsuo Shimada, Shuichi Iwahashi, 山田眞一郎, Yu Saitou, Mami Kanamoto, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Toru Utsunomiya and Hidenori Miyake : Laparoscopic hepatectomy could be the first choice of treatment in selected patients with hepatocellular., Society of American Gastrointestinal and Endoscopic Surgeons 2013(SAGES), Baltimore, Apr. 2013.

国内講演発表:

1.	齋藤裕, 池本哲也, 脇悠平, 寺奥大貴, 山田眞一郎, 森根裕二, 島田光生 : 脂肪由来幹細胞から分化誘導した肝細胞様細胞の免疫原性獲得に関する研究, 第23回日本再生医療学会総会, 2024年3月.
2.	徳永卓哉, 脇悠平, 石橋広樹, 寺奥大貴, 山田眞一郎, 齋藤裕, 池本哲也, 森根裕二, 島田光生 : ADSCから分化したSchwann cell-like cellが神経修復へ与える影響に関する基礎的検討, 第23回日本再生医療学会総会, 2024年3月.
3.	脇悠平, 齋藤裕, 池本哲也, 寺奥大貴, 山田眞一郎, 森根裕二, 島田光生 : 脂肪由来幹細胞から分化誘導した肝細胞様細胞の尿素サイクル異常症モデルマウスへの移植効果, 第23回日本再生医療学会総会, 2024年3月.
4.	池本哲也, 齋藤裕, 脇悠平, 寺奥大貴, 山田眞一郎, 森根裕二, 島田光生 : 再生医療を用いた新たな膵β細胞(insulin producing cell:IPC)移植戦略の樹立に関する研究, 第23回日本再生医療学会総会, 2024年3月.
5.	寺奥大貴, 脇悠平, 森根裕二, 池本哲也, 齋藤裕, 山田眞一郎, 島田光生 : 腫瘍関連マクロファージ(TAM)とのcrosstalkを介したLenvatinib耐性肝細胞癌における悪性度獲得機序, 第56回制癌剤適応研究会, 2024年2月.
6.	山田苑子, 久保みゆ, 和泉優奈, 野村和弘, 神村盛一郎, 柏原秀也, 齋藤裕, 北村嘉章, 島田光生, 濵田康弘, 阪上浩 : 簡便に得られるデータから作成した四肢骨格筋量を予測する回帰式の妥当性検証, 第27回日本病態栄養学会年次学術集会, 2024年1月.
7.	寺奥大貴, 森根裕二, 池本哲也, 齋藤裕, 山田眞一郎, 脇悠平, 島田光生 : Atezolizmab+Bevacizumab療法ならびにTremelimumab+Durvalumab療法により縮小が得られ肝切除を施行し得たVp4を伴う進行肝細胞癌の一例, 第29回日本肝がん分子標的治療研究会, 2024年1月.
8.	寺奥大貴, 森根裕二, 池本哲也, 齋藤裕, 山田眞一郎, 脇悠平, 島田光生 : 切除可能境界膵癌における集学的治療の意義, 第120回日本消化器病学会四国支部例会, 2023年12月.
9.	齋藤裕, 森根裕二, 山田眞一郎, 寺奥大貴, 池本哲也, 島田光生 : 腹腔鏡下肝切除におけるPitfall -心房細動アブレーション後医原性心房中隔欠損を介した奇異性塞栓症-, 第36回日本内視鏡外科学会総会, 2023年12月.
10.	山田眞一郎, 森根裕二, 池本哲也, 齋藤裕, 寺奥大貴, 島田光生 : 最大腫瘍径×個数を用いた新たなresectabilityと治療戦略の提唱, 第45回日本肝臓学会西部会, 2023年12月.
11.	齋藤裕, 森根裕二, 山田眞一郎, 寺奥大貴, 池本哲也, 島田光生 : 肝内胆管癌における新たな予後予測 - MRI拡散強調画像と腫瘍浸潤リンパ球 –, 第45回日本肝臓学会西部会, 2023年12月.
12.	森根裕二, 齋藤裕, 島田光生 : 進行肝細胞癌における至適肝切除適応の再考とconversion surgeryの意義, 第45回日本肝臓学会西部会, 2023年12月.
13.	齋藤裕 : 肝胆膵手術支援の新展開 - Extended reality・ホログラム・メタバース –, 第32回日本コンピュータ外科学会大会, 2023年12月.
14.	和田佑馬, 髙須千絵, 森根裕二, 池本哲也, 齋藤裕, 山田眞一郎, 脇悠平, 寺奥大貴, 吉川幸造, 徳永卓哉, 中尾寿宏, 西正暁, 柏原秀也, 良元俊昭, 島田光生 : 肝細胞癌におけるエクソソームmiRNAを介したLenvatinib耐性機序の検討, 第34回日本消化器癌発生学会総会, 2023年11月.
15.	脇悠平, 森根裕二, 寺奥大貴, 山田眞一郎, 齋藤裕, 池本哲也, 島田光生 : 肝細胞癌微小環境におけるNrf2シグナルを介した癌細胞とTAMの相互作用, 第34回日本消化器癌発生学会総会, 2023年11月.
16.	山田眞一郎, 森根裕二, 池本哲也, 齋藤裕, 脇悠平, 寺奥大貴, 島田光生 : 大建中湯(TU-100)のNASH発癌抑制効果に関する検討, 第34回日本消化器癌発生学会総会, 2023年11月.
17.	寺奥大貴, 森根裕二, 池本哲也, 齋藤裕, 山田眞一郎, 脇悠平, 野間隆礼, 島田光生 : 80歳以上の高齢者膵癌に対する膵頭十二指腸切除の治療成績, 第85回日本臨床外科学会総会, 2023年11月.
18.	山田眞一郎, 森根裕二, 池本哲也, 齋藤裕, 脇悠平, 寺奥大貴, 島田光生 : 大腸癌多発肝転移における最大腫瘍径×個数を用いた肝切除基準と集学的治療方針の提唱, 第85回日本臨床外科学会総会, 2023年11月.
19.	齋藤裕, 池本哲也, 島田光生 : ヒト脂肪由来間葉系幹細胞を用いた新たな肝細胞様細胞移植の樹立にむけて, JDDW 2023, 2023年11月.
20.	森根裕二, 齋藤裕, 島田光生 : 脈管侵襲陽性肝細胞癌の至適治療法は肝切除です, JDDW 2023, 2023年11月.
21.	松本力三, 西尾進, 森田沙瑛, 湯浅麻美, 平田有紀奈, 齋藤裕, 友成哲, 尾矢剛志, 坂東良美, 佐田政隆 : 術前診断が困難であった肝臓原発リンパ管腫の1例, 第33回日本超音波産学会四国地方会学術集会, 2023年10月.
22.	脇悠平, 森根裕二, 野間隆礼, 寺奥大貴, 山田眞一郎, 齋藤裕, 池本哲也, 島田光生 : 微小環境におけるエクソソームを介した薬剤肝細胞癌の悪性度増強と耐性機序の解明, 第61回日本癌治療学会学術集会, 2023年10月.
23.	寺奥大貴, 森根裕二, 池本哲也, 齋藤裕, 山田眞一郎, 脇悠平, 野間隆礼, 島田光生 : 再発肝細胞癌に対する肝切除成績, 第61回日本癌治療学会学術集会, 2023年10月.
24.	寺奥大貴, 森根裕二, 池本哲也, 齋藤裕, 山田眞一郎, 脇悠平, 野間隆礼, 島田光生 : 膵・胆管合流異常における胆道上皮PD-L1発現, 第46回日本膵・胆管合流異常研究会, 2023年9月.
25.	寺奥大貴, 齋藤裕, 杉本真樹, 森根裕二, 山田眞一郎, 池本哲也, 島田光生 : 胆道手術における3D胆道造影Extended realityによる手術支援, 第17回肝癌治療ナビゲーション研究会, 2023年8月.
26.	齋藤裕, 杉本真樹, 森根裕二, 山田眞一郎, 寺奥大貴, 池本哲也, 島田光生 : 肝胆膵手術支援の新展開-Extended reality・ホログラム・メタバース-, 第50回日本膵切研究会, 2023年8月.
27.	寺奥大貴, 山田眞一郎, 齋藤裕, 池本哲也, 森根裕二, 島田光生 : 症例, 第59回日本肝癌研究会, 2023年7月.
28.	山田眞一郎, 森根裕二, 池本哲也, 齋藤裕, 寺奥大貴, 島田光生 : 肝細胞癌における微小環境クロストークによるLenvatinib耐性機序の検討, 第59回日本肝癌研究会, 2023年7月.
29.	森根裕二, 齋藤裕, 山田眞一郎, 寺奥大貴, 脇悠平, 池本哲也, 島田光生 : 肉眼的門脈浸潤を伴う進行肝細胞癌の治療戦略, 第59回日本肝癌研究会, 2023年7月.
30.	齋藤裕, 森根裕二, 山田眞一郎, 寺奥大貴, 山下祥子, 常山幸一 : 組織発生学的特徴からみた肝内胆管癌の病理診断, 第59回日本肝癌研究会, 2023年7月.
31.	脇悠平, 森根裕二, 齋藤裕, 山田眞一郎, 寺奥大貴, 野間隆礼, 池本哲也, 島田光生 : 内科的治療後再発・遺残肝細胞に対するRescue肝切除の意義, 第78回日本消化器外科学会総会, 2023年7月.
32.	池本哲也, 島田光生, 森根裕二, 齋藤裕, 山田眞一郎, 脇悠平, 寺奥大貴 : 徳島大学病院全体と消化器・移植外科のFRT回避に係る連携とOODAループ, 第78回日本消化器外科学会総会, 2023年7月.
33.	山田眞一郎, 森根裕二, 池本哲也, 齋藤裕, 脇悠平, 寺奥大貴, 野間隆礼, 島田光生 : EOBによる肝予備能評価と最大腫瘍径×個数を用いた肝切除限界の提唱, 第78回日本消化器外科学会総会, 2023年7月.
34.	寺奥大貴, 森根裕二, 池本哲也, 齋藤裕, 山田眞一郎, 脇悠平, 野間隆礼, 島田光生 : 高齢者膵癌に対する膵頭十二指腸切除術の適応と限界, 第78回日本消化器外科学会総会, 2023年7月.
35.	齋藤裕, 森根裕二, 池本哲也, 山田眞一郎, 寺奥大貴, 山田苑子, 阪上浩, 鎌田基夢, 松浦哲也, 島田光生 : 肥満を有する肝細胞癌患者に対する術前栄養運動介入の有用性 - ERAS導入による手術成績の向上 –, 第78回日本消化器外科学会総会, 2023年7月.
36.	森根裕二, 齋藤裕, 山田眞一郎, 寺奥大貴, 宮崎克己, 脇悠平, 池本哲也, 島田光生 : 肉眼的門脈浸潤を伴う進行肝細胞癌の治療戦略, 第78回日本消化器外科学会総会, 2023年7月.
37.	齋藤裕, 森根裕二, 山田眞一郎, 寺奥大貴, 池本哲也, 山田苑子, 阪上浩, 鎌田基夢, 松浦哲也, 島田光生 : 肥満を有する肝細胞癌患者に対する術前栄養運動介入の有用性-ERAS導入による手術成績の向上 –, 日本外科代謝栄養学会第60回学術集会, 2023年7月.
38.	松本力三, 西尾進, 大豆本圭, 森田沙瑛, 湯浅麻美, 平田有紀奈, 山尾雅美, 齋藤裕, 楠瀬賢也, 山田博胤, 島田光生, 佐田政隆 : 後腹膜リンパ節転移を生じたBurned-out testicular tumorの1例, 第48回日本超音波検査学会学術集会, 2023年6月.
39.	森田沙瑛, 西尾進, 松本力三, 山口夏美, 湯浅麻美, 平田有紀奈, 山尾雅美, 齋藤裕, 楠瀬賢也, 山田博胤, 島田光生, 佐田政隆 : 分枝膵管型IPMNに由来した膵管内乳頭粘液性腺癌の一例, 第48回日本超音波検査学会学術集会, 2023年6月.
40.	寺奥大貴, 森根裕二, 池本哲也, 齋藤裕, 山田眞一郎, 脇悠平, 仲須千春, 島田光生 : PD-L1 expression of biliary epithelium in pancreaticobiliary maljunction, 第35回日本肝胆膵外科学会学術集会, 2023年6月.
41.	山田眞一郎, 森根裕二, 池本哲也, 齋藤裕, 脇悠平, 寺奥大貴, 島田光生 : New strategy for CRLM using Maximum Diameter x Number: MDN, 第35回日本肝胆膵外科学会学術集会, 2023年6月.
42.	齋藤裕, 森根裕二, 山田眞一郎, 寺奥大貴, 池本哲也, 山田眞一郎, 西麻希, 阪上浩, 鎌田基夢, 松浦哲也, 島田光生 : Preoperative weight loss program for high body mass index patients undergoing liver resection for hepatocellular carcinoma - Surgical outcomes of ERAS protocol, 第35回日本肝胆膵外科学会学術集会, 2023年6月.
43.	池本哲也, 島田光生, 森根裕二, 齋藤裕, 山田眞一郎, 脇悠平, 寺奥大貴 : Establishment of investigator initiated clinical trial as a future cell transplantation for to complement existing transplantations, 第35回日本肝胆膵外科学会学術集会, 2023年6月.
44.	森根裕二, 齋藤裕, 山田眞一郎, 寺奥大貴, 宮崎克己, 脇悠平, 池本哲也, 島田光生 : Reconsideration of indication of hepatic for advanced hepatocellular carcinoma and significance of conversion surgery, 第35回日本肝胆膵外科学会学術集会, 2023年6月.
45.	寺奥大貴, 森根裕二, 池本哲也, 齋藤裕, 山田眞一郎, 脇悠平, 野間隆礼, 島田光生 : 肝細胞癌におけるNrf2/VEGFシグナルを介したTumor-associated macrophage (TAM)との相互作用, 第44回癌免疫外科研究会, 2023年6月.
46.	山田眞一郎, 森根裕二, 池本哲也, 齋藤裕, 寺奥大貴, 島田光生 : 術前の心構え「AWA spirits」に基づいたtraining systemによる肝胆膵外科の若手教育, 日本消化器病学会四国支部第119回例会, 2023年6月.
47.	寺奥大貴, 森根裕二, 池本哲也, 齋藤裕, 山田眞一郎, 島田光生 : StageIII/IVa肝細胞癌におけるMRI拡散強調画像ADC値とTumor infiltrative lymphocyte (TIL), 第59回日本肝臓学会総会, 2023年6月.
48.	山田眞一郎, 森根裕二, 池本哲也, 齋藤裕, 島田光生 : ヒト脂肪由来間葉系幹細胞を用いた新たな肝細胞様細胞移植の樹立にむけて, 第59回日本肝臓学会総会, 2023年6月.
49.	齋藤裕, 森根裕二, 島田光生 : 進行肝細胞癌に対する外科治療の新展開-肝癌微小環境におけるNrf2に着目した新たなアプローチ-, 第59回日本肝臓学会総会, 2023年6月.
50.	山田眞一郎, 森根裕二, 池本哲也, 齋藤裕, 寺奥大貴, 島田光生 : 高齢者に対する肝胆膵手術におけるFrailtyの意義に関する検討, 第48回日本外科系連合学会学術集会, 2023年6月.
51.	齋藤裕, 森根裕二, 山田眞一郎, 寺奥大貴, 池本哲也, 島田光生 : 進行肝細胞癌における至適肝切除適応の再考とConversion surgeryの意義, 第48回日本外科系連合学会学術集会, 2023年6月.
52.	池本哲也, 島田光生, 森根裕二, 齋藤裕, 山田眞一郎, 寺奥大貴 : 徳島大学病院における医療安全管理上の患者アドボカシーの実情と展望, 第48回日本外科系連合学会学術集会, 2023年6月.
53.	森大樹, 山田眞一郎, 森根裕二, 池本哲也, 齋藤裕, 脇悠平, 寺奥大貴, 野間隆礼 : EOB予備能評価に基づいた至適肝切除, 第123回日本外科学会定期学術集会, 2023年4月.
54.	野間隆礼, 森根裕二, 齋藤裕, 山田眞一郎, 寺奥大貴, 池本哲也, 島田光生 : 再発肝細胞癌に対する肝切除の意義, 第123回日本外科学会定期学術集会, 2023年4月.
55.	寺奥大貴, 齋藤裕, 森根裕二, 池本哲也, 山田眞一郎, 山田苑子, 西麻希, 阪上浩, 鎌田基夢, 松浦哲也, 島田光生 : 肝細胞癌における肥満患者への術前栄養運動介入の有用性, 第123回日本外科学会定期学術集会, 2023年4月.
56.	脇悠平, 森根裕二, 池本哲也, 齋藤裕, 山田眞一郎, 寺奥大貴, 仲須千春 : Lenvatinib耐性肝細胞癌における癌微小環境を介した悪性度獲得機序の解明, 第123回日本外科学会定期学術集会, 2023年4月.
57.	池本哲也, 島田光生, 齋藤裕, 脇悠平, 寺奥大貴, 山田眞一郎, 森根裕二 : 再生医療によるインスリン産生細胞自家移植戦略は1型糖尿病治療を変える, 第123回日本外科学会定期学術集会, 2023年4月.
58.	山田眞一郎, 森根裕二, 池本哲也, 齋藤裕, 脇悠平, 寺奥大貴, 仲須千春 : EOBによる肝予備能評価と最大腫瘍径×個数を用いた肝切除限界の提唱, 第123回日本外科学会定期学術集会, 2023年4月.
59.	齋藤裕, 杉本真樹, 森根裕二, 池本哲也, 徳永卓哉, 山田眞一郎, 寺奥大貴, 岩田貴, 島田光生 : 消化器外科ナビゲーションの新展開 -Extended reality・ホログラム・メタバース –, 第123回日本外科学会定期学術集会, 2023年4月.
60.	森根裕二, 齋藤裕, 山田眞一郎, 寺奥大貴, 池本哲也, 島田光生 : 進行肝細胞癌における至適肝切除適応の再考とConversion surgeryの意義, 第123回日本外科学会定期学術集会, 2023年4月.
61.	徳永卓哉, 齋藤裕, 杉本真樹, 吉川幸造, 中尾寿宏, 西正暁, 柏原秀也, 髙須千絵, 和田佑馬, 良元俊昭, 山下祥子, 岩川陽介, 島田光生 : 経肛門アプローチを用いた腹腔鏡下側方郭清の手術手技と短期成績 ∼Hologramによるシミュレーションの有用性∼, 第122回日本外科学会定期学術集会, 2023年4月.
62.	脇悠平, 池本哲也, 齋藤裕, 寺奥大貴, 山田眞一郎, 森根裕二, 島田光生 : ADSCから分化したinsulin producing cell移植時の自己免疫による影響に関する検討, 第22回日本再生医療学会総会, 2023年3月.
63.	齋藤裕, 陳述海, 脇悠平, 池本哲也, 寺奥大貴, 山田眞一郎, 森根裕二, 島田光生 : ヒト脂肪由来間葉系幹細胞を用いた新たな肝細胞様細胞移植の樹立にむけて, 第22回日本再生医療学会総会, 2023年3月.
64.	池本哲也, 島田光生, 齋藤裕, 脇悠平, 寺奥大貴, 山田眞一郎, 森根裕二 : 間葉系幹細胞を用いた新たなβ細胞補填治療法樹立に向けて, 第22回日本再生医療学会総会, 2023年3月.
65.	脇悠平, 池本哲也, 齋藤裕, 寺奥大貴, 山田眞一郎, 森根裕二, 島田光生 : 再生医療によって作成されたinsulin producing cell移植後の自己免疫による影響に関する基礎的検討, 第50回日本膵・膵島移植学会学術集会, 2023年3月.
66.	池本哲也, 島田光生, 齋藤裕, 脇悠平, 寺奥大貴, 和田佑馬, 山田眞一郎, 森根裕二 : 再生医療を用いたβ細胞補填治療法に関する膵島移植とのクロストーク, 第50回日本膵・膵島移植学会学術集会, 2023年3月.
67.	寺奥大貴, 脇悠平, 仲須千春, 森根裕二, 池本哲也, 齋藤裕, 山田眞一郎, 島田光生 : Lenvatinib耐性肝細胞癌におけるNrf2を介した悪性度上昇と薬剤耐性獲得機序の検討, 第55回制癌剤適応研究会, 2023年2月.
68.	那須七海, 山田苑子, 滝本真望, 関本大介, 柏原秀也, 齋藤裕, 島田光生, 濵田康弘 : 膵液瘻高リスク患者における膵頭十二指腸切除術後の早期経口摂取と膵液瘻との関連, 第26回日本病態栄養学会年次学術集会, 2023年1月.
69.	脇悠平, 森根裕二, 池本哲也, 齋藤裕, 山田眞一郎, 寺奥大貴, 島田光生 : Lenvatinib耐性肝細胞癌における癌微小環境を介した悪性度獲得と薬剤耐性獲得機序の解明, 第27回日本肝がん分子標的治療研究会, 2023年1月.
70.	山田眞一郎, 森根裕二, 齋藤裕, 寺奥大貴, 池本哲也, 島田光生 : 肝細胞癌BCLC intermediate stageにおけるMaximum tumor diameter × number の意義, 第27回日本肝がん分子標的治療研究会, 2023年1月.
71.	森大樹, 森根裕二, 石橋広樹, 池本哲也, 齋藤裕, 山田眞一郎, 寺奥大貴, 山下祥子, 常山幸一, 島田光生 : 慢性炎症状態の膵・胆管合流異常におけるNLRP3活性化を介した腫瘍微小環境と発癌に関する検討, 第33回日本消化器癌発生学会総会, 2022年11月.
72.	山田眞一郎, 森根裕二, 池本哲也, 齋藤裕, 寺奥大貴, 脇悠平, 野間隆礼, 島田光生 : 大腸癌肝転移におけるoncological/liver functional resectabilityの定義と集学的治療戦略, 第84回日本臨床外科学会総会, 2022年11月.
73.	齋藤裕, 森根裕二, 山田眞一郎, 寺奥大貴, 池本哲也, 島田光生 : 進行肝細胞癌に対する外科切除成績とConversion surgeryの意義, 第84回日本臨床外科学会総会, 2022年11月.
74.	池本哲也, 島田光生, 山田眞一郎, 寺奥大貴, 齋藤裕, 森根裕二 : de novo B型肝炎管理体制構築に向けた取り組み, 第84回日本臨床外科学会総会, 2022年11月.
75.	齋藤裕, 森根裕二, 池本哲也, 山田眞一郎, 寺奥大貴, 山田苑子, 西麻希, 阪上浩, 鎌田基夢, 松浦哲也, 島田光生 : 肥満を有する肝細胞癌患者に対する術前栄養運動介入の有用性, 第118回日本消化器病学会四国支部例会, 2022年11月.
76.	寺奥大貴, 森根裕二, 池本哲也, 齋藤裕, 山田眞一郎, 仲須千春, 髙橋叡, 野間隆礼, 島田光生 : StageIII/IV肝細胞癌における拡散強調画像ADC値の意義, 第33回日本消化器癌発生学会総会, 2022年11月.
77.	髙須千絵, 森根裕二, 池本哲也, 齋藤裕, 山田眞一郎, 寺奥大貴, 島田光生 : 大腸癌肝転移における発育形式と予後に関する検討, 第84回日本臨床外科学会総会, 2022年11月.
78.	髙須千絵, 仲須千春, 森根裕二, 池本哲也, 齋藤裕, 山田眞一郎, 寺奥大貴, 脇悠平, 島田光生 : Nrf2を基軸とした癌微小環境クロストークによる肝細胞癌Lenvatinib耐性機序解明に関する研究, 第33回日本消化器癌発生学会総会, 2022年11月.
79.	寺奥大貴, 森根裕二, 池本哲也, 齋藤裕, 山田眞一郎, 島田光生 : 肝細胞癌におけるlymphocyte/C-reactive protein ratio(LCR)の有用性, JDDW 2022, 2022年10月.
80.	山田眞一郎, 森根裕二, 池本哲也, 齋藤裕, 寺奥大貴, 島田光生 : 高齢者膵癌切除例におけるフレイルの影響に関する検討, JDDW 2022, 2022年10月.
81.	仲須千春, 森根裕二, 池本哲也, 齋藤裕, 山田眞一郎, 脇悠平, 寺奥大貴, 島田光生 : 肝細胞癌におけるNrf2に着目したレンバチニブ耐性獲得機序についての検討, 第60回日本癌治療学会学術集会, 2022年10月.
82.	寺奥大貴, 森根裕二, 池本哲也, 齋藤裕, 山田眞一郎, 仲須千春, 島田光生 : 肝癌微小環境におけるNrf2/VEGFシグナルを介した肝癌細胞とTAMの相互作用, 第60回日本癌治療学会学術集会, 2022年10月.
83.	齋藤裕, 森根裕二, 山田眞一郎, 寺奥大貴, 良元俊昭, 西麻希, 阪上浩, 島田光生 : 肥満肝細胞癌患者に対する術前栄養運動介入の有用性 -ERAS導入による手術成績の向上-, 第60回日本癌治療学会学術集会, 2022年10月.
84.	山田眞一郎, 森根裕二, 池本哲也, 齋藤裕, 寺奥大貴, 島田光生 : 高齢者膵癌切除例の予後におけるフレイルの影響に関する検討, 第60回日本癌治療学会学術集会, 2022年10月.
85.	池本哲也, 徳永卓哉, 脇悠平, 寺奥大貴, 山田眞一郎, 齋藤裕, 森根裕二, 島田光生 : Schwann-like cell分化誘導による末梢神経損傷修復に関する基礎的検討, 第60回日本癌治療学会学術集会, 2022年10月.
86.	森根裕二, 齋藤裕, 山田眞一郎, 寺奥大貴, 池本哲也, 島田光生 : 進行肝細胞癌に対する肝切除の意義, 第60回日本癌治療学会学術集会, 2022年10月.
87.	脇悠平, 齋藤裕, 池本哲也, 陳術海, 寺奥大貴, 山田眞一郎, 森根裕二, 島田光生 : ヒト脂肪由来間葉系幹細胞から肝細胞様細胞の創出-肝不全・代謝性肝疾患に対する肝移植から細胞治療へ, 第58回日本移植学会総会, 2022年10月.
88.	齋藤裕, 島田光生, 寺奥大貴, 山田眞一郎, 池本哲也, 森根裕二 : 脳死肝移植ドナー不足解消にむけての普及啓発活動 - 医療系学生に対するドナーアクション(命の授業)の必要性 –, 第58回日本移植学会総会, 2022年10月.
89.	池本哲也, 島田光生, 齋藤裕, 寺奥大貴, 山田眞一郎, 森根裕二 : 再生医療を用いた移植治療確立へ向けた戦略∼新たなβ細胞補充治療法, 第58回日本移植学会総会, 2022年10月.
90.	森大樹, 森根裕二, 石橋広樹, 池本哲也, 齋藤裕, 山田眞一郎, 寺奥大貴, 山下祥子, 常山幸一, 島田光生 : 慢性炎症化下の膵・胆管合流異常におけるNLRP3活性化を介した腫瘍微小環境と発癌に関する検討, 第45回日本膵・胆管合流異常研究会, 2022年9月.
91.	寺奥大貴, 森根裕二, 池本哲也, 齋藤裕, 山田眞一郎, 島田光生 : 肝細胞癌腫瘍微小環境におけるNrf2/VEGFシグナルを介した癌細胞とTAMの相互作用, 第81回日本癌学会学術総会, 2022年9月.
92.	野間隆礼, 森根裕二, 池本哲也, 齋藤裕, 山田眞一郎, 寺奥大貴, 島田光生 : 再発膵癌に対する残膵切除の治療成績, 第97回中国四国外科学会総会/第27回中国四国内視鏡外科研究会, 2022年9月.
93.	山田眞一郎, 森根裕二, 池本哲也, 齋藤裕, 寺奥大貴, 野間隆礼, 島田光生 : 大腸癌肝転移におけるresectabilityの定義と集学的治療戦略, 第97回中国四国外科学会総会/第27回中国四国内視鏡外科研究会, 2022年9月.
94.	齋藤裕, 杉本真樹, 森根裕二, 池本哲也, 山田眞一郎, 寺奥大貴, 島田光生 : 術中ホログラム胆道造影を駆使した胆道手術支援, 第97回中国四国外科学会総会/第27回中国四国内視鏡外科研究会, 2022年9月.
95.	齋藤裕, 杉本真樹, 森根裕二, 寺奥大貴, 山田眞一郎, 池本哲也, 島田光生 : 術中ホログラム胆道造影を駆使した胆道手術支援, 第16回肝癌治療ナビゲーション研究会, 2022年9月.
96.	仲須千春, 島田光生, 森根裕二, 池本哲也, 齋藤裕, 山田眞一郎, 寺奥大貴, 沖川昌平 : MRI拡散強調画像から見たミラノ基準内肝細胞癌の予後予測に関する検討, 第77回日本消化器外科学会総会, 2022年7月.
97.	寺奥大貴, 森根裕二, 池本哲也, 齋藤裕, 山田眞一郎, 島田光生 : 膵癌残膵再発に対する残膵切除の治療成績, 第77回日本消化器外科学会総会, 2022年7月.
98.	齋藤裕, 森根裕二, 池本哲也, 山田眞一郎, 寺奥大貴, 良元俊昭, 西麻希, 阪上浩, 島田光生 : 肥満を有する肝細胞癌患者に対する術前栄養運動介入の有用性, 第77回日本消化器外科学会総会, 2022年7月.
99.	池本哲也, 齋藤裕, 島田光生, 沖川昌平, 寺奥大貴, 山田眞一郎, 森根裕二 : 再生医療を用いた細胞移植治療確立へ向けた戦略∼移植外科医・レシピエント双方の負担軽減という視点から, 第77回日本消化器外科学会総会, 2022年7月.
100.	山田眞一郎, 森根裕二, 池本哲也, 齋藤裕, 寺奥大貴, 島田光生 : 大腸癌肝転移におけるoncological/liver functional resectabilityの定義とBRに対する集学的治療戦略, 第77回日本消化器外科学会総会, 2022年7月.
101.	森根裕二, 齋藤裕, 山田眞一郎, 寺奥大貴, 池本哲也, 島田光生 : 進行肝細胞癌に対する肝切除の意義, 第77回日本消化器外科学会総会, 2022年7月.
102.	髙須千絵, 仲須千春, 森根裕二, 池本哲也, 齋藤裕, 山田眞一郎, 寺奥大貴, 濵田康弘, 沖川昌平, 島田光生 : 肝細胞癌におけるmiRNA-132, 142-5pを介したLenvatinib耐性機序の検討, 第77回日本消化器外科学会総会, 2022年7月.
103.	山田眞一郎, 森根裕二, 池本哲也, 齋藤裕, 寺奥大貴, 島田光生 : 肝細胞癌におけるSorafenib/Lenvatinib耐性機序の検討, 第26回日本肝がん分子標的治療研究会, 2022年6月.
104.	齋藤裕, 森根裕二, 山田眞一郎, 寺奥大貴, 宮崎克己, 池本哲也, 島田光生 : 進行肝細胞癌に対する外科切除成績とConversion surgeryの意義, 第26回日本肝がん分子標的治療研究会, 2022年6月.
105.	森根裕二, 齋藤裕, 山田眞一郎, 寺奥大貴, 池本哲也, 島田光生 : 進行肝細胞癌に対する肝切除を中心とした治療戦略, 第31回日本癌病態治療研究会, 2022年6月.
106.	齋藤裕, 森根裕二, 山田眞一郎, 寺奥大貴, 宮崎克己, 池本哲也, 島田光生 : 進行肝細胞癌に対する外科切除成績とConversion surgeryの意義, 第117回日本消化器病学会四国支部例会, 2022年6月.
107.	池本哲也, 島田光生, 森根裕二, 齋藤裕, 山田眞一郎, 寺奥大貴 : 消化器・移植外科から発信する手術室医療安全, 第47回日本外科系連合学会学術集会, 2022年6月.
108.	Hiroki Teraoku, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, 沖川昌平, Tetsuya Ikemoto and Mitsuo Shimada : Associations between the ADC values based on MRI diffusion-weighted images and tumor-infiltrative lymphocytes in Stage III / IV hepatocellular carcinoma, 第34回日本肝胆膵外科学会・学術集会, Jun. 2022.
109.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou and Hiroki Teraoku : Impact of frailty on resected pancreatic cancer in elderly patients, 第34回日本肝胆膵外科学会・学術集会, Jun. 2022.
110.	Yu Saitou, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Hiroki Teraoku, Masaaki Nishi, Hiroshi Sakaue and Mitsuo Shimada : Weight loss program for high body mass index patients undergoing liver resection for hepatocellular carcinoma, 第34回日本肝胆膵外科学会・学術集会, Jun. 2022.
111.	Tetsuya Ikemoto, Yu Saitou, Mitsuo Shimada, Hiroki Teraoku, Shin-ichiro Yamada and Yuji Morine : Establishment of investigator initiated clinical trial for insulin producing cells from ADSC with Tokushima protocol to complement pancreas/islet transplantation., 第34回日本肝胆膵外科学会・学術集会, Jun. 2022.
112.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : Role of surgical resection for advanced hepatocellular carcinoma focused on conversion surgery in MTA era, 第34回日本肝胆膵外科学会・学術集会, Jun. 2022.
113.	齋藤裕, 杉本真樹, 森根裕二, 池本哲也, 徳永卓哉, 山田眞一郎, 寺奥大貴, 島田光生 : 術中ホログラム胆道造影を駆使した胆道手術支援, 第31回日本コンピュータ外科学会大会, 2022年6月.
114.	Hiroki Teraoku, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, 沖川昌平, Tetsuya Ikemoto and Mitsuo Shimada : Significance of the ADC values based on MRI DWI in Stage / HCC, 第67回国際外科学会日本部会総会, Jun. 2022.
115.	森根裕二, 齋藤裕, 島田光生 : 進行肝細胞癌に対する集学的治療におけるConversion surgeryの意義, 第58回日本肝臓学会総会, 2022年6月.
116.	髙須千絵, 仲須千春, 森根裕二, 池本哲也, 齋藤裕, 山田眞一郎, 寺奥大貴, 沖川昌平, 島田光生 : 肝細胞癌におけるmiRNA-X,Yを介したLenvatinib耐性機序の検討, 第26回日本肝がん分子標的治療研究会, 2022年6月.
117.	Toshiaki Yoshimoto, Takuya Tokunaga, Yu Saitou, Hideya Kashihara, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada, 山下祥子, 岩川陽介 and Mitsuo Shimada : Intraoperative holographic image-guided lateral pelvic lymph node dissection in a transanal approach for rectal cancer, CARS 2022, Jun. 2022.
118.	徳永卓哉, 杉本真樹, 齋藤裕, 吉川幸造, 中尾寿宏, 西正暁, 柏原秀也, 髙須千絵, 和田佑馬, 良元俊昭, 島田光生 : 経肛門アプローチ併用ハイブリッド側方リンパ節郭清に対するホログラムの有用性, 第31回日本コンピュータ外科学会大会, 2022年6月.
119.	石橋広樹, 森根裕二, 齋藤裕, 森大樹, 横田典子, 島田光生 : 小児膵SPNに対する腹腔鏡下脾温存膵体尾部切除術, 第59回日本小児外科学会学術集会, 2022年5月.
120.	寺奥大貴, 森根裕二, 池本哲也, 齋藤裕, 山田眞一郎, 島田光生 : 症例, 第58回日本肝癌研究会, 2022年5月.
121.	山田眞一郎, 森根裕二, 池本哲也, 齋藤裕, 寺奥大貴, 沖川昌平, 島田光生 : 大腸癌肝転移におけるoncological/liver functional resectabilityの定義とBRに対する集学的治療戦略, 第58回日本肝癌研究会, 2022年5月.
122.	森根裕二, 齋藤裕, 山田眞一郎, 寺奥大貴, 池本哲也, 島田光生 : 進行肝細胞癌に対する肝切除の意義, 第58回日本肝癌研究会, 2022年5月.
123.	齋藤裕, 杉本真樹, 森根裕二, 池本哲也, 山田眞一郎, 寺奥大貴, 島田光生 : 術中ホログラム胆道造影を駆使した肝胆道手術支援, 第58回日本肝癌研究会, 2022年5月.
124.	森根裕二, 齋藤裕, 山田眞一郎, 寺奥大貴, 池本哲也, 島田光生 : 再発肝細胞癌に対する肝切除の意義, 第58回日本肝癌研究会, 2022年5月.
125.	徳永卓哉, 齋藤裕, 杉本真樹, 吉川幸造, 中尾寿宏, 西正暁, 柏原秀也, 髙須千絵, 和田佑馬, 良元俊昭, 山下祥子, 岩川陽介, 島田光生 : 経肛門アプローチを用いた腹腔鏡下側方郭清の手術手技と短期成績∼Hologramによるシミュレーションの有用性∼, 第122回日本外科学会定期学術集会, 2022年4月.
126.	山田眞一郎, 森根裕二, 池本哲也, 齋藤裕, 寺奥大貴, 沖川昌平, 山下祥子 : 高齢者膵癌切除例におけるフレイルの影響に関する検討, 第108回日本消化器病学会総会, 2022年4月.
127.	森根裕二, 齋藤裕, 島田光生 : 進行肝細胞癌に対する集学的治療におけるConversion Surgeryの意義, 第108回日本消化器病学会総会, 2022年4月.
128.	髙橋叡, 寺奥大貴, 森根裕二, 齋藤裕, 山田眞一郎, 沖川昌平, 池本哲也, 島田光生 : Stage III/IV 肝細胞癌におけるMRI拡散強調画像をもとにしたADC値の有用性に関する検討, 第122回日本外科学会定期学術集会, 2022年4月.
129.	寺奥大貴, 森根裕二, 齋藤裕, 山田眞一郎, 沖川昌平, 池本哲也, 島田光生 : Borderline resectableに着目した切除可能分類に基づく膵癌治療成績に関する検討, 第122回日本外科学会定期学術集会, 2022年4月.
130.	山田眞一郎, 森根裕二, 池本哲也, 齋藤裕, 寺奥大貴, 沖川昌平, 島田光生 : 膵癌切除例における早期再発の危険因子に関する検討, 第122回日本外科学会定期学術集会, 2022年4月.
131.	荒川悠佑, 寺奥大貴, 山田眞一郎, 齋藤裕, 池本哲也, 森根裕二, 島田光生 : 切除可能膵癌における術後予後予測因子としてのCRP・アルブミン比(CAR)の有用性, 第122回日本外科学会定期学術集会, 2022年4月.
132.	齋藤裕, 杉本真樹, 森根裕二, 池本哲也, 山田眞一郎, 寺奥大貴, 宮崎克己, 島田光生 : 術中ホログラム胆道造影を駆使した胆道手術支援, 第122回日本外科学会定期学術集会, 2022年4月.
133.	池本哲也, 島田光生, 齋藤裕, 沖川昌平, 寺奥大貴, 山田眞一郎, 森根裕二 : 自己脂肪から作成したインスリン産生細胞自家移植が拓く再生医療の未来, 第122回日本外科学会定期学術集会, 2022年4月.
134.	髙須千絵, 森根裕二, 池本哲也, 齋藤裕, 山田眞一郎, 寺奥大貴, 沖川昌平, 島田光生 : 間葉系幹細胞から肝細胞様細胞の誘導におけるNrf2の働きに関する検討, 第122回日本外科学会定期学術集会, 2022年4月.
135.	池本哲也, 徳永卓哉, 齋藤裕, 沖川昌平, 寺奥大貴, 山田眞一郎, 森根裕二, 島田光生 : 脂肪由来幹細胞から分化誘導したSchwann-like cellに関する研究, 第21回日本再生医療学会総会, 2022年3月.
136.	滝本真望, 山田苑子, 那須七海, 加木屋菜津美, 青谷望美, 黒川有美子, 鈴木佳子, 柏原秀也, 齋藤裕, 島田光生, 濵田康弘 : GLIM(Global Leadership Initiative on Malnutrition)基準の筋肉量減少を判定する指標の検討, 第24回・第25回日本病態栄養学会年次学術集会, 2022年1月.
137.	山田苑子, 那須七海, 加木屋菜津美, 滝本真望, 黒川有美子, 柏原秀也, 齋藤裕, 島田光生, 濵田康弘 : 消化器癌患者において低筋量と低筋力のいずれが予後予測に有用か, 第24回・第25回日本病態栄養学会年次学術集会, 2022年1月.
138.	沖川昌平, 森根裕二, 池本哲也, 齋藤裕, 山田眞一郎, 寺奥大貴, 仲須千春, 島田光生 : VEGF阻害はTAMの機能を減弱させる, 第25回日本肝がん分子標的治療研究会, 2022年1月.
139.	齋藤裕, 森根裕二, 島田光生 : 肝内胆管癌におけるMRI拡散強調画像を用いた新たな予後予測, 第44回日本肝臓学会西部会, 2021年12月.
140.	森根裕二, 齋藤裕, 島田光生 : 進行肝細胞癌に対する集学的治療におけるConversion surgeryの意義, 第44回日本肝臓学会西部会, 2021年12月.
141.	寺奥大貴, 森根裕二, 山田眞一郎, 池本哲也, 齋藤裕, 島田光生 : 腹腔鏡下膵体尾部切除の手術手技と定型化, 第34回日本内視鏡外科学会総会, 2021年12月.
142.	髙須千絵, 高露萍, 山田眞一郎, 森根裕二, 池本哲也, 齋藤裕, 沖川昌平, 宮崎克己, 島田光生 : Nrf2を介した微小環境クロストークによる肝細胞癌薬剤耐性機序解明に関する研究, 第32回日本消化器癌発生学会総会, 2021年11月.
143.	徳永卓哉, 杉本真樹, 齋藤裕, 吉川幸造, 中尾寿宏, 西正暁, 柏原秀也, 髙須千絵, 和田佑馬, 良元俊昭, 山下祥子, 岩川陽介, 島田光生 : 直腸癌に対する経肛門的アプローチにおけるホログラムと尿道造影を併用した術中ナビゲーション, 第30回日本コンピュータ外科学会大会, 2021年11月.
144.	髙須千絵, 森根裕二, 池本哲也, 齋藤裕, 山田眞一郎, 寺奥大貴, 島田光生 : 大腸癌肝転移における免疫逃避機構の働き, 第83回日本臨床外科学会総会, 2021年11月.
145.	沖川昌平, 森根裕二, 池本哲也, 齋藤裕, 山田眞一郎, 宮崎克己, 仲須千春, 島田光生 : VEGF阻害はTAMの悪性度を減じる, 第32回日本消化器癌発生学会総会, 2021年11月.
146.	寺奥大貴, 高露萍, 森根裕二, 池本哲也, 齋藤裕, 山田眞一郎, 島田光生 : 肝細胞癌におけるNrf2-PINK-1axisを介したLenvatinib耐性機序の検討, 第32回日本消化器癌発生学会総会, 2021年11月.
147.	山田眞一郎, 高露萍, 森根裕二, 池本哲也, 齋藤裕, 沖川昌平, 宮崎克己, 島田光生 : ソラフェニブ耐性肝細胞癌の腫瘍微小環境形成におけるBAFF/BAFF受容体の役割, 第32回日本消化器癌発生学会総会, 2021年11月.
148.	山田眞一郎, 高露萍, 森根裕二, 池本哲也, 齋藤裕, 沖川昌平, 島田光生 : 肝細胞癌におけるソラフェニブ耐性獲得機序に関する検討, 第32回日本消化器癌発生学会総会, 2021年11月.
149.	齋藤裕, 杉本真樹, 森根裕二, 池本哲也, 徳永卓哉, 山田眞一郎, 寺奥大貴, 岩田貴, 島田光生 : 消化器外科におけるホログラム次世代手術支援, 第30回日本コンピュータ外科学会大会, 2021年11月.
150.	寺奥大貴, 山田眞一郎, 齋藤裕, 池本哲也, 森根裕二, 島田光生 : One stop shop を目指したEOB-MRIによる部分肝機能評価，切除限界予測と腫瘍悪性度の評価に関する検討, 第116回日本消化器病学会四国支部例会, 2021年11月.
151.	寺奥大貴, 森根裕二, 池本哲也, 齋藤裕, 山田眞一郎, 島田光生 : 再発膵癌に対する残膵切除の治療成績, 第83回日本臨床外科学会総会, 2021年11月.
152.	齋藤裕, 杉本真樹, 森根裕二, 池本哲也, 山田眞一郎, 寺奥大貴, 宮崎克己, 島田光生 : Extended reality(VR・AR・MR)を駆使した手術ナビゲーション, 第83回日本臨床外科学会総会, 2021年11月.
153.	齋藤裕, 森根裕二, 池本哲也, 山田眞一郎, 寺奥大貴, 宮崎克己, 島田光生 : 地方から世界に通用する一流の外科医を目指した取り組み, 第83回日本臨床外科学会総会, 2021年11月.
154.	森根裕二, 齋藤裕, 山田眞一郎, 寺奥大貴, 宮崎克己, 池本哲也, 島田光生 : 進行肝細胞癌に対する外科切除成績とConversion surgeryの意義, 第83回日本臨床外科学会総会, 2021年11月.
155.	池本哲也, 島田光生, 森根裕二, 齋藤裕, 山田眞一郎, 寺奥大貴 : 外科医をも守る消化器・移植外科から発信する手術室医療安全, 第83回日本臨床外科学会総会, 2021年11月.
156.	齋藤裕, 杉本真樹, 島田光生 : 消化器外科手術におけるホログラム手術ナビゲーション, JDDW 2021, 2021年11月.
157.	山下祥子, 森根裕二, 石橋広樹, 居村暁, 池本哲也, 森大樹, 齋藤裕, 山田眞一郎, 常山幸一, 島田光生 : 膵・胆管合流異常におけるNLRP3を介した腫瘍微小環境と発癌に関する検討, 第57回日本胆道学会学術集会, 2021年10月.
158.	沖川昌平, 山田眞一郎, 森根裕二, 池本哲也, 齋藤裕, 寺奥大貴, 宮崎克己, 島田光生 : DWI-MRIによる進行胆嚢癌の腫瘍悪性度評価, 第57回日本胆道学会学術集会, 2021年10月.
159.	山田眞一郎, 宮崎克己, 森根裕二, 池本哲也, 齋藤裕, 寺奥大貴, 沖川昌平, 山下祥子, 島田光生 : 肝内胆管癌予後規定因子としての腫瘍浸潤リンパ球の意義, 第57回日本胆道学会学術集会, 2021年10月.
160.	山田眞一郎, 高露萍, 森根裕二, 池本哲也, 齋藤裕, 沖川昌平, 山下祥子, 宮崎克己, 島田光生 : ソラフェニブ耐性肝細胞癌の腫瘍微小環境形成におけるBAFF/BAFF受容体の役割, 第80回日本癌学会学術総会, 2021年9月.
161.	齋藤裕, 居村暁, 森根裕二, 池本哲也, 山田眞一郎, 寺奥大貴, 宮崎克己, 島田光生 : 生体肝移植術後短期長期成績に関する検討, 第57回日本移植学会総会, 2021年9月.
162.	寺奥大貴, 齋藤裕, 池本哲也, 宮崎克己, 山田眞一郎, 森根裕二, 三宅雅人, 親泊政一, 島田光生 : ヒト脂肪由来間葉系幹細胞を基にした機能的肝細胞様細胞の分化誘導, 第57回日本移植学会総会, 2021年9月.
163.	池本哲也, 齋藤裕, 宮崎克己, 沖川昌平, 寺奥大貴, 山田眞一郎, 森根裕二, 島田光生 : 再生医療を用いたインスリン産生細胞自家移植による1型糖尿病根治治療確立へ向けた戦略, 第57回日本移植学会総会, 2021年9月.
164.	山田眞一郎, 齋藤裕, 森根裕二, 池本哲也, 寺奥大貴, 杉本真樹, 島田光生 : Extended reality(VR・AR・MR)を駆使した手術ナビゲーション-マイクロ波手術デバイスAcrosurg®使用経験も含めて-, 第15回肝がんナビゲーション研究会, 2021年9月.
165.	齋藤裕, 池本哲也, 宮崎克己, 徳田和憲, 山田眞一郎, 居村暁, 森根裕二, 三宅雅人, 親泊政一, 島田光生 : ヒト脂肪由来間葉系幹細胞から肝細胞様細胞の創出-肝不全・代謝性肝疾患に対する肝移植から細胞治療へ-, 第263回徳島医学会学術集会(令和3年度夏期), 2021年8月.
166.	山田眞一郎, 高露萍, 森根裕二, 宮崎克己, 徳田和憲, 沖川昌平, 齋藤裕, 池本哲也, 居村暁, 島田光生 : ソラフェニブ耐性肝細胞癌の腫瘍微小環境形成におけるBAFF/BAFF受容体の役割, 第57回日本肝癌研究会, 2021年7月.
167.	齋藤裕, 森根裕二, 居村暁, 池本哲也, 山田眞一郎, 寺奥大貴, 宮崎克己, 島田光生 : DAA治療後SVR症例は発癌Potentialが高く進行病期に関与する, 第57回日本肝癌研究会, 2021年7月.
168.	森根裕二, 齋藤裕, 山田眞一郎, 寺奥大貴, 宮崎克己, 池本哲也, 居村暁, 島田光生 : 進行肝細胞癌集学的治療における外科切除の役割:Conversion Surgery成績も含めて, 第57回日本肝癌研究会, 2021年7月.
169.	髙橋叡, 山田眞一郎, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 寺奥大貴, 宮崎克己, 島田光生 : DWI-MRIによる進行胆嚢癌の腫瘍悪性度評価, 第76回日本消化器外科学会総, 2021年7月.
170.	仲須千春, 池本哲也, 徳永卓哉, 宮崎克己, 徳田和憲, 山田眞一郎, 齋藤裕, 居村暁, 森根裕二, 島田光生 : 脂肪由来幹細胞からSchwann-like cellの効果的分化誘導方法の研究, 第76回日本消化器外科学会総会, 2021年7月.
171.	山下祥子, 森根裕二, 石橋広樹, 居村暁, 池本哲也, 森大樹, 齋藤裕, 山田眞一郎, 常山幸一, 島田光生 : 膵・胆管合流異常におけるNLRP3活性化と発癌に関する検討, 第76回日本消化器外科学会総会, 2021年7月.
172.	宮崎克己, 山田眞一郎, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 山下祥子, 尾矢剛志, 常山幸一, 島田光生 : 肝内胆管癌予後規定因子としての腫瘍浸潤リンパ球の意義, 第76回日本消化器外科学会総会, 2021年7月.
173.	徳田和憲, 森根裕二, 宮崎克己, 山下祥子, 沖川昌平, 山田眞一郎, 齋藤裕, 池本哲也, 居村暁, 島田光生 : 肝細胞癌の腫瘍微小環境におけるOsteopontinを介したCAF-TAM interactionについての検討, 第76回日本消化器外科学会総会, 2021年7月.
174.	和田佑馬, 森根裕二, 齋藤裕, 居村暁, 池本哲也, 西正暁, 山田眞一郎, 徳田和憲, 寺奥大貴, 島田光生 : 癌微小環境における大建中湯の癌細胞増殖抑制効果, 第76回日本消化器外科学会総会, 2021年7月.
175.	山田眞一郎, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 寺奥大貴, 山下祥子, 宮崎克己, 島田光生 : 高齢者に対する肝胆膵手術におけるFrailtyの意義に関する検討, 第76回日本消化器外科学会総会, 2021年7月.
176.	Yu Saitou, Maki Sugimoto, Yuji Morine, Tetsuya Ikemoto, Takuya Tokunaga, Hiroki Teraoku, Katsuki Miyazaki, Takashi Iwata and Mitsuo Shimada : Navigation of rectal and hepatobiliary pancreatic surgery with intraoperative hologram, 第76回日本消化器外科学会総会, Jul. 2021.
177.	池本哲也, 徳田和憲, 齋藤裕, 宮崎克己, 寺奥大貴, 沖川昌平, 山田眞一郎, 居村暁, 森根裕二 : 消化器外科領域の幹細胞トランスレーショナルリサーチにおける医工連携, 第76回日本消化器外科学会総会, 2021年7月.
178.	寺奥大貴, 森根裕二, 山田眞一郎, 宮崎克己, 齋藤裕, 池本哲也, 居村暁, 島田光生 : 両葉多発大腸癌肝転移に対する肝切除適応基準とConversion Surgery, 第76回日本消化器外科学会総会, 2021年7月.
179.	森根裕二, 齋藤裕, 山田眞一郎, 寺奥大貴, 宮崎克己, 池本哲也, 居村暁, 島田光生 : 進行肝細胞癌集学的治療における外科切除の役割:Conversion Surgery成績も含めて, 第76回日本消化器外科学会総会, 2021年7月.
180.	山田眞一郎, 森根裕二, 池本哲也, 齋藤裕, 寺奥大貴, 山下祥子, 宮崎克己, 島田光生 : 高齢者に対する肝胆膵手術におけるFrailtyの意義に関する検討, 第115回日本消化器病学会四国支部例会, 2021年6月.
181.	齋藤裕, 山田眞一郎, 居村暁, 森根裕二, 島田光生 : ヒト脂肪由来間葉系幹細胞から肝細胞様細胞の創出- 肝不全・代謝性肝疾患に対する肝移植から細胞移植へ –, 第57回日本肝臓学会総会, 2021年6月.
182.	宮崎克己, 齋藤裕, 清水真祐子, 森根裕二, 池本哲也, 山田眞一郎, 常山幸一, 島田光生 : 小胞体ストレス応答に着目した非アルコール性脂肪肝炎の肝切除後肝再生/肝不全に関する研究, 第47回日本急性肝不全研究会, 2021年6月.
183.	Katsuki Miyazaki, Yu Saitou, Mayuko Shimizu, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shin-ichiro Yamada, Kazunori Tokuda, Koichi Tsuneyama and Mitsuo Shimada : Endoplasmic reticulum stress response deficiency is a major cause of poor liver regeneration after hepatectomy in nonalcoholic steatohepatitis, 第33回日本肝胆膵外科学会学術集会, Jun. 2021.
184.	Hiroki Teraoku, Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Katsuki Miyazaki : Significance of frailty for eldery patients in HPB surgery, 第33回日本肝胆膵外科学会学術集会, Jun. 2021.
185.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Kazunori Tokuda, Hiroki Teraoku, Shohei Okikawa, Shoko Yamashita, Katsuki Miyazaki and Mitsuo Shimada : Treatment strategy of multiple colorectal liver metastasis-Criteria for upfront surgery and Conversion Surgery-, 第33回日本肝胆膵外科学会学術集会, Jun. 2021.
186.	Yu Saitou, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shin-ichiro Yamada, Hiroki Teraoku, Maki Sugimoto and Mitsuo Shimada : Intraoperative support with 3D holographic cholangiography in biliary surgery, 第33回日本肝胆膵外科学会学術集会, Jun. 2021.
187.	Tetsuya Ikemoto, Kazunori Tokuda, Mitsuo Shimada, Yuji Morine, Satoru Imura, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku and Katsuki Miyazaki : Clinical application of auto-transplantation of generated insulin-producing cells from ADSC with Tokushima protocol, 第33回日本肝胆膵外科学会学術集会, Jun. 2021.
188.	宮崎克己, 齋藤裕, 清水真祐子, 森根裕二, 居村暁, 池本哲也, 山田眞一郎, 徳田和憲, 沖川昌平, 山下祥子, 常山幸一, 島田光生 : 非アルコール性脂肪性肝疾患(NAFLD)における肝切除後肝再生機能不全に関する研究- 小胞体ストレス応答不全の観点より -, 第 121 回日本外科学会定期学術集会, 2021年4月.
189.	森根裕二, 齋藤裕, 山田眞一郎, 徳田和憲, 沖川昌平, 宮崎克己, 池本哲也, 居村暁, 島田光生 : 肝門部領域胆管癌の切除成績と術後補助療法の意義, 第121回日本外科学会定期学術集会, 2021年4月.
190.	徳永卓哉, 島田光生, 齋藤裕, 吉川幸造, 東島潤, 西正暁, 柏原秀也, 髙須千絵, 江藤祥平, 良元俊昭, 杉本真樹 : ホログラムと術中尿道造影を駆使した経会陰的直腸切断術(TpAPR), 第121回日本外科学会定期学術集会, 2021年4月.
191.	山崎寛門, 齋藤裕, 居村暁, 森根裕二, 池本哲也, 山田眞一郎, 杉本真樹, 島田光生 : 術中Real-time 3D胆管造影を併用した胆道手術, 第121回日本外科学会定期学術集会, 2021年4月.
192.	髙橋叡, 齋藤裕, 池本哲也, 徳田和憲, 宮崎克己, 山田眞一郎, 居村暁, 森根裕二, 島田光生 : 脂肪由来幹細胞ADSCからのSuper HLC (肝細胞様細胞)の創出, 第121回日本外科学会定期学術集会, 2021年4月.
193.	徳田和憲, 池本哲也, 宮崎克己, 山下祥子, 沖川昌平, 山田眞一郎, 齋藤裕, 居村暁, 森根裕二, 島田光生 : Adipose derived stem cellから作製したInsulin producing cellの臨床応用に向けた保存方法に関する研究, 第121回日本外科学会定期学術集会, 2021年4月.
194.	齋藤裕, 友成哲, 居村暁, 森根裕二, 池本哲也, 山田眞一郎, 高山哲治, 島田光生 : 進行肝細胞癌に対する集学的治療 - 分子標的治療薬使用によるConversion Surgery –, 第121回日本外科学会定期学術集会, 2021年4月.
195.	山下祥子, 森根裕二, 石橋広樹, 居村暁, 池本哲也, 森大樹, 齋藤裕, 山田眞一郎, 常山幸一, 島田光生 : 膵・胆管合流異常における腫瘍微小環境と発癌に関する検討, 第121回日本外科学会定期学術集会, 2021年4月.
196.	寺奥大貴, 高露萍, 島田光生, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 山田眞一郎, 徳田和憲, 沖川昌平, 山下祥子, 宮崎克己 : 肝細胞癌におけるSorafenib耐性獲得機序に関する検討, 第121回日本外科学会定期学術集会, 2021年4月.
197.	沖川昌平, 森根裕二, 徳田和憲, 齋藤裕, 山田眞一郎, 山下祥子, 宮崎克己, 池本哲也, 居村暁, 島田光生 : 腫瘍微小環境におけるOsteopontinの意義, 第121回日本外科学会定期学術集会, 2021年4月.
198.	山田眞一郎, 陳術海, 島田光生, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 徳田和憲, 沖川昌平, 山下祥子, 宮崎克己 : 肝細胞癌微小環境におけるPAI-1発現の意義に関する検討, 2021年4月.
199.	池本哲也, 島田光生, 徳田和憲, 宮崎克己, 山田眞一郎, 齋藤裕, 居村暁, 森根裕二 : 再生医療を用いたインスリン枯渇状態の患者に対する自律的インスリン分泌細胞自己移植に関するAMED橋渡し研究, 第121回日本外科学会定期学術集会, 2021年4月.
200.	徳田和憲, 池本哲也, 宮崎克己, 山下祥子, 沖川昌平, 山田眞一郎, 齋藤裕, 居村暁, 森根裕二, 島田光生 : 脂肪由来幹細胞から作製したインスリン産生細胞の至適保存方法に関する研究, 第20回日本再生医療学会総会, 2021年3月.
201.	齋藤裕, 池本哲也, 宮崎克己, 徳田和憲, 山田眞一郎, 居村暁, 森根裕二, 三宅雅人, 親泊政一, 島田光生 : ヒト脂肪由来間葉系幹細胞から肝細胞様細胞の創出, 第20回日本再生医療学会総会, 2021年3月.
202.	池本哲也, 徳永卓哉, 沖川昌平, 徳田和憲, 山田眞一郎, 齋藤裕, 居村暁, 森根裕二, 島田光生 : 脂肪由来幹細胞から分化誘導したSchwann-like cellの基礎的検討, 第20回日本再生医療学会総会, 2021年3月.
203.	森根裕二, 齋藤裕, 山田眞一郎, 徳田和憲, 沖川昌平, 宮崎克己, 池本哲也, 居村暁, 島田光生 : 徳島大学の肝胆膵外科における若手教育-特に内視鏡手術に焦点をあてて-, 第33回日本内視鏡外科学会, 2021年3月.
204.	齋藤裕, 池本哲也, 宮崎克己, 徳田和憲, 山田眞一郎, 居村暁, 森根裕二, 三宅雅人, 親泊政一, 島田光生 : ヒト脂肪由来間葉系幹細胞から肝細胞様細胞の創出- 肝不全・代謝性肝疾患に対する肝移植から細胞治療へ -, 第262回徳島医学会学術集会, 2021年3月.
205.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Masato Yoshikawa and Katsuki Miyazaki : Significance of frailty for elderly patients in HPB surgery, 第32回日本肝胆膵外科学会学術集会, Feb. 2021.
206.	Yu Saitou, Tetsuya Ikemoto, Yusuke Arakawa, Luping Gao, Shin-ichiro Yamada, Satoru Imura, Yuji Morine and Mitsuo Shimada : Effective 3D culture of hepatocyte like cells human adipose derived mesenchymal stem cells, 第32回日本肝胆膵外科学会学術集会, Feb. 2021.
207.	Yu Saitou, Tetsuya Ikemoto, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Shin-ichiro Yamada, Masato Yoshikawa, Katsuki Miyazaki, Maki Sugimoto and Mitsuo Shimada : Intraoperative support with 3D holographic cholangiography and indocyanine green navigation, 第32回日本肝胆膵外科学会学術集会, Feb. 2021.
208.	Katsuki Miyazaki, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Kazunori Tokuda, Masato Yoshikawa and Mitsuo Shimada : The impact of frailty as a prognostic factor of colorectal liver metastasis, 第32回日本肝胆膵外科学会学術集会, Feb. 2021.
209.	Yusuke Arakawa, Katsuki Miyazaki, Masato Yoshikawa, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : The value of CRP albumin ratio in patient with resectable pancreas cancer, 第32回日本肝胆膵外科学会学術集会, Feb. 2021.
210.	Tetsuya Ikemoto, Kazunori Tokuda, Mitsuo Shimada, Yuji Morine, Satoru Imura, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa and Katsuki Miyazaki : Basic research for aiming non-clinical PoC acquisition of insulin producing cells from ADSC with Tokushima protocol, 第32回日本肝胆膵外科学会学術集会, Feb. 2021.
211.	Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa, Katsuki Miyazaki and Mitsuo Shimada : Optimal surgical treatment including lymph nodes dissection and adjuvant chemotherapy for intrahepatic cholangiocarcinoma, 第32回日本肝胆膵外科学会学術集会, Feb. 2021.
212.	Satoru Imura, Katsuki Miyazaki, Masato Yoshikawa, Kazunori Tokuda, Shin-ichiro Yamada, Yu Saitou, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Standardization and stepwise training for safe laparoscopic hepatectomy, 第32回日本肝胆膵外科学会学術集会, Feb. 2021.
213.	山田眞一郎, 高露泙, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 徳田和憲, 沖川昌平, 山下祥子, 宮崎克己 : 肝細胞癌におけるSorafenib耐性獲得機序に関する検討, 第23回日本肝がん分子標的治療研究会, 2021年1月.
214.	齋藤裕, 友成哲, 山田眞一郎, 居村暁, 池本哲也, 森根裕二, 高山哲治, 島田光生 : 進行肝細胞癌に対する集学的治療-分子標的治療薬使用によるConversion Surgery-, 第23回日本肝がん分子標的治療研究会, 2021年1月.
215.	山田眞一郎, 島田光生, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 齋藤裕, 吉川雅登, 徳田和憲, 宮崎克己 : 肝胆膵領域悪性腫瘍におけるNrf2・VEGFに着目した腫瘍関連マクロファージ活性化についての検討, 第29回日本癌病態治療研究, 2021年1月.
216.	齋藤裕, 高露萍, 池本哲也, 荒川悠佑, 宮崎克己, 吉川雅登, 山田眞一郎, 居村暁, 森根裕二, 島田光生 : GSK3 inhibitorsを用いた脂肪由来間葉系幹細胞から肝細胞様細胞への3次元分化誘導, 第38回日本肝移植学会学術集, 2020年12月.
217.	齋藤裕, 森根裕二, 居村暁, 池本哲也, 山田眞一郎, 吉川雅登, 宮崎克己, 杉本真樹, 島田光生 : Hologramを用いた術中手術支援-術中Real-time3D胆管造影を併用した胆道手術-, 第45回日本外科系連合学会学術集会, 2020年12月.
218.	山田眞一郎, 島田光生, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 齋藤裕, 吉川雅登, 宮崎克己 : 肝細胞癌に対する肝切除術におけるFrailtyの意義に関する検討, 第56回日本肝癌研究会, 2020年12月.
219.	齋藤裕, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 山田眞一郎, 吉川雅登, 宮崎克己, 島田光生 : DAA治療後SVR症例は発癌Potentialが高く進行病期に関与する, 第56回日本肝癌研究会, 2020年12月.
220.	森根裕二, 島田光生, 居村暁, 池本哲也, 荒川悠佑, 齋藤裕, 山田眞一郎, 吉川雅登, 宮崎克己 : 大腸癌同時性肝転移に対する治療戦略-肝切除適応基準とConversion Surgery-, 第56回日本肝癌研究会, 2020年12月.
221.	宮崎克己, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 齋藤裕, 山田眞一郎 : 肝内胆管癌予後規定因子としてのLymphocyte / CRP ratio (LCR)の意義, 第75回日本消化器外科学会総会, 2020年12月.
222.	良元俊昭, 池本哲也, 森根裕二, 居村暁, 齋藤裕, 山田眞一郎, 吉川雅登, 宮崎克己, 武原悠花子, 島田光生 : 膵切除周術期における栄養指標からみた人工膵臓の有用性, 第75回日本消化器外科学会総会, 2020年12月.
223.	吉川雅登, 森根裕二, 山田眞一郎, 宮崎克己, 徳田和憲, 齋藤裕, 荒川悠佑, 池本哲也, 居村暁, 島田光生 : DWI-MRIのADC値を用いた転移性肝癌の切除後予後予測，抗癌剤効果予測に関する検討, 第75回日本消化器外科学会総会, 2020年12月.
224.	徳田和憲, 森根裕二, 山田眞一郎, 居村暁, 池本哲也, 荒川悠佑, 齋藤裕, 吉川雅登, 宮崎克己, 島田光生 : 転移性肝癌切除症例におけるFrailの重要性についての検討, 第75回日本消化器外科学会総会, 2020年12月.
225.	山田眞一郎, 島田光生, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 齋藤裕, 吉川雅登, 宮崎克己 : 胆嚢癌の悪性度評価におけるADCの有用性に関する検討, 第75回日本消化器外科学会総会, 2020年12月.
226.	齋藤裕, 居村暁, 森根裕二, 池本哲也, 荒川悠佑, 山田眞一郎, 吉川雅登, 宮崎克己, 島田光生 : DAA治療後SVR症例は発癌Potentialが高く進行病期に関与する, 第75回日本消化器外科学会総会, 2020年12月.
227.	荒川悠佑, 宮崎克己, 吉川雅登, 山田眞一郎, 齋藤裕, 池本哲也, 居村暁, 森根裕二, 島田光生 : 当院の肝胆膵手術症例におけるSSIサーベイランスによる検討, 第75回日本消化器外科学会総会, 2020年12月.
228.	池本哲也, 島田光生, 森根裕二, 居村暁, 荒川悠佑, 齋藤裕, 山田眞一郎, 吉川雅登, 宮崎克己 : 長期予後と患者QoLに着目した膵全摘症例の検討, 第75回日本消化器外科学会総会, 2020年12月.
229.	森根裕二, 島田光生, 居村暁, 池本哲也, 荒川悠佑, 齋藤裕, 山田眞一郎, 吉川雅登, 宮崎克己 : 大腸癌同時性肝転移に対する治療戦略-肝切除適応基準とConversion Surgery-, 第75回日本消化器外科学会総会, 2020年12月.
230.	居村暁, 宮崎克己, 吉川雅登, 徳田和憲, 山田眞一郎, 齋藤裕, 荒川悠佑, 池本哲也, 森根裕二, 島田光生 : 腹腔鏡下肝左葉切除の標準化への取り組み ∼手技定型化とstepwise training∼, 第75回日本消化器外科学会総会, 2020年12月.
231.	宮崎克己, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 山田眞一郎, 徳田和憲, 沖川昌平, 山下祥子, 尾矢剛志, 常山幸一, 島田光生 : 肝内胆管癌予後規定因子としてのリンパ球CRP比の意義と腫瘍浸潤リンパ球との関係, 第31回日本消化器癌発生学会総会, 2020年11月.
232.	山田眞一郎, 高露萍, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 宮崎克己, 島田光生 : ソラフェニブ耐性肝癌において，Nrf2は幹細胞性・遊走能・ABCトランスポーター発現を促進する, 第31回日本消化器癌発生学会総会, 2020年11月.
233.	齋藤裕, 島田光生 : VR・AR・MRを駆使した手術ナビゲーション, 第29回日本コンピュータ外科学会大会, 2020年11月.
234.	森根裕二, 森大樹, 齋藤裕, 山田眞一郎, 池本哲也, 居村暁, 石橋広樹, 島田光生 : 膵・胆管合流異常の発癌メカニズムに関する基礎研究:徳島大学の場合, 第43回日本膵・胆管合流異常研究会, 2020年11月.
235.	齋藤裕, 杉本真樹, 島田光生 : Hologramを用いた術中手術支援 -術中Real-time 3D胆管造影を併用した胆道手術-, JDDW2020, 2020年11月.
236.	宮崎克己, 齋藤裕, 高露萍, 池本哲也, 山田眞一郎, 居村暁, 森根裕二, 三宅雅人, 親泊政一, 島田光生 : ヒト脂肪由来間葉系幹細胞から分化誘導した肝細胞様細胞の遺伝子発現解析, 第56回日本移植学会総会, 2020年11月.
237.	徳田和憲, 池本哲也, 宮崎克己, 沖川昌平, 山田眞一郎, 齋藤裕, 居村暁, 森根裕二, 島田光生 : 脂肪由来幹細胞から分化誘導したインスリン産生細胞の凍結保存方法についての検討, 第56回日本移植学会総会, 2020年11月.
238.	池本哲也, 徳田和憲, 齋藤裕, 宮崎克己, 山田眞一郎, 居村暁, 森根裕二, 島田光生 : 移植医から提案する再生医療技術を用いたインスリン産生細胞自家移植による1型糖尿病根治へ向けた戦略, 第56回日本移植学会総会, 2020年11月.
239.	齋藤裕, 居村暁, 宮崎克己, 山田眞一郎, 池本哲也, 森根裕二, 島田光生 : 医療系学生に対するDonor Action(命の授業)の必要性, 第56回日本移植学会総会, 2020年10月.
240.	山田眞一郎, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 宮崎克己, 島田光生 : 膵癌切除症例における，Frailtyの意義に関する検討, 第82回日本臨床外科学会総会, 2020年10月.
241.	池本哲也, 徳田和憲, 齋藤裕, 宮崎克己, 山田眞一郎, 居村暁, 森根裕二, 島田光生 : 再生医療技術による1型糖尿病根治へ向けたシーズの臨床応用に関する検討, 第82回日本臨床外科学会総会, 2020年10月.
242.	山田眞一郎, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 徳田和憲, 沖川昌平, 山下祥子, 宮崎克己, 島田光生 : Microbiome, HSCに着目した大建中湯の消化器癌に対する多面的効果の検討, 第82回日本臨床外科学会総会, 2020年10月.
243.	齋藤裕, 居村暁, 森根裕二, 池本哲也, 山田眞一郎, 杉本真樹, 島田光生 : Hologramを用いた次世代術中手術支援 -術中Real-time 3D胆管造影を併用した胆道手術-, 第82回日本臨床外科学会総会, 2020年10月.
244.	湯浅麻美, 西尾進, 森田沙瑛, 松本力三, 平田有紀奈, 山尾雅美, 田中貴大, 齋藤裕, 島田光生, 佐田政隆 : 神経内分泌癌との鑑別が困難であった膵腺房細胞癌の1例, 日本超音波医学会第30回四国地方会学術集会, 2020年10月.
245.	宮崎克己, 齋藤裕, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 山田眞一郎, 徳田和憲, 吉川雅登, 島田光生 : 膵頭十二指腸切除術(PD)術後合併症回避に向けた腹腔動脈起始部圧迫症候群の周術期管理, 第56回日本腹部救急医学会総会, 2020年10月.
246.	山田眞一郎, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 宮崎克己, 島田光生, 高露泙 : ソラフェニブ耐性肝細胞癌において，Nrf2は肝細胞性，遊走能，ABC transporterの発現を上昇させる, 第79回日本癌学会学術集会, 2020年10月.
247.	齋藤裕, 池本哲也, 荒川悠佑, 居村暁, 森根裕二, 島田光生 : 3次元培養によるヒト脂肪由来間葉系幹細胞から肝細胞様細胞への効率的分化誘導, 第56回日本肝臓学会総会, 2020年8月.
248.	宮崎克己, 山田眞一郎, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 齋藤裕, 徳田和憲, 吉川雅登, 島田光生 : 肝内胆管癌予後規定因子としてのLymphocyte / CRP ratio (LCR)の意義, 第120回日本外科学会定期学術集会, 2020年8月.
249.	吉川雅登, 森根裕二, 山田眞一郎, 宮崎克己, 徳田和憲, 齋藤裕, 荒川悠佑, 池本哲也, 居村暁, 島田光生 : DWI-MRIのADC値を用いた転移性肝癌の予後予測に関する検討, 第120回日本外科学会定期学術集会, 2020年8月.
250.	荒川悠佑, 宮崎克己, 吉川雅登, 山田眞一郎, 齋藤裕, 池本哲也, 居村暁, 森根裕二, 島田光生 : 膵癌術後予後予測因子としての術前fibrinogen:血小板比の有用性, 第120回日本外科学会定期学術集会, 2020年8月.
251.	森根裕二, 居村暁, 池本哲也, 荒川悠佑, 齋藤裕, 山田眞一郎, 徳田和憲, 吉川雅登, 宮崎克己, 島田光生 : 切除可能大腸癌限局性肝転移の治療指針, 第120回日本外科学会定期学術集会, 2020年8月.
252.	池本哲也, 島田光生, 森根裕二, 居村暁, 荒川悠佑, 齋藤裕, 山田眞一郎, 徳田和憲, 吉川雅登 : 外科医の視点から開発された皮下脂肪から分離した脂肪由来幹細胞のインスリン産生細胞移植に関する研究, 第120回日本外科学会定期学術集会, 2020年8月.
253.	徳田和憲, 池本哲也, 高露萍, 森根裕二, 居村暁, 齋藤裕, 山田眞一郎, 吉川雅登, 宮崎克己, 島田光生 : 肪由来幹細胞(ADSC)から肝細胞様細胞(HLC)への分化誘導における3D培養の有用性, 第120回日本外科学会定期学術集会, 2020年8月.
254.	山田眞一郎, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 齋藤裕, 吉川雅登, 宮崎克己, 島田光生 : 膵癌切除症例におけるFrailの意義に関する検討, 第120回日本外科学会定期学術集会, 2020年8月.
255.	齋藤裕, 島田光生, 杉本真樹, 居村暁, 森根裕二, 池本哲也, 荒川悠佑, 山田眞一郎, 吉川雅登, 宮崎克己 : Holographyを用いた次世代術中手術支援とICG蛍光法による肝離断navigation, 第120回日本外科学会定期学術集会, 2020年8月.
256.	居村暁, 宮崎克己, 吉川雅登, 徳田和憲, 山田眞一郎, 齋藤裕, 荒川悠佑, 池本哲也, 森根裕二, 島田光生 : 小型肝癌に対する肝実質温存肝区画切除は妥当である, 第120回日本外科学会定期学術集会, 2020年8月.
257.	宮崎克己, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 齋藤裕, 山田眞一郎, 徳田和憲, 吉川雅登, 島田光生 : 肝内胆管癌予後規定因子としてのLymphocyte/CRP ratio(LCR)の意義, 第113回日本消化器病学会四国支部例会, 2020年6月.
258.	齋藤裕, 森根裕二, 居村暁, 池本哲也, 山田眞一郎, 宮崎克己, 島田光生 : DAA治療後SVR症例は発癌Potentialが高く進行病期に関与する, 第113回日本消化器病学会四国支部例会, 2020年6月.
259.	徳田和憲, 池本哲也, 島田光生, 齋藤裕, 吉川雅登, 山田眞一郎, 荒川悠佑, 居村暁, 森根裕二 : 亜鉛イオンに着目したADSCから製造したInsulin-producing cell 成熟度に関する検討, 第19回日本再生医療学会総会, 2020年5月.
260.	齋藤裕, 池本哲也, 荒川悠佑, 宮崎克己, 山田眞一郎, 居村暁, 森根裕二, 島田光生 : GSK3 inhibitorsを用いた脂肪由来間葉系幹細胞から肝細胞様細胞への3次元分化誘導, 第19回日本再生医療学会総会, 2020年5月.
261.	池本哲也, 島田光生, 徳田和憲, 齋藤裕, 吉川雅登, 宮崎克己, 山田眞一郎, 荒川悠佑, 居村暁, 森根裕二 : T1DM患者から採取された脂肪組織から分離したADSCから製造したInsulin-producing cellに関する検討, 第19回日本再生医療学会総会, 2020年5月.
262.	青谷望美, 山田苑子, 加木屋菜津美, 谷村真優, 鈴木佳子, 柏原秀也, 齋藤裕, 島田光生, 濵田康弘 : 消化器癌患者における術前栄養評価としてのESPEN提唱栄養不良診断法の臨床的有用性, 第35回日本臨床栄養代謝学会学術集会, 2020年2月.
263.	宮崎克己, 山田眞一郎, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 齋藤裕, 徳田和憲, 吉川雅登, 島田光生 : 肝内胆管癌予後規定因子としてのLymphocyte / CRP ratio (LCR)の意義, 第53回制癌剤適応研究会, 2020年2月.
264.	吉川雅登, 山田眞一郎, 森根裕二, 宮崎克己, 徳田和憲, 齋藤裕, 荒川悠佑, 池本哲也, 居村暁, 島田光生 : 転移性肝癌におけるDWI-MRIのADC値を用いた予後予測に関する検討, 第53回制癌剤適応研究会, 2020年2月.
265.	山田眞一郎, 島田光生, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 吉川雅登, 宮崎克己 : 腫瘍関連マクロファージを介した肝胆膵癌の悪性度獲得に関する検討, 第53回制癌剤適応研究会, 2020年2月.
266.	齋藤裕, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 山田眞一郎, 吉川雅登, 宮崎克己, 島田光生 : NBNC肝細胞癌の発癌と進展の分子標的からみた治療戦略, 第53回制癌剤適応研究会, 2020年2月.
267.	吉川雅登, 池本哲也, 良元俊昭, 山田眞一郎, 齋藤裕, 荒川悠佑, 居村暁, 森根裕二, 島田光生 : 膵切除周術期における人工膵臓を用いた血糖管理の有用性, 第260回徳島医学学会学術集会, 2020年2月.
268.	青谷望美, 山田苑子, 加木屋菜津美, 滝本真望, 谷村真優, 鈴木佳子, 柏原秀也, 齋藤裕, 島田光生, 濵田康弘 : 消化器癌患者の術前評価におけるESPEN 提唱栄養不良診断基準の各診断項目と予後との関連, 第23回日本病態栄養学会年次学術集会, 2020年1月.
269.	齋藤裕, 友成哲, 山田眞一郎, 荒川悠佑, 池本哲也, 森根裕二, 居村暁, 高山哲治, 島田光生 : 分子標的治療薬によりConversion Hepatectomyを施行し得た進行肝細胞癌の3例, 第21回日本肝がん分子標的治療研究会, 2020年1月.
270.	友成哲, 田中宏典, 田中貴大, 谷口達哉, 齋藤裕, 居村暁, 島田光生, 高山哲治 : 進行肝癌におけるLenvatinibを用いたConversion Therapyの可能性―肝切除, Microwave ablation, 肝動脈塞栓術による追加治療の検討―., 第21回日本肝がん分子標的治療研究会, 2020年1月.
271.	山田眞一郎, 島田光生, 森根裕二, 居村暁, 池本哲也, 齋藤裕 : MRIを利用した肝切除限界予測と，腫瘍悪性度評価に関する検討, 第43回日本肝臓学会西部会, 2019年12月.
272.	齋藤裕, 杉本真樹, 島田光生 : Hologramを用いた次世代術前術中手術支援, 第28回日本コンピュータ外科学会大会, 2019年11月.
273.	山田眞一郎, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 島田光生 : 肝細胞癌に対する肝切除術におけるFrailtyの意義に関する検討, JDDW2019, 2019年11月.
274.	吉川雅登, 池本哲也, 良元俊昭, 山田眞一郎, 齋藤裕, 荒川悠佑, 居村暁, 森根裕二, 島田光生 : 膵切除周術期における人工膵臓を用いた血糖管理の有用性, 第81回日本臨床外科学会総会, 2019年11月.
275.	齋藤裕, 居村暁, 森根裕二, 池本哲也, 山田眞一郎, 吉川雅登, 杉本真樹 : ホログラムとウェアラブル近赤外蛍光法による肝切除手術支援, 第81回日本臨床外科学会総会, 2019年11月.
276.	池本哲也, 徳田和憲, 吉川雅登, 山田眞一郎, 齋藤裕, 荒川悠佑, 居村暁, 森根裕二, 島田光生 : insulin-producing cell移植の細胞移植治療への臨床応用に向けた研究, 第81回日本臨床外科学会総会, 2019年11月.
277.	山田眞一郎, 島田光生, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 吉川雅登, 宮崎克己 : 肝細胞癌に対する肝切除術におけるFrailtyの意義に関する検討, 第81回日本臨床外科学会総会, 2019年11月.
278.	森根裕二, 山田眞一郎, 池本哲也, 齋藤裕, 荒川悠佑, 吉川雅登, 居村暁, 島田光生 : 腸管Microbiome解析を加えた大建中湯の消化器疾患に対する多面的効果の検討, 第81回日本臨床外科学会総会, 2019年11月.
279.	山田眞一郎, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 吉川雅登, 良元俊昭, 宮崎克己, 島田光生 : 肝細胞癌に対する肝切除術におけるFrailtyの意義に関する検討, 第57回日本癌治療学会学術集会, 2019年10月.
280.	森根裕二, 居村暁, 池本哲也, 荒川悠佑, 齋藤裕, 山田眞一郎, 吉川雅登, 島田光生 : 臨床病理学的特徴と腫瘍悪性度解析からみたNBNC肝細胞癌の治療戦略, 第57回日本癌治療学会学術集会, 2019年10月.
281.	吉川雅登, 齋藤裕, 高露萍, 池本哲也, 荒川悠佑, 宮崎克己, 居村暁, 森根裕二, 島田光生 : GSK3 inhibitorsを用いた脂肪由来間葉系幹細胞から肝細胞様細胞への分化誘導, 第55回日本移植学会総会, 2019年10月.
282.	齋藤裕, 居村暁, 宮崎克己, 吉川雅登, 荒川悠佑, 池本哲也, 森根裕二, 島田光生 : 脳死肝移植ドナー不足解消にむけての取り組み- 医療系学生に対するDonor Action(命の授業)の必要性 –, 第55回日本移植学会総会, 2019年10月.
283.	荒川悠佑, 齋藤裕, 高露萍, 池本哲也, 宮崎克己, 吉川雅登, 山田眞一郎, 居村暁, 森根裕二, 島田光生 : 脂肪由来幹細胞からインスリン産生細胞への分化誘導における赤色LEDの有用性に関する研究, 第55回日本移植学会総会, 2019年10月.
284.	池本哲也, 齋藤裕, 居村暁, 森根裕二, 徳田和憲, 山田眞一郎, 吉川雅登, 島田光生 : 再生医療技術を用いたinsulin-producing cell移植の臨床応用に向けた研究, 第55回日本移植学会総会, 2019年10月.
285.	武原悠花子, 森根裕二, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 山田眞一郎, 岩橋祥子, 常山幸一, 島田光生 : SSTR2, Bcl2発現からみた肝内胆管癌の組織発生学的分類, 第55回日本胆道学会学術集会, 2019年10月.
286.	山田眞一郎, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 吉川雅登, 良元俊昭, 島田光生 : MRI拡散強調画像から見た肝内胆管癌の腫瘍悪性度に関する検討, 第55回日本胆道学会学術集会, 2019年10月.
287.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa and Katsuki Miyazaki : Prognostic prediction of mass-forming intrahepatic cholangiocarcinoma from ADC value of DWI-MRI, JSH International Liver Conference, Oct. 2019.
288.	荒川悠佑, 宮崎克己, 吉川雅登, 山田眞一郎, 齋藤裕, 池本哲也, 居村暁, 森根裕二, 島田光生 : 肝癌細胞におけるNrf2に着目した腫瘍関連マクロファージ活性化の検討, 第78回日本癌学会学術総会, 2019年9月.
289.	齋藤裕, 居村暁, 森根裕二, 池本哲也, 荒川悠佑, 山田眞一郎, 吉川雅登, 宮崎克己, 杉本真樹, 島田光生 : Hologramを用いた次世代術前術中手術支援とICG蛍光法による肝離断navigation, 第14回肝癌治療ナビゲーション研究会, 2019年9月.
290.	吉川雅登, 岩橋祥子, 池本哲也, 森根裕二, 居村暁, 荒川悠佑, 齋藤裕, 山田眞一郎, 宮崎克己, 常山幸一, 島田光生 : 卵巣様間質を伴う非粘液性嚢胞腺腫の二例, 第71回日本消化器画像診断研究会, 2019年9月.
291.	山田眞一郎, 島田光生, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 齋藤裕, 吉川雅登, 宮崎克己 : MRI拡散強調画像から見た肝内胆管癌の腫瘍悪性度に関する検討, 第71回日本消化器画像診断研究会, 2019年9月.
292.	齋藤裕, 居村暁, 宮崎克己, 吉川雅登, 荒川悠佑, 池本哲也, 森根裕二, 島田光生 : 脳死肝移植ドナー不足解消にむけての取り組み- 医療系学生に対するDonor Action(命の授業)の必要性-, 第37回日本肝移植学会, 2019年7月.
293.	荒川悠佑, 齋藤裕, 高露萍, 池本哲也, 宮崎克己, 吉川雅登, 居村暁, 森根裕二, 島田光生 : GSK3 inhibitorsを用いた脂肪由来間葉系幹細胞から肝細胞様細胞への分化誘導, 第37回日本肝移植学会, 2019年7月.
294.	岩橋祥子, 森根裕二, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 山田眞一郎, 常山幸一, 島田光生 : SSTR2・Bcl2発現による肝内胆管癌組織発生学的特徴に関する検討, 第74回日本消化器外科学会総会, 2019年7月.
295.	岩橋衆一, 島田光生, 池本哲也, 森根裕二, 居村暁, 齋藤裕, 山田眞一郎 : 長期成績に着目した膵全摘症例の検討 -術後QOL評価に着目して-, 第74回日本消化器外科学会総会, 2019年7月.
296.	居村暁, 山田眞一郎, 齋藤裕, 岩橋衆一, 池本哲也, 森根裕二, 島田光生 : 肝細胞癌に対する系統的肝区画切除は妥当である, 第74回日本消化器外科学会総会, 2019年7月.
297.	山田眞一郎, 島田光生, 森根裕二, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕 : 肝細胞癌の肝切除術におけるFrailtyの意義に関する検討, 第74回日本消化器外科学会総会, 2019年7月.
298.	齋藤裕, 居村暁, 森根裕二, 池本哲也, 岩橋衆一, 山田眞一郎, 杉本真樹, 島田光生 : ホログラム術中胆道造影とウェアラブル近赤外蛍光法による肝切除手術支援, 第74回日本消化器外科学会総会, 2019年7月.
299.	森根裕二, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 山田眞一郎, 島田光生 : 肝内胆管癌の治療戦略:至適切除範囲と補助療法の効果, 第74回日本消化器外科学会総会, 2019年7月.
300.	Tetsuya Ikemoto, Mitsuo Shimada, Masao Fuketa, Shinsuke Katoh, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Satoru Imura and Yuji Morine : The utilization of `Big Data' in gastroenterological surgery, 第74回日本消化器外科学会総会, Jul. 2019.
301.	山田苑子, 大岩優, 齋藤裕, 青谷望美, 加木屋菜津美, 谷村真優, 菊井聡子, 鈴木佳子, 松村晃子, 柏原秀也, 島田光生, 濵田康弘 : 消化器癌患者における術前栄養・予後指標としてのPhase Angle の臨床的実用性の検討, 日本外科代謝栄養学会, 2019年7月.
302.	齋藤裕, 居村暁, 森根裕二, 池本哲也, 岩橋衆一, 山田眞一郎, 杉本真樹, 島田光生 : ホログラムとウェアラブル近赤外蛍光法による肝切除手術支援, 第55回日本肝癌研究会, 2019年7月.
303.	山田眞一郎, 島田光生, 森根裕二, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕 : EOB-MRIを用いた新たな肝切除基準の有用性, 第55回日本肝癌研究会, 2019年7月.
304.	森根裕二, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 山田眞一郎, 島田光生 : 肝内胆管癌の治療戦略:至適切除範囲と補助療法の効果, 第55回日本肝癌研究会, 2019年7月.
305.	居村暁, 山田眞一郎, 齋藤裕, 岩橋衆一, 池本哲也, 森根裕二, 島田光生 : 肝癌に対する腹腔鏡肝切除の現状と今後の適応拡大, 第55回日本肝癌研究会, 2019年7月.
306.	吉川雅登, 和田佑馬, 池本哲也, 森根裕二, 居村暁, 荒川悠佑, 齋藤裕, 山田眞一郎, 岩橋祥子, 島田光生 : 脂肪由来幹細胞からのインスリン産生細胞分化誘導に関する研究, 第26回外科侵襲とサイトカイン研究会, 2019年7月.
307.	山田眞一郎, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 吉川雅登, 良元俊昭, 島田光生 : DWI-MRIのADC値を用いたSorafenibの効果予測に関する検討, 第20回日本肝がん分子標的治療研究会, 2019年6月.
308.	池本哲也, 島田光生, 泓田正雄, 加藤真介, 山田眞一郎, 齋藤裕, 岩橋衆一, 居村暁, 森根裕二 : 医療安全に関するAI活用と新たなアラートシステム構築, 第44回日本外科系連合学会学術集会, 2019年6月.
309.	宮崎克己, 齋藤裕, 居村暁, 森根裕二, 池本哲也, 岩橋衆一, 山田眞一郎, 島田光生 : A case of preoperative nutritional and exercise intervention in HCC patient with alcoholic liver cirrhosis, 第31回日本肝胆膵外科学会学術集会, 2019年6月.
310.	齋藤裕, 居村暁, 森根裕二, 池本哲也, 岩橋衆一, 山田眞一郎, 杉本真樹, 島田光生 : Intraoperative support using holographic cholangiography and near-infrared fluorescence imaging, 第31回日本肝胆膵外科学会学術集会, 2019年6月.
311.	岩橋衆一, 島田光生, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 山田眞一郎 : The effect of hepatic stellate cells on hepatocellular carcinoma progression, 第31回日本肝胆膵外科学会学術集会, 2019年6月.
312.	森根裕二, 山田眞一郎, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 島田光生 : Standardization of surgical technique in laparoscopic distal pancreatectomy, 第31回日本肝胆膵外科学会学術集会, 2019年6月.
313.	山田眞一郎, 森根裕二, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 和田佑馬, 良元俊昭, 太田昇吾, 島田光生 : Prognostic prediction of apparent diffusion coefficient obtained by diffusion-weighted MRI in mass-forming intrahepatic cholangiocarcinoma, 第31回日本肝胆膵外科学会学術集会, 2019年6月.
314.	齋藤裕, 居村暁, 森根裕二, 池本哲也, 岩橋衆一, 山田眞一郎, 島田光生 : Goal for board certified HBP surgeon, 第31回日本肝胆膵外科学会学術集会, 2019年6月.
315.	池本哲也, 島田光生, 森根裕二, 居村暁, 岩橋衆一, 齋藤裕, 山田眞一郎 : Our scientific approaches and investigation for Japanese Kampo Medicine in hepato-biliary-pancreatic diseases; especially TU-100 and TJ-48, 第31回日本肝胆膵外科学会学術集会, 2019年6月.
316.	居村暁, 山田眞一郎, 齋藤裕, 岩橋衆一, 池本哲也, 森根裕二, 島田光生 : Evaluation of liver function using signal intensity of EOB-MRI for safe hepatectomy, 第31回日本肝胆膵外科学会学術集会, 2019年6月.
317.	齋藤裕, 居村暁, 森根裕二, 池本哲也, 岩橋衆一, 山田眞一郎, 杉本真樹, 島田光生 : ホログラムとウェアラブル近赤外蛍光法による肝切除手術支援, 第73回手術手技研究会, 2019年5月.
318.	山田眞一郎, 島田光生, 森根裕二, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 和田佑馬, 良元俊昭, 西山光恵, 五十嵐康 : 大建中湯(TU-100)のNASH発癌抑制効果に関する検討, 第105回日本消化器病学会総会, 2019年5月.
319.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Shin-ichiro Yamada and Mitsuo Shimada : Usefulness of "one-stop shop" liver surgery simulation using EOB-MRI., ILLS2019, May 2019.
320.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi and Yu Saitou : Standardization of surgical technique in laparoscopic left hemihepatectomy., ILLS2019, May 2019.
321.	髙須千絵, 森根裕二, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 山田眞一郎, 和田佑馬, 良元俊昭, 太田昇吾, 島田光生 : 大腸癌肝転移における免疫逃避機構は原発巣と異なる可能性がある, 第119回日本外科学会定期学術集会, 2019年4月.
322.	宮崎克己, 岩橋祥子, 池本哲也, 森根裕二, 居村暁, 岩橋衆一, 齋藤裕, 山田眞一郎, 常山幸一, 島田光生 : 卵巣様間質を伴う非粘液性嚢胞腺腫の2例, 第119回日本外科学会定期学術集会, 2019年4月.
323.	岩橋祥子, 森根裕二, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 山田眞一郎, 常山幸一, 島田光生 : SSTR2発現からみた肝内胆管癌の組織発生学的分類, 第119回日本外科学会定期学術集会, 2019年4月.
324.	太田昇吾, 島田光生, 池本哲也, 森根裕二, 居村暁, 岩橋衆一, 齋藤裕, 山田眞一郎, 和田佑馬, 良元俊昭, 岩橋祥子 : Insulin-producing cell(IPC)分化成熟と亜鉛イオン濃度相関に関する研究, 第119回日本外科学会定期学術集会, 2019年4月.
325.	良元俊昭, 森根裕二, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 髙須千絵, 山田眞一郎, 和田佑馬, 太田昇吾, 岩橋祥子, 島田光生 : 青色LED光のOpn3を介した大腸癌抑制効果 (第2報), 第119回日本外科学会定期学術集会, 2019年4月.
326.	和田佑馬, 森根裕二, 齋藤裕, 居村暁, 池本哲也, 岩橋衆一, 山田眞一郎, 良元俊昭, 太田昇吾, 島田光生 : 癌微小環境における大建中湯の肝星細胞活性化制御・癌細胞オートファジーを介した癌細胞増殖抑制効果, 第119回日本外科学会定期学術集会, 2019年4月.
327.	齋藤裕, 居村暁, 森根裕二, 池本哲也, 岩橋衆一, 山田眞一郎, 杉本真樹, 島田光生 : ホログラム術中胆道造影とウェアラブル近赤外蛍光法による肝切除手術支援, 第119回日本外科学会定期学術集会, 2019年4月.
328.	山田眞一郎, 島田光生, 森根裕二, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 良元俊昭, 岩橋祥子, 西山光恵, 五十嵐康 : 大建中湯(TU-100)のNASH発癌抑制効果に関する検討, 第119回日本外科学会定期学術集会, 2019年4月.
329.	岩橋衆一, 池本哲也, 和田佑馬, 森根裕二, 居村暁, 齋藤裕, 山田眞一郎, 良元俊昭, 太田昇吾, 島田光生 : 臨床応用に向けたインスリン産生細胞分化誘導に関する研究, 第119回日本外科学会定期学術集会, 2019年4月.
330.	森根裕二, 島田光生, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 山田眞一郎, 東島潤 : 大腸癌肝転移に対する肝切除を中心とした治療戦略 - Upfront肝切除適応基準と切除不能例に対するConversion surgery-, 第119回日本外科学会定期学術集会, 2019年4月.
331.	太田昇吾, 島田光生, 池本哲也, 森根裕二, 居村暁, 岩橋衆一, 齋藤裕, 山田眞一郎, 和田佑馬, 良元俊昭, 岩橋祥子 : Insulin-producing cell(IPC)分化成熟と亜鉛イオン濃度相関に関する研究, 第18回日本再生医療学会総会, 2019年3月.
332.	和田佑馬, 池本哲也, 居村暁, 岩橋衆一, 齋藤裕, 山田眞一郎, 太田昇吾, 岩橋祥子, 島田光生 : 脂肪由来幹細胞からのインスリン産生細胞分化誘導に関する研究, 第18回日本再生医療学会総会, 2019年3月.
333.	山田眞一郎, 島田光生, 森根裕二, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 和田佑馬, 良元俊昭 : 肝胆膵領域癌におけるNrf2に着目した腫瘍関連マクロファージ活性化の検討, 第52回制癌剤適応研究会, 2019年3月.
334.	青谷望美, 山田苑子, 齋藤裕, 柏原秀也, 加木屋菜津美, 谷村真優, 菊井聡子, 鈴木佳子, 松村晃子, 濵田康弘 : 消化器癌患者におけるEDC栄養不良診断と各種栄養指標との関連, 第38回食事療法学会, 2019年3月.
335.	山田眞一郎, 島田光生, 森根裕二, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕 : 当科における腹腔鏡下膵体尾部切除術の定型化と成績に関する検討, 第33回四国内視鏡外科研究会, 2019年2月.
336.	良元俊昭, 島田光生, 森根裕二, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 山田眞一郎 : Lenvatinib投与中に呼吸不全を併発し急激な悪化の転機をたどった肝細胞癌多発肺転移の1例, 第2回徳島外科医会, 2019年2月.
337.	山田眞一郎, 島田光生, 森根裕二, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕 : 当科における腹腔鏡下膵体尾部切除術の定型化と成績に関する検討, 第2回徳島外科医会, 2019年2月.
338.	和田佑馬, 岩橋衆一, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 馮睿, 島田光生 : 腫瘍関連マクロファージに着目した肝癌細胞悪性度上昇の検討, 第19回日本肝がん分子標的治療研究会, 2019年1月.
339.	山田眞一郎, 島田光生, 森根裕二, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 和田佑馬 : MRI拡散強調画像から見た肝内胆管癌の腫瘍悪性度に関する検討, 第19回日本肝がん分子標的治療研究会, 2019年1月.
340.	菊井聡子, 山田苑子, 西麻希, 筑後桃子, 鈴木佳子, 松村晃子, 柏原秀也, 齋藤裕, 濵田康弘 : 肥満を有する肝細胞癌患者に対し肝切除術前に行なった減量の影響, 第22回日本病態栄養学会年次学術集会, 2019年1月.
341.	青谷望美, 山田苑子, 齋藤裕, 柏原秀也, 大岩優, 加木屋菜津美, 谷村真優, 鈴木佳子, 松村晃子, 濵田康弘 : 消化器癌患者におけるESPEN提唱の栄養不良診断基準の臨床的有用性, 第22回日本病態栄養学会学術集会, 2019年1月.
342.	和田佑馬, 池本哲也, 岩橋衆一, 森根裕二, 齋藤裕, 山田眞一郎, 西正暁, 居村暁, 島田光生 : 膵島保護におけるNrf2を介した Epigallocatechin-3-gallate (EGCG)の効果, 第48回創傷治癒学会, 2018年11月.
343.	齋藤裕, 居村暁, 森根裕二, 池本哲也, 岩橋衆一, 山田眞一郎, 杉本真樹, 島田光生 : 肝切除における術中手術支援のブレイクスル- -Virtual Reality & 肝離断Navigation –, 第80回日本臨床外科学会総会, 2018年11月.
344.	居村暁, 山田眞一郎, 齋藤裕, 岩橋衆一, 池本哲也, 森根裕二, 島田光生 : Evaluation of liver function for safe and radical hepatectomy in elderly patients (高齢者肝切除の安全性・根治性向上のための肝機能評価), 第80回日本臨床外科学会総会, 2018年11月.
345.	岩橋衆一, 島田光生, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 良元俊昭 : 大腸癌切除不能両葉多発肝転移におけるConversion後予後に関する検討-FOLFOXIRI療法の有用性-, 第80回日本臨床外科学会総会, 2018年11月.
346.	山田眞一郎, 島田光生, 森根裕二, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 良元俊昭 : 当科における腹腔鏡下膵体尾部切除術の定型化と成績に関する検討, 第10回膵臓内視鏡外科研究会・第12回肝臓内視鏡外科研究会, 2018年11月.
347.	岩橋衆一, 島田光生, 森根裕二, 馮睿, 居村暁, 池本哲也, 齋藤裕, 良元俊昭 : 肝癌細胞におけるNrf2に着目した腫瘍関連マクロファージ活性化の検討, 第29回日本消化器癌発生学会総会, 2018年11月.
348.	齋藤裕, 杉本真樹, 島田光生 : Virtual Realityを用いた肝切除における術中手術支援, 第27回日本コンピュータ外科学会大会, 2018年11月.
349.	岩橋衆一, 島田光生, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 寺奥大貴 : 肝癌細胞におけるNrf2に着目した腫瘍関連マクロファージ活性化の検討, JDDW2018, 2018年11月.
350.	齋藤裕, 杉本真樹, 島田光生 : 肝胆膵手術における解剖把握のためのVirtual Reality(VR)によるSimulationと術中手術支援, JDDW2018, 2018年11月.
351.	岩橋衆一, 島田光生, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 山田眞一郎 : 肝癌細胞におけるNrf2に着目した腫瘍関連マクロファージ活性化の検討, 第56回日本癌治療学会学術集会, 2018年10月.
352.	山田眞一郎, 島田光生, 森根裕二, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 和田佑馬, 良元俊昭, 太田昇吾 : MRI拡散強調画像から見た肝内胆管癌の腫瘍悪性度に関する検討, 第56回日本癌治療学会学術集会, 2018年10月.
353.	齋藤裕, 島田光生, 居村暁, 山田眞一郎, 岩橋衆一, 池本哲也, 森根裕二 : 脳死肝移植ドナー不足解消にむけての取り組み-医療系学生に対するDonor Action(命の授業)の必要性-, 第54回日本移植学会総会, 2018年10月.
354.	和田佑馬, 池本哲也, 森根裕二, 岩橋衆一, 齋藤裕, 山田眞一郎, 居村暁, 島田光生 : Nrf2経路によるEGCGの膵島保護効果, 第54回日本移植学会総会, 2018年10月.
355.	池本哲也, 島田光生, 居村暁, 森根裕二, 岩橋衆一, 齋藤裕, 和田佑馬, 太田昇吾 : 臨床応用を目指した間葉系幹細胞から創生されるインスリン産生細胞による糖尿病の治療法確立に関する研究, 第54回日本移植学会総会, 2018年10月.
356.	齋藤裕, 居村暁, 森根裕二, 池本哲也, 岩橋衆一, 山田眞一郎, 杉本真樹, 島田光生 : Virtual Realityを用いた肝切除における術中手術支援, 第13回肝癌治療シミュレーション研究会, 2018年9月.
357.	齋藤裕, 森大樹, 森根裕二, 矢田圭吾, 石橋広樹, 馬渡一論, 髙橋章, 島田光生 : メタボローム解析を用いた膵・胆管合流異常の胆汁中発癌物質の同定, 第54回日本胆道学会学術集会, 2018年9月.
358.	Rui Feng, Yuji Morine, Tetsuya Ikemoto, Satoru Imura, Shuichi Iwahashi, Shuichi Iwahashi, Yu Saitou and Mitsuo Shimada : Nrf2ActivationDriveMacrophagesPolarizationAndCancerCellEpithelial-Mesenchymal Transition During Interaction, 第77回日本癌学会学術集会, Sep. 2018.
359.	池本哲也, 島田光生, 太田昇吾, 和田佑馬, 齋藤裕, 岩橋衆一, 居村暁, 森根裕二 : 膵癌患者における末梢血Tr1細胞が反映するPDL-1発現の意義に関する検討, 第77回日本癌学会学術集会, 2018年9月.
360.	山田眞一郎, 和田佑馬, 森根裕二, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 和田佑馬, 太田昇吾 : 造影効果から見た肝内胆管癌の腫瘍悪性度に関する検討, 第54回日本胆道学会学術集会, 2018年9月.
361.	岩橋衆一, 島田光生, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 良元俊昭, 和田佑馬, 太田昇吾 : 長期予後に着目した膵全摘症例の検討-近年の化学療法の発展に伴う治療選択肢として-, 第27回消化器疾患病態治療研究会, 2018年9月.
362.	良元俊昭, 島田光生, 岩橋衆一, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 山田眞一郎 : Nrf2に着目した肝癌細胞における腫瘍関連マクロファージ活性化の検討, 第18回日本肝がん分子標的治療研究会, 2018年7月.
363.	岩橋衆一, 島田光生, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 寺奥大貴 : EOB-MRIは肝予備能を加味した術前simulationとして有用である, 第73回日本消化器外科学会総会, 2018年7月.
364.	齋藤裕, 居村暁, 森根裕二, 池本哲也, 岩橋衆一, 寺奥大貴, 杉本真樹, 島田光生 : 肝切除における解剖把握のためのVirtual Reality(VR)によるSimulationと術中手術支援, 第73回日本消化器外科学会総会, 2018年7月.
365.	池本哲也, 島田光生, 森根裕二, 居村暁, 岩橋衆一, 齋藤裕, 和田佑馬, 寺奥大貴, 太田昇吾 : NCDデータからみた地方における消化器外科手術の特色と安全性評価に関する検討, 第73回日本消化器外科学会総会, 2018年7月.
366.	森根裕二, 島田光生, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 寺奥大貴 : 肝内胆管癌に対する総合的治療戦略, 第73回日本消化器外科学会総会, 2018年7月.
367.	居村暁, 寺奥大貴, 齋藤裕, 岩橋衆一, 池本哲也, 森根裕二, 島田光生 : 手技定型化とstepwise training による安全な腹腔鏡下肝左葉切除, 第73回日本消化器外科学会総会, 2018年7月.
368.	寺奥大貴, 島田光生, 森根裕二, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 和田佑馬, 太田昇吾 : CT動脈相の造影効果から見た肝内胆管癌の腫瘍悪性度に関する検討, 第73回日本消化器外科学会総会, 2018年7月.
369.	池本哲也, 島田光生, 森根裕二, 居村暁, 岩橋衆一, 齋藤裕, 寺奥大貴 : 長期予後に着目した膵全摘症例の検討-近年の化学療法の発展に伴う治療選択肢として-, 第49回日本膵臓学会大会, 2018年6月.
370.	山田眞一郎, 齋藤裕, 岩橋衆一, 池本哲也, 居村暁, 森根裕二, 常山幸一, 島田光生 : 症例, 第54回日本肝癌研究会, 2018年6月.
371.	岩橋衆一, 島田光生, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 寺奥大貴 : 肝星細胞はIL-6を介して肝癌細胞の悪性度増強・転移促進に寄与する, 第54回日本肝癌研究会, 2018年6月.
372.	齋藤裕, 森根裕二, 島田光生, 居村暁, 池本哲也, 岩橋衆一, 東島潤 : 同時性大腸癌肝転移に対する治療戦略, 第54回日本肝癌研究会, 2018年6月.
373.	森根裕二, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 寺奥大貴, 島田光生 : 肝内胆管癌に対する総合的治療戦略, 第54回日本肝癌研究会, 2018年6月.
374.	居村暁, 齋藤裕, 岩橋衆一, 池本哲也, 森根裕二, 島田光生 : 肝癌に対する腹腔鏡肝切除の現状と今後の適応拡大, 第54回日本肝癌研究会, 2018年6月.
375.	岩橋祥子, 齋藤裕, 森根裕二, 居村暁, 池本哲也, 岩橋衆一, 寺奥大貴, 島田光生, 常山幸一 : 自然退縮を認めたInflammatory hepatocellular adenomaの一例, 第109回日本消化器病学会四国支部例会, 2018年6月.
376.	池本哲也, 島田光生, 森根裕二, 居村暁, 岩橋衆一, 齋藤裕, 和田佑馬, 太田昇吾 : 集学的治療としての膵全摘症例の検討, 第109回日本消化器病学会四国支部例会, 2018年6月.
377.	池本哲也, 島田光生, 加藤真介, 寺奥大貴, 齋藤裕, 岩橋衆一, 居村暁, 森根裕二 : 消化器・移植外科から発信する手術室の医療安全と効率化の両立, 第43回日本外科系連合学会学術集会, 2018年6月.
378.	齋藤裕, 居村暁, 島田光生 : 脳死肝移植ドナー不足解消にむけての取り組み―医療系学生に対するDonor Actionの必要性―, 第54回日本肝臓学会総会, 2018年6月.
379.	Yu Saitou, Satoru Imura, Hiroki Teraoku, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine, 杉本真樹 and Mitsuo Shimada : Simulation and intraoperative support with virtual reality (VR)for anatomical grasp in hepatectomy., 第30回日本肝胆膵外科学会学術集会, Jun. 2018.
380.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Hiroki Teraoku : Usefulness of 'one-stop shop' liver surgery simulation including estimation of total and regional liver functional reserve using EOB-MRI, 第30回日本肝胆膵外科学会学術集会, Jun. 2018.
381.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou and Hiroki Teraoku : Investigations for total pancreatectomy-focused on short-and long-term outcome-, 第30回日本肝胆膵外科学会学術集会, Jun. 2018.
382.	Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Hiroki Teraoku, Jun Higashijima, Chie Takasu and Mitsuo Shimada : Treatment guidance in resectable colorectal liver metastasis., 第30回日本肝胆膵外科学会学術集会, Jun. 2018.
383.	Satoru Imura, Hiroki Teraoku, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Our educational system for safe and reliable hepatectomy., 第30回日本肝胆膵外科学会学術集会, Jun. 2018.
384.	Hiroki Teraoku, Tetsuya Ikemoto, Shogo Oota, Yuuma Wada, Yu Saitou, Shuichi Iwahashi, Satoru Imura, Yuji Morine and Mitsuo Shimada : Preoperative care and surgical management for elderly and/or high-risk patients, 第30回日本肝胆膵外科学会学術集会, Jun. 2018.
385.	Yuuma Wada, Yuji Morine, Hiroki Teraoku, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, shogo ohta and Mitsuo Shimada : Significance of hypoxia inducible factor-1 expression in liver metastasis of colorectal cancer., 第30回日本肝胆膵外科学会学術集会, Jun. 2018.
386.	岩橋衆一, 島田光生, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 寺奥大貴 : 末梢血Tr1比率はIPMNの悪性度評価に有用である, 第27回日本癌病態治療研究会, 2018年5月.
387.	岩橋衆一, 島田光生, 居村暁, 森根裕二, 池本哲也, 齋藤裕, 寺奥大貴 : 発光ダイオード(LED)の波長強度可変装置による肝細胞保護に関する研究, 第36回日本肝移植研究会, 2018年5月.
388.	齋藤裕, 島田光生, 居村暁, 寺奥大貴, 岩橋衆一, 池本哲也, 森根裕二 : 医療系学生に対するDonor Actionの必要性- 移植医療理解・意思表示率向上にむけての取り組み –, 第36回日本肝移植研究会, 2018年5月.
389.	東島潤, 島田光生, 森根裕二, 居村暁, 池本哲也, 吉川幸造, 森大樹, 徳永卓哉, 西正暁, 岩橋衆一, 齋藤裕, 柏原秀也, 髙須千絵, 矢田圭吾 : Academic surgeon 育成のための新たな研修への取り組み―大学病院と市中病院の新たな連携―, 第36回臨床研修研究会, 2018年4月.
390.	宮崎克己, 齋藤裕, 森根裕二, 居村暁, 池本哲也, 岩橋衆一, 寺奥大貴, 常山幸一, 島田光生 : 自然退縮を認めたInflammatory hepatocellular adenomaの一例, 第118回日本外科学会定期学術集会, 2018年4月.
391.	齋藤裕, 池本哲也, 岩橋衆一, 寺奥大貴, 居村暁, 森根裕二, 島田光生 : Epigallocatechin gallate(EGCG)による脂肪由来間葉系幹細胞(ADSC)からInsulin producing cell(IPC)への効率的な分化誘導に関する研究, 第118回日本外科学会定期学術集会, 2018年4月.
392.	齋藤裕, 居村暁, 森根裕二, 池本哲也, 岩橋衆一, 寺奥大貴, 杉本真樹, 島田光生 : 肝予備能を加味したOne Stop Shop SimulationとMixed realityによる新たなNavigation, 第118回日本外科学会定期学術集会, 2018年4月.
393.	森根裕二, 島田光生, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 寺奥大貴, 東島潤 : 同時性大腸癌肝転移に対する治療戦略, 第118回日本外科学会定期学術集会, 2018年4月.
394.	居村暁, 寺奥大貴, 齋藤裕, 岩橋衆一, 池本哲也, 森根裕二, 島田光生 : Lifting methodを駆使した安全・確実な開腹肝切除, 第118回日本外科学会定期学術集会, 2018年4月.
395.	和田佑馬, 森根裕二, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 寺奥大貴, 太田昇吾, 島田光生 : 大腸癌肝転移におけるHypoxia Inducible Factor-1発現の意義 -肝転移巣・原発巣における腫瘍悪性度評価-, 第118回日本外科学会定期学術集会, 2018年4月.
396.	寺奥大貴, 島田光生, 森根裕二, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 和田佑馬, 太田昇吾 : 肝内胆管癌の造影効果による腫瘍悪性度評価の検討, 第118回日本外科学会定期学術集会, 2018年4月.
397.	岩橋衆一, 島田光生, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 和田佑馬, 寺奥大貴 : Epigallocatechin-3-gallateはNrf2を介して膵島保護作用を有する, 第118回日本外科学会定期学術集会, 2018年4月.
398.	池本哲也, 島田光生, 森根裕二, 居村暁, 岩橋衆一, 齋藤裕, 和田佑馬, 寺奥大貴, 太田昇吾 : 臨床応用を目指した間葉系幹細胞から創生されるインスリン産生細胞による糖尿病の治療法確立に関する研, 第118回日本外科学会定期学術集会, 2018年4月.
399.	寺奥大貴, 島田光生, 居村暁, 森根裕二, 池本哲也, 岩橋衆一, 齋藤裕, 和田佑馬, 太田昇吾 : Sorafenib投与症例におけるHCC長期生存例の検討, 第51回制癌剤適応研究会, 2018年3月.
400.	岩橋衆一, 島田光生, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 寺奥大貴 : 肝星細胞はIL-9を介して肝癌細胞増強・転移促進に寄与する, 第51回制癌剤適応研究会, 2018年3月.
401.	大岩優, 山田苑子, 齋藤裕, 青谷望美, 谷村真優, 鈴木佳子, 松村晃子, 濵田康弘 : 消化器癌患者における術前栄養指標としての Phase Angle の臨床的実用性の検討, 第33回日本静脈経腸栄学会, 2018年2月.
402.	久保みゆ, 山田苑子, 林遼, 北尾緑, 谷村真優, 鈴木佳子, 齋藤裕, 松村晃子, 神村盛一郎, 三好仁美, 島田亜紀, 武田憲昭, 濵田康弘 : 24時間尿中クレアチニン排泄量を用いた頭頸部癌患者の骨格筋量評価, 第33回日本静脈経腸栄学会, 2018年2月.
403.	林遼, 山田苑子, 久保みゆ, 北尾緑, 谷村真優, 鈴木佳子, 齋藤裕, 松村晃子, 濵田康弘 : 初回治療の頭頸部癌患者における悪液質の罹患率とその臨床像, 第33回日本静脈経腸栄学会学術集会, 2018年2月.
404.	大岩優, 山田苑子, 齋藤裕, 青谷望美, 谷村真優, 鈴木佳子, 松村晃子, 濵田康弘 : 消化器癌患者における Phase Angle を用いた術前栄養評価の検討, 第21回日本病態栄養学会学術集会, 2018年1月.
405.	岩橋衆一, 島田光生, 居村暁, 森根裕二, 池本哲也, 齋藤裕, 寺奥大貴 : 肝星細胞はIL-6を介して肝癌細胞増強・転移促進に寄与する, 第17回日本肝がん分子標的治療研究会, 2018年1月.
406.	久保みゆ, 山田苑子, 林遼, 北尾緑, 谷村真優, 鈴木佳子, 齋藤裕, 松村晃子, 神村盛一郎, 三好仁美, 島田亜紀, 武田憲昭, 濵田康弘 : 頭頸部癌患者において24時間尿中クレアチニン排泄量は骨格筋量評価に有用か, 第21回日本病態栄養学会年次学術集会, 2018年1月.
407.	久保みゆ, 山田苑子, 林遼, 北尾緑, 谷村真優, 鈴木佳子, 齋藤裕, 松村晃子, 神村盛一郎, 三好仁美, 島田亜紀, 武田憲昭, 濵田康弘 : 頭頸部癌患者において24時間尿中クレアチニン排泄量は骨格筋量評価に有用, 日本病態栄養学会誌, Vol.21, 2018年1月.
408.	林遼, 山田苑子, 久保みゆ, 北尾緑, 谷村真優, 鈴木佳子, 齋藤裕, 松村晃子, 濵田康弘 : 頭頸部癌患者における悪液質の罹患率及び各種栄養指標との関連, 第21回日本病態栄養学会学術集会, 2018年1月.
409.	岩橋衆一, 島田光生, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 寺奥大貴 : 当科における腹腔鏡(補助)下膵体尾部切除術の検討, 第9回膵臓内視鏡外科研究会, 2017年12月.
410.	齋藤裕, 居村暁, 森根裕二, 池本哲也, 岩橋衆一, 寺奥大貴, 杉本真樹, 島田光生 : 若手医師による術前術中3Dsimulation画像を用いた腹腔鏡下手術の定型化, 第11回肝臓内視鏡外科研究会, 2017年12月.
411.	居村暁, 寺奥大貴, 齋藤裕, 岩橋衆一, 池本哲也, 森根裕二, 島田光生 : 手技定型化による安全な腹腔鏡下肝左葉切除, 第11回肝臓内視鏡外科研究会, 2017年12月.
412.	和田佑馬, 池本哲也, 森根裕二, 岩橋衆一, 齋藤裕, 寺奥大貴, 太田昇吾, 居村暁, 島田光生 : Nef2-Keap1経路の膵島保護作用におけるEpigallocatechin-3-gallate(EGCG)の役割, 第47回日本創傷治癒学会, 2017年11月.
413.	岩橋祥子, 池本哲也, 齋藤裕, 森根裕二, 居村暁, 岩橋衆一, 寺奥大貴, 島田光生 : 併存疾患多数のStageⅣa膵体部癌に対し集学的補助で化学療法jを導入し長期生存を得た一例, 第79回日本臨床外科学会総会, 2017年11月.
414.	太田昇吾, 和田佑馬, 寺奥大貴, 齋藤裕, 岩橋衆一, 池本哲也, 森根裕二, 居村暁, 島田光生 : 初回切除後再発膵癌に対する再切除の有用性, 第79回日本臨床外科学会総会, 2017年11月.
415.	池本哲也, 島田光生, 森根裕二, 居村暁, 岩橋衆一, 齋藤裕, 寺奥大貴, 太田昇吾 : 超高齢者に対する肝切除の妥当性に関する検討 -85歳以上の超高齢者にも肝切除は安全に施行可能である, 第79回日本臨床外科学会総会, 2017年11月.
416.	岩橋衆一, 島田光生, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 寺奥大貴 : Modified de-rotation法による完全動脈先行処理を用いた膵頭十二指腸切除術, 第79回日本臨床外科学会総会, 2017年11月.
417.	森根裕二, 島田光生, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 寺奥大貴, 髙須千絵, 東島潤 : 大腸癌切除不能両葉多発肝転移に対するFOLFOXIRI療法の有用性, 第79回日本臨床外科学会総会, 2017年11月.
418.	寺奥大貴, 齋藤裕, 島田光生 : 肝胆膵外科手術における免疫指標を加味した新たな周術期栄養評価, 第108回日本消化器病学会四国支部例会, 2017年11月.
419.	寺奥大貴, 島田光生, 森根裕二, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 和田佑馬, 太田昇吾 : One stop shopを目指したEOB-MRIによる部分切除術肝機能評価, 第26回日本コンピュータ外科学会大会, 2017年10月.
420.	和田佑馬, 森根裕二, 吉川幸造, 東島潤, 西正暁, 岩橋衆一, 柏原秀也, 髙須千絵, 齋藤裕, 石川大地, 寺奥大貴, 池本哲也, 居村暁, 島田光生 : 青色LED光は光受容体(opsin3)を介し癌細胞増殖を抑制する, 第55回日本癌治療学会学術集会, 2017年10月.
421.	齋藤裕, 森根裕二, 居村暁, 池本哲也, 岩橋衆一, 寺奥大貴, 島田光生 : 肝内胆管癌における局在・浸潤形式別悪性度, 第55回日本癌治療学会学術集会, 2017年10月.
422.	岩橋衆一, ガイベアハマドアンマール, 島田光生, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 寺奥大貴 : 人工知能を用いた肝細胞癌再発予測因子の検討, 第55回日本癌治療学会学術集会, 2017年10月.
423.	齋藤裕, 居村暁, 森根裕二, 太田昇吾, 寺奥大貴, 岩橋衆一, 池本哲也, 島田光生 : 肝切除におけるVirtual Reality(VR) 画像を駆使した胆管解剖把握のための術中Navigation System, 第12回肝癌治療シミュレーション研究会, 2017年9月.
424.	池本哲也, 島田光生, 石川大地, 寺奥大貴, 齋藤裕, 岩橋衆一, 居村暁, 森根裕二 : IL driven IL-10 Tr1細胞による細胞レベルのRO/R1手術達成評価に関する検討, 第76回日本癌学会学術総会, 2017年9月.
425.	寺奥大貴, 池本哲也, 和田佑馬, 太田昇吾, 齋藤裕, 岩橋衆一, 居村暁, 森根裕二, 島田光生, 常山幸一 : 単純性嚢胞との鑑別に苦慮したnonmucinous cyctadenoma の1例, 第67回日本消化器画像診断研究会, 2017年9月. (キーワード) 第67回日本消化器画像診断研究会
426.	寺奥大貴, 池本哲也, 森根裕二, 岩橋衆一, 齋藤裕, 和田佑馬, 太田昇吾, 居村暁, 島田光生 : Nrf2-Keap1制御系を介したEpigallocatechin-3-gallate(EGCG)による膵島保護作用に関する検討, 第53回日本移植学会総会, 2017年9月.
427.	池本哲也, 島田光生, 居村暁, 森根裕二, 岩橋衆一, 齋藤裕, 寺奥大貴 : 膵島移植に対するブレイクスルーとしてのAdipose tissue derived stem cellsからの効果的Insulin-producing cells創生, 第53回日本移植学会総会, 2017年9月.
428.	齋藤裕, 島田光生, 居村暁, 寺奥大貴, 岩橋衆一, 池本哲也, 森根裕二 : 脳死肝移植を推進するための学生に対するDonor Actionの必要性について, 第53回日本移植学会総会, 2017年9月.
429.	岩橋衆一, 島田光生, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 寺奥大貴 : 赤色発光ダイオード(LED)は肝細胞保護作用を有する, 第255回徳島医学会学術集会, 2017年8月.
430.	髙須千絵, 森根裕二, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 石川大地, 吉川雅登, 市井啓仁, 島田光生 : 転写因子制御による肝虚血再灌流障害の新たな治療法の開発, 第255回徳島医学会学術集会, 2017年8月.
431.	髙田厚史, 池本哲也, 岩橋衆一, 齋藤裕, 森根裕二, 居村暁, 島田光生 : Epigallocatechin-3-gallate(EGCG)によるNrf2-Keap1制御系を介した膵島保護作用に関する検討, 第72回日本消化器外科学会総, 2017年7月.
432.	齋藤裕, 島田光生, 瓜生原葉子, 居村暁, 良元俊昭, 髙田厚史, 吉川雅登, 岩橋衆一, 池本哲也, 森根裕二 : 脳死肝移植を推進するための学生に対するDonor Actionの必要性について, 第72回日本消化器外科学会総会, 2017年7月.
433.	岩橋衆一, 島田光生, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 吉川雅登, 良元俊昭, 髙田厚史 : One stop shopを目指したEOB-MRIによる部分肝機能評価, 第72回日本消化器外科学会総会, 2017年7月.
434.	良元俊昭, 島田光生, 森根裕二, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 石川大地, 吉川雅登, 東島潤 : 大腸癌肝転移に切除基準と腫瘍悪性度評価, 第72回日本消化器外科学会総会, 2017年7月.
435.	池本哲也, 島田光生, 森根裕二, 居村暁, 岩橋衆一, 齋藤裕, 吉川雅登 : 肝胆膵手術における人工膵臓血糖管理の有用性に関する検討, 第72回日本消化器外科学会総会, 2017年7月.
436.	森根裕二, 島田光生, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 吉川雅登, 寺奥大貴 : 肝内胆管癌における局在・浸潤形式別悪性度, 第72回日本消化器外科学会総会, 2017年7月.
437.	居村暁, 吉川雅登, 寺奥大貴, 齋藤裕, 岩橋衆一, 池本哲也, 森根裕二, 島田光生 : 高度門脈侵襲陽性肝癌に対する集学的治療戦略, 第72回日本消化器外科学会総会, 2017年7月.
438.	齋藤裕, 奥村仙示, 森根裕二, 平山明由, 良元俊昭, 吉川雅登, 岩橋衆一, 池本哲也, 居村暁, 島田光生 : メタボローム解析を用いた肝切除後代謝物解析と肝再生因子の解明, 日本外科代謝栄養学会第54回学術集会, 2017年7月.
439.	寺奥大貴, 島田光生, 森根裕二, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 吉川雅登, 良元俊昭, 髙田厚史, 常山幸一 : 症例, 第53回日本肝癌研究会, 2017年7月.
440.	齋藤裕, 居村暁, 森根裕二, 池本哲也, 岩橋衆一, 吉川雅登, 良元俊昭, 島田光生 : 術前Prognostic nutritional index(PNI)は肝癌術後短期・長期予後予測因子になる, 第53回日本肝癌研究会, 2017年7月.
441.	岩橋衆一, 島田光生, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 寺奥大貴 : 超高齢者に対する肝切除の妥当性に関する検討, 第53回日本肝癌研究会, 2017年7月.
442.	居村暁, 良元俊昭, 髙田厚史, 吉川雅登, 寺奥大貴, 齋藤裕, 岩橋衆一, 池本哲也, 森根裕二, 島田光生 : ntermediate stage肝癌に対する肝切除の有用性, 第53回日本肝癌研究会, 2017年7月.
443.	森根裕二, 島田光生, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 吉川雅登 : NBNC肝細胞癌における臨床病理学的・分子生物学的特徴の解析, 第53回日本肝癌研究会, 2017年7月.
444.	濵田康弘, 齋藤裕, 鈴木佳子, 安井苑子, 山田静恵, 西麻希, 松村晃子, 高橋路子, 宇佐美眞 : 栄養サポートチーム(NST)活動の活性化に必要なものとは?, 第42回日本外科系連合学会学術集会, 2017年6月.
445.	鈴木佳子, 安井苑子, 齋藤裕, 濵田康弘 : 患者の栄養管理を支える栄養サポートチーム(NST), 日本外科系連合学会雑誌, Vol.42, 2017年6月.
446.	大岩優, 安井苑子, 谷村真優, 鈴木佳子, 松浦明香, 齋藤裕, 山田静恵, 松村晃子, 島田光生, 濵田康弘 : 消化器癌患者における主観的包括的栄養評価(SGA)による術前栄養評価の妥当性の検討, 日本外科系連合学会雑誌, Vol.42, 2017年6月.
447.	岩橋祥子, 池本哲也, 島田光生, 吉川雅登, 寺奥大貴, 齋藤裕, 岩橋衆一, 居村暁, 森根裕二, 常山幸一 : 単純性嚢胞との鑑別に苦慮した極めて稀な膵嚢胞の1例, 第42回日本外科系連合学会学術集会, 2017年6月.
448.	池本哲也, 島田光生, 加藤真介, 吉川雅登, 寺奥大貴, 齋藤裕, 岩橋衆一, 居村暁, 森根裕二 : 徳島大学病院GRMからみた手術室安全管理の取り組み, 第42回日本外科系連合学会学術集会, 2017年6月.
449.	齋藤裕, 寺奥大貴, 岩橋衆一, 池本哲也, 居村暁, 森根裕二, 島田光生 : 肝内胆管癌におけるSFRP1発現低下は予後不良因子となる, 第16回日本肝がん分子標的治療研究会, 2017年6月.
450.	太田昇吾, 島田光生, 森根裕二, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 寺奥大貴 : 超高齢者に対する肝切除の妥当性に関する検討-85歳以上の超高齢者にも安全に施行可能である-, 第107回日本消化器病学会四国支部例, 2017年6月.
451.	久保みゆ, 山田苑子, 谷村真優, 林遼, 北尾緑, 鈴木佳子, 齋藤裕, 松村晃子, 島田亜紀, 武田憲昭, 濵田康弘 : 頭頸部癌患者における24時間尿中クレアチニン排泄量を用いた骨格筋量の評価, Trend of Nutrition, Vol.2, No.2, 116, 2017年6月.
452.	大岩優, 谷村真優, 山田苑子, 齋藤裕, 西正暁, 松原あつみ, 薄井静流, 鈴木佳子, 島田光生, 濵田康弘 : 消化器癌患者の術前栄養評価における主観的包括的栄養評価(SGA)の妥当性の検討, Trend of Nutrition, Vol.2, No.2, 110, 2017年6月.
453.	居村暁, 石川大地, 齋藤裕, 岩橋衆一, 池本哲也, 森根裕二, 島田光生 : Intermediate stageの肝癌に対する切除の有効性の検討, 第53回日本肝臓学会総会, 2017年6月.
454.	Yuuma Wada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Masato Yoshikawa and Mitsuo Shimada : Treatment outcome for recurrent pancreatic cancer, 第29回日本肝胆膵外科学会学術集会(第6回アジア太平洋肝胆膵学会), Jun. 2017.
455.	Shuichi Iwahashi, AHMAD AMMAR GHAIBEH, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa and Hiroki Teraoku : Predictability of postoperative recurrence on hepatocellular carcinoma through the alternating decision tree, 第29回日本肝胆膵外科学会学術集会(第6回アジア太平洋肝胆膵学会), Jun. 2017.
456.	Rui Feng, Yuji Morine, Tetsuya Ikemoto, Satoru Imura, Shuichi Iwahashi, Yu Saitou and Mitsuo Shimada : Photobiomodulation with red light emitting diodes accelerates hepatocytes proliferation through ROS/ERK pathway, 第29回日本肝胆膵外科学会学術集会(第6回アジア太平洋肝胆膵学会), Jun. 2017.
457.	Hiroki Teraoku, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou and Masato Yoshikawa : EOB-MRI is useful for `one stop shop` modality based on functional liver volume, 第29回日本肝胆膵外科学会学術集会(第6回アジア太平洋肝胆膵学会), Jun. 2017.
458.	Masato Yoshikawa, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Atsushi Takata, Toshiaki Yoshimoto and Mitsuo Shimada : Stylization of laparoscopic surgery using 3D simulation for young surgeo, 第29回日本肝胆膵外科学会学術集会(第6回アジア太平洋肝胆膵学会), Jun. 2017.
459.	Tetsuya Ikemoto, Mitsuo Shimada, Daichi Ishikawa, Masato Yoshikawa, Yu Saitou, Shuichi Iwahashi, Satoru Imura and Yuji Morine : Tr1 cells and Foxp3+regulatory T cell as a diagnostic biomarker for reflecting pathological agressiveness of cystic neoplasm of pancreas, 第29回日本肝胆膵外科学会学術集会(第6回アジア太平洋肝胆膵学会), Jun. 2017.
460.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Masato Yoshikawa and Hiroki Teraoku : Treatment strategy for colorectal liver matastasis-Surgical criteria for initially resectable and assessment toward conversion for unresectable cases-, 第29回日本肝胆膵外科学会学術集会(第6回アジア太平洋肝胆膵学会, Jun. 2017.
461.	Satoru Imura, Atsushi Takata, Toshiaki Yoshimoto, Masato Yoshikawa, Hiroki Teraoku, Daichi Ishikawa, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Liver resection for hepatocellular carcinoma of BCLC intermediate stage, 第29回日本肝胆膵外科学会学術集会(第6回アジア太平洋肝胆膵学会), Jun. 2017.
462.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto and Mitsuo Shimada : Preoperative prognostic nutritional index (PNI) predicts both short and long-term outcomes after liver resection for hepatocellular carcinoma., IASGO Advanced Postgraduate Course in Yokohama, Jun. 2017.
463.	齋藤裕, 島田光生, 居村暁, 良元俊昭, 髙田厚史, 吉川雅登, 岩橋衆一, 池本哲也, 森根裕二 : 脳死肝移植を推進するための学生に対するDonor Actionの必要性について, 第35回日本肝移植研究会, 2017年6月.
464.	岩橋衆一, 島田光生, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 吉川雅登, 良元俊昭 : Tr1細胞とFoxp3調節性T細胞は消化器担癌状態におけるバイオマーカーとして有用である, 第26回日本癌病態治療研究会, 2017年6月.
465.	岩橋衆一, 島田光生, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 吉川雅登, 良元俊昭 : 肝葉切除術後に施行した膵切除術2例の経験, 第71回手術手技研究会, 2017年5月.
466.	宮崎克己, 齋藤裕, 森根裕二, 常山幸一, 居村暁, 池本哲也, 岩橋衆一, 吉川雅登, 良元俊昭, 髙田厚史, 島田光生 : 限局性結節性過形成(FNH)術後に再発増殖し肝不全で死亡した一例, 第117回日本外科学会定期学術集会, 2017年4月.
467.	太田昇吾, 森根裕二, 吉川雅登, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 石川大地, 髙田厚史, 良元俊昭, 髙須千絵, 東島潤, 島田光生 : 膵癌術後残膵再発に対する再切除導入効果の検証, 第117回日本外科学会定期学術集会, 2017年4月.
468.	良元俊昭, 吉川幸造, 森根裕二, 東島潤, 西正暁, 柏原秀也, 髙須千絵, 岩橋衆一, 齋藤裕, 石川大地, 吉川雅登, 髙田厚史, 池本哲也, 居村暁, 島田光生 : 青色LED光は光受容体(opsin)を介し癌細胞増殖を抑制する, 第117回日本外科学会定期学術集会, 2017年4月.
469.	髙田厚史, 東島潤, 石川大地, 吉川雅登, 柏原秀也, 齋藤裕, 岩橋衆一, 西正暁, 吉川幸造, 島田光生 : 腸管吻合におけるKono-S吻合の有用性に関する検討, 第117回日本外科学会定期学術集会, 2017年4月.
470.	寺奥大貴, 島田光生, 池本哲也, 居村暁, 岩橋衆一, 齋藤裕, 吉川雅登, 良元俊昭 : 当科における膵全摘症例の検討-術後短期成績・長期予後の両面に着目して-, 第117回日本外科学会定期学術集会, 2017年4月.
471.	吉川雅登, Rui Feng, 森根裕二, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 石川大地, 髙田厚史, 良元俊昭, 髙須千絵, 東島潤, 島田光生 : 肝細胞に対するROS/ ERK pathwayを介した赤色LED光の細胞増殖促進効果, 第117回日本外科学会定期学術集会, 2017年4月.
472.	石川大地, 良元俊昭, 髙田厚史, 吉川雅登, 髙須千絵, 齋藤裕, 岩橋衆一, 池本哲也, 居村暁, 森根裕二, 島田光生 : 大腸癌の発癌・腫瘍進展におけるmicroRNA-449aの意義, 第117回日本外科学会定期学術集会, 2017年4月.
473.	川下陽一郎, 森根裕二, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 髙須千絵, 石川大地, 吉川雅登, 髙田厚史, 良元俊昭, 寺奥大貴, 島田光生 : 肝内胆管癌におけるHSF1発現の意義, 第117回日本外科学会定期学術集会, 2017年4月.
474.	岩橋衆一, 島田光生, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 吉川雅登, 良元俊昭, 髙田厚史 : Cancer-associated fibroblastsを介した膵癌細胞におけるnab-paclitaxelの効果, 第117回日本外科学会定期学術集会, 2017年4月.
475.	池本哲也, 島田光生, 石川大地, 森根裕二, 居村暁, 東島潤, 岩橋衆一, 齋藤裕, 髙須千絵, 吉川雅登, 良元俊昭 : Tr1細胞とFoxp3調節性T細胞による腫瘍免疫状態を反映する免疫学的バイオマーカー探索, 第117回日本外科学会定期学術集会, 2017年4月.
476.	居村暁, 髙田厚史, 良元俊昭, 吉川雅登, 寺奥大貴, 石川大地, 齋藤裕, 髙須千絵, 岩橋衆一, 東島潤, 池本哲也, 森根裕二, 島田光生 : 肝切除シミュレーション・ナビゲーションを駆使した若手教育法の確立, 第117回日本外科学会定期学術集会, 2017年4月.
477.	岩橋衆一, 島田光生, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 吉川雅登, 良元俊昭 : 発光ダイオード(LED)の波長強度可変装置による肝細胞保護に関する研究, 第117回日本外科学会定期学術集会, 2017年4月.
478.	齋藤裕, 奥村仙示, 森根裕二, 平山明由, 梶浦大資, 多々納浩, 居村暁, 池本哲也, 岩橋衆一, 吉川雅登, 良元俊昭, 髙田厚史, 島田光生 : メタボローム解析を用いた肝切除後代謝物解析と肝再生因子の解明, 第117回日本外科学会定期学術集会, 2017年4月.
479.	森根裕二, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 石川大地, 吉川雅登, 東島潤, 髙須千絵 : 大腸癌肝転移における治療指針 - 原発・転移巣の腫瘍悪性度は相関しない?, 第117回日本外科学会定期学術集会, 2017年4月.
480.	森根裕二, 石橋広樹, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 石川大地, 吉川雅登, 島田光生 : 「胆道拡張症，膵・胆管合流異常症の標準術式は?-小児外科および成人外科の立場から-」, 第117回日本外科学会定期学術集会, 2017年4月.
481.	齋藤裕, 森根裕二, 吉川雅登, 髙田厚史, 良元俊昭, 岩橋衆一, 池本哲也, 居村暁, 島田光生 : 肝内胆管癌におけるHeat shock factor 1(HSF1)発現の意義, 第50回制癌剤適応研究会, 2017年3月.
482.	岩橋衆一, 島田光生, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 吉川雅登, 髙田厚史, 良元俊昭 : 末梢血Tr1細胞とFoxp3陽性調節性T細胞は消化器担癌状態におけるバイオマーカーとして有用である, 第50回制癌剤適応研究会, 2017年3月.
483.	髙田厚史, 池本哲也, 岩橋衆一, 森根裕二, 齋藤裕, 居村暁, 島田光生 : Epigallocatechin-3-gallate(EGCG)によるNrf2-Keap1制御系を介した膵島保護作用に関する検討, 第44回日本膵・膵島移植研究会, 2017年3月.
484.	池本哲也, 島田光生, 岩橋衆一, 良元俊昭, 吉川雅登, 齋藤裕, 森根裕二, 居村暁 : 8 ADSCによるInsulin-producing cell(IPCs)作成における効果的新規分化誘導方法に関する検討, 第44回日本膵・膵島移植研究会, 2017年3月.
485.	岩橋衆一, 島田光生, 池本哲也, 齋藤裕, 良元俊昭 : 465nm-LED光照射による癌幹細胞制御に関する研究, 第16回日本再生医療学会総会, 2017年3月.
486.	池本哲也, 島田光生, 岩橋衆一, 齋藤裕, 良元俊昭 : ADSCによるInsulin-producing cell(IPCs)作成における効果的新規分化誘導方法に関する検討, 第16回日本再生医療学会総会, 2017年3月.
487.	安井苑子, 齋藤裕, 谷佳子, 山田静恵, 粟田由佳, 西麻希, 菊井聡子, 橋本脩平, 足立知咲, 松村晃子, 島田光生, 濵田康弘 : NST介入により短期間で体脂肪減量に成功した腹壁瘢痕ヘルニア術前の高度肥満の1症例, 第36回日本食事療法学会, 2017年3月.
488.	良元俊昭, 齋藤裕, 森根裕二, 常山幸一, 居村暁, 池本哲也, 岩橋衆一, 吉川雅登, 髙田厚史, 島田光生 : 限局性結節性過形成(FNH)術後に再発増殖し肝不全で死亡した一例-切除肝・病理解剖をふまえて-, 第66回日本消化器画像診断研究会, 2017年2月.
489.	松原あつみ, 安井苑子, 齋藤裕, 谷村真優, 松浦明香, 大岩優, 西麻希, 山田静恵, 谷佳子, 松村晃子, 島田光生, 濵田康弘 : 胃癌・膵癌患者における術前栄養評価と予後との関連, 第32回日本静脈経腸栄養学会学術集会, 2017年2月.
490.	岩橋衆一, 島田光生, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 吉川雅登, 髙田厚史, 良元俊昭 : 膵腫瘍性病変におけるType1 regulatory T細胞の臨床的有用性の検討-Type1 regulatory T細胞は診断・再発予測バイオマーカーとして有用である-, 第254回徳島医学会学術集会, 2017年2月.
491.	齋藤裕, 森根裕二, 吉川雅登, 髙田厚史, 良元俊昭, 岩橋衆一, 池本哲也, 居村暁, 島田光生 : 肝門部胆管癌超ハイリスク症例に対して根治術施行し術後管理, 第25回徳島外科術後管理研究会, 2017年2月.
492.	Toshiaki Yoshimoto, Masato Yoshikawa, Daichi Ishikawa, Atsushi Takata, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : Long-term survivors of HCC using sorafenib, 2nd Eastern &Western Association Liver Tumors(EWALT), Jan. 2017.
493.	吉川雅登, 森根裕二, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 石川大地, 髙田厚史, 良元俊昭, 島田光生 : 肝細胞癌術後再発予後不良因子としてのCEAの意義, 第15回日本肝がん分子標的治療研究会, 2017年1月.
494.	齋藤裕, 森根裕二, 川下陽一郎, 吉川雅登, 岩橋衆一, 池本哲也, 居村暁, 島田光生 : 肝内胆管癌におけるHeat shock factor1(HSF1)発現の意義, 第15回日本肝がん分子標的治療研究会, 2017年1月.
495.	松原あつみ, 安井苑子, 齋藤裕, 谷村真優, 松浦明香, 大岩優, 西麻希, 山田静恵, 谷佳子, 松村晃子, 島田光生, 濵田康弘 : 胃癌・膵癌患者の予後予測に有用な栄養評価法の検討, 第20回日本病態栄養学会年次学術集会, 2017年1月.
496.	岩橋衆一, 島田光生, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 矢田圭吾, 森大樹, 石橋広樹 : 小児先天性胆道拡張症の胆道上皮における発癌関連遺伝子発現の検討, 第106回日本消化器病学会四国支部例会, 2016年12月.
497.	吉川雅登, Rui Feng, 森根裕二, 居村暁, 池本哲也, 東島潤, 西正暁, 岩橋衆一, 齋藤裕, 髙須千絵, 石川大地, 髙田厚史, 良元俊昭, 島田光生 : 肝細胞に対するROS/ERK pathwayを介した赤色LED光の細胞増殖促進効果, 第46回日本創傷治癒学会, 2016年12月.
498.	居村暁, 吉川雅登, 寺奥大貴, 石川大地, 齋藤裕, 岩橋衆一, 荒川悠佑, 池本哲也, 森根裕二, 島田光生 : 定型化と教育システムがもたらす安全な腹腔鏡下左葉切除, 第29回日本内視鏡外科学会総会, 2016年12月.
499.	吉川雅登, 齋藤裕, 森根裕二, 居村暁, 池本哲也, 岩橋衆一, 石川大地, 髙田厚史, 良元俊昭, 島田光生 : 若手医師による術前術中3D simulation画像を用いた腹腔鏡下手術の定型化, 第25回日本コンピュータ外科学会大会, 2016年11月.
500.	良元俊昭, 山田眞一郎, 島田光生, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 吉川雅登, 髙田厚史, 髙須千絵 : EOB-MRIを用いた新たな肝切除限界予測の可能性, 第78回日本臨床外科学会総会, 2016年11月.
501.	吉川雅登, 森根裕二, 島田光生, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 石川大地, 髙田厚史, 良元俊昭 : 再発膵癌に対する再切除の有用性の検討, 第78回日本臨床外科学会総会, 2016年11月.
502.	髙田厚史, 島田光生, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 岩橋衆一, 齋藤裕, 石川大地, 吉川雅登, 良元俊昭 : 当科における若手医師の腹腔鏡手術トレーニングの現状と効果, 第78回日本臨床外科学会総会, 2016年11月.
503.	岩橋衆一, 島田光生, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 石川大地, 吉川雅登, 髙田厚史, 良元俊昭 : 若手外科医でも安全・確実に施行できる肝葉切除術, 第78回日本臨床外科学会総会, 2016年11月.
504.	齋藤裕, 森根裕二, 髙田厚史, 良元俊昭, 吉川雅登, 石川大地, 岩橋衆一, 池本哲也, 居村暁, 島田光生 : 膵頭十二指腸切除術に対するModified de-rotation法を用いた`` Complete artery-f irst approach'', 第78回日本臨床外科学会総会, 2016年11月.
505.	池本哲也, 島田光生, 森根裕二, 居村暁, 岩橋衆一, 齋藤裕, 石川大地, 吉川雅登, 良元俊昭 : 膵全摘における人工膵臓の有用性における検討, 第78回日本臨床外科学会総会, 2016年11月.
506.	森根裕二, 島田光生, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 石川大地, 寺奥大貴, 吉川雅登, 髙須千絵, 荒川悠佑, 東島潤 : 大腸癌切除不能多発肝転移に対する治療戦略, 第78回日本臨床外科学会総会, 2016年11月.
507.	居村暁, 吉川雅登, 寺奥大貴, 石川大地, 齋藤裕, 岩橋衆一, 荒川悠佑, 池本哲也, 森根裕二, 島田光生 : グリソン一括による肝門処理のコツとピットフォール, 第78回日本臨床外科学会総会, 2016年11月.
508.	吉川雅登, 森根裕二, 池本哲也, 髙田厚史, 良元俊昭, 石川大地, 齋藤裕, 岩橋衆一, 居村暁, 島田光生 : 当科における切除不能・再発進行膵癌に対する治療成績, 第54回日本癌治療学会学術集会, 2016年10月.
509.	石川大地, 川下陽一郎, 良元俊昭, 髙田厚史, 吉川雅登, 齋藤裕, 岩橋衆一, 池本哲也, 森根裕二, 居村暁, 島田光生 : FBXW7発現は転移性肝癌における切除後再発予測因子となる, 第54回日本癌治療学会学術集会, 2016年10月.
510.	岩橋衆一, 島田光生, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 石川大地, 吉川雅登, 寺奥大貴, 髙田厚史, 良元俊昭 : 末梢血Tr1細胞とFoxp3調節性T細胞は担癌状態におけるバイオメーカーとして有用である, 第54回日本癌治療学会学術集会, 2016年10月.
511.	西尾進, 齋藤裕, 鳥居裕太, 平田有紀奈, 山尾雅美, 松本力三, 岩本誠司, 髙尾正一郎, 山田博胤, 佐田政隆 : 巨大肝嚢胞の2切除例, 日本超音波医学会第26回四国地方会学術集会, 2016年10月.
512.	岩橋衆一, 島田光生, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 石川大地, 吉川雅登 : 消化器癌におけるヒストンアセチル化の抗腫瘍効果, 第75回日本癌学会学術集会, 2016年10月.
513.	池本哲也, 島田光生, 石川大地, 森根裕二, 居村暁, 岩橋衆一, 齋藤裕, 山田眞一郎, 吉川雅登, 良元俊昭 : Tr1とFoxp3陽性調節性T細胞は担癌患者の腫瘍免疫に関する検討, 第75回日本癌学会学術集会, 2016年10月.
514.	良元俊昭, 齋藤裕, 髙田厚史, 吉川雅登, 石川大地, 岩橋衆一, 池本哲也, 森根裕二, 居村暁, 島田光生 : 脳死肝移植を推進するための学生に対するドナーアクションの必要性について, 第52回日本移植学会総会, 2016年9月.
515.	齋藤裕, 居村暁, 吉川雅登, 石川大地, 岩橋衆一, 池本哲也, 森根裕二, 島田光生 : 徳島におけるABO不適合生体肝移植の成績, 第52回日本移植学会総会, 2016年9月.
516.	池本哲也, 島田光生, 居村暁, 森根裕二, 岩橋衆一, 齋藤裕, 吉川雅登, 良元俊昭 : 脂肪由来幹細胞によるInsulin-producing cell作成における新規分化誘導方法に関する検討, 第52回日本移植学会総会, 2016年9月.
517.	髙田厚史, 島田光生, 森根裕二, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 石川大地, 吉川雅登, 良元俊昭 : 術前診断が困難であった肝偽リンパ腫の1例, 第65回日本消化器画像診断研究会, 2016年9月.
518.	松原あつみ, 安井苑子, 齋藤裕, 谷村真優, 松浦明香, 大岩優, 谷佳子, 松村晃子, 島田光生, 濵田康弘 : 胃癌・膵癌患者における術前栄養評価と予後との関連, 第8回日本静脈経腸栄養学会四国支部会学術集会, Vol.8, 45, 2016年9月.
519.	髙田厚史, 良元俊昭, 吉川雅登, 石川大地, 齋藤裕, 岩橋衆一, 荒川悠佑, 池本哲也, 森根裕二, 居村暁, 島田光生 : 若手医師による術前術中3D simulation画像を用いた腹腔鏡下手術の定型化, 第11回肝癌治療シミュレーション研究会, 2016年9月.
520.	岩橋衆一, 島田光生, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 吉川雅登, 良元俊昭, 髙田厚史 : RFA後肝細胞癌再発例はEMT誘導を介し腫瘍悪性度が増強する, 第35回Microwave Surgery研究会, 2016年9月.
521.	居村暁, 吉川雅登, 齋藤裕, 岩橋衆一, 池本哲也, 森根裕二, 島田光生 : 担癌グリソン枝マイクロ波凝固による肝小範囲切除の工夫, 第35回Microwave Surgery研究会, 2016年9月.
522.	馮睿, 島田光生, 森根裕二, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 髙田厚史, 良元俊昭 : Cancer-associated fibroblastsに着目した膵癌細胞におけるnab-paclitaxcelの効果, 第27回日本消化器癌発生学会総会, 2016年9月.
523.	吉川雅登, 島田光生, 森根裕二, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 石川大地, 髙田厚史, 良元俊昭 : 肝細胞癌術後再発予後不良因子としてのCEAの意義, 第27回日本消化器癌発生学会総会, 2016年9月.
524.	石川大地, 寺奥大貴, 髙田厚史, 吉川雅登, 髙須千絵, 齋藤裕, 岩橋衆一, 池本哲也, 居村暁, 森根裕二, 島田光生 : 転移性肝癌における腫瘍悪性度制御因子としてのTHBS-1の役割, 第27回日本消化器癌発生学会総会, 2016年9月.
525.	岩橋衆一, 島田光生, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 吉川雅登, 髙田厚史, 良元俊昭 : 消化器癌における末梢血Tr1細胞とFoxp3調節性T細胞の有用性の検討, 第27回日本消化器癌発生学会総会, 2016年9月.
526.	森根裕二, 島田光生, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 石川大地, 寺奥大貴, 吉川雅登 : 肝内胆管癌の腫瘍悪性度評価と制御の可能性, 第27回日本消化器癌発生学会総会, 2016年9月.
527.	髙田厚史, 島田光生, 森根裕二, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 石川大地, 吉川雅登, 良元俊昭 : 胆道癌術後肝内再発に対する肝切除導入効果の検証, 第91回中国四国外科学会総会/第21回中国四国内視鏡外科研究会, 2016年9月.
528.	髙須千絵, 森根裕二, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 石川大地, 吉川雅登, 市井啓仁, 島田光生 : 転写因子制御による肝虚血再灌流障害の新たな治療法の開発., 第253回徳島医学会学術集会, 2016年7月.
529.	Yu Saitou, Toshiaki Yoshimoto, Atsushi Takata, Masato Yoshikawa, Hiroki Teraoku, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : Boot Camp in Tokushima University., 第71回日本消化器外科学会総会, Jul. 2016.
530.	Yu Saitou, Atsushi Takata, Hiroki Teraoku, Masato Yoshikawa, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : The analysis in non-tumor liver tissue to prevent the recurrence after curative treatment of hepatocellular carcinoma., 第71回日本消化器外科学会総会, Jul. 2016.
531.	Tetsuya Ikemoto, Mitsuo Shimada, Satoru Imura, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa and Hiroki Teraoku : A new strategy forachieving effective islet transplantation with adipose tissue derved stem cells., 第71回日本消化器外科学会総会, Jul. 2016.
532.	森根裕二, 島田光生, 石橋広樹, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 石川大地, 吉川雅登 : 全国集計からみた膵・胆管合流異常症の臨床摘特徴と術式選択の現状., 第71回日本消化器外科学会総会, 2016年7月.
533.	吉川雅登, 齋藤裕, 居村暁, 良元俊昭, 髙田厚史, 石川大地, 岩橋衆一, 池本哲也, 森根裕二, 島田光生 : ABO不適合生体肝移植後にCMV感染治療に難渋した一例., 第34回日本肝移植研究会, 2016年7月.
534.	岩橋衆一, 島田光生, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 石川大地, 吉川雅登, 髙田厚史, 良元俊昭 : NO阻害と転写活性制御からの虚血再灌流障害., 第34回日本肝移植研究会, 2016年7月.
535.	齋藤裕, 良元俊昭, 髙田厚史, 吉川雅登, 寺奥大貴, 山田眞一郎, 池本哲也, 森根裕二, 居村暁, 島田光生 : 脳死肝移植を推進するための学生に対するドナーアクションの必要性について., 第34回日本肝移植研究会, 2016年7月.
536.	齋藤裕, 安井苑子, 吉川雅登, 寺奥大貴, 山田眞一郎, 池本哲也, 森根裕二, 居村暁, 濵田康弘, 島田光生 : 肝硬変合併肝切除症例における栄養・免疫状態の特徴, 第52回日本肝癌研究会, 2016年7月.
537.	良元俊昭, 島田光生, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 山田眞一郎, 寺奥大貴, 吉川雅登, 髙田厚史 : 症例, 第52回日本肝癌研究会, 2016年7月.
538.	居村暁, 吉川雅登, 寺奥大貴, 石川大地, 山田眞一郎, 齋藤裕, 岩橋衆一, 池本哲也, 森根裕二, 島田光生 : Intermediate stageの肝癌に対する肝切除は有効か?, 第52回日本肝癌研究会, 2016年7月.
539.	森根裕二, 島田光生, 居村暁, 池本哲也, 岩橋衆一, 齋藤裕, 山田眞一郎, 寺奥大貴, 吉川雅登 : 肝内胆管癌における発生部位別悪性度., 第52回日本肝癌研究会, 2016年7月.
540.	良元俊昭, 吉川幸造, 松本規子, 髙田厚史, 齋藤裕, 吉川雅登, 池本哲也, 居村暁, 森根裕二, 石川大地, 岩橋衆一, 島田光生 : 青色LED光のヒト癌細胞株に対する効果., 第105回日本消化器病学会四国支部例会, 2016年6月.
541.	吉川雅登, 森根裕二, 池本哲也, 髙田厚史, 良元俊昭, 石川大地, 齋藤裕, 岩橋衆一, 居村暁, 島田光生 : 切除不能・再発進行膵癌に対する治療成績., 第105回日本消化器病学会四国支部例会, 2016年6月.
542.	髙田厚史, 島田光生, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 山田眞一郎, 荒川悠佑, 岩橋衆一, 石川大地, 吉川雅登, 寺奥大貴, 良元俊昭 : HCCに対して初回RFA治療早期にリンパ節再発をきたし外科的切除を施行した症例., 第41回日本外科系連合学会学術集会, 2016年6月.
543.	齋藤裕, 髙田厚史, 吉川雅登, 寺奥大貴, 山田眞一郎, 池本哲也, 森根裕二, 居村暁, 島田光生 : PDに対するModified de-rotationを用いた``Complate artery-firstn approach''., 第41回日本外科系連合学会学術集会, 2016年6月.
544.	良元俊昭, C Enkbold, 髙田厚史, 吉川雅登, 石川大地, 齋藤裕, 岩橋衆一, 池本哲也, 森根裕二, 居村暁, 島田光生 : 肝内胆管癌における細胞周期調節因子Fbxw7発現低下の臨床病理学的意義., 第14回日本肝がん分子標的治療研究会, 2016年6月.
545.	岩橋衆一, 島田光生, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 石川大地, 吉川雅登, 良元俊昭, 髙田厚史 : RFA後肝細胞癌再発例はEMT誘導を介し腫瘍悪性度が増強する., 第14回日本肝がん分子標的治療研究会, 2016年6月.
546.	山田眞一郎, 島田光生, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 吉川雅登, 寺奥大貴, 髙田厚史, 良元俊昭 : EOB-MRIを用いた機能的肝容積による新たな肝切除基準., 第28回日本肝胆膵外科学会・学術集会, 2016年6月.
547.	池本哲也, 島田光生, 石川大地, 森根裕二, 居村暁, 齋藤裕, 山田眞一郎, 寺奥大貴, 吉川雅登 : Tr1細胞とFoxp3調節性T細胞による膵嚢胞性疾患に関する正確な免疫学的指標探索に関する研究., 第28回日本肝胆膵外科学会・学術集会, 2016年6月.
548.	齋藤裕, 髙田厚史, 寺奥大貴, 吉川雅登, 山田眞一郎, 池本哲也, 森根裕二, 居村暁, 島田光生 : 胆道癌術後肝内再発に対する肝切除導入効果の検証., 第28回日本肝胆膵外科学会・学術集会, 2016年6月.
549.	吉川雅登, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 山田眞一郎, 寺奥大貴, 髙田厚史, 良元俊昭, 島田光生 : 当科における胆道再建における肝管空腸吻合法の工夫., 第28回日本肝胆膵外科学会・学術集会, 2016年6月.
550.	寺奥大貴, 森根裕二, 池本哲也, 齋藤裕, 山田眞一郎, 吉川雅登, 髙須千絵, 東島潤, 川下陽一郎, 髙田厚史, 良元俊昭, 居村暁, 島田光生 : 大腸癌肝転移肝切除症例におけるThrombospondin1(THBS)発現の意義とその分子メカニズムの検討., 第28回日本肝胆膵外科学会・学術集会, 2016年6月.
551.	森根裕二, 島田光生, 居村暁, 池本哲也, 齋藤裕, 山田眞一郎, 石川大地, 寺奥大貴, 吉川雅登, 東島潤 : 大腸癌多発肝転移に対する長期生存を目指した治療戦略., 第28回日本肝胆膵外科学会・学術集会, 2016年6月.
552.	居村暁, 山田眞一郎, 齋藤裕, 池本哲也, 森根裕二, 島田光生 : 門脈・肝静脈解剖に基づく合理的な系統的肝切除∼副右肝静脈灌流領域切除を伴う拡大前区域切除., 第28回日本肝胆膵外科学会・学術集会, 2016年6月.
553.	齋藤裕, 良元俊昭, 髙田厚史, 吉川雅登, 寺奥大貴, 山田眞一郎, 池本哲也, 森根裕二, 居村暁, 島田光生 : 徳島におけるABO不適合生体肝移植症例の成績., 第42回日本急性肝不全研究会, 2016年5月.
554.	寺奥大貴, 島田光生, 森根裕二, 居村暁, 池本哲也, 東島潤, 川下陽一郎, 齋藤裕, 髙須千絵, 山田眞一郎, 吉川雅登, 髙田厚史, 良元俊昭 : 転移性肝癌における腫瘍悪性度制御因子としてのHIF-1の役割., 第102回日本消化器病学会総会, 2016年4月.
555.	山田眞一郎, 島田光生, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 吉川雅登, 寺奥大貴, 良元俊昭, 髙田厚史, 髙須千絵 : EOB-MRIを用いた新たな肝切除基準の可能性, 第102回日本消化器病学会総会, 2016年4月.
556.	太田昇吾, 森根裕二, 島田光生, 居村暁, 池本哲也, 齋藤裕, 山田眞一郎, 寺奥大貴, 吉川幸造, 髙田厚史, 良元俊昭 : 胆道癌術後肝内再発に対する肝切除導入効果の検証, 第116回日本外科学会定期学術集会, 2016年4月.
557.	岩橋祥子, 島田光生, 森根裕二, 居村暁, 池本哲也, 東島潤, 川下陽一郎, 齋藤裕, 髙須千絵, 山田眞一郎, 吉川雅登, 寺奥大貴, 髙田厚史, 良元俊昭 : 急速な進展を来したラブドイド様退形成性癌の一例., 第116回日本外科学会定期学術集会, 2016年4月.
558.	関勇輔, 島田光生, 森根裕二, 居村暁, 池本哲也, 東島潤, 川下陽一郎, 齋藤裕, 髙須千絵, 山田眞一郎, 吉川雅登, 寺奥大貴, 髙田厚史, 良元俊昭 : RFA術後にリンパ節再発をきたし外科切除を施行した肝細胞癌の1例 -RFA術後再発におけるEMT誘導を介した悪性度獲得について-., 第116回日本外科学会定期学術集会, 2016年4月.
559.	川下陽一郎, 島田光生, 居村暁, 森根裕二, 池本哲也, 東島潤, 齋藤裕, 髙須千絵, 山田眞一郎, 寺奥大貴, 吉川雅登, 髙田厚史, 良元俊昭, 小川博久 : 転移性肝癌におけるFbxw7低発現は再発予測因子である., 第116回日本外科学会定期学術集会, 2016年4月.
560.	吉川雅登, 島田光生, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 山田眞一郎, 寺奥大貴, 髙田厚史, 良元俊昭 : 肝細胞癌術後再発予後不良因子としてのCEAの意義, 第116回日本外科学会定期学術集会, 2016年4月.
561.	寺奥大貴, 島田光生, 森根裕二, 居村暁, 池本哲也, 東島潤, 川下陽一郎, 齋藤裕, 髙須千絵, 山田眞一郎, 吉川雅登, 髙田厚史, 良元俊昭 : 転移性肝癌における腫瘍悪性度制御因子としてのThrombospondin-1(THBS-1)の役割- 第2報 THBS-1制御メカニズムについて -, 第116回日本外科学会定期学術集会, 2016年4月.
562.	山田眞一郎, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 吉川幸造, 寺奥大貴, 良元俊昭, 髙田厚史, 髙須千絵 : EOB-MRIを用いた新たな肝切除基準の可能性., 第116回日本外科学会定期学術集会, 2016年4月.
563.	齋藤裕, 良元俊昭, 髙田厚史, 吉川雅登, 寺奥大貴, 山田眞一郎, 池本哲也, 森根裕二, 居村暁, 島田光生 : HDAC阻害剤は脂肪由来幹細胞からインスリン分泌細胞への分化誘導を促進する., 第116回日本外科学会定期学術集会, 2016年4月.
564.	森根裕二, 島田光生, 居村暁, 池本哲也, 齋藤裕, 山田眞一郎, 石川大地, 寺奥大貴, 吉川雅登 : 肝内胆管癌に対する至適術式と集学的治療., 第116回日本外科学会定期学術集会, 2016年4月.
565.	山田眞一郎, 島田光生, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 吉川幸造, 寺奥大貴, 高田厚史, 良元俊昭 : 肝細胞癌症例におけるNEK2発現による腫瘍悪性度評価, 第49回制癌剤適応研究会, 2016年3月.
566.	池本哲也, 島田光生, 居村暁, 森根裕二, 齋藤裕, 山田眞一郎, 吉川雅登, 寺奥大貴, 良元俊昭 : 脂肪由来幹細胞による膵島移植・膵島再生に関する新たな戦略, 第43回日本膵・膵島移植研究会, 2016年3月.
567.	谷村真優, 安井苑子, 齋藤裕, 松原あつみ, 山田静恵, 谷佳子, 松村晃子, 島田光生, 濵田康弘 : 消化器癌患者における術前栄養評価におけるSGAとODAとの検討, 第31回日本静脈経腸栄養学会, 2016年2月.
568.	齋藤裕, 吉川雅登, 寺奥大貴, 山田眞一郎, 池本哲也, 森根裕二, 居村暁, 島田光生 : 36.3mm細径鉗子を用いたreduced port Lap-Cに関する検討, 第30回四国内視鏡外科研究会, 2016年2月.
569.	寺奥大貴, 島田光生, 石川大地, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 髙須千絵, 山田眞一郎, 吉川雅登, 高田厚史, 良元俊昭 : 消化器担癌状態のバイオマーカーとしての末梢血Tr1細胞とFoxp3調節性T細胞の有用性に関する検討, 第252回徳島医学会学術集会, 2016年2月.
570.	山田眞一郎, 島田光生, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 吉川雅登, 寺奥大貴, 高田厚史 : 肝細胞癌症例におけるNEK2発現による腫瘍悪性度評価, 第252回徳島医学会学術集会, 2016年2月.
571.	良元俊昭, 島田光生, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 吉川雅登, 寺奥大貴, 山田眞一郎, 高田厚史 : Sorafenib+poly surgeryによるHCC長期生存例∼orafenib投与長期生存条件の検討∼, 第13回日本肝がん分子標的治療研究会, 2016年1月.
572.	谷村真優, 安井苑子, 齋藤裕, 松原あつみ, 山田静恵, 谷佳子, 松村晃子, 島田光生, 濵田康弘 : 消化器癌患者におけるSGAを用いた術前栄養スクリーニングとODAの検討, 第19回日本病態栄養学会, 2016年1月.
573.	寺奥大貴, 朱呈瞻, 髙田厚史, 良元俊昭, 吉川雅登, 山田眞一郎, 齋藤裕, 池本哲也, 居村暁, 森根裕二, 島田光生 : 加齢肝再生における肝星細胞の役割, 第22回外科侵襲とサイトカイン研究会, 2015年12月.
574.	髙田厚史, 島田光生, 居村暁, 森根裕二, 池本哲也, 荒川悠佑, 岩橋衆一, 齋藤裕, 山田眞一郎, 吉川雅登, 寺奥大貴 : HCCに対して初回RFA治療後早期にリンパ節再発をきたし外科的切除を施行した症例, 第41回日本肝臓学会西部会, 2015年12月.
575.	吉川雅登, 山田眞一郎, 髙田厚史, 良元俊昭, 寺奥大貴, 齋藤裕, 池本哲也, 居村暁, 森根裕二, 島田光生 : 肝内胆管癌との鑑別が困難であった原発性放線菌症の一例, 第41回日本肝臓学会西部会, 2015年12月.
576.	吉川雅登, Wubetu Gizachew Yismaw, 髙田厚史, 良元俊昭, 寺奥大貴, 山田眞一郎, 齋藤裕, 池本哲也, 森根裕二, 居村暁, 島田光生 : 脂肪由来幹細胞からインスリン分泌細胞への分化誘導におけるバルプロ酸の分化促進, 第45回日本創傷治癒学会, 2015年11月.
577.	吉川雅登, 山田眞一郎, 髙田厚史, 良元俊昭, 寺奥大貴, 齋藤裕, 池本哲也, 森根裕二, 居村暁, 柴田啓志, 三宅秀則, 島田光生 : ソラフェニブ投与後長期生存例の検討∼切除を含む集学的治療の重要性∼, 第77回日本臨床外科学会総会, 2015年11月.
578.	寺奥大貴, 島田光生, 森根裕二, 居村暁, 池本哲也, 東島潤, 齋藤裕, 髙須千絵, 山田眞一郎, 吉川雅登, 髙田厚史, 良元俊昭 : 若手外科医教育のための膵頭十二指腸切除における3D simulationの有用性, 第77回日本臨床外科学会総会, 2015年11月.
579.	齋藤裕, 安井苑子, 吉川雅登, 寺奥大貴, 山田眞一郎, 池本哲也, 森根裕二, 居村暁, 濵田康弘, 島田光生 : 肝胆膵外科手術における免疫指標を加味した新たな周術期栄養評価, 第77回日本臨床外科学会総会, 2015年11月.
580.	森根裕二, 島田光生, 居村暁, 池本哲也, 齋藤裕, 山田眞一郎, 寺奥大貴, 吉川雅登, 髙須千絵, 東島潤 : 大腸癌多発肝転移に対する治療戦略, 第77回日本臨床外科学会総会, 2015年11月.
581.	居村暁, 髙田厚史, 良元俊昭, 寺奥大貴, 吉川雅登, 山田眞一郎, 髙須千絵, 齋藤裕, 池本哲也, 森根裕二, 島田光生 : 肝臓外科における画像シミュレーション, 第77回日本臨床外科学会総会, 2015年11月.
582.	居村暁, 髙田厚史, 良元俊昭, 寺奥大貴, 吉川雅登, 山田眞一郎, 髙須千絵, 齋藤裕, 池本哲也, 森根裕二, 島田光生 : 肝切除における高齢者の特徴と戦略, 第77回日本臨床外科学会総会, 2015年11月.
583.	山田眞一郎, 良元俊昭, 髙田厚史, 寺奥大貴, 吉川雅登, 齋藤裕, 池本哲也, 居村暁, 森根裕二, 島田光生 : 腹腔鏡下肝切除術の適応拡大と標準化への工夫安全な腹腔鏡下肝切除の標準化に向けて ∼適応拡大に先立つ着実な手技の定型化∼, 第9回肝臓内視鏡外科研究会, 2015年11月.
584.	吉川雅登, 山田眞一郎, 島田光生, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 寺奥大貴, 髙田厚史, 良元俊昭 : 分肝機能に着目したEOB-MRIによる肝予備能評価の有用性, 第24回日本コンピュータ外科学会大会, 2015年11月.
585.	寺奥大貴, 髙田厚史, 良元俊昭, 吉川雅登, 山田眞一郎, 齋藤裕, 池本哲也, 森根裕二, 居村暁, 島田光生 : 肝内胆管癌におけるFbxw7発現低下と臨床病理学的意義 - 細胞増殖・EMT誘導との関連に着目して -, 第26回日本消化器癌発生学会総会, 2015年11月.
586.	森根裕二, 島田光生, 宇都宮徹, 居村暁, 池本哲也, 齋藤裕, 山田眞一郎, 寺奥大貴, 吉川雅登 : 肝細胞癌におけるEpigenetic遺伝子制御の可能性, 第26回日本消化器癌発生学会総会, 2015年11月.
587.	寺奥大貴, 山田眞一郎, 良元俊昭, 高田厚史, 吉川雅登, 齋藤裕, 池本哲也, 森根裕二, 居村暁, 島田光生, 三宅秀則 : RFA術後にリンパ節再発をきたし外科切除を施行した肝細胞癌の1例 -RFA術後再発におけるEMT誘導を介した悪性度獲得について-, 日本消化器病学会四国支部第104回例会, 2015年11月.
588.	山田眞一郎, 島田光生, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 吉川雅登, 寺奥大貴 : 肝細胞癌症例におけるNEK2発現の意義に関する検討, 第53回日本癌治療学会学術集会, 2015年10月.
589.	髙田厚史, 島田光生, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 岩橋衆一, 齋藤裕, 山田眞一郎, 寺奥大貴, 吉川雅登 : 大腸癌肝転移症例における肝転移巣のKISS1発現に関する検討, 第53回日本癌治療学会学術集会, 2015年10月.
590.	寺奥大貴, 島田光生, 居村暁, 森根裕二, 池本哲也, 東島潤, 荒川悠佑, 岩橋衆一, 齋藤裕, 髙須千絵, 山田眞一郎, 石川大地, 吉川雅登 : 大腸癌肝転移肝切除症例におけるThrombospondin-1(THBS1)発現の意義, 第74回日本癌学会学術総会, 2015年10月.
591.	池本哲也, 島田光生, 石川大地, 寺奥大貴, 吉川雅登, 山田眞一郎, 齋藤裕, 髙須千絵, 居村暁, 森根裕二 : Tr1細胞と調節性T細胞の坦癌患者における臨床的意義に関する研究, 第74回日本癌学会学術総会, 2015年10月.
592.	池本哲也, 島田光生, 石川大地, 森根裕二, 居村暁, 齋藤裕, 髙須千絵, 山田眞一郎, 寺奥大貴, 吉川雅登, 良元俊昭 : Tr1細胞とFoxp3調節性T細胞による消化器担癌状態の正確な診断バイオマーカー探索に関する研究, JDDW 2015, 2015年10月.
593.	吉川雅登, 髙須千絵, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 山田眞一郎, 寺奥大貴, 市井啓仁, 島田光生 : NO阻害と転写活性制御に着目した虚血再灌流傷害治療に向けた基礎的検討, 第51回日本移植学会総会, 2015年10月.
594.	山田眞一郎, 池本哲也, 島田光生, 森根裕二, 居村暁, 齋藤裕, 髙須千絵, 吉川雅登, 寺奥大貴, 髙田厚史, 良元俊昭 : 脳死肝移植を推進するための学生に対するドナーアクションの必要性について, 第51回日本移植学会総会, 2015年10月.
595.	池本哲也, 島田光生, 居村暁, 森根裕二, 齋藤裕, 山田眞一郎, 寺奥大貴, 吉川雅登 : 脂肪由来幹細胞が拓く膵島細胞移植成績向上に関する展望と課題, 第51回日本移植学会総会, 2015年10月.
596.	森根裕二, 島田光生, 居村暁, 池本哲也, 荒川悠佑, 岩橋衆一, 齋藤裕, 山田眞一郎, 寺奥大貴, 吉川雅登 : 肝内胆管癌に対する至適術式と集学的治療戦略, 第51回日本肝癌研究会, 2015年7月.
597.	居村暁, 吉川雅登, 寺奥大貴, 山田眞一郎, 齋藤裕, 岩橋衆一, 荒川悠佑, 池本哲也, 森根裕二, 島田光生 : 脾機能亢進症を合併した肝癌に対する脾摘+肝切除の有用性, 第51回日本肝癌研究会, 2015年7月.
598.	吉川雅登, 島田光生, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 岩橋衆一, 齋藤裕, 髙須千絵, 山田眞一郎 : 肝細胞癌における腫瘍マーカー発現とEpithelial-mesenchymal transitionに関する検討, 第70回日本消化器外科学会総会, 2015年7月.
599.	寺奥大貴, 島田光生, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 岩橋衆一, 齋藤裕, 山田眞一郎, 吉川雅登 : 大腸癌肝転移における腫瘍内Ki67発現の意義, 第70回日本消化器外科学会総会, 2015年7月.
600.	山田眞一郎, 吉川雅登, 寺奥大貴, 居村暁, 齋藤裕, 岩橋衆一, 荒川悠佑, 池本哲也, 森根裕二, 島田光生 : 安全な腹腔鏡下切除の標準化に向けて∼適応拡大に先立つ着実な手技の定型化∼, 第70回日本消化器外科学会総会, 2015年7月.
601.	岩橋衆一, 島田光生, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 齋藤裕, 山田眞一郎, 吉川雅登, 寺奥大貴 : 肝予備能評価におけるEOB-MRI肝細胞相の有用性の検討, 第70回日本消化器外科学会総会, 2015年7月.
602.	池本哲也, 島田光生, 森根裕二, 居村暁, 吉川幸造, 荒川悠佑, 岩橋衆一, 矢田圭吾, 齋藤裕, 山田眞一郎 : 肝切除周術期におけるTU-100に関するトランスレーショナルリサーチ, 第70回日本消化器外科学会総会, 2015年7月.
603.	荒川悠佑, 島田光生, 吉川雅登, 寺奥大貴, 山田眞一郎, 齋藤裕, 岩橋衆一, 池本哲也, 森根裕二, 居村暁 : 小胞体ストレス応対に着目した加齢肝再生不全における肝星細胞の役割についての検討, 第70回日本消化器外科学会総会, 2015年7月.
604.	森根裕二, 島田光生, 居村暁, 池本哲也, 荒川悠佑, 岩橋衆一, 齋藤裕, 山田眞一郎, 寺奥大貴, 吉川雅登 : 肝内胆管癌に対する至適術式と集学的治療戦略, 第70回日本消化器外科学会総会, 2015年7月.
605.	齋藤裕 : 肝胆膵外科手術における周術期栄養評価の有用性に関する研究-体成分分析装置と主観的包括的アセスメントSGA-, 第52回日本外科代謝栄養学会学術集会, 2015年7月.
606.	齋藤裕, 安井苑子, 寺奥大貴, 吉川雅登, 山田眞一郎, 髙須千絵, 池本哲也, 森根裕二, 居村暁, 濵田康弘, 島田光生 : 肝胆膵外科手術における周術期栄養評価の有用性に関する研究-体成分分析装置と主観的包括的アセスメントSGA -, 日本外科代謝栄養学会第52回学術集会, 2015年7月.
607.	岩橋衆一, 島田光生, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 齋藤裕, 山田眞一郎, 寺奥大貴, 吉川雅登, Gizachew Yismaw : Epigallocatechin gallateはABCトランスポーターを介してstemnessを解除する, 第24 回日本癌病態治療研究会, 2015年6月.
608.	吉川雅登, 山田眞一郎, 島田光生, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 岩橋衆一, 齋藤裕, 石川大地, 寺奥大貴, 良元俊昭, 髙田厚史, 三宅秀則 : 肝細胞癌切除症例に対するRFA後肝細胞癌再発例はEMT誘導を介して予後不良となる, 第103回例会日本消化器病学会総会四国支部, 2015年6月.
609.	山田眞一郎, 齋藤裕, 岩橋衆一, 荒川悠佑, 池本哲也, 森根裕二, 居村暁, 柴田啓志, 三宅秀則, 島田光生 : ソラフェニブ投与後長期生存例の検証-切除を含む集学的治療の重要性-, 第103回例会日本消化器病学会総会四国支部, 2015年6月.
610.	齋藤裕, 安井苑子, 吉川雅登, 寺奥大貴, 山田眞一郎, 岩橋衆一, 荒川悠佑, 池本哲也, 森根裕二, 居村暁, 濵田康弘, 島田光生 : 肝胆膵外科手術におけるNST介入による周術期栄養評価, 第40回日本外科系連合学会学術集会, 2015年6月.
611.	良元俊昭, 島田光生, 居村暁, 森根裕二, 池本哲也, 荒川悠佑, 岩橋衆一, 齋藤裕, 寺奥大貴, 吉川雅登 : 若手外科医にも安全な3mm細径鉗子を用いたreduced port Lap-C, 第40回日本外科系連合学会学術集会, 2015年6月.
612.	齋藤裕, 安井苑子, 吉川雅登, 寺奥大貴, 山田眞一郎, 岩橋衆一, 荒川悠佑, 池本哲也, 森根裕二, 居村暁, 濵田康弘, 島田光生 : 肝胆膵外科手術における周術期栄養評価の有用性に関する研究‐体成分分析装置と主観的包括的アセスメント‐, 第27回日本肝胆膵外科学会, 2015年6月.
613.	吉川雅登, 島田光生, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 岩橋衆一, 齋藤裕, 山田眞一郎, 石川大地, 寺奥大貴 : 肝細胞癌における腫瘍マーカー発現とEMTに関する検討, 第27回日本肝胆膵外科学会, 2015年6月.
614.	寺奥大貴, 島田光生, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 東島潤, 岩橋衆一, 齋藤裕, 髙須千絵, 山田眞一郎, 石川大地, 吉川雅登 : 大腸癌肝転移肝切除症例におけるThrombospondin-1(THBS1)発現の意義, 第27回日本肝胆膵外科学会, 2015年6月.
615.	山田眞一郎, 吉川雅登, 寺奥大貴, 齋藤裕, 髙須千絵, 岩橋衆一, 荒川悠佑, 東島潤, 池本哲也, 居村暁, 森根裕二, 島田光生 : 脾機能亢進症を合併した肝癌に対する脾摘+肝切除の有用性, 第27回日本肝胆膵外科学会, 2015年6月.
616.	齋藤裕, エンヘボルトチンボルト, 吉川雅登, 寺奥大貴, 石川大地, 岩橋衆一, 荒川悠佑, 池本哲也, 森根裕二, 居村暁, 島田光生 : 肝内胆管癌におけるFbxw7発現低下と臨床病理的意義-細胞増殖・EMT誘導との関連-, 第27回日本肝胆膵外科学会, 2015年6月.
617.	岩橋衆一, 島田光生, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 齋藤裕, 山田眞一郎, 吉川雅登, 寺奥大貴 : 3mm細径鉗子を用いたreduced port Lap-C, 第27回日本肝胆膵外科学会, 2015年6月.
618.	荒川悠佑, 島田光生, 山田眞一郎, 齋藤裕, 岩橋衆一, 池本哲也, 森根裕二, 居村暁 : 下右肝静脈温存，上中右肝静脈ドレナージ領域を含む合理的拡大肝前区域切除術, 第27回日本肝胆膵外科学会, 2015年6月.
619.	池本哲也, 島田光生, 森根裕二, 居村暁, 荒川悠佑, 岩橋衆一, 齋藤裕, 山田眞一郎, 寺奥大貴, 吉川雅登, 良元俊昭 : Borderline resectable膵癌に対する治療成績の検討, 第27回日本肝胆膵外科学会, 2015年6月.
620.	池本哲也, 島田光生, 森根裕二, 居村暁, 齋藤裕, 山田眞一郎, 寺奥大貴, 吉川雅登, 良元俊昭 : 指導医の立場から見た若手外科医教育のための膵頭十二指腸切除における3Dsimulationの有用性, 第27回日本肝胆膵外科学会, 2015年6月.
621.	居村暁, 吉川雅登, 寺奥大貴, 山田眞一郎, 齋藤裕, 岩橋衆一, 荒川悠佑, 池本哲也, 森根裕二, 島田光生 : 肝予備能評価におけるEOB-MRI肝細胞相の有用性, 第27回日本肝胆膵外科学会, 2015年6月.
622.	山田眞一郎, 吉川雅登, 寺奥大貴, 齋藤裕, 髙須千絵, 岩橋衆一, 荒川悠佑, 池本哲也, 居村暁, 森根裕二, 島田光生 : 安全な腹腔鏡下肝切除の標準化に向けて-左葉系肝切除における着実な手技の定型化-, 第27回日本肝胆膵外科学会, 2015年6月.
623.	森根裕二, 島田光生, 居村暁, 池本哲也, 荒川悠佑, 岩橋衆一, 齋藤裕, 山田眞一郎, 寺奥大貴, 吉川雅登 : 肝内胆管癌に対する至適術式と集学的治療戦略, 第27回日本肝胆膵外科学会, 2015年6月.
624.	谷村真優, 松浦明香, 安井苑子, 齋藤裕, 山田静恵, 谷佳子, 松村晃子, 島田光生, 濵田康弘 : 消化器癌患者の術前栄養評価におけるSGAとODAとの相関, 第7回日本静脈経腸栄養学会四国支部会学術集会, 2015年6月.
625.	居村暁, 吉川雅登, 寺奥大貴, 山田眞一郎, 齋藤裕, 岩橋衆一, 荒川悠佑, 池本哲也, 森根裕二, 島田光生 : 吻合部狭窄のない胆管-胆管吻合手技の工夫-, 第33回日本肝移植研究会, 2015年5月.
626.	齋藤裕 : 大量肝切除モデルラットにおける茶Catechinの効果, 第30回日本shock学会総会, 2015年5月.
627.	山田眞一郎, 島田光生, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 齋藤裕, 岩橋衆一, 齋藤裕, 吉川雅登, 寺奥大貴 : 分肝機能に着目したEOB-MRIによる肝予備能評価の有用性, 第51回日本肝臓学会総会, 2015年5月.
628.	岩橋衆一, 島田光生, 谷口達哉, 森根裕二, 居村暁, 池本哲也, 齋藤裕, 山田眞一郎, 楠本彩子 : 当県肝疾患診療における円滑な地域連携推進のための活動について, 第51回日本肝臓学会総会, 2015年5月.
629.	居村暁, 吉川雅登, 寺奥大貴, 山田眞一郎, 齋藤裕, 岩橋衆一, 荒川悠佑, 池本哲也, 森根裕二, 島田光生 : 脾機能亢進症を合併した肝癌に対する非的+肝切除の有用性, 第51回日本肝臓学会総会, 2015年5月.
630.	齋藤裕, 山田眞一郎, 池本哲也, 森根裕二, 居村暁 : 肝不全におけるMEIN投与の有用性-基礎から臨床-, 第41回日本急性肝不全研究会, 2015年5月.
631.	山田眞一郎, 吉川雅登, 寺奥大貴, 齋藤裕, 岩橋衆一, 荒川悠佑, 池本哲也, 森根裕二, 居村暁, 島田光生 : 若手外科医教育のための膵頭十二指腸切除における3D simulationの有用性, 第69回手術手技研究会, 2015年5月.
632.	齋藤裕, 吉川雅登, 寺奥大貴, 山田眞一郎, 岩橋衆一, 荒川悠佑, 池本哲也, 森根裕二, 居村暁, 島田光生 : 術前3Dシミュレーションを使用した膵頭十二指腸切除におけるmodified de-rotation, 第69回手術手技研究会, 2015年5月.
633.	岩橋衆一, 島田光生, 寺奥大貴, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 齋藤裕, 山田眞一郎, 東島潤, 髙須千絵, 吉川雅登 : Epigallocatechin gallateの消化器癌における抗腫瘍効果の検討, 第101回日本消化器病学会総会, 2015年4月.
634.	髙須千絵, 森根裕二, 居村暁, 荒川悠佑, 岩橋衆一, 齋藤裕, 山田眞一郎, 石川大地, 島田光生 : 肝虚血再灌流障害の発生・進展機序の解明と統合的治療法開発の取り組み, 第115回日本外科学会定期学術集会, 2015年4月.
635.	矢田圭吾, 森大樹, 石橋広樹, 髙須千絵, 寺奥大貴, 吉川雅登, 齋藤裕, 岩橋衆一, 荒川悠佑, 池本哲也, 森根裕二, 居村暁, 島田光生 : 大建中湯(TU-100)は胆道閉鎖症ラットモデル由来の肝星細胞活性化を抑制する, 第115回日本外科学会定期学術集会, 2015年4月.
636.	太田昇吾, 齋藤裕, 吉川雅登, 寺奥大貴, 石川大地, 山田眞一郎, 岩橋衆一, 荒川悠佑, 池本哲也, 森根裕二, 居村暁, 島田光生 : ソラフェニブ投与後切除可能となり長期生存が得られたFGF4強発現進行肝細胞癌の症例, 第115回日本外科学会定期学術集会, 2015年4月.
637.	髙田厚史, 島田光生, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 岩橋衆一, 齋藤裕, 山田眞一郎, 吉川雅登, 寺奥大貴 : 大腸癌肝転移症例における肝転移巣のKiss1発現は独立予後規定因子となる, 第115回日本外科学会定期学術集会, 2015年4月.
638.	石川大地, 島田光生, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 岩橋衆一, 齋藤裕, 山田眞一郎, 寺奥大貴, 吉川雅登 : 大腸癌におけるmicroRNA-449a発現の意義, 第115回日本外科学会定期学術集会, 2015年4月.
639.	山田眞一郎, 島田光生, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 岩橋衆一, 齋藤裕, 石川大地, 寺奥大貴, 吉川雅登 : 肝内胆管癌における細胞周期調節因子Fbxw7の発現低下は独立予後規定因子である, 第115回日本外科学会定期学術集会, 2015年4月.
640.	吉川雅登, 寺奥大貴, 石川大地, 山田眞一郎, 齋藤裕, 髙須千絵, 岩橋衆一, 荒川悠佑, 東島潤, 池本哲也, 居村暁, 森根裕二, 島田光生 : 肝細胞癌における腫瘍マーカー発現は無再発予後因子となる, 第115回日本外科学会定期学術集会, 2015年4月.
641.	寺奥大貴, 島田光生, 居村暁, 森根裕二, 池本哲也, 荒川悠佑, 東島潤, 岩橋衆一, 齋藤裕, 髙須千絵, 山田眞一郎, 石川大地, 吉川雅登 : 大腸癌肝転移におけるThrombospondin-1(THBS1)発現の意義, 第115回日本外科学会定期学術集会, 2015年4月.
642.	荒川悠佑, 島田光生, 寺奥大貴, 吉川雅登, 石川大地, 山田眞一郎, 齋藤裕, 髙須千絵, 岩橋衆一, 池本哲也, 森根裕二, 居村暁, 東島潤 : 加齢肝再生不全における肝星細胞の役割についての検討, 第115回日本外科学会定期学術集会, 2015年4月.
643.	岩橋衆一, 島田光生, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 齋藤裕, 山田眞一郎, 寺奥大貴, 吉川雅登 : Epigallocatechin gallateはABCトランスポーター関連因子を介して抗腫瘍効果を発揮する, 第115回日本外科学会定期学術集会, 2015年4月.
644.	池本哲也, 島田光生, 森根裕二, 居村暁, 荒川悠佑, 東島潤, 岩橋衆一, 齋藤裕, 山田眞一郎, 石川大地 : 術前3DシミュレーションおよびVSSを使用した膵頭十二指腸切除における modified de-rotation method, 第115回日本外科学会定期学術集会, 2015年4月.
645.	森根裕二, 島田光生, 居村暁, 池本哲也, 荒川悠佑, 岩橋衆一, 齋藤裕, 山田眞一郎, 石川大地, 寺奥大貴, 髙須千絵, 東島潤, 三宅秀則 : 大腸癌多発肝転移に対する長期生存を目指した治療戦略, 第115回日本外科学会定期学術集会, 2015年4月.
646.	居村暁, 岩橋衆一, 荒川悠佑, 東島潤, 池本哲也, 森根裕二, 三宅秀則, 島田光生, 吉川雅登, 寺奥大貴, 石川大地, 山田眞一郎, 齋藤裕, 髙須千絵 : 手技定型化が可能にした門脈·肝静脈解剖に基づく合理的な系統的肝切除-副右肝静脈灌流領域切除を伴う拡大前区域切除術-, 第115回日本外科学会定期学術集会, 2015年4月.
647.	齋藤裕, 安井苑子, 吉川雅登, 寺奥大貴, 山田眞一郎, 岩橋衆一, 金本真美, 荒川悠佑, 池本哲也, 森根裕二, 居村暁, 濵田康弘, 島田光生 : 肝胆膵外科手術における周術期栄養評価の有用性に関する研究-体成分分析装置と主観的包括アセスメントSGA-, 第115日本外科学会定期学術集会, 2015年4月.
648.	吉川雅登, 良元俊昭, 寺奥大貴, 山田眞一郎, 齋藤裕, 岩橋衆一, 荒川悠佑, 池本哲也, 居村暁, 森根裕二, 島田光生 : 肝門部胆管癌に対する拡大肝右葉切除後，門脈血栓・大量腹水により管理に難渋した1例, 第23回徳島外科術後管理研究会, 2015年2月.
649.	吉川雅登, 島田光生, 寺奥大貴, 石川大地, 山田眞一郎, 齋藤裕, 髙須千絵, 岩橋衆一, 荒川悠佑, 東島潤, 池本哲也, 居村暁, 森根裕二 : 肝細胞癌における腫瘍マーカー発現は無再発予後因子となる, 第250回徳島医学会学術集会, 2015年2月.
650.	山田眞一郎, 齋藤裕, 岩橋衆一, 荒川悠佑, 池本哲也, 居村暁, 森根裕二, 島田光生 : ソラフェニブ投与後長期生存例の検証 ∼切除を含む集学的治療の重要性∼, 第11回日本肝がん分子標的治療研究会, 2015年1月.
651.	良元俊昭, 島田光生, 居村暁, 森根裕二, 池本哲也, 荒川悠佑, 岩橋衆一, 齋藤裕, 山田眞一郎, 石川大地, 吉川雅登, 寺奥大貴 : ソラフェニブ投与後切除可能となり長期生存が得られたFGF4強発現進行肝細胞癌の症例, 第102回日本消化器病学会四国支部例会, 2014年11月. (キーワード) 国内学会
652.	吉川雅登, 島田光生, 寺奥大貴, Wubetu Gizchew Yismaw, 石川大地, 山田眞一郎, 齋藤裕, 岩橋衆一, 荒川悠佑, 池本哲也, 森根裕二, 居村暁 : 肝細胞癌におけるSTAT4発現は腫瘍免疫を反映し予後因子となる, 第76回日本臨床外科学会総会, 2014年11月. (キーワード) 国内学会
653.	寺奥大貴, 島田光生, 居村暁, 森根裕二, 池本哲也, 荒川悠佑, 金本真美, 岩橋衆一, 齋藤裕, 石川大地, 吉川雅登 : 肝細胞癌におけるLine1メチル化レベルは肝切除後予後因子となる, 第76回日本臨床外科学会総会, 2014年11月. (キーワード) 国内学会
654.	齋藤裕, 島田光生, 居村暁, 森根裕二, 池本哲也, 荒川悠佑, 岩橋衆一, 山田眞一郎, 石川大地, 吉川雅登, 寺奥大貴 : 立体臓器モデルによる3D virtual hepatectomyと術中navigation systemを駆使した肝切除, 第76回日本臨床外科学会総会, 2014年11月. (キーワード) 国内学会
655.	池本哲也, 島田光生, 森根裕二, 居村暁, 荒川悠佑, 岩橋衆一, 齋藤裕, 山田眞一郎, 石川大地 : 膵頭十二指腸切除術に対する取り組みと在院期間短縮についての検討, 第76回日本臨床外科学会総会, 2014年11月. (キーワード) 国内学会
656.	森根裕二, 島田光生, 居村暁, 池本哲也, 荒川悠佑, 岩橋衆一, 齋藤裕, 山田眞一郎, 石川大地, 東島潤, 髙須千絵, 三宅秀則 : 切除不能大腸癌肝転移に対する治療戦略, 第76回日本臨床外科学会総会, 2014年11月. (キーワード) 国内学会
657.	居村暁, 吉川雅登, 寺奥大貴, 石川大地, 山田眞一郎, 齋藤裕, 岩橋衆一, 荒川悠佑, 池本哲也, 森根裕二, 島田光生 : 若手肝臓外科医を育成するための取り組み∼3Dプリンターによる術中ナビゲーションと評価シートによるフィードバック∼, 第76回日本臨床外科学会総会, 2014年11月. (キーワード) 国内学会
658.	山田眞一郎, 島田光生, 石川大地, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 岩橋衆一, 齋藤裕 : 肝細胞癌におけるSTAT4発現は細胞性免疫の制御に関与し予後因子となり得る, 第25回日本消化器癌発生学会総会, 2014年11月. (キーワード) 国内学会
659.	岩橋衆一, 島田光生, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 齋藤裕, 吉川雅登, 寺奥大貴 : Epigallocatechin gallateは安全性の高い新規抗腫瘍剤として有用である, 第25回日消化器癌発生学会総会, 2014年11月. (キーワード) 国内学会
660.	齋藤裕, 島田光生, 居村暁, 森根裕二, 池本哲也, 荒川悠佑, 岩橋衆一, 山田眞一郎, 石川大地, 吉川雅登, 寺奥大貴 : 立体臓器モデルによる3D-virtual hepatectomyと術中navigation systemを用いた肝切除, 第23回日本コンピュータ外科学会, 2014年11月. (キーワード) 国内学会
661.	荒川悠佑, 島田光生, 石川大地, 山田眞一郎, 齋藤裕, 髙須千絵, 岩橋衆一, 金本真美, 池本哲也, 森根裕二, 居村暁, 宇都宮徹, 三宅秀則 : 高齢者における肝再生不全の肝星細胞からのアプローチ, 第22回日本消化器関連学会週間(JDDW), 2014年10月. (キーワード) 国内学会
662.	居村暁, 石川大地, 山田眞一郎, 齋藤裕, 岩橋衆一, 髙須千絵, 荒川悠佑, 池本哲也, 森根裕二, 宇都宮徹, 島田光生 : 根治性からみた進行肝癌初回治療法の選択, 第22回日本消化器関連学会週間(JDDW), 2014年10月. (キーワード) 国内学会
663.	岩橋衆一, 島田光生, 居村暁, 森根裕二, 池本哲也, 荒川悠佑, 齋藤裕, 石川大地, 吉川雅登, 寺奥大貴, 髙須千絵 : 3mm細径鉗子を用いたReduced Port Lap-Cに関する検討, 第27回日本内視鏡外科学会総会, 2014年10月. (キーワード) 国内学会
664.	山田眞一郎, Gizachew Yismaw, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 岩橋衆一, 齋藤裕, 石川大地, 吉川雅登, 寺奥大貴, 島田光生 : 分枝鎖アミノ酸はオートファジーを介してインスリン存在下の癌細胞増殖を抑制する, 第73回日本癌学会学術総会, 2014年9月. (キーワード) 国内学会
665.	石川大地, 島田光生, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 岩橋衆一, 齋藤裕, 山田眞一郎, 寺奥大貴, Gizachew Yismaw : 肝細胞癌におけるSTAT4発現は細胞性免疫の制御に関与し予後因子となり得る, 第73回日本癌学会学術総会, 2014年9月. (キーワード) 国内学会
666.	岩橋衆一, 島田光生, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 齋藤裕, 髙須千絵, 石川大地, 吉川雅登, 寺奥大貴, Yismaw Gizachew : 安全な新規抗腫瘍剤としてのエピガロカテキンガレート, 第73回日本癌学会学術総会, 2014年9月. (キーワード) 国内学会
667.	池本哲也, 島田光生, 居村暁, 森根裕二, 荒川悠佑, 森大樹, 岩橋衆一, 齋藤裕, 山田眞一郎, 石川大地 : 紫令湯による膵島破壊抑制機序の解明に関する免疫学的検討, 第50回日本移植学会総会, 2014年9月. (キーワード) 国内学会
668.	齋藤裕, 寺奥大貴, 吉川雅登, 石川大地, 山田眞一郎, 岩橋衆一, 荒川悠佑, 池本哲也, 森根裕二, 居村暁, 島田光生 : 肝星細胞からみた加齢肝再生不全の検討, 第50回日本移植学会総会, 2014年9月. (キーワード) 国内学会
669.	岩橋衆一, 島田光生, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 齋藤裕, 山田眞一郎, 石川大地 : RFA後肝細胞癌再発例においてEMT誘導を介し腫瘍悪性度が増強する, 第89回中国四国外科学会総会(第19回中国四国内視鏡外科研究会), 2014年9月. (キーワード) 国内学会
670.	齋藤裕, 島田光生, 居村暁, 森根裕二, 池本哲也, 荒川悠佑, 岩橋衆一, 石川大地, 寺奥大貴, 吉川雅登 : 下右肝静脈温存，上右肝静脈とドレナージ領域を含む合理的拡大肝S8切除術, 第89回中国四国外科学会総会(第19回中国四国内視鏡外科研究会), 2014年9月. (キーワード) 国内学会
671.	齋藤裕, 島田光生, 宇都宮徹, 居村暁, 森根裕二, 池本哲也, 荒川悠佑, 金本真美, 岩橋衆一, 石川大地, 東島潤 : 肝内胆管癌におけるFBXW7発現低下と臨床病理学的意義, 第52回日本癌治療学会学術集会, 2014年8月. (キーワード) 国内学会
672.	荒川悠佑, 島田光生, 宇都宮徹, 居村暁, 森根裕二, 池本哲也, 金本真美, 岩橋衆一, 齋藤裕, 髙須千絵, 東島潤 : 肝内胆管癌に対するGFP術後補助療法の有用性, 第52回日本癌治療学会学術集会, 2014年8月. (キーワード) 国内学会
673.	居村暁, 齋藤裕, 髙須千絵, 岩橋衆一, 荒川悠佑, 東島潤, 池本哲也, 森根裕二, 宇都宮徹, 島田光生 : ソラフェニブ投与後長期生存例の検証:切除を含む集学的治療の重要性, 第52回日本癌治療学会学術集会, 2014年8月. (キーワード) 国内学会
674.	吉川雅登, 島田光生, 宇都宮徹, 居村暁, 森根裕二, 池本哲也, 荒川悠佑, 金本真美, 岩橋衆一, 齋藤裕, 東島潤 : 肝細胞癌におけるサルコペニアと臨床病理学的意義, 第52回日本癌治療学会学術集会, 2014年8月. (キーワード) 国内学会
675.	石川大地, 島田光生, 宇都宮徹, 居村暁, 森根裕二, 池本哲也, 荒川悠佑, 金本真美, 齋藤裕, 山田眞一郎 : MicroRNA-449a発現低下は大腸癌の腫瘍進展に関与し予後不良因子となる, 第52回日本癌治療学会学術集会, 2014年8月. (キーワード) 国内学会
676.	岩橋衆一, 島田光生, 宇都宮徹, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 金本真美, 齋藤裕, 石川大地 : RFA後肝細胞癌再発例においてはEMT誘導を介し腫瘍悪性度が増強する, 第52回日本癌治療学会学術集会, 2014年8月. (キーワード) 国内学会
677.	森根裕二, 島田光生, 宇都宮徹, 居村暁, 池本哲也, 荒川悠佑, 金本真美, 岩橋衆一, 齋藤裕, 石川大地, 東島潤, 髙須千絵 : 切除不能大腸癌肝転移に対する肝切除を基軸とした治療戦略, 第52回日本癌治療学会学術集会, 2014年8月. (キーワード) 国内学会
678.	寺奥大貴, 島田光生, 宇都宮徹, 居村暁, 森根裕二, 池本哲也, 荒川悠佑, 金本真美, 岩橋衆一, 齋藤裕 : 肝細胞癌における顕微鏡的門脈浸潤(vp)予測因子の検討, 第69回日本消化器外科学会, 2014年7月. (キーワード) 国内学会
679.	山田眞一郎, 島田光生, 宇都宮徹, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 金本真美, 岩橋衆一, 齋藤裕 : RFA後肝細胞癌再発例においてEMT誘導を介し腫瘍悪性度が増強する-microRNA発現に着目して-, 第69回日本消化器外科学会, 2014年7月. (キーワード) 国内学会
680.	石川大地, 島田光生, 宇都宮徹, 森根裕二, 居村暁, 荒川悠佑, 金本真美, 岩橋衆一, 齋藤裕, 山田眞一郎 : 肝細胞癌におけるSTAT4発現は腫瘍免疫を反映し予後因子となる, 第69回日本消化器外科学会, 2014年7月. (キーワード) 国内学会
681.	金本真美, 島田光生, 宇都宮徹, 居村暁, 森根裕二, 池本哲也, 荒川悠佑, 岩橋衆一, 髙須千絵, 齋藤裕 : 肝胆膵外科手術における周術期栄養評価方法としてのInBodyを用いた体組成分析の有用性に関する検討, 第69回日本消化器外科学会, 2014年7月. (キーワード) 国内学会
682.	齋藤裕, 島田光生, 宇都宮徹, 居村暁, 森根裕二, 池本哲也, 荒川悠佑, 金本真美, 岩橋衆一, 髙須千絵 : 肝細胞癌におけるLine1 methylation statusは予後因子となる, 第69回日本消化器外科学会, 2014年7月. (キーワード) 国内学会
683.	岩橋衆一, 島田光生, 宇都宮徹, 居村暁, 森根裕二, 池本哲也, 荒川悠佑, 金本真美, 齋藤裕, 石川大地 : 安全性の高い新規抗腫瘍剤としてのEpigallocatechin gallate-癌幹細胞治療抵抗性解除をめざして-, 第69回日本消化器外科学会, 2014年7月. (キーワード) 国内学会
684.	荒川悠佑, 島田光生, 石川大地, 齋藤裕, 髙須千絵, 岩橋衆一, 池本哲也, 森根裕二, 居村暁, 三宅秀則 : 80歳以上超高齢者における肝切除の妥当性に関する検討-肝星細胞に着目した加齢再生不全機序の解明-, 第69回日本消化器外科学会, 2014年7月. (キーワード) 国内学会
685.	池本哲也, 島田光生, 宇都宮徹, 森根裕二, 居村暁, 荒川悠佑, 岩橋衆一, 齋藤裕, 石川大地 : 3D virtual imageと術中navigation systemがもたらした革新的画像技術を用いた安全な肝切除, 第69回日本消化器外科学会, 2014年7月. (キーワード) 国内学会
686.	森根裕二, 島田光生, 宇都宮徹, 池本哲也, 荒川悠佑, 金本真美, 岩橋衆一, 齋藤裕, 髙須千絵, 三宅秀則 : 切除不能転移性肝癌に対する"Early Conversion"を目指したFOLFOXILI療法の可能性, 第69回日本消化器外科学会, 2014年7月. (キーワード) 国内学会
687.	居村暁, 石川大地, 齋藤裕, 岩橋衆一, 金本真美, 荒川悠佑, 池本哲也, 森根裕二, 宇都宮徹, 島田光生 : 肝切除を基軸とした進行肝癌にたいする集学的治療戦略, 第69回日本消化器外科学会, 2014年7月. (キーワード) 国内学会
688.	吉川雅登, 島田光生, 石川大地, 山田眞一郎, 齋藤裕, 岩橋衆一, 荒川悠佑, 池本哲也, 森根裕二, 居村暁 : 予後不良因子を有する進行胆嚢癌における術後補助GFP療法の効果, 第39回日本外科系連合学会学術集会, 2014年7月. (キーワード) 校内学会
689.	岩橋衆一, 島田光生, 居村暁, 森根裕二, 池本哲也, 荒川悠佑, 齋藤裕, 山田眞一郎, 石川大地 : RFA後肝細胞癌再発例はEMT誘導を介して腫瘍悪性度が増強する-RFA後肝細胞癌における肝移植適応に関して-, 第32回日本肝移植研究会, 2014年7月. (キーワード) 国内学会
690.	荒川悠佑, 島田光生, 石川大地, 齋藤裕, 岩橋衆一, 池本哲也, 森根裕二, 居村暁 : 肝星細胞からみた加齢肝再生不全の検討, 第32回日本肝移植研究会, 2014年7月. (キーワード) 国内学会
691.	髙須千絵, 居村暁, 齋藤裕, 岩橋衆一, 荒川悠佑, 池本哲也, 森根裕二, 宇都宮徹, 島田光生 : ソラフェニブ投与後長期生存例の検証, 第10回日本肝がん分子標的治療研究会, 2014年6月. (キーワード) 国内学会
692.	齋藤裕, 島田光生, 宇都宮徹, 居村暁, 森根裕二, 池本哲也, 荒川悠佑, 金本真美, 岩橋衆一, 石川大地 : 3D virtual hepatectomyと術中navigation systemを用いた肝切除, 第39回日本外科系連合学会学術集会, 2014年6月. (キーワード) 国内学会
693.	石川大地, 島田光生, 山田眞一郎, 齋藤裕, 金本真美, 荒川悠佑, 池本哲也, 森根裕二, 居村暁 : 肝細胞癌におけるSTAT4発現は細胞性免疫の制御に関与し予後因子となり得る, 第39回日本外科系連合学会学術集会, 2014年6月. (キーワード) 国内学会
694.	山田眞一郎, 島田光生, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 金本真美, 岩橋衆一, 齋藤裕, 石川大地 : 脂肪由来幹細胞(ADSCs)の膵島細胞保護作用にはIL-6ではなくVEGFシグナルが関与する, 第39回日本外科系連合学会学術集会, 2014年6月. (キーワード) 国内学会
695.	岩橋衆一, 島田光生, 宇都宮徹, 居村暁, 森根裕二, 池本哲也, 荒川悠佑, 金本真美, 齋藤裕, 石川大地 : RFA後肝細胞癌再発例におけるEMT関連遺伝子発現の意義, 第39回日本外科系連合学会学術集会, 2014年6月. (キーワード) 国内学会
696.	池本哲也, 島田光生, 宇都宮徹, 居村暁, 森根裕二, 荒川悠佑, 齋藤裕, 岩橋衆一, 山田眞一郎, 石川大地 : Celiac axis compression syndromeにより術後管理に難渋して膵頭十二指腸切除術, 第39回日本外科系連合学会学術集会, 2014年6月. (キーワード) 国内学会
697.	岩橋衆一, 島田光生, 宇都宮徹, 居村暁, 森根裕二, 池本哲也, 荒川悠佑, 金本真美, 齋藤裕, 石川大地 : 肝細胞癌切除症例におけるRFAの影響-EMTマーカー発現に着目して-, 第26回日本肝胆膵外科学会学術集会, 2014年6月. (キーワード) 国内学会
698.	金本真美, 島田光生, 宇都宮徹, 居村暁, 森根裕二, 池本哲也, 荒川悠佑, 森大樹, 岩橋衆一, 髙須千絵, 齋藤裕 : InBodyを用いた体組成分析の肝胆膵外科手術における周術期栄養評価の有用性に関する検討, 第26回日本肝胆膵外科学会学術集会, 2014年6月. (キーワード) 国内学会
699.	荒川悠佑, 島田光生, 石川大地, 齋藤裕, 髙須千絵, 岩橋衆一, 金本真美, 池本哲也, 森根裕二, 居村暁, 宇都宮徹 : pT2胆嚢癌術後における予後不良因子陽性例に対する術後GFP療法の有用性, 第26回日本肝胆膵外科学会学術集会, 2014年6月. (キーワード) 国内学会
700.	森根裕二, 島田光生, 宇都宮徹, 居村暁, 池本哲也, 荒川悠佑, 金本真美, 岩橋衆一, 齋藤裕, 山田眞一郎, 石川大地 : 切除不能転移性肝癌に対する"Early Conversion"を目指したFOLFOKILI療法の可能性, 第26回日本肝胆膵外科学会学術集会, 2014年6月. (キーワード) 国内学会
701.	居村暁, 石川大地, 齋藤裕, 髙須千絵, 岩橋衆一, 金本真美, 荒川悠佑, 池本哲也, 森根裕二, 宇都宮徹, 島田光生 : 3D virtual image とNavigation systemがもたらした革新的画像技術を駆使した肝切除, 第26回日本肝胆膵外科学会学術集会, 2014年6月. (キーワード) 国内学会
702.	宇都宮徹, 島田光生, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 金本真美, 岩橋衆一, 齋藤裕, 山田眞一郎, 石川大地 : 肝内胆管癌に対する系統系リンパ節郭清の意義と術後補助療法の効果, 第26回日本肝胆膵外科学会学術集会, 2014年6月. (キーワード) 国内学会
703.	齋藤裕, 島田光生, 宇都宮徹, 居村暁, 森根裕二, 池本哲也, 荒川悠佑, 金本真美, 岩橋衆一, 山田眞一郎, 石川大地 : 80歳以上超高齢者における肝切除の妥当性に関する検討-術前栄養評価から見た高齢者の特徴-, 第26回日本肝胆膵外科学科学術集会, 2014年6月. (キーワード) 国内学会
704.	齋藤裕, 島田光生, 宇都宮徹, 居村暁, 森根裕二, 荒川悠佑, 金本真美, 岩橋衆一, 石川大地 : RFA後肝細胞癌再発例においてEMT誘導wp介し腫瘍悪性度が増強する-microRNA発現に着目して-, 第50回日本肝癌研究会, 2014年6月. (キーワード) 国内学会
705.	森根裕二, 島田光生, 宇都宮徹, 居村暁, 池本哲也, 荒川悠佑, 金本真美, 岩橋衆一, 齋藤裕, 山田眞一郎, 石川大地 : 切除不能転移性肝癌に対する"Early Conversion"を目指したFOLFOXILI療法の可能性, 第50回日本肝癌研究会, 2014年6月. (キーワード) 国内学会
706.	居村暁, 齋藤裕, 岩橋衆一, 荒川悠佑, 池本哲也, 森根裕二, 宇都宮徹, 島田光生 : ソラフェニブ投与後長期生存例の検証:切除を含む集学的治療の重要性, 第50回日本肝癌研究会, 2014年6月. (キーワード) 国内学会
707.	岩橋衆一, 島田光生, 宇都宮徹, 居村暁, 森根裕二, 池本哲也, 荒川悠佑, 金本真美, 齋藤裕, 石川大地 : 徳島県におけるより円滑な地域連携・病診連携推進のための活動について, 第50回日本肝臓学会総会, 2014年5月. (キーワード) 国内学会
708.	荒川悠佑, 島田光生, 石川大地, 山田眞一郎, 齋藤裕, 髙須千絵, 岩橋衆一, 金本真美, 森大樹, 池本哲也, 森根裕二, 宇都宮徹, 三宅秀則 : 肝星細胞による加齢肝再生不全機序の検討, 第50回日本肝臓学会総会, 2014年5月. (キーワード) 国内学会
709.	石川大地, 島田光生, 宇都宮徹, 森根裕二, 居村暁, 池本哲也, 居村暁, 池本哲也, 荒川悠佑, 森大樹, 金本真美, 岩橋衆一, 齋藤裕, 山田眞一郎 : 肝細胞癌におけるSTAT4発現は細胞性免疫の制御に関与し予後因子となり得る, 第50回日本肝臓学会総会, 2014年5月. (キーワード) 国内学会
710.	居村暁, 石川大地, 山田眞一郎, 齋藤裕, 岩橋衆一, 金本真美, 荒川悠佑, 池本哲也, 森根裕二, 宇都宮徹, 島田光生 : 局所再発させない適確な症例選択がRFA成績向上につながる∼組織学的門脈浸潤(vp)陽性肝癌を予測し，RFA適応外へ∼, 第50回日本肝臓学会総会, 2014年5月. (キーワード) 国内学会
711.	齋藤裕, 寺奥大貴, 吉川雅登, 石川大地, 山田眞一郎, 岩橋衆一, 荒川悠佑, 池本哲也, 森根裕二, 居村暁, 島田光生 : 高齢者の肝再生不全の機序解明と治療への応用, 第40回日本急性肝不全研究会, 2014年5月. (キーワード) 国内学会
712.	齋藤裕, 島田光生, 宇都宮徹, 居村暁, 森根裕二, 池本哲也, 荒川悠佑, 金本真美, 岩橋衆一, 髙須千絵, 石川大地 : HCCRFA治療後にリンパ節転移再発を繰り返す症例, 第100回日本消化器病学会総会, 2014年4月. (キーワード) 国内学会
713.	吉川雅登, 島田光生, 石川大地, 齋藤裕, 岩橋衆一, 金本真美, 森大樹, 荒川悠佑, 池本哲也, 森根裕二, 居村暁, 宇都宮徹, 三宅秀則 : 若手外科医のための膵頭十二指腸切除における術前3Dsimulationの有用性, 第114回日本外科学会定期学術集会, 2014年4月. (キーワード) 国内学会
714.	寺奥大貴, 島田光生, 宇都宮徹, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 森大樹, 金本真美, 岩橋衆一, 齋藤裕, 山田眞一郎, 石川大地 : 進行胆嚢癌の予後因子と術後補助GFP療法の効果, 第114回日本外科学会定期学術集会, 2014年4月. (キーワード) 国内学会
715.	荒川悠佑, 島田光生, 石川大地, 山田眞一郎, 齋藤裕, 髙須千絵, 岩橋衆一, 金本真美, 池本哲也, 森根裕二, 居村暁, 宇都宮徹, 三宅秀則 : 肝星細胞からみた加齢肝再生不全の検討, 第114回日本外科学会定期学術集会, 2014年4月. (キーワード) 国内学会
716.	山田眞一郎, 島田光生, 宇都宮徹, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 金本真美, 岩橋衆一, 齋藤裕, 石川大地 : 肝細胞癌切除症例に対するRFAの影響(第2報)-RFA後肝細胞癌再発例はEMT誘導を介して予後不良となる-, 第114回日本外科学会定期学術集会, 2014年4月. (キーワード) 国内学会
717.	齋藤裕, 島田光生, 宇都宮徹, 石川大地, 山田眞一郎, 髙須千絵, 岩橋衆一, 金本真美, 荒川悠佑, 森大樹, 池本哲也, 森根裕二, 居村暁, 三宅秀則 : 脂肪由来幹細胞の細胞保護効果には臓器特異性がある, 第114回日本外科学会定期学術集会, 2014年4月. (キーワード) 国内学会
718.	岩橋衆一, 島田光生, 宇都宮徹, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 金本真美, 齋藤裕, 石川大地 : 癌肝細胞治療抵抗性にEpigenetic修飾が関与する(第2報)-Methylation statusと遺伝子発現の変化に着目して-, 第114回日本外科学会定期学術集会, 2014年4月. (キーワード) 国内学会
719.	石川大地, 島田光生, 髙須千絵, 齋藤裕, 岩橋衆一, 金本真美, 荒川悠佑, 池本哲也, 森根裕二, 居村暁, 宇都宮徹 : 肝細胞癌におけるSTAT4発現は細胞性免疫の制御に関与し予後因子となり得る, 第114回日本外科学会定期学術集会, 2014年4月. (キーワード) 国内学会
720.	森根裕二, 島田光生, 宇都宮徹, 居村暁, 池本哲也, 荒川悠佑, 金本真美, 岩橋衆一, 齋藤裕, 石川大地 : 大腸癌肝転移のconversion surgeryを目指した治療戦略, 第114回日本外科学会定期学術集会, 2014年4月. (キーワード) 国内学会
721.	Toru Utsunomiya, Mitsuo Shimada, 石川大地, Yu Saitou, Shuichi Iwahashi, Mami Kanamoto, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Chie Takasu : Role of epigenetic modulation in both tumor and non-tumor liver tissues on risk of recurrence after hepatectomy for hepatocellular carcinoma: A possible implication for personalized medicine, 第114回日本外科学会定期学術集会, Apr. 2014.
722.	岩橋衆一, 島田光生, 宇都宮徹, 居村暁, 森根裕二, 池本哲也, 荒川悠佑, 金本真美, 齋藤裕, 石川大地 : 癌幹細胞治療抵抗性におけるEpigenetic修飾の関与-Methylation statusの変化に着目して-, 第47回制癌剤適応研究会, 2014年3月. (キーワード) 国内学会
723.	池本哲也, 島田光生, 宇都宮徹, 居村暁, 森根裕二, 森大樹, 荒川悠佑, 金本真美, 岩橋衆一, 齋藤裕, 山田眞一郎, 石川大地 : 紫令湯による糖尿病発症マウスの膵島破壊抑制機序の免疫学的検討, 第41回日本膵・膵島移植研究会, 2014年3月. (キーワード) 国内学会
724.	岩橋衆一, 島田光生, 宇都宮徹, 居村暁, 森根裕二, 池本哲也, 荒川悠佑, 金本真美, 齋藤裕, 石川大地 : 癌肝細胞治療抵抗性におけるEpigenetic修飾の関与―Methylation statusの変化に着目して―, 第47回制癌剤適応研究会, 2014年3月.
725.	池本哲也, 島田光生, 宇都宮徹, 居村暁, 森根裕二, 森大樹, 荒川悠佑, 金本真美, 岩橋衆一, 齋藤裕, 山田眞一郎, 石川大地 : 紫令湯による糖尿病発症マウスの膵島破壊抑制機序の免疫学的検討, 第41回日本膵・膵島移植研究会, 2014年3月.
726.	宮崎克己, 島田光生, 池本哲也, 宇都宮徹, 居村暁, 森根裕二, 森大樹, 荒川悠佑, 金本真美, 岩橋衆一, 齋藤裕, 石川大地, 三宅秀則 : 経皮的ラジオ波焼灼療法による遅発生横隔膜ヘルニア篏頓(横行結腸)の1例, 第50回日本腹部救急医学会, 2014年3月. (キーワード) 国内学会
727.	池本哲也, 島田光生, 宇都宮徹, 居村暁, 森根裕二, 森大樹, 荒川悠佑, 金本真美, 岩橋衆一, 齋藤裕, 石川大地 : 膵切除後腹腔内出血に対するIVRに関する検討, 第50回日本腹部救急医学会, 2014年3月. (キーワード) 国内学会
728.	宮崎克己, 島田光生, 池本哲也, 宇都宮徹, 居村暁, 森根裕二, 森大樹, 荒川悠佑, 金本真美, 岩橋衆一, 齋藤裕, 石川大地, 三宅秀則 : 経皮的ラジオ波焼灼療法による遅発生横隔膜ヘルニア篏頓(横行結腸)の1例, 第50回日本腹部救急医学会, 2014年3月.
729.	池本哲也, 島田光生, 宇都宮徹, 居村暁, 森根裕二, 森大樹, 荒川悠佑, 金本真美, 岩橋衆一, 齋藤裕, 石川大地 : 膵切除後腹腔内出血に対するIVRに関する検討, 第50回日本腹部救急医学会, 2014年3月.
730.	荒川悠佑, 島田光生, 石川大地, 山田眞一郎, 齋藤裕, 髙須千絵, 岩橋衆一, 金本真美, 森大樹, 池本哲也, 森根裕二, 居村暁, 宇都宮徹, 三宅秀則 : 高齢者に対する肝切除後の肝再生不全の機序解明とその対策:ベッドサイからベンチへのアプローチ, 第248回徳島医学会学術集会(平成25年度冬期), 2014年2月. (キーワード) 国内学会
731.	石川大地, 島田光生, 山田眞一郎, 齋藤裕, 岩橋衆一, 金本真美, 荒川悠佑, 池本哲也, 森根裕二, 居村暁, 宇都宮徹 : 肝細胞癌におけるSTAT4発現は細胞性免疫の制御に関与し予後因子となり得る, 第248回徳島医学会学術集会(平成25年度冬期), 2014年2月. (キーワード) 国内学会
732.	荒川悠佑, 島田光生, 石川大地, 山田眞一郎, 齋藤裕, 髙須千絵, 岩橋衆一, 金本真美, 森大樹, 池本哲也, 森根裕二, 居村暁, 宇都宮徹, 三宅秀則 : 高齢者に対する肝切除後の肝再生不全の機序解明とその対策:ベッドサイドからベンチへのアプローチ, 第248回徳島医学会学術集会, 2014年2月.
733.	荒川悠佑, 島田光生, 石川大地, 山田眞一郎, 齋藤裕, 岩橋衆一, 金本真美, 池本哲也, 森根裕二, 居村暁, 宇都宮徹 : 進行肝細胞癌に対するソラフェニブと外科治療を組み合わせた治療成績, 第9回日本肝がん分子標的治療研究会, 2014年1月. (キーワード) 国内学会
734.	荒川悠佑, 島田光生, 石川大地, 山田眞一郎, 齋藤裕, 岩橋衆一, 金本真美, 池本哲也, 森根裕二, 居村暁, 宇都宮徹 : 進行肝細胞癌に対するソラフェニブと外科治療を組み合わせた治療成績, 第9回日本肝がん分子標的治療研究会, 2014年1月.
735.	齋藤裕, 島田光生, 宇都宮徹, 石川大地, 山田眞一郎, 岩橋衆一, 金本真美, 荒川悠佑, 池本哲也, 森根裕二, 居村暁, 髙須千絵, 三宅秀則 : 脂肪由来幹細胞の細胞保護効果には臓器特異性がある, 第20回外科侵襲とサイトカイン研究会, 2013年12月.
736.	金本真美, 島田光生, 宇都宮徹, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 森大樹, 岩橋衆一, 齋藤裕, 石川大地 : Vessel sealing systemを用いた肝嚢胞に対する単孔式腹腔鏡下嚢胞開窓術の有用性, 第26回日本内視鏡外科学会総会, 2013年11月.
737.	居村暁, 島田光生, 宇都宮徹, 森根裕二, 池本哲也, 荒川悠佑, 金本真美, 岩橋衆一, 齋藤裕, 山田眞一郎, 石川大地, 三宅秀則 : 肝細胞癌における短期・長期予後から見た鏡視下手術の妥当性, 第26回日本内視鏡外科学会総会, 2013年11月.
738.	齋藤裕, 島田光生, 宇都宮徹, 居村暁, 森根裕二, 池本哲也, 荒川悠佑, 金本真美, 岩橋衆一, 石川大地, 髙須千絵 : 3D virtual hepatectomyと術中navigation systemを用いた肝切除, 第26回日本内視鏡外科学会総会, 2013年11月.
739.	池本哲也, 島田光生, 宇都宮徹, 森根裕二, 居村暁, 吉川幸造, 森大樹, 荒川悠佑, 金本真美, 岩橋衆一, 齋藤裕, 石川大地 : 肝胆膵外科領域における漢方製剤使用が周術期管理に与える影響に関する検討, 第23回外科漢方研究会学術集会, 2013年11月.
740.	森根裕二, 島田光生, 宇都宮徹, 居村暁, 池本哲也, 吉川幸造, 荒川悠佑, 金本真美, 岩橋衆一, 齋藤裕, 石川大地 : 肝癌切除術施行後における臨床的な役割, 第23回外科漢方研究会学術集会, 2013年11月.
741.	石川大地, 島田光生, 山田眞一郎, 齋藤裕, 岩橋衆一, 金本真美, 荒川悠佑, 池本哲也, 森根裕二, 居村暁, 宇都宮徹 : IPMNにおける梢血調節性T細胞比率による術前悪性度予測と上皮間葉転換, 第75回日本臨床外科学会総会, 2013年11月.
742.	金本真美, 島田光生, 宇都宮徹, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 森大樹, 岩橋衆一, 齋藤裕, 山田眞一郎, 石川大地, 髙須千絵, 三宅秀則 : 予後不良因子を有する進行胆嚢癌における術後補助GFP療法の効果, 第75回日本臨床外科学会総会, 2013年11月.
743.	池本哲也, 島田光生, 宇都宮徹, 居村暁, 森根裕二, 森大樹, 荒川悠佑, 金本真美, 岩橋衆一, 齋藤裕, 石川大地, 三宅秀則 : Borderline resectable膵癌に対する治療成績の検討, 第75回日本臨床外科学会総会, 2013年11月.
744.	居村暁, 島田光生, 宇都宮徹, 森根裕二, 池本哲也, 荒川悠佑, 金本真美, 岩橋衆一, 齋藤裕, 山田眞一郎, 石川大地, 三宅秀則 : 肝癌切除例からみた日本に適したステージ分類∼取り扱い規約とUICCの比較から∼, 第75回日本臨床外科学会総会, 2013年11月.
745.	荒川悠佑, 島田光生, 宇都宮徹, 居村暁, 森根裕二, 池本哲也, 金本真美, 岩橋衆一, 齋藤裕, 髙須千絵, 佐藤宏彦, 三宅秀則 : 胆道癌切除例における術後補助GFP療法及び，再発症例に対する再肝切除の有用性, 第75回日本臨床外科学会総会, 2013年11月.
746.	森根裕二, 島田光生, 宇都宮徹, 居村暁, 池本哲也, 荒川悠佑, 金本真美, 岩橋衆一, 齋藤裕, 石川大地, 三宅秀則 : 大腸癌肝転移のconversion surgeryを目指した治療戦略, 第75回日本臨床外科学会総会, 2013年11月.
747.	宇都宮徹, 島田光生, 石川大地, 齋藤裕, 岩橋衆一, 金本真美, 荒川悠佑, 池本哲也, 森根裕二, 居村暁 : 高度進行肝癌に対する治療戦略―術後補助IFP療法およびソラフェニブ・手術併用の有用性―, 第75回日本臨床外科学会総会, 2013年11月.
748.	齋藤裕, 島田光生, 宇都宮徹, 山田眞一郎, 森根裕二, 池本哲也, 荒川悠佑, 金本真美, 岩橋衆一, 石川大地 : 80歳以上超高齢者における肝切・PDの妥当性に関する検討, 第75回日本臨床外科学会総会, 2013年11月.
749.	居村暁, 島田光生, 宇都宮徹, 森根裕二, 池本哲也, 荒川悠佑, 金本真美, 岩橋衆一, 齋藤裕, 石川大地 : 術中ヒヤリハットから得た教訓に基づくStep by stepでの手技工夫, 第7回肝臓内視鏡外科研究会, 2013年11月.
750.	荒川悠佑, 島田光生, 石川大地, 山田眞一郎, 髙須千絵, 齋藤裕, 岩橋衆一, 金本真美, 池本哲也, 森根裕二, 居村暁, 宇都宮徹, 三宅秀則 : 高齢者の肝再生不全の機序解明と治療への応用, 第43回日本創傷治癒学会, 2013年11月.
751.	齋藤裕, 島田光生, 宇都宮徹, 山田眞一郎, 森根裕二, 池本哲也, 森大樹, 荒川悠佑, 金本真美, 岩橋衆一, 石川大地, 髙須千絵 : 超高齢者における肝胆膵手術の妥当性に関する検討―癌根治によるQOL向上を目指して―, 第51回日本癌治療学会学術集会, 2013年10月.
752.	岩橋衆一, 島田光生, 宇都宮徹, 居村暁, 森根裕二, 池本哲也, 荒川悠佑, 森大樹, 金本真美, 齋藤裕, 髙須千絵, 石川大地, 三宅秀則 : 徳島県における肝癌診療連携ネットワークについて, 第51回日本癌治療学会学術集会, 2013年10月.
753.	池本哲也, 島田光生, 宇都宮徹, 居村暁, 森根裕二, 森大樹, 荒川悠佑, 金本真美, 岩橋衆一, 齋藤裕, 山田眞一郎, 石川大地, 三宅秀則 : IPMNにおける悪性度予想に関するバイオマーカーとしてのEMT関連因子, 第51回日本癌治療学会学術集会, 2013年10月.
754.	居村暁, 島田光生, 宇都宮徹, 森根裕二, 池本哲也, 荒川悠佑, 金本真美, 岩橋衆一, 齋藤裕, 髙須千絵, 山田眞一郎, 三宅秀則 : 進行肝癌に対するソラフェニブの治療成績―Conversionできた著効例の検討とあわせて―, 第51回日本癌治療学会学術集会, 2013年10月.
755.	森根裕二, 島田光生, 宇都宮徹, 居村暁, 池本哲也, 荒川悠佑, 金本真美, 岩橋衆一, 齋藤裕, 山田眞一郎, 石川大地, 髙須千絵, 三宅秀則 : 大腸癌肝転移に対する治療戦略―外科切除の適応とconversion surgery―, 第51回日本癌治療学会学術集会, 2013年10月.
756.	荒川悠佑, 島田光生, 石川大地, 山田眞一郎, 齋藤裕, 金本真美, 池本哲也, 森根裕二, 居村暁, 岩橋衆一, 宇都宮徹 : 進行肝細胞癌に対するソラフェニブと外科治療を組み合わせた治療成績, JDDW 2013 第21回日本消化器関連学会週間, 2013年10月.
757.	石川大地, 島田光生, 宇都宮徹, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 金本真美, 岩橋衆一, 齋藤裕, 森大樹, 矢田圭吾, 三宅秀則 : IPMNにおけるTwist1，Bmi1発現に関する検討, 第72回日本癌学会学術総会, 2013年10月.
758.	岩橋衆一, 島田光生, 宇都宮徹, 居村暁, 森根裕二, 池本哲也, 荒川悠佑, 金本真美, 齋藤裕, 石川大地 : 癌幹細胞の治療抵抗性獲得におけるepigenetic修飾の意義, 第72回日本癌学会学術総会, 2013年10月.
759.	齋藤裕, 島田光生, 宇都宮徹, 池本哲也, 山田眞一郎, 森根裕二, 居村暁, 森大樹, 荒川悠佑, 金本真美, 岩橋衆一, 髙須千絵, 浅野間理仁 : 脂肪由来幹細胞の傷害肝へのホーミング効果―癌幹細胞転移メカニズムへの応用―, 第72回日本癌学会学術総会, 2013年10月.
760.	宇都宮徹, 齋藤裕, 居村暁, 森根裕二, 池本哲也, 金本真美, 荒川悠佑, 岩橋衆一, 齋藤裕, 山田眞一郎, 石川大地, 田嶋敦, 井本逸勢 : ゲノムワイドなDNAメチル化解析に基づく非B非C肝癌例の非癌部肝組織におけるDNAメチル化異常の特徴, 第72回日本癌学会学術総会, 2013年10月.
761.	齋藤裕, 島田光生, 宇都宮徹, 居村暁, 森根裕二, 池本哲也, 荒川悠佑, 金本真美, 岩橋衆一, 石川大地 : 3D virtual hepatectomyと術中navigation systemを用いた肝切除, 第8回肝癌治療シミュレーション研究会, 2013年9月.
762.	齋藤裕, 島田光生, 宇都宮徹, 居村暁, 森根裕二, 池本哲也, 荒川悠佑, 金本真美, 岩橋衆一, 山田眞一郎, 石川大地 : 3Dvirtual hepatectomyと術中navigation systemを用いた肝切除, 第22回日本コンピュータ外科学会, 2013年9月.
763.	荒川悠佑, 島田光生, 石川大地, 山田眞一郎, 齋藤裕, 髙須千絵, 岩橋衆一, 金本真美, 池本哲也, 居村暁, 森根裕二, 宇都宮徹 : ラットsmall-for-size graft modelにおける脾臓内遺伝子発現の変化Ingenuity Pathway Analysisを用いた検討, 第49回日本移植学会総会, 2013年9月.
764.	池本哲也, 島田光生, 宇都宮徹, 居村暁, 森根裕二, 森大樹, 荒川悠佑, 金本真美, 岩橋衆一, 齋藤裕, 山田眞一郎, 髙須千絵 : 脂肪由来幹細胞を用いた膵島移植成績向上に関する展望と課題, 第49回日本移植学会総会, 2013年9月.
765.	居村暁, 島田光生, 宇都宮徹, 森根裕二, 池本哲也, 荒川悠佑, 金本真美, 岩橋衆一, 齋藤裕, 山田眞一郎, 三宅秀則 : C型肝硬変に対するABO不適合肝移植後の低用量Peg-IFN/RBV療法の有用性, 第49回日本移植学会総会, 2013年9月.
766.	齋藤裕, 島田光生, 宇都宮徹, 池本哲也, 山田眞一郎, 石川大地, 岩橋衆一, 金本真美, 荒川悠佑, 森大樹, 森根裕二, 居村暁 : ヒト脂肪由来幹細胞による肝傷害軽減効果に関する基礎的検討, 第49回日本移植学会総会, 2013年9月.
767.	石川大地, 島田光生, 宇都宮徹, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 金本真美, 岩橋衆一, 齋藤裕, 三宅秀則 : IPMNにおけるTwist1，Bmi1発現の意義, 第24回日本消化器癌発生学会総会, 2013年9月.
768.	宇都宮徹, 島田光生, 石川大地, 山田眞一郎, 齋藤裕, 岩橋衆一, 金本真美, 荒川悠佑, 池本哲也, 森根裕二, 居村暁 : 肝細胞癌の癌部と非癌部の両方におけるFbxw7高発現は術後再発の独立危険因子である, 第24回日本消化器癌発生学会総会, 2013年9月.
769.	齋藤裕, 島田光生, 宇都宮徹, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 森大樹, 金本真美, 岩橋衆一 : Vessel sealing systemを用いた肝嚢胞に対する単孔式内視鏡手術, 2nd Reduced Port Surgery Forum 第9回 Needlescopic Surgery meeting/第7回単孔式内視鏡手術研究会, 2013年8月.
770.	岩橋衆一, 島田光生, 宇都宮徹, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 金本真美, 齋藤裕, 山田眞一郎, 石川大地, 三宅秀則 : 右側肝円策をと伴う肝門部胆管癌切除例からみた肝区域分類の把握, 第49回日本肝癌研究会, 2013年7月.
771.	石川大地, 島田光生, 山田眞一郎, 齋藤裕, 岩橋衆一, 金本真美, 荒川悠佑, 池本哲也, 森根裕二, 居村暁, 宇都宮徹 : 肝細胞癌の癌部・非癌部における細胞周期調節因子Fbxw7の発現低下は独立予後規定因子である, 第49回日本肝癌研究会, 2013年7月.
772.	居村暁, 石川大地, 浅野間理仁, 山田眞一郎, 齋藤裕, 岩橋衆一, 金本真美, 荒川悠佑, 池本哲也, 森根裕二, 宇都宮徹, 島田光生 : 肝細胞癌における顕微鏡的門脈浸潤(vp)予測因子の検討∼RFAが好ましくない肝癌の特徴∼, 第49回日本肝癌研究会, 2013年7月.
773.	荒川悠佑, 島田光生, 石川大地, 山田眞一郎, 浅野間理仁, 齋藤裕, 岩橋衆一, 金本真美, 池本哲也, 森根裕二, 居村暁, 宇都宮徹 : 高齢ドナー肝再生不全と加齢指標マーカーについての検討, 第31回日本肝移植研究会, 2013年7月.
774.	居村暁, 石川大地, 浅野間理仁, 山田眞一郎, 齋藤裕, 岩橋衆一, 金本真美, 荒川悠佑, 池本哲也, 森根裕二, 岩田貴, 宇都宮徹, 島田光生 : 脳死肝移植推進のための医学生への啓蒙活動の必要性∼ドナーアクションの一環としての取り組み∼, 第31回日本肝移植研究会, 2013年7月.
775.	石川大地, 島田光生, 宇都宮徹, 森根裕二, 居村暁, 池本哲也, 森大樹, 荒川悠佑, 金本真美, 岩橋衆一, 齋藤裕, 三宅秀則 : IPMNにおけるEMT関連因子(Twist1, Bmi1)発現の意義についての検討, 第99回日本消化器病学会四国支部例会/第110回日本消化器内視鏡学会四国支部例会, 2013年6月.
776.	荒川悠佑, 島田光生, 石川大地, 山田眞一郎, 齋藤裕, 岩橋衆一, 金本真美, 森大樹, 池本哲也, 森根裕二, 居村暁, 宇都宮徹, 三宅秀則 : 高齢ドナー肝再生不全と加齢指標マーカーについての検討, 第99回日本消化器病学会四国支部例会/第110回日本消化器内視鏡学会四国支部例会, 2013年6月.
777.	荒川悠佑, 島田光生, 石川大地, 山田眞一郎, 浅野間理仁, 齋藤裕, 岩橋衆一, 金本真美, 森大樹, 池本哲也, 居村暁, 森根裕二, 宇都宮徹, 三宅秀則, 髙須千絵 : 当科における非B非C型初発肝細胞癌切除症例の検討, 第25回日本肝胆膵外科学会・学術集会, 2013年6月.
778.	池本哲也, 島田光生, 宇都宮徹, 居村暁, 森根裕二, 森大樹, 荒川悠佑, 金本真美, 岩橋衆一, 齋藤裕, 山田眞一郎 : 膵IPMNにおけるNotch signallは調節性T細胞expansionおよび腫瘍EMTを増強する, 第25回日本肝胆膵外科学会・学術集会, 2013年6月.
779.	森根裕二, 島田光生, 宇都宮徹, 居村暁, 池本哲也, 荒川悠佑, 金本真美, 岩橋衆一, 齋藤裕, 山田眞一郎, 石川大地, 三宅秀則 : 大腸癌肝転移に対する治療戦略―外科切除の適応とconversion surgery―, 第25回日本肝胆膵外科学会・学術集会, 2013年6月.
780.	齋藤裕, 島田光生, 宇都宮徹, 森根裕二, 居村暁, 池本哲也, 荒川悠佑, 金本真美, 岩橋衆一, 山田眞一郎, 石川大地, 三宅秀則 : 安全・確実な肝葉切除のポイント―肝離断における出血制御テクニック―, 第25回日本肝胆膵外科学会・学術集会, 2013年6月.
781.	居村暁, 島田光生, 宇都宮徹, 森根裕二, 池本哲也, 荒川悠佑, 金本真美, 岩橋衆一, 齋藤裕, 山田眞一郎, 浅野間理仁, 三宅秀則 : 手技定型化による安全確実な肝葉切除術, 第25回日本肝胆膵外科学会・学術集会, 2013年6月.
782.	齋藤裕, 宇都宮徹, 島田光生, 居村暁, 森根裕二, 池本哲也, 森大樹, 荒川悠佑, 金本真美, 岩橋衆一, 山田眞一郎, 浅野間理仁, 石川大地, 三宅秀則 : 肝発癌母地に着目した肝細胞癌の治療戦略―DNA, miRNA, Methylationアレイを用いた非癌部肝組織の解析より―, 第113回日本外科学会定期学術集会, 2013年4月.
783.	荒川悠佑, 島田光生, 石川大地, 山田眞一郎, 浅野間理仁, 齋藤裕, 岩橋衆一, 金本真美, 森大樹, 池本哲也, 森根裕二, 居村暁, 宇都宮徹, 三宅秀則 : 高齢者の肝再生不全の機序解明と治療への応用, 第113回日本外科学会定期学術集会, 2013年4月.
784.	池本哲也, 島田光生, 宇都宮徹, 居村暁, 森根裕二, 森大樹, 荒川悠佑, 金本真美, 齋藤裕, 山田眞一郎, 浅野間理仁, 三宅秀則 : 脂肪由来幹細胞を用いた肝胆膵領域の再生医療に関するimpactと課題, 第113回日本外科学会定期学術集会, 2013年4月.

その他・研究会:

1.	徳永卓哉, 島田光生, 齋藤裕, 吉川幸造, 東島潤, 西正暁, 柏原秀也, 髙須千絵, 江藤祥平, 良元俊昭, 杉本真樹 : Trans-perineal APRにおける術前VR・MRシミュレーション, 第29回日本コンピュータ外科学会大会, 2020年11月.
2.	徳永卓哉, 島田光生, 吉川幸造, 宮谷知彦, 西正暁, 齋藤裕, 柏原秀也, 髙須千絵, 良元俊昭, 武原悠花子, 杉本真樹 : 直腸切断術TpTMEにおける術前VR・MRシミュレーションと術中尿道造影ナビゲーションの有用性, 第120回日本外科学会定期学術集会, 2020年8月.
3.	野村聡子, 山田苑子, 鈴木佳子, 山田静恵, 西麻希, 粟田由佳, 橋本脩平, 筑後桃子, 柏原秀也, 齋藤裕, 濵田康弘 : 肥満を有する肝細胞癌の患者に対する術前減量プロトコールの評価, 第260回徳島医学会学術集会, 2020年2月.
4.	山田苑子, 大岩優, 青谷望美, 加木屋菜津美, 滝本真望, 野村聡子, 鈴木佳子, 柏原秀也, 齋藤裕, 西正暁, 島田光生, 濵田康弘 : 消化器癌患者における術前栄養・予後指標としてのPhase angleの臨床的実用性の検討, 第260回徳島医学会学術集会, 2020年2月.
5.	菊井聡子, 山田苑子, 林明希, 武田滋郁, 西麻希, 鈴木佳子, 齋藤裕, 柏原秀也, 松村晃子, 濵田康弘 : 多職種の連携によりストマ周囲潰瘍の改善がみられた高齢患者の1症例, 第10回日本静脈経腸栄養学会四国支部会学術集会, 2018年9月.
6.	松村晃子, 菊井聡子, 山田苑子, 鈴木佳子, 齋藤裕, 柏原秀也, 吉野真理子, 濵田康弘 : 病院間で栄養管理を繋いだ一症例, 第10回日本静脈経腸栄養学会四国支部会学術集会, 2018年9月.
7.	齋藤裕, 安井苑子, 吉川雅登, 寺奥大貴, 山田眞一郎, 岩橋衆一, 金本真美, 荒川悠佑, 池本哲也, 森根裕二, 居村暁, 濵田康弘, 島田光生 : InBodyを用いた体組成分析の肝胆膵外科手術における周術期栄養評価の有用性に関する検討, 第249回徳島医学会学術集会, 2014年7月.

科学研究費補助金 (KAKEN Grants Database @ NII.ac.jp)

腫瘍微小環境におけるexosomal micro RNA-Nrf2 addictionの機序解明と治療法の確立 (研究課題/領域番号: 23K08072 )
脂肪由来幹細胞ADSCから誘導した肝細胞様細胞HLCの免疫原性獲得に関する研究 (研究課題/領域番号: 23K08028 )
オルガノイドを用いた脂肪由来幹細胞からの超高機能肝細胞様細胞の確立 (研究課題/領域番号: 23K24395 )
Nrf2を介したTAM-cancerクロストークによる肝癌薬剤耐性機序の解明 (研究課題/領域番号: 22K08753 )
NASHにおける肝転移抑制の機序解明に関する研究 (研究課題/領域番号: 22K08752 )
自己脂肪由来インスリン産生細胞自家移植における抗原性発現と細胞運命の研究 (研究課題/領域番号: 22K08734 )
脂肪幹細胞由来Schwann様細胞の骨盤内臓神経再生促進効果に関する研究 (研究課題/領域番号: 22K08713 )
肝星細胞制御による薬剤耐性肝癌の肝内転移抑制機構の解明 (研究課題/領域番号: 21K08620 )
鎖肛術後の排便機能障害に対する脂肪由来Schwann様細胞を用いた治療法の開発 (研究課題/領域番号: 21K08596 )
赤色LEDによる脂肪由来間葉系幹細胞ADSCから肝細胞様細胞HLCへの分化誘導 (研究課題/領域番号: 20K08928 )
NASH肝癌切除後における再発促進の機序解明に関する研究 (研究課題/領域番号: 19K09095 )
Nrf2を介した間葉系幹細胞から肝細胞への分化誘導法の開発 (研究課題/領域番号: 19K09094 )
術後排尿障害モデルにおける脂肪由来幹細胞制御による神経再生促進効果に関する研究 (研究課題/領域番号: 19K09072 )
methylation statusに着目したインスリン産生細胞分化度解明の研究 (研究課題/領域番号: 19K09045 )
Nrf2を介した間葉系幹細胞からIPCへの効率的な分化誘導 (研究課題/領域番号: 18K16281 )
肝星細胞制御による肝移植後グラフト内肝癌再発抑制機構の解明 (研究課題/領域番号: 18K08573 )
非アルコール性脂肪肝炎における肝再生機能不全の解明と統合的治療法の開発 (研究課題/領域番号: 18H02871 )
ADSCを用いた3次元培養による効果的膵島様細胞作成に関する研究 (研究課題/領域番号: 16K10429 )
胆管構造を有する機能的肝組織再構築に関する研究 (研究課題/領域番号: 16K10428 )
肝虚血再灌流傷害におけるB-cell発現の関連に関する研究 (研究課題/領域番号: 15K19857 )
肝発癌における脾臓の役割解明に関する研究 (研究課題/領域番号: 25893156 )
膵島移植における脂肪由来幹細胞を用いたIBMIR制御に関する研究 (研究課題/領域番号: 25462114 )
研究者番号（50548675）による検索

講師 : 齋藤裕

研究活動

専門分野

研究テーマ

著書・論文

著書:

学術論文(審査論文):

学術論文(紀要・その他):

総説・解説:

国際会議:

国内講演発表:

その他・研究会:

科学研究費補助金 (KAKEN Grants Database @ NII.ac.jp)

講師 : 齋藤 裕

研究活動

専門分野

研究テーマ

著書・論文

著書:

学術論文(審査論文):

学術論文(紀要・その他):

総説・解説:

国際会議:

国内講演発表:

その他・研究会:

科学研究費補助金 (KAKEN Grants Database @ NII.ac.jp)

講師 : 齋藤裕